Il33 antibodies and methods of using the same

ABSTRACT

The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. patent applicationSer. No. 16/845,121, filed on Apr. 10, 2020. U.S. patent applicationSer. No. 16/845,121 is a divisional application of U.S. patentapplication Ser. No. 15/562,228, filed on Sep. 27, 2017, which grantedas U.S. Pat. No. 10,668,150 on Jun. 2, 2020. U.S. patent applicationSer. No. 15/562,228 is a U.S. National Stage application ofInternational Patent Application No. PCT/EP2016/056973, filed on Mar.30, 2016, which is incorporated herein by reference. InternationalPatent Application No. PCT/EP2016/056973 claims benefit under 35 U.S.C.§ 119(e) of U.S. Provisional Application No. 62/140,913, filed on Mar.31, 2015.

REFERENCE TO THE SEQUENCE LISTING

This application incorporates by reference a Sequence Listing submittedelectronically with the application as an XML file entitled“IL33-105-US-PCD2-SeqListing.xml” created on Jul. 5, 2023, and having asize of 882 kilobytes.

FIELD OF THE INVENTION

The present disclosure relates to novel forms of IL-33; novel mutants ofIL-33; binding proteins, such as antibodies specific to any one of saidproteins, in particular binding proteins able to modulate the amount ofsaid form present; compositions comprising a protein or a bindingprotein, such as an antibody according to the present disclosure; anduse of any one of the same, particularly in therapy, for example in thetreatment of prevention of inflammatory disease. The disclosure hereinalso extends to assays for identifying and/or quantifying the differentforms of IL-33.

BACKGROUND OF THE INVENTION

Interleukin-33 (IL-33), also called IL-1F11, is a member of the IL-1family of cytokines that stimulates the generation of cells, cytokines,and immunoglobulins characteristic of a type two immune response. IL-33is a 270 amino acid protein, consisting of two domains: a homeodomainand a cytokine (IL-1-like) domain. The homeodomain contains a nuclearlocalization signal (NLS). IL-33 mediates signal transduction throughST2, a receptor expressed on Th2 cells, mast cells and a wide variety ofother cell types.

Schmitz et al. first identified IL-33 as the ligand for the orphanreceptor ST2 (also called IL-1R4) (Schmitz et al., Immunity 23(5)479-90(2005)). IL-33 receptor is formed from heterodimeric molecules. ST2 andIL-1R accessory protein (IL-1RAcP) dimerize to form an IL-33 receptor(ST2:IL-1RAcP). IL-1RAcP is a shared component of receptors for IL-1α,IL-1β, IL-1F6, IL1F8, and IL1F9. IL-1RAcP is not required for binding,but is critical for signaling. The TIR-domain of the IL-33 receptorrecruits MyD88 and TRAF6, and the receptor signal results in activationof NFκB and MAP Kinase pathways (Oboki et al., Allergology International59:143-160 (2010)). IL-33 receptor may potentially associate with otherreceptors and has been reported to interact with c-kit on mast cells(Drube et al., Blood 115:3899-3906 (2010))

Recently, IL-33 has been shown to bind a second IL-33 receptorheterodimeric complex: ST2 also forms a complex with another IL-1Rfamily molecule, “single Ig IL-1R-related molecule” (SIGIRR) (alsocalled Toll IL-1R8 (TIRE)) to fom ST2:SIGIRR. SIGIRR/TIR8 is consideredto act as a negative regulator of IL-1R and Toll-like receptor(TLR)-mediated immune responses (Garlanda et al., Trends Immunol.30:439-46 (2009)). In contrast to ST2:IL-1RAcP, ST2:SIGIRR seems to actas a negative regulator of IL-33 (Oboki et al. (2010)).

The only known ligand of the ST2 receptor is IL-33 (see, e.g., Schmitzet al., Immunity 23(5)479-90 (2005); Chackerian et al., J. Immunol.179(4):2551-5 (2007)). The ST2 receptor is expressed at baseline by Th2cells and mast cells, both cell types are known to be importantmediators of allergic asthma. The extracellular form of IL-33 stimulatestarget cells by binding to ST2 and subsequently activates NFκB and MAPKinase pathways, leading to a range of functional responses includingproduction of cytokines and chemokines. Soluble ST2 (sST2) is thought tobe a decoy receptor, preventing IL-33 signaling.

In humans, IL-33 was found to be expressed constitutively in smoothmuscle and in bronchial epithelia. Expression can be induced by IL-1βand TNF-α in lung and dermal fibroblasts (Schmitz et al. (2005)). Thelevels of soluble ST2 protein and IL-33 mRNA/protein are increased insera and tissues from patients with asthma (Oboki et al., AllergologyInternational 59:143-160 (2010)).

In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leadsto severe pathological changes in mucosal organs. Administration ofIL-33 to mice has potent inflammatory effects, including massive bloodeosinophilia, increased IL-5 and IgE serum levels, and goblet cellhyperplasia at mucosal surfaces (Schmitz et al. (2005)). Intraperitonealor intranasal administration of IL-33 to mice led to induction ofeosinophilic inflammation in the pulmonary and intestinal mucosa throughthe IL-13 and STAT6-dependent pathways (Oboki et al. (2010)).Accordingly, IL-33 may play a role in allergic diseases such as asthmaand other inflammatory airway diseases.

Some reports in the literature suggest that goblet cells secreteCXCL8/IL-8, and this is increased by IL-33 through ST2R-ERK pathway,suggesting a mechanism for enhanced airway inflammation in the asthmaticairway with goblet cell metaplasia (Clin Exp Allergy. 2014 April;44(4):540-52).

Therefore there has been interest in IL-33 as a therapeutic target.However, to date the therapeutic benefits of blocking this therapeutictarget have yet to be fully realised. The present inventors haveestablished for the first time that IL-33 exists in a reduced form (alsoreferred to herein as redIL-33) and an oxidized form. The inventors havecharacterized the oxidized form of IL-33 for the first time as describedherein. In vitro and in vivo studies by the inventors have shown thatdisappearance of redIL-33 (the reduced form) correlated with theappearance of oxidised IL-33. In physiological fluids in vitro, redIL-33is rapidly oxidised to form a disulphide bonded form. The oxidized form(also referred to herein as IL-33-DSB) has at least one (e.g. two)disulfide bonds, in between the cysteines selected from the groupCys208, Cys 227, Cys 232 and Cys259, (numbered with reference to fulllength human IL-33 as disclosed in UniProt O97560, residues 112 to 270of which are recited within SEQ ID NO. 632). It has previously beenunappreciated that the commercially available assays seem topredominantly detect this oxidized form. The present inventors thereforeneeded to devise assays to selectively detect the redIL-33 that isresponsible for interacting with ST2 and driving biological activityassociated with IL-33 release.

The reduced form appears to be the active form of the protein whichgenerates the signal cascade and in fact in vivo it appears that thereduced form is converted into the oxidized form as a mechanism forterminating the signaling through ST2. The present inventors have foundthat redIL-33 binds ST2 (FIG. 24A). In contrast, IL-33-DSB showed no ST2binding (FIG. 24B). This has lead the inventors to hypothesise that invivo oxidation could be a mechanism to turn off IL-33-ST2 activity. Inaddition, the present inventors have established for the first time thatthe oxidized form of IL-33 (IL-33-DSB) binds to receptor for advancedglycation end products (RAGE) and signals through this alternativepathway (FIG. 56 ).

The present inventors believe that this understanding may be utilized togenerate more effective therapeutic agents. In one embodiment, thepresent inventors have identified an antibody that preferntillay bindsthe oxidized form but surprisingly attenuates the activity of thereduced form by essentially catalyzing the conversion of the reducedform to the oxidized form. Advantageously this mechanism simply augmentsthe in vivo mechanism for for terminating the signaling through ST2.

In another embodiment, the inventors have identified an antibody thatpreferntillay binds the reduced form of IL-33 (redIL-33), withfemtomolar affinity, and attenuates and/or inhibits IL-33 mediatedsignaling through ST2. This antibody provides for the first time amechanism for treating or preventing IL-33/ST2 mediated inflammatoryresponses.

In a yet further embodiment, the antibodies of the present invention canattenuate or inhibit the previously unrecognized signaling pathway forIL-33-DSB through RAGE, and any IL-33/RAGE mediated effects. Theantibodies of the present invention may act by directly binding ofIL-33-DSB and attenuating or inhibiting the ligand/receptor interactionwith RAGE or alternatively may bind to redIL-33 and prevent or reduceits conversion to the IL-33-DSB thereby indirectly attenuating orinhibiting the ligand/receptor interaction with RAGE.

BRIEF SUMMARY OF THE INVENTION

Thus in a first aspect there is provided isolated IL-33 in a reducedfrom (redIL-33) or a binding fragment thereof.

In one aspect there is provided an isolated IL-33 protein stabilized ina reduced form by a modification that prevents the formation ofdisulphide bridges between the native cysteines. Such modifications maycomprise deletion of one or more cysteine residues, mutations whichreplace one or more native cysteines with an alternative amino acidand/or conjugation to a chemical entity.

In one embodiment there is provided a mutated form of IL-33 as describedherein, in particular as shown in SEQ ID NO: 634 to 648.

In one embodiment the chemical entity is biotin, which reduces oreliminates the ability of redIL-33 to be converted to IL-33-DSB.

In one aspect there is provided a mutant IL-33 wherein one or morecysteines are replaced with a non-cysteine amino acid, for examplewherein one, two, three, four or more cysteines selected from Cys-208,Cys-227, Cys-232 and Cys-259 are replaced, for example with an aminoacid such as serine. In one embodiment the cysteine residue isindependently selected from Cys-208, Cys-227, Cys-232 and Cys-259. Thusin one embodiment a mutant according to the present disclosure is unableto form one or both of the disulfide bonds in the IL-33-DSB.

In one embodiment the present disclosure is directed to an isolatedbinding molecule which attenuates the activity of redIL-33, including astabilized form thereof according to the present disclosure, for exampleinhibits said activity. In one embodiment the attenuation is throughspecifically binding redIL-33. In one embodiment the attenuation isthrough binding IL-33-DSB and, for example catalyzing or acceleratingthe conversion of redIL-33 to IL-33-DSB.

In one embodiment the attenuation down-regulates or turns offST2-dependent signaling.

In certain embodiments, the binding molecule or the antibody orantigen-binding fragment thereof of the present disclosure inhibitsIL-33 driven cytokine production, for example in mast cells.

In one embodiment the attenuation down-regulates or prevents IL-5release from the ST2 pathway.

In one embodiment the attenuation down-regulates or prevents eosinophilactivation.

In one embodiment the attenuation down-regulates or prevents NFκBrelease. In one embodiment the attenuation down-regulates or preventsIL-4 release. In one embodiment the attenuation down-regulates orprevents IL-6 release. In one embodiment the attenuation down-regulatesor prevents IL-8 release. In one embodiment the attenuationdown-regulates or prevents IL-13 release.

In certain embodiments, the binding molecule or the antibody orantigen-binding fragment thereof of the present disclosure attenuates orinhibits IL-33/RAGE mediated signaling. Attenuation or inhibition ofRAGE-mediated signaling can enhance epithelial migration relative tothat seen in an unmodulated IL-33 driven inflammatory response (see FIG.58 ). Such enhanced epithelial migration may play a role in tissuerepair and wound healing, particularly in lung tissue, such as lungepithelium.

In one embodiment, the present disclosure is directed to an isolatedbinding molecule which specifically binds to redIL-33 or a bindingfragment of redIL-33.

In one embodiment, the present disclosure is directed to an isolatedbinding molecule which specifically binds to redIL-33 and inhibitsbinding of the same to ST2.

In one embodiment, the present disclosure is directed to an isolatedbinding molecule which specifically binds to redIL-33 and inhibitssignalling of redIL-33 by physically blocking the interaction of IL-33with its receptor.

In one embodiment the present disclosure is directed to a molecule whichs binds IL-33 and catalyses the conversion of redIL-33 to IL-33-DSBthereby down-regulating or turning off ST-2 signalling.

In one embodiment the present disclosure is directed to a bindingmolecule with an competitive mode of action.

In one embodiment the present disclosure is directed to a bindingmolecule with an allosteric mode of action.

In some embodiments, the binding molecule of the invention comprises anantibody or antigen-binding fragment thereof.

The following formula employs the single letter amino acid code.

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises a CDRH1 of formula (I):

SYAMX  (I)

wherein X is an amino acid, for example S or N, such as S.

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises a CDRH2 of formula (II):

X₁IX₂X₃X₄X₅X₆X₇X₈X₉X₁₀X₁₁YADX₁₂VKG  (II)

wherein:

-   -   X₁ is A, G or S in particular A or G, such as A;    -   X₂ is A, D, G, N, S in particular A, D or S, such as S;    -   X₃ is A, D or G in particular A or G, such as G    -   X₄ is absent or D in particular absent;    -   X₅ is absent or G in particular absent;    -   X₆ is D, I or S in particular I or S, such as S;    -   X₇ is D, F, G or S in particular D or G, such as G;    -   X₈ is D, G, Q, S, T in particular G, Q or T, such as G;    -   X₉ is R or S in particular S;    -   X₁₀ is P or T in particular P;    -   X₁₁ is H or Y in particular Y; and    -   X12 is P or S in particular S.

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises a CDRH3 of formula (III):

X₁₃X₁₄X₁₅X₁₆X₁₇X₁₈X₁₉X₂₀X₂₁GGLRYPX₂₂  (III)

wherein:

-   -   X₁₃ is A, D, H, L or Q in particular D or Q, such as D;    -   X₁₄ is K or L in particular K;    -   X₁₅ is F or W in particular F;    -   X₁₆ is I or M in particular M;    -   X₁₇ is Q or E in particular Q;    -   X₁₈ is L or N in particular L;    -   X₁₉ is W or Y in particular W;    -   X₂₀ is A, G or V in particular G; and    -   X₂₁ is F or L in particular F.

In one embodiment the the binding molecule, such as an antibody orbinding fragment thereof comprises a CDRH1 of formula (I) and a CDRH2 offormula (II), as defined above.

In one embodiment the the binding molecule, such as an antibody orbinding fragment thereof comprises a CDRH1 of formula (I) and a CDRH3 offormula (III), as defined above.

In one embodiment the the binding molecule, such as an antibody orbinding fragment thereof comprises a CDRH2 of formula (II) and a CDRH3of formula (III), as defined above.

In one embodiment the the binding molecule, such as an antibody orbinding fragment thereof comprises a CDRH1 of formula (I) and a CDRH2 offormula (II), and a CDRH3 of formula (III) as defined above.

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises a CDRL1 of formula (IV):

SGEX₂₂X₂₃GDKYAA  (IV)

wherein:

-   -   X₂₂ is an amino acid, for example R or G, in particular R; and    -   X₂₃ is an amino acid, for example M or I, in particular M.

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises a CDRL2 of formula (V):

X₂₄DTKRPS  (V)

wherein:

-   -   X₂₄ is an amino acid, for example Q or R, in particular R.

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises a CDRL3 of formula (VI):

X₂₅VX26X₂₇X₂₈X₂₉X₃₀X₃₁X₃₂X₃₃  (VI)

wherein:

-   -   X₂₅ is E, G or Q in particular G or Q, such as G;    -   X₂₆ is I, K, L or W in particular L or W, such as W;    -   X₂₇ is A, D, K, Q, R or V in particular D or K, such as K;    -   X₂₈ is A, D, K, Q or S in particular Q or S, such as S;    -   X₂₉ is D, N or S in particular D or S, such as D;    -   X₃₀ is D, S or T in particular D or S, such as D;    -   X₃₁ is absent or T in particular absent;    -   X₃₂ is G or P in particular G; and    -   X₃₃ is I or V in particular V.

In one embodiment the the binding molecule, such as an antibody orbinding fragment thereof comprises a CDRL1 of formula (IV) and a CDRL2of formula (V), as defined above.

In one embodiment the the binding molecule, such as an antibody orbinding fragment thereof comprises a CDRL1 of formula (IV) and a CDRL3of formula (VI), as defined above.

In one embodiment the the binding molecule, such as an antibody orbinding fragment thereof comprises a CDRL2 of formula (V) and a CDRL3 offormula (VI), as defined above.

In one embodiment the the binding molecule, such as an antibody orbinding fragment thereof comprises a CDRL1 of formula (IV) and a CDRL2of formula (V), and a CDRL3 of formula (VI) as defined above.

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I) and CDRL1 of formula(IV).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I) and CDRL2 of formula(V).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I) and CDRL3 of formula(VI).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH2 of formula (II) and CDRL1 of formula(IV).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH2 of formula (II) and CDRL2 of formula(V).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH2 of formula (II) and CDRL3 of formula(VI).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH3 of formula (III) and CDRL1 of formula(IV).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH3 of formula (III) and CDRL2 of formula(V).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH3 of formula (III) and CDRL3 of formula(VI).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH2 of formula (II)and CDRL1 of formula (IV).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH2 of formula (II)and CDRL2 of formula (V).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH2 of formula (II)and CDRL3 of formula (VI).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH3 of formula (III)and CDRL1 of formula (IV).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH3 of formula (III)and CDRL2 of formula (V).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH3 of formula (II)and CDRL3 of formula (VI).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH2 of formula (II), CDRH3 of formula (III)and CDRL1 of formula (IV).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH2 of formula (II), CDRH3 of formula (III)and CDRL2 of formula (V).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH2 of formula (II), CDRH3 of formula (II)and CDRL3 of formula (VI).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH2 of formula (II),CDRH3 of formula (III) and CDRL1 of formula (IV).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH2 of formula (II),CDRH3 of formula (III) and CDRL2 of formula (V).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH2 of formula (II),CDRH3 of formula (II) and CDRL3 of formula (VI).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH2 of formula (II),CDRH3 of formula (III), CDRL1 of formula (IV) and CDRL2 of formula (V).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH2 of formula (II),CDRH3 of formula (III), CDRL1 of formula (IV) and CDRL3 of formula (VI).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH2 of formula (II),CDRH3 of formula (II), CDRL2 of formula (V) and CDRL3 of formula (VI).

In one embodiment the binding molecule, such as an antibody or bindingfragment thereof comprises CDRH1 of formula (I), CDRH2 of formula (II),CDRH3 of formula (II), CDRL1 of formula (IV), CDRL2 of formula (V) andCDRL3 of formula (VI).

In one embodiment the binding molecule of the disclosure comprises 3CDRs, for example in a heavy chain variable region independentlyselected from SEQ ID NO: 3, 4, 5, 13, 14, 15, 23, 24, 25, 33, 34, 35,43, 44, 45, 53, 54, 55, 63, 64, 65, 73, 74, 75, 83, 84, 85, 93, 94, 95,103, 104, 105, 113, 114, 115, 153, 154, 155, 163, 164, 165, 173, 174,175, 183, 184, 185, 193, 194, 195, 203, 204, 205, 213, 214, 215, 223,224, 225, 233, 234, 235, 243, 244, 245, 253, 254, 255, 263, 264, 265,273, 274, 275, 283, 284, 285, 293, 294, 295, 303, 304, 305, 313, 314,315, 353, 354, 355, 363, 364, 365, 373, 374, 375, 383, 384, 385, 393,394, 395, 403, 404, 405, 413, 414, 415, 453, 454, 455, 463, 464, 465,473, 474, 475, 483, 484, 485, 493, 494, 495, 503, 504, 505, 513, 514,515, 553, 554, 555, 563, 564, 565, 573, 574, 575, 583, 584 and 585.

In one embodiment the binding molecule of the disclosure comprises 3CDRs, for example in a light chain variable region independentlyselected from SEQ ID NO: 8, 9, 10, 18, 19, 20, 28, 29, 30, 38, 39, 40,48, 49, 50, 58, 59, 60, 68, 69, 70, 78, 79, 80, 88, 89, 90, 98, 99, 100,108, 109, 118, 119, 120, 158, 159, 160, 168, 169, 170, 178, 179, 180,188, 189, 190, 198, 199, 200, 208, 209, 210, 218, 219, 220, 228, 229,230, 238, 239, 240, 248, 249, 250, 258, 259, 260, 268, 269, 270, 278,279, 280, 288, 289, 290, 298, 299, 300 308, 309, 310, 318, 319, 320,328, 329, 330, 338, 339, 340, 348, 349, 350, 358, 359, 360, 368, 369 370378, 379, 380, 388, 389, 390, 398, 399, 400, 408, 409, 410, 418, 419,420, 428, 429, 430, 438, 439, 440, 448, 449, 450, 458, 459, 460, 468,469, 470, 478, 479, 480, 488, 489, 490, 498, 499, 500 508, 509, 510,518, 519, 520, 528, 529, 530, 538, 539, 540, 548, 549, 550, 558, 559,560, 568, 569, 570, 578, 579, 580, 588, 589, and 590.

In one embodiment the binding molecule of the disclosure comprises 3CDRs, for example in a heavy chain variable region independentlyselected from SEQ ID NO: 3, 4, 5, 13, 14, 15, 23, 24, 25, 33, 34, 35,43, 44, 45, 53, 54, 55, 63, 64, 65, 73, 74, 75, 83, 84, 85, 93, 94, 95,103, 104, 105, 113, 114, 115, 153, 154, 155, 163, 164, 165, 173, 174,175, 183, 184, 185, 193, 194, 195, 203, 204, 205, 213, 214, 215, 223,224, 225, 233, 234, 235, 243, 244, 245, 253, 254, 255, 263, 264, 265,273, 274, 275, 283, 284, 285, 293, 294, 295, 303, 304, 305, 313, 314,315, 353, 354, 355, 363, 364, 365, 373, 374, 375, 383, 384, 385, 393,394, 395, 403, 404, 405, 413, 414, 415, 453, 454, 455, 463, 464, 465,473, 474, 475, 483, 484, 485, 493, 494, 495, 503, 504, 505, 513, 514,515, 553, 554, 555, 563, 564, 565, 573, 574, 575, 583, 584 and 585, and3 CDRs, for example in a light chain variable region independentlyselected from SEQ ID NO: 8, 9, 10, 18, 19, 20, 28, 29, 30, 38, 39, 40,48, 49, 50, 58, 59, 60, 68, 69, 70, 78, 79, 80, 88, 89, 90, 98, 99, 100,108, 109, 118, 119, 120, 158, 159, 160, 168, 169, 170, 178, 179, 180,188, 189, 190, 198, 199, 200, 208, 209, 210, 218, 219, 220, 228, 229,230, 238, 239, 240, 248, 249, 250, 258, 259, 260, 268, 269, 270, 278,279, 280, 288, 289, 290, 298, 299, 300 308, 309, 310, 318, 319, 320,328, 329, 330, 338, 339, 340, 348, 349, 350, 358, 359, 360, 368, 369 370378, 379, 380, 388, 389, 390, 398, 399, 400, 408, 409, 410, 418, 419,420, 428, 429, 430, 438, 439, 440, 448, 449, 450, 458, 459, 460, 468,469, 470, 478, 479, 480, 488, 489, 490, 498, 499, 500 508, 509, 510,518, 519, 520, 528, 529, 530, 538, 539, 540, 548, 549, 550, 558, 559,560, 568, 569, 570, 578, 579, 580, 588, 589, and 590.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 3, 4 and 5, for example SEQ IDNO: 3 and 4, SEQ ID NO: 3 and 5, or SEQ ID NO: 4 and 5, such as a heavyvariable region comprising SEQ ID NO: 3 for CDRH1, SEQ ID NO: 4 forCDRH2 and SEQ ID NO: 5 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 13, 14 and 15, for example SEQ IDNO: 13 and 14, SEQ ID NO: 13 and 15, or SEQ ID NO: 14 and 15, such as aheavy variable region comprising SEQ ID NO: 13 for CDRH1, SEQ ID NO: 14for CDRH2 and SEQ ID NO: 15 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 23, 24 and 25, for example SEQ IDNO: 23 and 24, SEQ ID NO: 23 and 25, or SEQ ID NO: 24 and 25, such as aheavy variable region comprising SEQ ID NO: 23 for CDRH1, SEQ ID NO: 24for CDRH2 and SEQ ID NO: 25 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 33, 34 and 35, for example SEQ IDNO: 33 and 34, SEQ ID NO: 33 and 35, or SEQ ID NO: 34 and 35, such as aheavy variable region comprising SEQ ID NO: 33 for CDRH1, SEQ ID NO: 34for CDRH2 and SEQ ID NO: 35 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 43, 44 and 45, for example SEQ IDNO: 43 and 44, SEQ ID NO: 43 and 45, or SEQ ID NO: 44 and 45, such as aheavy variable region comprising SEQ ID NO: 43 for CDRH1, SEQ ID NO: 44for CDRH2 and SEQ ID NO: 45 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 53, 54 and 55, for example SEQ IDNO: 53 and 54, SEQ ID NO: 53 and 55, or SEQ ID NO: 54 and 55, such as aheavy variable region comprising SEQ ID NO: 53 for CDRH1, SEQ ID NO: 54for CDRH2 and SEQ ID NO: 55 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 63, 64 and 65, for example SEQ IDNO: 63 and 64, SEQ ID NO: 63 and 65, or SEQ ID NO: 64 and 65, such as aheavy variable region comprising SEQ ID NO: 63 for CDRH1, SEQ ID NO: 64for CDRH2 and SEQ ID NO: 65 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 73, 74 and 75, for example SEQ IDNO: 73 and 74, SEQ ID NO: 73 and 75, or SEQ ID NO: 74 and 75, such as aheavy variable region comprising SEQ ID NO: 73 for CDRH1, SEQ ID NO: 74for CDRH2 and SEQ ID NO: 75 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 83, 84 and 85, for example SEQ IDNO: 83 and 84, SEQ ID NO: 83 and 85, or SEQ ID NO: 84 and 85, such as aheavy variable region comprising SEQ ID NO: 83 for CDRH1, SEQ ID NO: 84for CDRH2 and SEQ ID NO: 85 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 93, 94 and 95, for example SEQ IDNO: 93 and 94, SEQ ID NO: 93 and 95, or SEQ ID NO: 94 and 95, such as aheavy variable region comprising SEQ ID NO: 93 for CDRH1, SEQ ID NO: 94for CDRH2 and SEQ ID NO: 95 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 103, 104 and 105, for example SEQID NO: 103 and 104, SEQ ID NO: 103 and 105, or SEQ ID NO: 104 and 105,such as a heavy variable region comprising SEQ ID NO: 103 for CDRH1, SEQID NO: 104 for CDRH2 and SEQ ID NO: 105 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 113, 114 and 115, for example SEQID NO: 113 and 114, SEQ ID NO: 113 and 115, or SEQ ID NO: 114 and 115,such as a heavy variable region comprising SEQ ID NO: 113 for CDRH1, SEQID NO: 114 for CDRH2 and SEQ ID NO: 115 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 123, 124 and 125, for example SEQID NO: 123 and 124, SEQ ID NO: 123 and 125, or SEQ ID NO: 124 and 25,such as a heavy variable region comprising SEQ ID NO: 123 for CDRH1, SEQID NO: 124 for CDRH2 and SEQ ID NO: 125 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 133, 134 and 135, for example SEQID NO: 133 and 134, SEQ ID NO: 133 and 135, or SEQ ID NO: 134 and 135,such as a heavy variable region comprising SEQ ID NO: 133 for CDRH1, SEQID NO: 134 for CDRH2 and SEQ ID NO: 135 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 143, 144 and 145, for example SEQID NO: 143 and 144, SEQ ID NO: 143 and 145, or SEQ ID NO: 144 and 145,such as a heavy variable region comprising SEQ ID NO: 143 for CDRH1, SEQID NO: 144 for CDRH2 and SEQ ID NO: 145 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 153, 154 and 155, for example SEQID NO: 153 and 154, SEQ ID NO: 153 and 155, or SEQ ID NO: 154 and 155,such as a heavy variable region comprising SEQ ID NO: 153 for CDRH1, SEQID NO: 154 for CDRH2 and SEQ ID NO: 155 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 163, 164 and 165, for example SEQID NO: 163 and 164, SEQ ID NO: 163 and 165, or SEQ ID NO: 164 and 165,such as a heavy variable region comprising SEQ ID NO: 163 for CDRH1, SEQID NO: 164 for CDRH2 and SEQ ID NO: 165 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 173, 174 and 175, for example SEQID NO: 173 and 174, SEQ ID NO: 173 and 175, or SEQ ID NO: 174 and 175,such as a heavy variable region comprising SEQ ID NO: 173 for CDRH1, SEQID NO: 174 for CDRH2 and SEQ ID NO: 175 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 183, 184 and 185, for example SEQID NO: 183 and 184, SEQ ID NO: 183 and 185, or SEQ ID NO: 184 and 185,such as a heavy variable region comprising SEQ ID NO: 183 for CDRH1, SEQID NO: 184 for CDRH2 and SEQ ID NO: 185 for CDRH3

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 193, 194 and 195, for example SEQID NO: 193 and 194, SEQ ID NO: 193 and or SEQ ID NO: 194 and 195, suchas a heavy variable region comprising SEQ ID NO: 193 for CDRH1, SEQ IDNO: 194 for CDRH2 and SEQ ID NO: 195 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 203, 204 and 205, for example SEQID NO: 203 and 204, SEQ ID NO: 203 and 205, or SEQ ID NO: 204 and 205,such as a heavy variable region comprising SEQ ID NO: 203 for CDRH1, SEQID NO: 204 for CDRH2 and SEQ ID NO: 205 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 213, 214 and 215, for example SEQID NO: 213 and 214, SEQ ID NO: 213 and 215, or SEQ ID NO: 214 and 215,such as a heavy variable region comprising SEQ ID NO: 213 for CDRH1, SEQID NO: 214 for CDRH2 and SEQ ID NO: 215 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 223, 224 and 225, for example SEQID NO: 223 and 224, SEQ ID NO: 223 and 225, or SEQ ID NO: 224 and 225,such as a heavy variable region comprising SEQ ID NO: 223 for CDRH1, SEQID NO: 224 for CDRH2 and SEQ ID NO: 225 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 233, 234 and 235, for example SEQID NO: 233 and 234, SEQ ID NO: 233 and 235, or SEQ ID NO: 234 and 235,such as a heavy variable region comprising SEQ ID NO: 233 for CDRH1, SEQID NO: 234 for CDRH2 and SEQ ID NO: 235 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 243, 244 and 245, for example SEQID NO: 243 and 244, SEQ ID NO: 243 and 245, or SEQ ID NO: 244 and 245,such as a heavy variable region comprising SEQ ID NO: 243 for CDRH1, SEQID NO: 244 for CDRH2 and SEQ ID NO: 245 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 253, 254 and 255, for example SEQID NO: 253 and 254, SEQ ID NO: 253 and 255, or SEQ ID NO: 254 and 255,such as a heavy variable region comprising SEQ ID NO: 253 for CDRH1, SEQID NO: 254 for CDRH2 and SEQ ID NO: 255 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 263, 264 and 265, for example SEQID NO: 263 and 264, SEQ ID NO: 263 and 265, or SEQ ID NO: 264 and 265,such as a heavy variable region comprising SEQ ID NO: 263 for CDRH1, SEQID NO: 264 for CDRH2 and SEQ ID NO: 265 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 273, 274 and 275, for example SEQID NO: 273 and 274, SEQ ID NO: 273 and 275, or SEQ ID NO: 274 and 275,such as a heavy variable region comprising SEQ ID NO: 273 for CDRH1, SEQID NO: 274 for CDRH2 and SEQ ID NO: 275 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 283, 284 and 285, for example SEQID NO: 283 and 284, SEQ ID NO: 283 and 285, or SEQ ID NO: 284 and 285,such as a heavy variable region comprising SEQ ID NO: 283 for CDRH1, SEQID NO: 284 for CDRH2 and SEQ ID NO: 285 for CDRH3

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 293, 294 and 295, for example SEQID NO: 293 and 294, SEQ ID NO: 293 and 295, or SEQ ID NO: 294 and 295,such as a heavy variable region comprising SEQ ID NO: 293 for CDRH1, SEQID NO: 294 for CDRH2 and SEQ ID NO: 295 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 303, 304 and 305, for example SEQID NO: 303 and 304, SEQ ID NO: 303 and 305, or SEQ ID NO: 304 and 305,such as a heavy variable region comprising SEQ ID NO: 303 for CDRH1, SEQID NO: 304 for CDRH2 and SEQ ID NO: 305 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 313, 314 and 315, for example SEQID NO: 313 and 314, SEQ ID NO: 313 and 315, or SEQ ID NO: 314 and 315,such as a heavy variable region comprising SEQ ID NO: 313 for CDRH1, SEQID NO: 314 for CDRH2 and SEQ ID NO: 315 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 323, 324 and 325, for example SEQID NO: 323 and 324, SEQ ID NO: 323 and 325, or SEQ ID NO: 324 and 325,such as a heavy variable region comprising SEQ ID NO: 323 for CDRH1, SEQID NO: 324 for CDRH2 and SEQ ID NO: 325 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 333, 334 and 335, for example SEQID NO: 333 and 334, SEQ ID NO: 333 and 335, or SEQ ID NO: 334 and 335,such as a heavy variable region comprising SEQ ID NO: 333 for CDRH1, SEQID NO: 334 for CDRH2 and SEQ ID NO: 335 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 343, 344 and 345, for example SEQID NO: 343 and 344, SEQ ID NO: 343 and 345, or SEQ ID NO: 344 and 345,such as a heavy variable region comprising SEQ ID NO: 343 for CDRH1, SEQID NO: 344 for CDRH2 and SEQ ID NO: 345 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 353, 354 and 355, for example SEQID NO: 353 and 354, SEQ ID NO: 353 and 355, or SEQ ID NO: 354 and 355,such as a heavy variable region comprising SEQ ID NO: 353 for CDRH1, SEQID NO: 354 for CDRH2 and SEQ ID NO: 355 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 363, 364 and 365, for example SEQID NO: 363 and 364, SEQ ID NO: 363 and 365, or SEQ ID NO: 364 and 365,such as a heavy variable region comprising SEQ ID NO: 363 for CDRH1, SEQID NO: 364 for CDRH2 and SEQ ID NO: 365 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 373, 374 and 375, for example SEQID NO: 373 and 374, SEQ ID NO: 373 and 375, or SEQ ID NO: 374 and 375,such as a heavy variable region comprising SEQ ID NO: 373 for CDRH1, SEQID NO: 374 for CDRH2 and SEQ ID NO: 375 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 383, 384 and 385, for example SEQID NO: 383 and 384, SEQ ID NO: 383 and 385, or SEQ ID NO: 384 and 385,such as a heavy variable region comprising SEQ ID NO: 383 for CDRH1, SEQID NO: 384 for CDRH2 and SEQ ID NO: 385 for CDRH3

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 393, 394 and 395, for example SEQID NO: 393 and 394, SEQ ID NO: 393 and 395, or SEQ ID NO: 394 and 395,such as a heavy variable region comprising SEQ ID NO: 393 for CDRH1, SEQID NO: 394 for CDRH2 and SEQ ID NO: 395 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 403, 404 and 405, for example SEQID NO: 403 and 404, SEQ ID NO: 403 and 405, or SEQ ID NO: 404 and 405,such as a heavy variable region comprising SEQ ID NO: 403 for CDRH1, SEQID NO: 404 for CDRH2 and SEQ ID NO: 405 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 413, 414 and 415, for example SEQID NO: 413 and 414, SEQ ID NO: 413 and 415, or SEQ ID NO: 414 and 415,such as a heavy variable region comprising SEQ ID NO: 413 for CDRH1, SEQID NO: 414 for CDRH2 and SEQ ID NO: 415 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 423, 424 and 425, for example SEQID NO: 423 and 424, SEQ ID NO: 423 and 425, or SEQ ID NO: 424 and 425,such as a heavy variable region comprising SEQ ID NO: 423 for CDRH1, SEQID NO: 424 for CDRH2 and SEQ ID NO: 425 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 433, 434 and 435, for example SEQID NO: 433 and 434, SEQ ID NO: 433 and 435, or SEQ ID NO: 434 and 435,such as a heavy variable region comprising SEQ ID NO: 433 for CDRH1, SEQID NO: 434 for CDRH2 and SEQ ID NO: 435 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 443, 444 and 445, for example SEQID NO: 443 and 444, SEQ ID NO: 443 and 445, or SEQ ID NO: 444 and 445,such as a heavy variable region comprising SEQ ID NO: 443 for CDRH1, SEQID NO: 444 for CDRH2 and SEQ ID NO: 445 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 453, 454 and 455, for example SEQID NO: 453 and 454, SEQ ID NO: 453 and 455, or SEQ ID NO: 454 and 455,such as a heavy variable region comprising SEQ ID NO: 453 for CDRH1, SEQID NO: 454 for CDRH2 and SEQ ID NO: 455 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 463, 464 and 465, for example SEQID NO: 463 and 464, SEQ ID NO: 463 and 465, or SEQ ID NO: 464 and 465,such as a heavy variable region comprising SEQ ID NO: 463 for CDRH1, SEQID NO: 464 for CDRH2 and SEQ ID NO: 465 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 473, 474 and 475, for example SEQID NO: 473 and 474, SEQ ID NO: 473 and 475, or SEQ ID NO: 474 and 475,such as a heavy variable region comprising SEQ ID NO: 473 for CDRH1, SEQID NO: 474 for CDRH2 and SEQ ID NO: 475 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 483, 484 and 485, for example SEQID NO: 483 and 484, SEQ ID NO: 483 and 485, or SEQ ID NO: 484 and 485,such as a heavy variable region comprising SEQ ID NO: 483 for CDRH1, SEQID NO: 484 for CDRH2 and SEQ ID NO: 485 for CDRH3

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 493, 494 and 495, for example SEQID NO: 493 and 494, SEQ ID NO: 493 and 495, or SEQ ID NO: 494 and 495,such as a heavy variable region comprising SEQ ID NO: 493 for CDRH1, SEQID NO: 494 for CDRH2 and SEQ ID NO: 495 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 503, 504 and 505, for example SEQID NO: 503 and 504, SEQ ID NO: 503 and 505, or SEQ ID NO: 504 and 505,such as a heavy variable region comprising SEQ ID NO: 503 for CDRH1, SEQID NO: 504 for CDRH2 and SEQ ID NO: 505 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 513, 514 and 515, for example SEQID NO: 513 and 514, SEQ ID NO: 513 and 515, or SEQ ID NO: 514 and 515,such as a heavy variable region comprising SEQ ID NO: 513 for CDRH1, SEQID NO: 514 for CDRH2 and SEQ ID NO: 515 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 523, 524 and 525, for example SEQID NO: 523 and 524, SEQ ID NO: 523 and 525, or SEQ ID NO: 524 and 525,such as a heavy variable region comprising SEQ ID NO: 523 for CDRH1, SEQID NO: 524 for CDRH2 and SEQ ID NO: 525 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 533, 534 and 535, for example SEQID NO: 533 and 534, SEQ ID NO: 533 and 535, or SEQ ID NO: 534 and 535,such as a heavy variable region comprising SEQ ID NO: 533 for CDRH1, SEQID NO: 534 for CDRH2 and SEQ ID NO: 535 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 543, 544 and 545, for example SEQID NO: 543 and 544, SEQ ID NO: 543 and 545, or SEQ ID NO: 544 and 545,such as a heavy variable region comprising SEQ ID NO: 543 for CDRH1, SEQID NO: 544 for CDRH2 and SEQ ID NO: 545 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 553, 554 and 555, for example SEQID NO: 553 and 554, SEQ ID NO: 553 and 555, or SEQ ID NO: 554 and 555,such as a heavy variable region comprising SEQ ID NO: 553 for CDRH1, SEQID NO: 554 for CDRH2 and SEQ ID NO: 555 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 563, 564 and 565, for example SEQID NO: 563 and 564, SEQ ID NO: 563 and 565, or SEQ ID NO: 564 and 565,such as a heavy variable region comprising SEQ ID NO: 563 for CDRH1, SEQID NO: 564 for CDRH2 and SEQ ID NO: 565 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 573, 574 and 575, for example SEQID NO: 573 and 574, SEQ ID NO: 573 and 575, or SEQ ID NO: 574 and 575,such as a heavy variable region comprising SEQ ID NO: 573 for CDRH1, SEQID NO: 574 for CDRH2 and SEQ ID NO: 575 for CDRH3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 583, 584 and 585, for example SEQID NO: 583 and 584, SEQ ID NO: 583 and 585, or SEQ ID NO: 584 and 585,such as a heavy variable region comprising SEQ ID NO: 583 for CDRH1, SEQID NO: 584 for CDRH2 and SEQ ID NO: 585 for CDRH3

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 8, 9 and 10, for example SEQ IDNO: 8 and 9, SEQ ID NO: 8 and 10, or SEQ ID NO: 9 and 10, such as alight variable region comprising SEQ ID NO: 8 for CDRL1, SEQ ID NO: 9for CDRL2 and SEQ ID NO: 10 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 18, 19 and 20, for example SEQ IDNO: 18 and 19, SEQ ID NO: 18 and 20, or SEQ ID NO: 19 and 20, such as alight variable region comprising SEQ ID NO: 18 for CDRL1, SEQ ID NO: 19for CDRL2 and SEQ ID NO: 20 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 28, 29 and 30, for example SEQ IDNO: 28 and 29, SEQ ID NO: 28 and 30, or SEQ ID NO: 29 and 30, such as alight variable region comprising SEQ ID NO: 28 for CDRL1, SEQ ID NO: 29for CDRL2 and SEQ ID NO: 30 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 38, 39 and 40, for example SEQ IDNO: 38 and 39, SEQ ID NO: 38 and 40, or SEQ ID NO: 39 and 40, such as alight variable region comprising SEQ ID NO: 38 for CDRL1, SEQ ID NO: 39for CDRL2 and SEQ ID NO: 40 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 48, 49 and 50, for example SEQ IDNO: 48 and 49, SEQ ID NO: 48 and 50, or SEQ ID NO: 49 and 50, such as alight variable region comprising SEQ ID NO: 48 for CDRL1, SEQ ID NO: 49for CDRL2 and SEQ ID NO: 50 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 58, 59 and 60, for example SEQ IDNO: 58 and 59, SEQ ID NO: 58 and 60, or SEQ ID NO: 59 and 60, such as alight variable region comprising SEQ ID NO: 58 for CDRL1, SEQ ID NO: 59for CDRL2 and SEQ ID NO: 60 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 68, 69 and 70, for example SEQ IDNO: 68 and 69, SEQ ID NO: 68 and 70, or SEQ ID NO: 69 and 70, such as alight variable region comprising SEQ ID NO: 68 for CDRL1, SEQ ID NO: 69for CDRL2 and SEQ ID NO: 70 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 78, 79 and 80, for example SEQ IDNO: 78 and 79, SEQ ID NO: 78 and 80, or SEQ ID NO: 79 and 80, such as alight variable region comprising SEQ ID NO: 78 for CDRL1, SEQ ID NO: 79for CDRL2 and SEQ ID NO: 80 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 88, 89 and 90, for example SEQ IDNO: 88 and 89, SEQ ID NO: 88 and 90, or SEQ ID NO: 89 and 90, such as alight variable region comprising SEQ ID NO: 88 for CDRL1, SEQ ID NO: 89for CDRL2 and SEQ ID NO: 90 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 98, 99 and 100, for example SEQID NO: 98 and 99, SEQ ID NO: 98 and 100, or SEQ ID NO: 99 and 100, suchas a light variable region comprising SEQ ID NO: 98 for CDRL1, SEQ IDNO: 99 for CDRL2 and SEQ ID NO: 100 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 108, 109 and 110, for example SEQID NO: 108 and 109, SEQ ID NO: 108 and 110, or SEQ ID NO: 109 and 110,such as a light variable region comprising SEQ ID NO: 108 for CDRL1, SEQID NO: 109 for CDRL2 and SEQ ID NO: 110 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 118, 119 and 120, for example SEQID NO: 118 and 119, SEQ ID NO: 118 and 120, or SEQ ID NO: 119 and 120,such as a light variable region comprising SEQ ID NO: 118 for CDRL1, SEQID NO: 119 for CDRL2 and SEQ ID NO: 120 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 128, 129 and 130, for example SEQID NO: 128 and 129, SEQ ID NO: 128 and 130, or SEQ ID NO: 129 and 130,such as a light variable region comprising SEQ ID NO: 128 for CDRL1, SEQID NO: 129 for CDRL2 and SEQ ID NO: 130 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 138, 139 and 140, for example SEQID NO: 138 and 139, SEQ ID NO: 138 and 140, or SEQ ID NO: 139 and 140,such as a light variable region comprising SEQ ID NO: 138 for CDRL1, SEQID NO: 139 for CDRL2 and SEQ ID NO: 140 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 148, 149 and 150, for example SEQID NO: 148 and 149, SEQ ID NO: 148 and 150, or SEQ ID NO: 149 and 150,such as a light variable region comprising SEQ ID NO: 148 for CDRL1, SEQID NO: 149 for CDRL2 and SEQ ID NO: 120 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 158, 159 and 160, for example SEQID NO: 158 and 159, SEQ ID NO: 158 and 160, or SEQ ID NO: 159 and 160,such as a light variable region comprising SEQ ID NO: 158 for CDRL1, SEQID NO: 159 for CDRL2 and SEQ ID NO: 160 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 168, 169 and 170, for example SEQID NO: 168 and 169, SEQ ID NO: 168 and 170, or SEQ ID NO: 169 and 170,such as a light variable region comprising SEQ ID NO: 168 for CDRL1, SEQID NO: 169 for CDRL2 and SEQ ID NO: 170 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 178, 179 and 180, for example SEQID NO: 178 and 179, SEQ ID NO: 178 and 180, or SEQ ID NO: 179 and 180,such as a light variable region comprising SEQ ID NO: 178 for CDRL1, SEQID NO: 179 for CDRL2 and SEQ ID NO: 180 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 188, 189 and 190, for example SEQID NO: 188 and 189, SEQ ID NO: 188 and 190, or SEQ ID NO: 189 and 190,such as a light variable region comprising SEQ ID NO: 188 for CDRL1, SEQID NO: 189 for CDRL2 and SEQ ID NO: 190 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 198, 199 and 200, for example SEQID NO: 198 and 199, SEQ ID NO: 198 and 200, or SEQ ID NO: 199 and 200,such as a light variable region comprising SEQ ID NO: 198 for CDRL1, SEQID NO: 199 for CDRL2 and SEQ ID NO: 200 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 208, 209 and 210, for example SEQID NO: 208 and 209, SEQ ID NO: 208 and 210, or SEQ ID NO: 209 and 210,such as a light variable region comprising SEQ ID NO: 208 for CDRL1, SEQID NO: 209 for CDRL2 and SEQ ID NO: 210 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 218, 219 and 220, for example SEQID NO: 218 and 219, SEQ ID NO: 218 and 220, or SEQ ID NO: 219 and 220,such as a light variable region comprising SEQ ID NO: 218 for CDRL1, SEQID NO: 219 for CDRL2 and SEQ ID NO: 220 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 228, 229 and 230, for example SEQID NO: 228 and 229, SEQ ID NO: 228 and 230, or SEQ ID NO: 229 and 230,such as a light variable region comprising SEQ ID NO: 228 for CDRL1, SEQID NO: 229 for CDRL2 and SEQ ID NO: 230 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 238, 239 and 240, for example SEQID NO: 238 and 239, SEQ ID NO: 238 and 240, or SEQ ID NO: 239 and 240,such as a light variable region comprising SEQ ID NO: 238 for CDRL1, SEQID NO: 239 for CDRL2 and SEQ ID NO: 240 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 248, 249 and 250, for example SEQID NO: 248 and 249, SEQ ID NO: 248 and 250, or SEQ ID NO: 249 and 250,such as a light variable region comprising SEQ ID NO: 248 for CDRL1, SEQID NO: 249 for CDRL2 and SEQ ID NO: 220 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 258, 259 and 260, for example SEQID NO: 258 and 259, SEQ ID NO: 258 and 260, or SEQ ID NO: 259 and 260,such as a light variable region comprising SEQ ID NO: 258 for CDRL1, SEQID NO: 259 for CDRL2 and SEQ ID NO: 260 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 268, 269 and 270, for example SEQID NO: 268 and 269, SEQ ID NO: 268 and 270, or SEQ ID NO: 269 and 270,such as a light variable region comprising SEQ ID NO: 268 for CDRL1, SEQID NO: 269 for CDRL2 and SEQ ID NO: 270 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 278, 279 and 280, for example SEQID NO: 278 and 279, SEQ ID NO: 278 and 280, or SEQ ID NO: 279 and 280,such as a light variable region comprising SEQ ID NO: 278 for CDRL1, SEQID NO: 279 for CDRL2 and SEQ ID NO: 280 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 288, 289 and 290, for example SEQID NO: 288 and 289, SEQ ID NO: 288 and 290, or SEQ ID NO: 289 and 290,such as a light variable region comprising SEQ ID NO: 288 for CDRL1, SEQID NO: 289 for CDRL2 and SEQ ID NO: 290 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 298, 299 and 300, for example SEQID NO: 298 and 299, SEQ ID NO: 298 and 300, or SEQ ID NO: 299 and 300,such as a light variable region comprising SEQ ID NO: 298 for CDRL1, SEQID NO: 299 for CDRL2 and SEQ ID NO: 300 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 308, 309 and 310, for example SEQID NO: 308 and 309, SEQ ID NO: 308 and 310, or SEQ ID NO: 309 and 310,such as a light variable region comprising SEQ ID NO: 308 for CDRL1, SEQID NO: 309 for CDRL2 and SEQ ID NO: 310 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 318, 319 and 320, for example SEQID NO: 318 and 319, SEQ ID NO: 318 and 320, or SEQ ID NO: 319 and 320,such as a light variable region comprising SEQ ID NO: 318 for CDRL1, SEQID NO: 319 for CDRL2 and SEQ ID NO: 320 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 328, 329 and 330, for example SEQID NO: 328 and 329, SEQ ID NO: 328 and 330, or SEQ ID NO: 329 and 330,such as a light variable region comprising SEQ ID NO: 328 for CDRL1, SEQID NO: 329 for CDRL2 and SEQ ID NO: 330 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 338, 339 and 340, for example SEQID NO: 338 and 339, SEQ ID NO: 338 and 340, or SEQ ID NO: 339 and 340,such as a light variable region comprising SEQ ID NO: 338 for CDRL1, SEQID NO: 339 for CDRL2 and SEQ ID NO: 340 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 348, 349 and 350, for example SEQID NO: 348 and 349, SEQ ID NO: 348 and 350, or SEQ ID NO: 349 and 350,such as a light variable region comprising SEQ ID NO: 348 for CDRL1, SEQID NO: 349 for CDRL2 and SEQ ID NO: 320 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 358, 359 and 360, for example SEQID NO: 358 and 359, SEQ ID NO: 358 and 360, or SEQ ID NO: 359 and 360,such as a light variable region comprising SEQ ID NO: 358 for CDRL1, SEQID NO: 359 for CDRL2 and SEQ ID NO: 360 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 368, 369 and 370, for example SEQID NO: 368 and 369, SEQ ID NO: 368 and 370, or SEQ ID NO: 369 and 370,such as a light variable region comprising SEQ ID NO: 368 for CDRL1, SEQID NO: 369 for CDRL2 and SEQ ID NO: 370 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 378, 379 and 380, for example SEQID NO: 378 and 379, SEQ ID NO: 378 and 380, or SEQ ID NO: 379 and 380,such as a light variable region comprising SEQ ID NO: 378 for CDRL1, SEQID NO: 379 for CDRL2 and SEQ ID NO: 380 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 388, 389 and 390, for example SEQID NO: 388 and 389, SEQ ID NO: 388 and 390, or SEQ ID NO: 389 and 390,such as a light variable region comprising SEQ ID NO: 388 for CDRL1, SEQID NO: 389 for CDRL2 and SEQ ID NO: 390 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 398, 399 and 400, for example SEQID NO: 398 and 399, SEQ ID NO: 398 and 400, or SEQ ID NO: 399 and 400,such as a light variable region comprising SEQ ID NO: 398 for CDRL1, SEQID NO: 399 for CDRL2 and SEQ ID NO: 400 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 408, 409 and 410, for example SEQID NO: 408 and 409, SEQ ID NO: 408 and 410, or SEQ ID NO: 409 and 410,such as a light variable region comprising SEQ ID NO: 408 for CDRL1, SEQID NO: 409 for CDRL2 and SEQ ID NO: 410 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 418, 419 and 420, for example SEQID NO: 418 and 419, SEQ ID NO: 418 and 420, or SEQ ID NO: 419 and 420,such as a light variable region comprising SEQ ID NO: 418 for CDRL1, SEQID NO: 419 for CDRL2 and SEQ ID NO: 420 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 428, 429 and 430, for example SEQID NO: 428 and 429, SEQ ID NO: 428 and 430, or SEQ ID NO: 429 and 430,such as a light variable region comprising SEQ ID NO: 428 for CDRL1, SEQID NO: 429 for CDRL2 and SEQ ID NO: 430 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 438, 439 and 440, for example SEQID NO: 438 and 439, SEQ ID NO: 438 and 440, or SEQ ID NO: 439 and 440,such as a light variable region comprising SEQ ID NO: 438 for CDRL1, SEQID NO: 439 for CDRL2 and SEQ ID NO: 440 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 448, 449 and 450, for example SEQID NO: 448 and 449, SEQ ID NO: 448 and 450, or SEQ ID NO: 449 and 450,such as a light variable region comprising SEQ ID NO: 448 for CDRL1, SEQID NO: 449 for CDRL2 and SEQ ID NO: 420 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 458, 459 and 460, for example SEQID NO: 458 and 459, SEQ ID NO: 458 and 460, or SEQ ID NO: 459 and 460,such as a light variable region comprising SEQ ID NO: 458 for CDRL1, SEQID NO: 459 for CDRL2 and SEQ ID NO: 460 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 468, 469 and 470, for example SEQID NO: 468 and 469, SEQ ID NO: 468 and 470, or SEQ ID NO: 469 and 470,such as a light variable region comprising SEQ ID NO: 468 for CDRL1, SEQID NO: 469 for CDRL2 and SEQ ID NO: 470 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 478, 479 and 480, for example SEQID NO: 478 and 479, SEQ ID NO: 478 and 480, or SEQ ID NO: 479 and 480,such as a light variable region comprising SEQ ID NO: 478 for CDRL1, SEQID NO: 479 for CDRL2 and SEQ ID NO: 480 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 488, 489 and 490, for example SEQID NO: 488 and 489, SEQ ID NO: 488 and 490, or SEQ ID NO: 489 and 490,such as a light variable region comprising SEQ ID NO: 488 for CDRL1, SEQID NO: 489 for CDRL2 and SEQ ID NO: 490 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 498, 499 and 500, for example SEQID NO: 498 and 499, SEQ ID NO: 498 and 500, or SEQ ID NO: 499 and 500,such as a light variable region comprising SEQ ID NO: 498 for CDRL1, SEQID NO: 499 for CDRL2 and SEQ ID NO: 500 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 508, 509 and 510, for example SEQID NO: 508 and 509, SEQ ID NO: 508 and 510, or SEQ ID NO: 509 and 510,such as a light variable region comprising SEQ ID NO: 508 for CDRL1, SEQID NO: 509 for CDRL2 and SEQ ID NO: 510 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 518, 519 and 520, for example SEQID NO: 518 and 519, SEQ ID NO: 518 and 520, or SEQ ID NO: 519 and 520,such as a light variable region comprising SEQ ID NO: 518 for CDRL1, SEQID NO: 519 for CDRL2 and SEQ ID NO: 520 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 528, 529 and 530, for example SEQID NO: 528 and 529, SEQ ID NO: 528 and 530, or SEQ ID NO: 529 and 530,such as a light variable region comprising SEQ ID NO: 528 for CDRL1, SEQID NO: 529 for CDRL2 and SEQ ID NO: 530 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 538, 539 and 540, for example SEQID NO: 538 and 539, SEQ ID NO: 538 and 540, or SEQ ID NO: 539 and 540,such as a light variable region comprising SEQ ID NO: 538 for CDRL1, SEQID NO: 539 for CDRL2 and SEQ ID NO: 540 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 548, 549 and 550, for example SEQID NO: 548 and 549, SEQ ID NO: 548 and 550, or SEQ ID NO: 549 and 550,such as a light variable region comprising SEQ ID NO: 548 for CDRL1, SEQID NO: 549 for CDRL2 and SEQ ID NO: 520 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 558, 559 and 560, for example SEQID NO: 558 and 559, SEQ ID NO: 558 and 560, or SEQ ID NO: 559 and 560,such as a light variable region comprising SEQ ID NO: 558 for CDRL1, SEQID NO: 559 for CDRL2 and SEQ ID NO: 560 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 568, 569 and 570, for example SEQID NO: 568 and 569, SEQ ID NO: 568 and 570, or SEQ ID NO: 569 and 570,such as a light variable region comprising SEQ ID NO: 568 for CDRL1, SEQID NO: 569 for CDRL2 and SEQ ID NO: 570 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 578, 579 and 580, for example SEQID NO: 578 and 579, SEQ ID NO: 578 and 580, or SEQ ID NO: 579 and 580,such as a light variable region comprising SEQ ID NO: 578 for CDRL1, SEQID NO: 579 for CDRL2 and SEQ ID NO: 580 for CDRL3.

In one embodiment the binding molecule of the disclosure comprises atleast one CDR selected from SEQ ID NO: 588, 589 and 590, for example SEQID NO: 588 and 589, SEQ ID NO: 588 and 590, or SEQ ID NO: 589 and 590,such as a light variable region comprising SEQ ID NO: 588 for CDRL1, SEQID NO: 589 for CDRL2 and SEQ ID NO: 590 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 103 for CDRH1, SEQ ID NO: 104 forCDRH2 and SEQ ID NO: 105 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 108, 109 and 120,in particular a light variable region comprising SEQ ID NO: 108 forCDRL1, SEQ ID NO: 109 for CDRL2 and SEQ ID NO: 120 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 113 for CDRH1, SEQ ID NO: 114 forCDRH2 and SEQ ID NO: 115 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 118, 119 and 120,in particular a light variable region comprising SEQ ID NO: 118 forCDRL1, SEQ ID NO: 119 for CDRL2 and SEQ ID NO: 120 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 123 for CDRH1, SEQ ID NO: 124 forCDRH2 and SEQ ID NO: 125 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 128, 129 and 130,in particular a light variable region comprising SEQ ID NO: 128 forCDRL1, SEQ ID NO: 129 for CDRL2 and SEQ ID NO: 130 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 133 for CDRH1, SEQ ID NO: 134 forCDRH2 and SEQ ID NO: 135 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 138, 139 and 140,in particular a light variable region comprising SEQ ID NO: 138 forCDRL1, SEQ ID NO: 139 for CDRL2 and SEQ ID NO: 140 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 143 for CDRH1, SEQ ID NO: 144 forCDRH2 and SEQ ID NO: 145 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 148, 149 and 150,in particular a light variable region comprising SEQ ID NO: 148 forCDRL1, SEQ ID NO: 149 for CDRL2 and SEQ ID NO: 150 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 153 for CDRH1, SEQ ID NO: 154 forCDRH2 and SEQ ID NO: 155 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 158, 159 and 160,in particular a light variable region comprising SEQ ID NO: 158 forCDRL1, SEQ ID NO: 159 for CDRL2 and SEQ ID NO: 160 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 163 for CDRH1, SEQ ID NO: 164 forCDRH2 and SEQ ID NO: 165 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 168, 169 and 170,in particular a light variable region comprising SEQ ID NO: 168 forCDRL1, SEQ ID NO: 169 for CDRL2 and SEQ ID NO: 170 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 173 for CDRH1, SEQ ID NO: 174 forCDRH2 and SEQ ID NO: 175 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 178, 179 and 180,in particular a light variable region comprising SEQ ID NO: 178 forCDRL1, SEQ ID NO: 179 for CDRL2 and SEQ ID NO: 180 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 183 for CDRH1, SEQ ID NO: 184 forCDRH2 and SEQ ID NO: 185 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 188, 189 and 190,in particular a light variable region comprising SEQ ID NO: 188 forCDRL1, SEQ ID NO: 189 for CDRL2 and SEQ ID NO: 190 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 193 for CDRH1, SEQ ID NO: 194 forCDRH2 and SEQ ID NO: 195 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 198, 199 and 200,in particular a light variable region comprising SEQ ID NO: 198 forCDRL1, SEQ ID NO: 199 for CDRL2 and SEQ ID NO: 200 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 203 for CDRH1, SEQ ID NO: 204 forCDRH2 and SEQ ID NO: 205 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 208, 209 and 220,in particular a light variable region comprising SEQ ID NO: 208 forCDRL1, SEQ ID NO: 209 for CDRL2 and SEQ ID NO: 220 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 213 for CDRH1, SEQ ID NO: 214 forCDRH2 and SEQ ID NO: 215 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 218, 219 and 220,in particular a light variable region comprising SEQ ID NO: 218 forCDRL1, SEQ ID NO: 219 for CDRL2 and SEQ ID NO: 220 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 223 for CDRH1, SEQ ID NO: 224 forCDRH2 and SEQ ID NO: 225 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 228, 229 and 230,in particular a light variable region comprising SEQ ID NO: 228 forCDRL1, SEQ ID NO: 229 for CDRL2 and SEQ ID NO: 230 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 233 for CDRH1, SEQ ID NO: 234 forCDRH2 and SEQ ID NO: 235 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 238, 239 and 240,in particular a light variable region comprising SEQ ID NO: 238 forCDRL1, SEQ ID NO: 239 for CDRL2 and SEQ ID NO: 240 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 243 for CDRH1, SEQ ID NO: 244 forCDRH2 and SEQ ID NO: 245 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 248, 249 and 250,in particular a light variable region comprising SEQ ID NO: 248 forCDRL1, SEQ ID NO: 249 for CDRL2 and SEQ ID NO: 250 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 253 for CDRH1, SEQ ID NO: 254 forCDRH2 and SEQ ID NO: 255 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 258, 259 and 260,in particular a light variable region comprising SEQ ID NO: 258 forCDRL1, SEQ ID NO: 259 for CDRL2 and SEQ ID NO: 260 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 263 for CDRH1, SEQ ID NO: 264 forCDRH2 and SEQ ID NO: 265 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 268, 269 and 270,in particular a light variable region comprising SEQ ID NO: 268 forCDRL1, SEQ ID NO: 269 for CDRL2 and SEQ ID NO: 270 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 273 for CDRH1, SEQ ID NO: 274 forCDRH2 and SEQ ID NO: 275 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 278, 279 and 280,in particular a light variable region comprising SEQ ID NO: 278 forCDRL1, SEQ ID NO: 279 for CDRL2 and SEQ ID NO: 280 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 283 for CDRH1, SEQ ID NO: 284 forCDRH2 and SEQ ID NO: 285 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 288, 289 and 290,in particular a light variable region comprising SEQ ID NO: 288 forCDRL1, SEQ ID NO: 289 for CDRL2 and SEQ ID NO: 290 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 293 for CDRH1, SEQ ID NO: 294 forCDRH2 and SEQ ID NO: 295 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 298, 299 and 300,in particular a light variable region comprising SEQ ID NO: 298 forCDRL1, SEQ ID NO: 299 for CDRL2 and SEQ ID NO: 300 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 303 for CDRH1, SEQ ID NO: 304 forCDRH2 and SEQ ID NO: 305 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 308, 309 and 320,in particular a light variable region comprising SEQ ID NO: 308 forCDRL1, SEQ ID NO: 309 for CDRL2 and SEQ ID NO: 320 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 313 for CDRH1, SEQ ID NO: 314 forCDRH2 and SEQ ID NO: 315 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 318, 319 and 320,in particular a light variable region comprising SEQ ID NO: 318 forCDRL1, SEQ ID NO: 319 for CDRL2 and SEQ ID NO: 320 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 323 for CDRH1, SEQ ID NO: 324 forCDRH2 and SEQ ID NO: 325 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 328, 329 and 330,in particular a light variable region comprising SEQ ID NO: 328 forCDRL1, SEQ ID NO: 329 for CDRL2 and SEQ ID NO: 330 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 333 for CDRH1, SEQ ID NO: 334 forCDRH2 and SEQ ID NO: 335 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 338, 339 and 340,in particular a light variable region comprising SEQ ID NO: 338 forCDRL1, SEQ ID NO: 339 for CDRL2 and SEQ ID NO: 340 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 343 for CDRH1, SEQ ID NO: 344 forCDRH2 and SEQ ID NO: 345 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 348, 349 and 350,in particular a light variable region comprising SEQ ID NO: 348 forCDRL1, SEQ ID NO: 349 for CDRL2 and SEQ ID NO: 350 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 353 for CDRH1, SEQ ID NO: 354 forCDRH2 and SEQ ID NO: 355 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 358, 359 and 360,in particular a light variable region comprising SEQ ID NO: 358 forCDRL1, SEQ ID NO: 359 for CDRL2 and SEQ ID NO: 360 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 363 for CDRH1, SEQ ID NO: 364 forCDRH2 and SEQ ID NO: 365 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 368, 369 and 370,in particular a light variable region comprising SEQ ID NO: 368 forCDRL1, SEQ ID NO: 369 for CDRL2 and SEQ ID NO: 370 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 373 for CDRH1, SEQ ID NO: 374 forCDRH2 and SEQ ID NO: 375 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 378, 379 and 380,in particular a light variable region comprising SEQ ID NO: 378 forCDRL1, SEQ ID NO: 379 for CDRL2 and SEQ ID NO: 380 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 383 for CDRH1, SEQ ID NO: 384 forCDRH2 and SEQ ID NO: 385 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 388, 389 and 390,in particular a light variable region comprising SEQ ID NO: 388 forCDRL1, SEQ ID NO: 389 for CDRL2 and SEQ ID NO: 390 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 393 for CDRH1, SEQ ID NO: 394 forCDRH2 and SEQ ID NO: 395 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 398, 399 and 400,in particular a light variable region comprising SEQ ID NO: 398 forCDRL1, SEQ ID NO: 399 for CDRL2 and SEQ ID NO: 400 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 403 for CDRH1, SEQ ID NO: 404 forCDRH2 and SEQ ID NO: 405 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 408, 409 and 420,in particular a light variable region comprising SEQ ID NO: 408 forCDRL1, SEQ ID NO: 409 for CDRL2 and SEQ ID NO: 420 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 413 for CDRH1, SEQ ID NO: 414 forCDRH2 and SEQ ID NO: 415 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 418, 419 and 420,in particular a light variable region comprising SEQ ID NO: 418 forCDRL1, SEQ ID NO: 419 for CDRL2 and SEQ ID NO: 420 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 423 for CDRH1, SEQ ID NO: 424 forCDRH2 and SEQ ID NO: 425 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 428, 429 and 430,in particular a light variable region comprising SEQ ID NO: 428 forCDRL1, SEQ ID NO: 429 for CDRL2 and SEQ ID NO: 430 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 433 for CDRH1, SEQ ID NO: 434 forCDRH2 and SEQ ID NO: 435 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 438, 439 and 440,in particular a light variable region comprising SEQ ID NO: 438 forCDRL1, SEQ ID NO: 439 for CDRL2 and SEQ ID NO: 440 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 443 for CDRH1, SEQ ID NO: 444 forCDRH2 and SEQ ID NO: 445 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 448, 449 and 450,in particular a light variable region comprising SEQ ID NO: 448 forCDRL1, SEQ ID NO: 449 for CDRL2 and SEQ ID NO: 450 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 453 for CDRH1, SEQ ID NO: 454 forCDRH2 and SEQ ID NO: 455 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 458, 459 and 460,in particular a light variable region comprising SEQ ID NO: 458 forCDRL1, SEQ ID NO: 459 for CDRL2 and SEQ ID NO: 460 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 463 for CDRH1, SEQ ID NO: 464 forCDRH2 and SEQ ID NO: 465 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 468, 469 and 470,in particular a light variable region comprising SEQ ID NO: 468 forCDRL1, SEQ ID NO: 469 for CDRL2 and SEQ ID NO: 470 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 473 for CDRH1, SEQ ID NO: 474 forCDRH2 and SEQ ID NO: 475 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 478, 479 and 480,in particular a light variable region comprising SEQ ID NO: 478 forCDRL1, SEQ ID NO: 479 for CDRL2 and SEQ ID NO: 480 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 483 for CDRH1, SEQ ID NO: 484 forCDRH2 and SEQ ID NO: 485 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 488, 489 and 490,in particular a light variable region comprising SEQ ID NO: 488 forCDRL1, SEQ ID NO: 489 for CDRL2 and SEQ ID NO: 490 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 493 for CDRH1, SEQ ID NO: 494 forCDRH2 and SEQ ID NO: 495 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 498, 499 and 500,in particular a light variable region comprising SEQ ID NO: 498 forCDRL1, SEQ ID NO: 499 for CDRL2 and SEQ ID NO: 500 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 503 for CDRH1, SEQ ID NO: 504 forCDRH2 and SEQ ID NO: 505 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 508, 509 and 520,in particular a light variable region comprising SEQ ID NO: 508 forCDRL1, SEQ ID NO: 509 for CDRL2 and SEQ ID NO: 520 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 513 for CDRH1, SEQ ID NO: 514 forCDRH2 and SEQ ID NO: 515 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 518, 519 and 520,in particular a light variable region comprising SEQ ID NO: 518 forCDRL1, SEQ ID NO: 519 for CDRL2 and SEQ ID NO: 520 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 523 for CDRH1, SEQ ID NO: 524 forCDRH2 and SEQ ID NO: 525 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 528, 529 and 530,in particular a light variable region comprising SEQ ID NO: 528 forCDRL1, SEQ ID NO: 529 for CDRL2 and SEQ ID NO: 530 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 533 for CDRH1, SEQ ID NO: 534 forCDRH2 and SEQ ID NO: 535 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 538, 539 and 540,in particular a light variable region comprising SEQ ID NO: 538 forCDRL1, SEQ ID NO: 539 for CDRL2 and SEQ ID NO: 540 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 543 for CDRH1, SEQ ID NO: 544 forCDRH2 and SEQ ID NO: 545 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 548, 549 and 550,in particular a light variable region comprising SEQ ID NO: 548 forCDRL1, SEQ ID NO: 549 for CDRL2 and SEQ ID NO: 550 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 553 for CDRH1, SEQ ID NO: 554 forCDRH2 and SEQ ID NO: 555 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 558, 559 and 560,in particular a light variable region comprising SEQ ID NO: 558 forCDRL1, SEQ ID NO: 559 for CDRL2 and SEQ ID NO: 560 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 563 for CDRH1, SEQ ID NO: 564 forCDRH2 and SEQ ID NO: 565 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 568, 569 and 570,in particular a light variable region comprising SEQ ID NO: 568 forCDRL1, SEQ ID NO: 569 for CDRL2 and SEQ ID NO: 570 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 573 for CDRH1, SEQ ID NO: 574 forCDRH2 and SEQ ID NO: 575 for CDRH3 and at least one CDR in a light chainvariable region independently selected from SEQ ID NO: 578, 579 and 580,in particular a light variable region comprising SEQ ID NO: 578 forCDRL1, SEQ ID NO: 579 for CDRL2 and SEQ ID NO: 580 for CDRL3.

In one embodiment a binding molecule of the disclosure comprises a heavyvariable region comprising SEQ ID NO: 583 for CDRH1, SEQ ID NO: 584 forCDRH2 and SEQ ID NO: 585 for CDRH3 and at least one CDR in a light chainvariable region independently selected fro SEQ ID NO: 588, 589 and 590,in particular a light variable region comprising SEQ ID NO: 588 forCDRL1, SEQ ID NO: 589 for CDRL2 and SEQ ID NO: 590 for CDRL3.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 2, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 7 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 2 and a variable lightregion of SEQ ID NO: 7.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 12, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 17 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 12 and a variable lightregion of SEQ ID NO: 17.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 22, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 27 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 22 and a variable lightregion of SEQ ID NO: 27.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 32, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 37 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 32 and a variable lightregion of SEQ ID NO: 37.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 52, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 57, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 52 and a variable lightregion of SEQ ID NO: 57.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 62, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 67, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 62 and a variable lightregion of SEQ ID NO: 67.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 72, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 77, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 72 and a variable lightregion of SEQ ID NO: 77.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 82, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 87, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 82 and a variable lightregion of SEQ ID NO: 87.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 92, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 97, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 92 and a variable lightregion of SEQ ID NO: 97.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 102, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 107 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 102 and a variable lightregion of SEQ ID NO: 107.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 112, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 117 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 112 and a variable lightregion of SEQ ID NO: 117.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 122, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 127 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 122 and a variable lightregion of SEQ ID NO: 127.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 132, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 137 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 132 and a variable lightregion of SEQ ID NO: 137.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 152, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 157, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 152 and a variable lightregion of SEQ ID NO: 157.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 162, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 167, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 162 and a variable lightregion of SEQ ID NO: 167.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 172, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 177, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 172 and a variable lightregion of SEQ ID NO: 177.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 182, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 187, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 182 and a variable lightregion of SEQ ID NO: 187.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 192, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 197, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 192 and a variable lightregion of SEQ ID NO: 197.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 202, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 207, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 202 and a variable lightregion of SEQ ID NO: 207.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 212, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 217, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 212 and a variable lightregion of SEQ ID NO: 217.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 222, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 227, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 222 and a variable lightregion of SEQ ID NO: 227.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 232, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 237, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 232 and a variable lightregion of SEQ ID NO: 237.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 242, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 247, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 242 and a variable lightregion of SEQ ID NO: 247.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 252, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 257, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 252 and a variable lightregion of SEQ ID NO: 257.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 262, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 267, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 262 and a variable lightregion of SEQ ID NO: 267.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 272, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 277, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 272 and a variable lightregion of SEQ ID NO: 277.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 282, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 287, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 282 and a variable lightregion of SEQ ID NO: 287.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 292, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 297, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 292 and a variable lightregion of SEQ ID NO: 297.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 302, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 307 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 302 and a variable lightregion of SEQ ID NO: 307.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 312, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 317 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 312 and a variable lightregion of SEQ ID NO: 317.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 322, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 327 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 322 and a variable lightregion of SEQ ID NO: 327.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 332, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 337 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 332 and a variable lightregion of SEQ ID NO: 337.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 352, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 357, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 352 and a variable lightregion of SEQ ID NO: 357.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 362, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 367, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 362 and a variable lightregion of SEQ ID NO: 367.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 372, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 377, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 372 and a variable lightregion of SEQ ID NO: 377.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 382, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 387, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 382 and a variable lightregion of SEQ ID NO: 387.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 392, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 397, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 392 and a variable lightregion of SEQ ID NO: 397.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 402, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 407 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 402 and a variable lightregion of SEQ ID NO: 407.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 412, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 417 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 412 and a variable lightregion of SEQ ID NO: 417.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 422, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 427 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 422 and a variable lightregion of SEQ ID NO: 427.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 432, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 437 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 432 and a variable lightregion of SEQ ID NO: 437.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 452, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 457, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 452 and a variable lightregion of SEQ ID NO: 457.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 462, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 467, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 462 and a variable lightregion of SEQ ID NO: 467.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 472, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 477, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 472 and a variable lightregion of SEQ ID NO: 477.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 482, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 487, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 482 and a variable lightregion of SEQ ID NO: 487.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 492, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 497, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 492 and a variable lightregion of SEQ ID NO: 497.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 502, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 507 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 502 and a variable lightregion of SEQ ID NO: 507.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 512, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 517 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 512 and a variable lightregion of SEQ ID NO: 517.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 522, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 527 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 522 and a variable lightregion of SEQ ID NO: 527.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 532, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 537 for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 532 and a variable lightregion of SEQ ID NO: 537.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 552, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 557, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 552 and a variable lightregion of SEQ ID NO: 557.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 562, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 567, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 562 and a variable lightregion of SEQ ID NO: 567.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 572, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 577, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 572 and a variable lightregion of SEQ ID NO: 577.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 582, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 587, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 582 and a variable lightregion of SEQ ID NO: 587.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 592, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 594, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 592 and a variable lightregion of SEQ ID NO: 59.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 596, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 598, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 596 and a variable lightregion of SEQ ID NO: 598.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 600, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 602, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 600 and a variable lightregion of SEQ ID NO: 602.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 604, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 606, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 604 and a variable lightregion of SEQ ID NO: 606.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 608, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 610, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 608 and a variable lightregion of SEQ ID NO: 610.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 612, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 614, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 612 and a variable lightregion of SEQ ID NO: 614.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 616, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 618, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 616 and a variable lightregion of SEQ ID NO: 618.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 620, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 622, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 620 and a variable lightregion of SEQ ID NO: 622.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 624, for example as a variableregion in a heavy chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable region of SEQ ID NO: 626, for example as a variableregion in a light chain.

In one embodiment the binding molecule of the present disclosurecomprises a variable heavy region of SEQ ID NO: 624 and a variable lightregion of SEQ ID NO: 626.

In another embodiment, the present disclosure is directed to an isolatedantibody or antigen-binding fragment thereof which specifically binds toIL-33, comprising a VH and VL, wherein the VH has an amino acid sequenceat least 90%, for example 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100%identical to a VH as disclosed above e.g. SEQ ID NO: 182 or SEQ ID NO616

In another embodiment, the present disclosure is directed to an isolatedantibody or antigen-binding fragment thereof which specifically binds toIL-33, comprising a VH and VL, wherein a VH as disclosed above, e.g. inSEQ ID NO: 182 or SEQ ID NO 616, has a sequence with 1, 2, 3 or 4 aminoacids in the framework independently replaced with a different aminoacid or deleted.

In another embodiment, the present disclosure is directed to an isolatedantibody or antigen-binding fragment thereof which specifically binds toIL-33, comprising a VH and VL, wherein the VL has an amino acid sequenceat least 90%, for example 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100%identical to a VL as disclosed above, e.g. SEQ ID NO: 187 or SEQ ID NO618.

In another embodiment, the present disclosure is directed to an isolatedantibody or antigen-binding fragment thereof which specifically binds toIL-33, comprising a VH and VL, wherein a VL disclosed above, e.g. in SEQID NO: 187 or SEQ ID NO 618, has a sequence with 1, 2, 3 or 4 aminoacids in the framework independently replaced with a different aminoacid or deleted.

In another embodiment, the present disclosure is directed to an isolatedantibody or antigen-binding fragment thereof which specifically binds toIL-33, comprising a VH and VL, wherein the VH has an amino acid sequenceat least 90%, for example 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100%identical to a VH as disclosed above, e.g. SEQ ID NO: 182 or SEQ ID NO.616, and VL has an amino acid sequence at least 90%, for example 91, 92,93, 94, 95, 96, 97, 98, 99 or 100% identical to a VL as disclosed above,e.g. SEQ ID NO: 187 or or SEQ ID NO 618.

In another embodiment, the present disclosure is directed to an isolatedantibody or antigen-binding fragment thereof which specifically binds toIL-33, comprising a VH and VL, wherein a VH a VH as disclosed above e.g.SEQ ID NO: 182 or SEQ ID NO 616 has a sequence with 1, 2, 3 or 4 aminoacids in the framework are independently replaced with a different aminoacid or deleted a VL disclosed above, e.g. in SEQ ID NO: 187 or SEQ IDNO 618 has a sequence with 1, 2, 3 or 4 amino acids in the framework areindependently replaced with a different amino acid or deleted.

In one embodiment there is provided an antibody or binding fragmentwhich cross-blocks a binding molecule, for example an antibody orbinding fragment according to the present disclosure, in particularwherein said antibody or binding fragment binds the same epitope as amolecule disclosed herein.

In some embodiments, the binding molecule or the antibody orantigen-binding fragment thereof is a human antibody, a chimericantibody, or a humanized antibody. In some embodiments, the bindingmolecule or the antibody or antigen-binding fragment thereof is anaturally-occurring antibody, an scFv fragment, an Fab fragment, anF(ab′)2 fragment, a minibody, a diabody, a triabody, a tetrabody, or asingle chain antibody. In some embodiments, the binding molecule or theantibody or antigen-binding fragment thereof is a monoclonal antibody.

In another embodiment, the present disclosure is directed to apolynucleotide encoding the binding molecule or the antibody orantigen-binding fragment thereof of the disclosure, in particular asdescribed herein. In certain embodiments, the polynucleotide encodes theVH of an antibody or antigen-binding fragment thereof of the disclosure.In certain embodiments, the polynucleotide encodes a VL of an antibodyor antigen-binding fragment thereof of the disclosure.

In some embodiments, the disclosure is directed to a vector comprisingthe polynucleotide of the disclosure.

In some embodiments, the disclosure is directed to a compositioncomprising the polynucleotide or a vector of the disclosure.

In another embodiment, there is provided a host cell comprising thepolynucleotide or a vector of the disclosure.

In another embodiment, the disclosure herein is directed to a method ofproducing an anti-IL-33 antibody or antigen-binding fragment thereof,comprising culturing the host cell of the disclosure, and recoveringsaid antibody or antigen-binding fragment thereof. In some embodiments,the disclosure is directed to an anti-IL-33 antibody or antigen-bindingfragment thereof produced by a method of the disclosure.

In another embodiment, the disclosure is directed to a pharmaceuticalcomposition comprising a binding molecule or an antibody orantigen-binding fragment thereof of the disclosure and a carrier.

In another embodiment, the disclosure is directed to a method fortreating a subject with an inflammatory condition comprisingadministering to said subject an effective amount of an antibody orantigen-binding fragment according to the present disclosure thatinhibits IL-33 driven cytokine production.

In another embodiment, there is provided a method of treating a subjectwith an inflammatory condition comprising administering a bindingmolecule of the present disclosure or a composition comprising the same.

In one aspect there is provided a binding molecule of the presentdisclosure or a composition comprising the same for use in treatment,for example an inflammatory condition, in particular as describedherein.

In one embodiment there is provided the use of a binding molecule of thepresent disclosure or a composition comprising the same in themanufacture of a medication for the treatment or prevention of aninflammatory condition.

In one embodiment the inflammatory condition is selected from asthma,chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis, afibroproliferative disease (for example pulmonary fibrosis), pulmonaryeosinophilia, pleural malignancy, rheumatoid arthritis, collagenvascular disease, atherosclerotic vascular disease, uticaria,inflammatory bowel disease (for example Crohn's disease or Coeliacdisease), systemic lupus erythematosus, progressive systemic sclerosis,Wegner's granulomatosis, septic shock and Bechet's disease.

In some embodiments, the inflammatory condition is an allergic disorder,for example asthma, chronic rhinosinusitis, food allergy, eczma ordermatitis, in particular asthma, such as refractory asthma (alsoreferred to as severe asthma).

In some embodiments the inflammatory response or condition is in theairway of said subject.

In one embodiment the inflammatory response or condition is in smoothmuscle.

In another embodiment, the disclosure is directed to a method forpreventing an inflammatory response in a subject comprisingadministering to said subject an effective amount of an antibody orantigen-binding fragment thereof that binds IL-33 and does not blockIL-33 from binding to ST2 wherein ST2 signalling is reduced.

In another embodiment, the disclosure is directed to a method forpreventing an inflammatory response in a subject comprisingadministering to said subject an effective amount of an antibody orantigen-binding fragment according to the present disclosure thatinhibits IL-33 driven cytokine production.

In another embodiment, the disclosure is directed to a method forpreventing an inflammatory response in a subject comprisingadministering to said subject an effective amount of a binding moleculeor an antibody or antigen-binding fragment thereof of the disclosure.

In another embodiment, the disclosure is directed to a method ofidentifying a therapeutic antibody or antigen-binding fragment thereofcomprising selecting for an antibody or antigen-binding fragment thereofthat binds to IL-33, wherein said antibody or antigen-binding fragmentthereof does not block IL-33 from binding to ST2 and inhibits IL-33driven cytokine production.

In one embodiment there is provided immunizing a host with redIL-33, forexample stabilized in the reduced form, a or mutant thereof which has areduced capacity to form disulfide bonds, in particular a reducedcapacity to form a disulfide bond at one or more locations independentlyselected from Cys-208, Cys-227, Cys-232 and Cys-259. In one embodimentthe method further comprises the steps of screen antibodies from thehost, for example employing functional assays and isolating and/orreplicating at least the variable regions from at least one of the saidantibodies.

In embodiment there is provided use of redIL-33, for example stabilizedin the reduced form, a or mutant thereof which has a reduced capacity toform disulfide bonds, in particular a reduced capacity to form adisulfide bond at one or more locations independently selected fromCys-208, Cys-227, Cys-232 and Cys-259, to identify an inhibitor of theST2 signalling, in particular an antibody or binding fragment thereofspecific to redIL-33. In one embodiment the use employs interrogating alibrary, for example a phage display antibody library employing saidprotein or active fragment thereof.

In some embodiments, the antibody or antigen-binding fragment thereof ofthe disclosure does not inhibit NFκB signaling.

In one embodiment there is provided a method of identifying orgenerating a binding molecule of the present disclosure employingredIL-33 or a mutant of the present disclosure (referred to hereincollectively as a protein of the present disclosure). In one embodimentthe method comprises the step of interrogating a library with proteinsof the present disclosure to identify a binding molecule. In oneembodiment the method comprises immunizing a host with a protein of thepresent disclosure.

In one embodiment there is provided an epitope from IL-33, which isbound by a binding molecule, such as an antibody or binding fragmentthereof, as disclosed herein, in particular a catalytic epitope, i.e. anepitope the binding of which augments the rate of conversion of theIL-33 reduced form to the oxidized form.

In another embodiment, the disclosure is directed to a method fordetecting redIL-33 expression in a sample.

DETAILED DESCRIPTION OF THE INVENTION I. Definitions

“Isolated” as employed herein refers to a protein in a non-naturalenvironment in particular isolated from nature, for example the termdoes not include the protein in vivo, nor the protein in a sample takenfrom a human or animal body. Generally proteins will be in a carriersuch as a liquid or media, or may be formulated, frozen or freeze driedand all of these forms may be encompassed by “isolated” as appropriate.In one embodiment isolated does not refer to protein in a gel, forexample a gel employed in Western blot analysis or similar.

IL-33 protein as employed herein refers to interleukin 33, in particulara mammalian interleukin 33 protein, for example human protein depositedwith UniProt number O95760. However, given the present inventorsfindings, it clear that this entity is not a single species but insteadexists as reduced and oxidized form. Given the rapid oxidation of thereduced form in vivo, for example in the period 5 minutes to 40 minutes,and in vitro, generally prior art references to IL-33 are in factreferences to the oxidized form. Furthermore, commercial assays appearto quantify this oxidized form.

Oxidized IL-33, IL-33-DSB (disulfide bonded) and DSB IL-33 are employedinterchangeably herein.

Oxidized IL-33 as employed herein refers to a protein visible as adistinct band, for example by western blot analysis under non-reducingconditions, in particular with a mass 4 Da less than the correspondingreduced from. In particular, it refers to a protein with one or twodisulphide bonds between the cysteines independently selected fromcysteines 208. 227, 232 and 259. In one embodiment the oxidized IL-33shows no binding to ST2.

Reduced IL-33 and redIL-33 are employed interchangeably herein.

Reduced IL-33 as employed herein refers to form of the IL-33 that bindsto ST2 and triggers ST2 dependent signalling. In particular cysteines208, 227, 232 and 259 of the reduced form are not disulfide bonded. Anactive fragment of redIL-33 as employed herein refers to a fragment withcomparable activity to redIL-33, for example a similar extent ofST2-dependent signaling. In one embodiment an active fragment is 20, 3040, 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98 or 99% of the activity ofthe full length redIL-33.

ST-2 dependent signalling as employed herein refers to the IL-33/ST2system where IL-33 recognition by ST2 promotes dimerization withIL1-RAcP on the cell surface and within the cell recruitment of receptorcomplex components MyD88, TRAF6 and IRAK1-4 to intracellular TIR domain.Thus ST-2 dependent signalling may be interrupted by perturbing theinteraction of IL-33 with ST2 or alternatively by interrupting theinteraction with IL-1RAcP.

“Stabilized in a reduced form” as employed herein refers to amodification which encourages the proteins to adopt or stay in thereduced from or prevents the formation of oxidized IL-33.

In one embodiment the stabilization is by conjugation to a chemicalentity, for example biotinylation. redIL-33 has a tendency to bemono-biotinylated when exposed at neutral pH to the —SH reactive reagentbiotin-BMCC (Available from Thermo scientific). The analysis performedby the present inventors suggests that the biotinylation occurs atCys208. Biotinylation at this location appears to block and/or reduceoxidation of the protein. Whilst not wishing to be bound by theory thein silico analysis performed by the inventors suggests that Cys208 is apotential intiator of the activities required for conformational changesand oxidation of the protein.

In one embodiment the stabilization is biotinylation at Cys208.

In one embodiment Cys208 is replaced by an amino acid, such as serine.In one embodiment Cys227 is replaced by an amino acid, such as serine.In one embodiment Cys232 is replaced by an amino acid, such as serine.In one embodiment Cys259 is replaced by an amino acid, such as serine.In one embodiment Cys208 and 227 are independently replaced by an aminoacid, such as serine. In one embodiment Cys208 and 232 are independentlyreplaced by an amino acid, such as serine. In one embodiment Cys208 and259 are independently replaced by an amino acid, such as serine. In oneembodiment Cys208, 227 and 232 are independently replaced by an aminoacid, such as serine. In one embodiment Cys208, 227 and 259 areindependently replaced by an amino acid, such as serine. In oneembodiment Cys208, 232 and 259 are independently replaced by an aminoacid, such as serine. In one embodiment Cys227, 232 and 259 areindependently replaced by an amino acid, such as serine. In oneembodiment Cys208, 227, 232 and 259 are independently replaced by anamino acid, such as serine.

Mutation as employed herein refers to a change in the amino acidsequence or a change in a polynucleotide sequence such that the aminoacid encoded by the polynucleotide is different or some other tangible,for example functional difference is achieved. In particular the changemay comprise the deletion or substitution of an amino residue. Codonoptimization or redundancy in the genetic code is not a mutation in thecontext of the present application.

Mutation will generally be employed herein wherein there is an aminoacid or polynucleotide sequence change to the native or wild-typeprotein, whereas variant will be employed when discussing changes tonovel sequences.

Native as employed herein refers to an entity, such as an amino acidwhich is found in the wild-type sequence or is otherwise naturallyoccurring.

Conjugated as employed herein refers to a connection joining twoentities or fragments, for example a bond, such as a con-valent bond.

An entity as employed herein refers to an “element”, molecule, fragment,atom, component or the like.

A chemical entity is a molecule or fragment of the type prepared bysynthetic chemical processes.

In one embodiment the stabilization is by mutation of the IL-33 protein,for example a point mutation, in particular replacing one or morecysteine amino acids with an alternative amino acid, for example serine.An alternative amino acid as employed in this context refers to anon-cysteine amino acid. In one embodiment the amino acid is anon-naturally occurring amino acid. In one embodiment the amino acid isa naturally occurring amino acid. In one embodiment the amino acid isproteinaceous. In one embodiment the amino acid is serine, which isadvantageous because it is a conservative substitution and generallyactivity of the protein is retained, after this substitution.

Stabilization of the redIL-33 is important because it fixes the form ofIL-33 in the active conformation, which can in turn be used as a tool tofind binding molecules that attenuate the protein's activity. In oneembodiment the stabilized protein is employed to interrogate a libraryof molecules such as a phage library of antibodies or syntheticlibraries of antibodies. In one embodiment the stabilized protein isemployed to immunize a host, thereby providing for the first time anopportunity to generate antibodies specific to the reduced form.

“Attenuates the activity of” as employed herein refers to reducing therelevant activity or stopping the relevant activity. Generallyattenuation and inhibition are employed interchangeably herein unlessthe context indicates otherwise.

In one embodiment the attenuation is by binding redIL-33. In oneembodiment the binding molecule, such as an antibody or binding fragmentthereof is specific to redIL-33, that is to say it has a greateraffinity for redIL-33 than for oxidized form, for example 1, 2, 3, 4, 5greater affinity or more. This is referred to herein as a redIL-33specific antibody.

In one embodiment a redIL-33 specific antibody binds such that itsterically blocks binding to the receptor ST2.

In one embodiment a redIL-33 specific antibody binds such that itsterically blocks binding to the receptor IL-1RAcP.

In one embodiment a redIL-33 specific antibody binds such that itallosterically blocks binding to the receptor ST2.

In one embodiment a redIL-33 specific antibody binds such that itallosterically blocks binding to the receptor IL-1RAcP.

In one embodiment a redIL-33 specific antibody binds such that itallosterically blocks signaling through the receptor ST2, but may bindST2 and/or IL-1RAcP.

In one embodiment the antibody binds the oxidized form of IL-33 andcatalyses conversion of the reduced form to the oxidized form. Whilstnot wishing to be bound by theory it may be that by binding the oxidizedform, the equilibrium of the process is changed in favour of conversionto the oxidized form.

It is to be noted that the term “a” or “an” entity refers to one or moreof that entity; for example, “an anti-IL-33 antibody” is understood torepresent one or more anti-IL-33 antibodies. As such, the terms “a” (or“an”), “one or more,” and “at least one” can be used interchangeablyherein.

As used herein, the term “polypeptide” is intended to encompass asingular “polypeptide” as well as plural “polypeptides,” and refers to amolecule composed of monomers (amino acids) linearly linked by amidebonds (also known as peptide bonds). The term “polypeptide” refers toany chain or chains of two or more amino acids, and does not refer to aspecific length of the product. Thus, peptides, dipeptides, tripeptides,oligopeptides, “amino acid chain,” or any other term used to refer to achain or chains of two or more amino acids, are included within thedefinition of “polypeptide,” and the term “polypeptide” may be usedinstead of, or interchangeably with any of these terms. The term“polypeptide” is also intended to refer to the products ofpost-expression modifications of the polypeptide, including withoutlimitation glycosylation, acetylation, phosphorylation, amidation,derivatization by known protecting/blocking groups, proteolyticcleavage, or modification by non-naturally occurring amino acids. Apolypeptide may be derived from a natural biological source or producedby recombinant technology, but is not necessarily translated from adesignated nucleic acid sequence. It may be generated in any manner,including by chemical synthesis.

Polypeptides with a defined three-dimensional structure are referred toas folded, and polypeptides that do not possess a definedthree-dimensional structure, but rather can adopt a large number ofdifferent conformations, are referred to as unfolded. As used herein,the term glycoprotein refers to a protein coupled to at least onecarbohydrate moiety that is attached to the protein via anoxygen-containing or a nitrogen-containing side chain of an amino acidresidue, e.g., a serine residue or an asparagine residue.

An “isolated” polypeptide or a fragment, variant, or derivative thereofis intended to refer to a polypeptide that is not in its natural milieu.No particular level of purification is required. For example, anisolated polypeptide can be removed from its native or naturalenvironment. Recombinantly produced polypeptides and proteins expressedin host cells are considered isolated for purpose of the disclosure, asare native or recombinant polypeptides that have been separated,fractionated, or partially or substantially purified by any suitabletechnique.

Protein as employed herein refers to a polypeptide with secondary andtertiary structure.

Also included as polypeptides of the present disclosure are fragments,derivatives, analogs, or variants of the foregoing polypeptides, and anycombination thereof.

The terms “fragment,” “variant,” “derivative,” and “analog”, for examplewhen referring to a protein or polypeptide of the present disclosure,such as a anti-IL-33 antibodies or antibody polypeptides of the presentdisclosure include any polypeptides that retain at least some of theantigen-binding properties of the corresponding antibody or antibodypolypeptide of the disclosure. Fragments of polypeptides of the presentdisclosure include proteolytic fragments, as well as deletion fragments,in addition to specific antibody fragments discussed elsewhere herein.Variants of anti-IL-33 antibodies and antibody polypeptides of thepresent disclosure include fragments as described above, and alsopolypeptides with altered amino acid sequences due to amino acidsubstitutions, deletions, or insertions. Variants may occur naturally orbe non-naturally occurring. Non-naturally occurring variants may beproduced using art-known mutagenesis techniques.

Variant polypeptides may comprise conservative or non-conservative aminoacid substitutions, deletions, or additions. Variant polypeptides mayalso be referred to herein as “polypeptide analogs.” As used herein a“derivative” of, for example an anti-IL-33 antibody or antibodypolypeptide, refers to a subject polypeptide having one or more residueschemically derivatized by reaction of a functional side group. Alsoincluded as “derivatives” are those peptides that contain one or morenaturally occurring amino acid derivatives of the twenty standard aminoacids. For example, 4-hydroxyproline may be substituted for proline;5-hydroxylysine may be substituted for lysine; 3-methylhistidine may besubstituted for histidine; homoserine may be substituted for serine; andornithine may be substituted for lysine. Derivatives of anti-IL-33antibodies and antibody polypeptides of the present disclosure, mayinclude polypeptides that have been altered so as to exhibit additionalfeatures not found on the reference antibody or antibody polypeptide ofthe disclosure.

The term “polynucleotide” is intended to encompass a singular nucleicacid as well as plural nucleic acids, and refers to an isolated nucleicacid molecule or construct, e.g., messenger RNA (mRNA) or plasmid DNA(pDNA). A polynucleotide may comprise a conventional phosphodiester bondor a non-conventional bond (e.g., an amide bond, such as found inpeptide nucleic acids (PNA)). The term “nucleic acid” refers to any oneor more nucleic acid segments, e.g., DNA or RNA fragments, present in apolynucleotide. By “isolated” nucleic acid or polynucleotide is intendeda nucleic acid molecule, DNA or RNA, that has been removed from itsnative environment. For example, a recombinant polynucleotide encodingan anti-IL-33 binding molecule, e.g., an antibody or antigen bindingfragment thereof, contained in a vector is considered isolated for thepurposes of the present disclosure. Further examples of an isolatedpolynucleotide include recombinant polynucleotides maintained inheterologous host cells or purified (partially or substantially)polynucleotides in solution. Isolated RNA molecules include in vivo orin vitro RNA transcripts of polynucleotides of the present disclosure.Isolated polynucleotides or nucleic acids according to the presentdisclosure further include such molecules produced synthetically. Inaddition, a polynucleotide or a nucleic acid may be or may include aregulatory element such as a promoter, ribosome binding site, or atranscription terminator.

As used herein, a “coding region” is a portion of nucleic acid thatconsists of codons translated into amino acids. Although a “stop codon”(TAG, TGA, or TAA) is not translated into an amino acid, it may beconsidered to be part of a coding region, but any flanking sequences,for example promoters, ribosome binding sites, transcriptionalterminators, introns, and the like, are not part of a coding region. Twoor more coding regions of the present disclosure can be present in asingle polynucleotide construct, e.g., on a single vector, or inseparate polynucleotide constructs, e.g., on separate (different)vectors. Furthermore, any vector may contain a single coding region, ormay comprise two or more coding regions, e.g., a single vector mayseparately encode an immunoglobulin heavy chain variable region and animmunoglobulin light chain variable region. In addition, a vector,polynucleotide, or nucleic acid of the disclosure may encodeheterologous coding regions, either fused or unfused to a nucleic acidencoding an anti-IL-33 antibody or fragment, variant, or derivativethereof. Heterologous coding regions include without limitationspecialized elements or motifs, such as a secretory signal peptide or aheterologous functional domain.

In certain embodiments, the polynucleotide or nucleic acid is DNA. Inthe case of DNA, a polynucleotide comprising a nucleic acid that encodesa polypeptide normally may include a promoter and/or other transcriptionor translation control elements operably associated with one or morecoding regions. An operable association is when a coding region for agene product, e.g., a polypeptide, is associated with one or moreregulatory sequences in such a way as to place expression of the geneproduct under the influence or control of the regulatory sequence(s).Two DNA fragments (such as a polypeptide coding region and a promoterassociated therewith) are “operably associated” if induction of promoterfunction results in the transcription of mRNA encoding the desired geneproduct and if the nature of the linkage between the two DNA fragmentsdoes not interfere with the ability of the expression regulatorysequences to direct the expression of the gene product or interfere withthe ability of the DNA template to be transcribed. Thus, a promoterregion would be operably associated with a nucleic acid encoding apolypeptide if the promoter was capable of effecting transcription ofthat nucleic acid. The promoter may be a cell-specific promoter thatdirects substantial transcription of the DNA only in predeterminedcells. Other transcription control elements, besides a promoter, forexample enhancers, operators, repressors, and transcription terminationsignals, can be operably associated with the polynucleotide to directcell-specific transcription. Suitable promoters and other transcriptioncontrol regions are disclosed herein.

A variety of transcription control regions are known to those skilled inthe art. These include, without limitation, transcription controlregions that function in vertebrate cells, such as, but not limited to,promoter and enhancer segments from cytomegaloviruses (the immediateearly promoter, in conjunction with intron-A), simian virus 40 (theearly promoter), and retroviruses (such as Rous sarcoma virus). Othertranscription control regions include those derived from vertebrategenes such as actin, heat shock protein, bovine growth hormone andrabbit β-globin, as well as other sequences capable of controlling geneexpression in eukaryotic cells. Additional suitable transcriptioncontrol regions include tissue-specific promoters and enhancers as wellas lymphokine-inducible promoters (e.g., promoters inducible byinterferons or interleukins).

Similarly, a variety of translation control elements are known to thoseof ordinary skill in the art. These include, but are not limited to,ribosome binding sites, translation initiation and termination codons,and elements derived from picornaviruses (particularly an internalribosome entry site, or IRES, also referred to as a CITE sequence).

In other embodiments, a polynucleotide of the present disclosure is RNA,for example, in the form of messenger RNA (mRNA).

Polynucleotide and nucleic acid coding regions of the present disclosuremay be associated with additional coding regions that encode secretoryor signal peptides, which direct the secretion of a polypeptide encodedby a polynucleotide of the present disclosure. According to the signalhypothesis, proteins secreted by mammalian cells have a signal peptideor secretory leader sequence that is cleaved from the mature proteinonce export of the growing protein chain across the rough endoplasmicreticulum has been initiated. Those of ordinary skill in the art areaware that polypeptides secreted by vertebrate cells generally have asignal peptide fused to the N-terminus of the polypeptide, which iscleaved from the complete or “full length” polypeptide to produce asecreted or “mature” form of the polypeptide. In certain embodiments,the native signal peptide, e.g., an immunoglobulin heavy chain or lightchain signal peptide is used, or a functional derivative of thatsequence that retains the ability to direct the secretion of thepolypeptide that is operably associated with it. Alternatively, aheterologous mammalian signal peptide, or a functional derivativethereof, may be used. For example, the wild-type leader sequence may besubstituted with the leader sequence of human tissue plasminogenactivator (TPA) or mouse β-glucuronidase.

A “binding molecule” or “antigen binding molecule” of the presentdisclosure refers in its broadest sense to a molecule that specificallybinds an antigenic determinant. In one embodiment, the binding moleculespecifically binds to IL-33, in particular redIL-33 or IL-33-DSB. Inanother embodiment, a binding molecule of the disclosure is an antibodyor an antigen-binding fragment thereof.

In another embodiment, a binding molecule of the disclosure comprises atleast one heavy or light chain CDR of a reference antibody molecule. Inanother embodiment, a binding molecule of the disclosure comprises atleast six CDRs from one or more reference antibody molecules.

The present disclosure is directed to certain anti-IL-33 antibodies, orantigen-binding fragments, variants, or derivatives thereof.

Antibody as employed herein refers to an immunoglobulin molecule asdiscussed below in more detail, in particular a full-length antibody ora molecule comprising a full-length antibody, for example a DVD-Ig moleand the like.

A binding fragment is an epitope/antigen binding fragment of an antibodyfragment, for example comprising a binding, in particular comprising 6CDRs, such as 3 CDRs in heavy variable region and 3 CDRs in lightvariable region.

Unless specifically referring to full-sized antibodies such as naturallyoccurring antibodies, the term “anti-IL-33 antibodies” encompassesfull-sized antibodies as well as antigen-binding fragments, variants,analogs, or derivatives of such antibodies, e.g., naturally occurringantibody or immunoglobulin molecules or engineered antibody molecules orfragments that bind antigen in a manner similar to antibody molecules.

As used herein, “human” or “fully human” antibodies include antibodieshaving the amino acid sequence of a human immunoglobulin and includeantibodies isolated from human immunoglobulin libraries or from animalstransgenic for one or more human immunoglobulins and that do not expressendogenous immunoglobulins. Completely human antibodies are particularlydesirable for therapeutic treatment of human patients. Human antibodiescan be made by a variety of methods known in the art including phagedisplay methods using antibody libraries derived from humanimmunoglobulin sequences as described in Vaughan et al., Nat.Biotech./4:309-314 (1996), Sheets et al., Proc. Nat'l. Acad. Sci.95:6157-6162 (1998), Hoogenboom and Winter, J. Mol. Biol. 227:381(1992), and Marks et al., J. Mol. Biol. 222:581 (1991)). Techniques forthe generation and use of antibody phage libraries are also describedin, e.g., U.S. Pat. Nos. 5,969,108, 6,172,197, 5,885,793, 6,521,404;6,544,731; 6,555,313; 6,582,915; 6,593,081; 6,300,064; 6,653,068;6,706,484; and 7,264,963; and Rothe et al., J. Mol. Biol., 376:1382(2008) (each of which is incorporated by reference in its entirety). Inaddition, as known in the art, human antibodies can be produced usingtransgenic mice which are incapable of expressing functional endogenousimmunoglobulins, but which can express human immunoglobulin genes. Foran overview of this technology, see Lonberg and Huszar, Int. Rev.Immunol. 13:65-93 (1995). “Human” or “fully human” antibodies alsoinclude antibodies comprising at least the variable domain of a heavychain, or at least the variable domains of a heavy chain and a lightchain, where the variable domain(s) have the amino acid sequence ofhuman immunoglobulin variable domain(s).

“Human” or “fully human” antibodies also include “human” or “fullyhuman” antibodies, as described above, that comprise, consistessentially of, or consist of, variants (including derivatives) ofantibody molecules (e.g., the VH regions and/or VL regions) describedherein, which antibodies or fragments thereof immunospecifically bind toa IL-33 polypeptide or fragment or variant thereof according to thepresent disclosure.

Standard techniques known to those of skill in the art can be used tointroduce mutations in the nucleotide sequence encoding a humananti-IL-33 antibody, including, but not limited to, site-directedmutagenesis and PCR-mediated mutagenesis which result in amino acidsubstitutions. In one embodiment the variants (including derivatives)encode less than 50 amino acid substitutions, less than 40 amino acidsubstitutions, less than 30 amino acid substitutions, less than 25 aminoacid substitutions, less than 20 amino acid substitutions, less than 15amino acid substitutions, less than 10 amino acid substitutions, lessthan 5 amino acid substitutions, less than 4 amino acid substitutions,less than 3 amino acid substitutions, or less than 2 amino acidsubstitutions relative to the reference VH region, CDRH1, CDRH2, CDRH3,VL region, CDRL1, CDRL2, or CDRL3.

In certain embodiments, the amino acid substitutions are conservativeamino acid substitution, discussed further below. Alternatively,mutations can be introduced randomly along all or part of the codingsequence, such as by saturation mutagenesis, and the resultant mutantscan be screened for biological activity to identify mutants that retainactivity (e.g., the ability to bind an IL-33 polypeptide, e.g., human,primate, murine, or any combination of human, primate and murine IL-33).Such variants (or derivatives thereof) of “human” or “fully human”antibodies can also be referred to as human or fully human antibodiesthat are “optimized” or “optimized for antigen binding” and include, butare not limited to, antibodies that have improved affinity to antigen,antibodies with altered antigen specificity, or antibodies with reducedpotential structural liabilities.

Basic immunoglobulin structures in vertebrate systems are relativelywell understood. See, e.g., Harlow et al. (1988) Antibodies: ALaboratory Manual (2nd ed.; Cold Spring Harbor Laboratory Press).

As will be discussed in more detail below, the term “immunoglobulin”comprises various broad classes of polypeptides that can bedistinguished biochemically. Those skilled in the art will appreciatethat heavy chains are classified as gamma, mu, alpha, delta, or epsilon,(γ, μ, α, δ, ε) with some subclasses among them (e.g., γ1-γ4). It is thenature of this chain that determines the “class” of the antibody as IgG,IgM, IgA IgG, or IgE, respectively. The immunoglobulin subclasses(isotypes) e.g., IgG1, IgG2, IgG3, IgG4, IgA1, etc. are wellcharacterized and are known to confer functional specialization.Modified versions of each of these classes and isotypes are readilydiscernable to the skilled artisan in view of the instant disclosureand, accordingly, are within the scope of the instant disclosure. Whilethe following discussion will generally be directed to the IgG class ofimmunoglobulin molecules, all immunoglobulin classes are clearly withinthe scope of the present disclosure. With regard to IgG, a standardimmunoglobulin molecule comprises two identical light chain polypeptidesof molecular weight approximately 23,000 Daltons, and two identicalheavy chain polypeptides of molecular weight 53,000-70,000. The fourchains are typically joined by disulfide bonds in a “Y” configurationwherein the light chains bracket the heavy chains starting at the mouthof the “Y” and continuing through the variable region.

Light chains are classified as either kappa or lambda (κ, λ). Each heavychain class may be bound with either a kappa or lambda light chain. Ingeneral, the light and heavy chains are covalently bonded to each other,and the “tail” portions of the two heavy chains are bonded to each otherby covalent disulfide linkages or non-covalent linkages when theimmunoglobulins are generated either by hybridomas, B cells orgenetically engineered host cells. In the heavy chain, the amino acidsequences run from an N-terminus at the forked ends of the Yconfiguration to the C-terminus at the bottom of each chain.

The base of the antibody “Y” is called the Fc (Fragment, crystallizable)region, and is composed of two heavy chains that contribute two or threeconstant domains depending on the class of the antibody. Thus, the Fcregion binds to a specific class of Fc receptors, and other immunemolecules, such as complement proteins. Both the light and heavy chainsare divided into regions of structural and functional homology. Theterms “constant” and “variable” are used functionally. In this regard,it will be appreciated that the variable domains of both the light (VX,or VK) and heavy (VH) chain portions determine antigen recognition andspecificity. Conversely, the constant domains of the light chain (CL)and the heavy chain (CH1, CH2 or CH3) confer important biologicalproperties such as secretion, transplacental mobility, Fc receptorbinding, complement binding, and the like. By convention the numberingof the constant region domains increases as they become more distal fromthe antigen binding site or amino-terminus of the antibody. TheN-terminal portion is a variable region and at the C-terminal portion isa constant region; the CH3 and CL domains actually comprise thecarboxy-terminus of the heavy and light chain, respectively.

As indicated above, the variable region allows the antibody toselectively recognize and specifically bind epitopes on antigens. Thatis, the VL domain and VH domain, or subset of the complementaritydetermining regions (CDRs) within these variable domains, of an antibodycombine to form the variable region that defines a three dimensionalantigen binding site. This quaternary antibody structure forms theantigen binding site present at the end of each arm of the Y. Morespecifically, the antigen binding site is defined by three CDRs on eachof the VH and VL chains. In some instances, e.g., certain immunoglobulinmolecules derived from camelid species or engineered based on camelidimmunoglobulins, a complete immunoglobulin molecule may consist of heavychains only, with no light chains. See, e.g., Hamers-Casterman et al.,Nature 363:446-448 (1993).

In naturally occurring antibodies, the six “complementarity determiningregions” or “CDRs” present in each antigen binding domain are short,non-contiguous sequences of amino acids that are specifically positionedto form the antigen binding domain as the antibody assumes its threedimensional configuration in an aqueous environment. The remainder ofthe amino acids in the antigen binding domains, referred to as“framework” regions, show less inter-molecular variability. Theframework regions largely adopt a β-sheet conformation and the CDRs formloops that connect, and in some cases form part of, the β-sheetstructure. Thus, framework regions act to form a scaffold that providesfor positioning the CDRs in correct orientation by inter-chain,non-covalent interactions. The antigen binding domain formed by thepositioned CDRs defines a surface complementary to the epitope on theimmunoreactive antigen. This complementary surface promotes thenon-covalent binding of the antibody to its cognate epitope. The aminoacids comprising the CDRs and the framework regions, respectively, canbe readily identified for any given heavy or light chain variable domainby one of ordinary skill in the art, since they have been preciselydefined (see below).

In the case where there are two or more definitions of a term that isused and/or accepted within the art, the definition of the term as usedherein is intended to include all such meanings unless explicitly statedto the contrary. A specific example is the use of the term“complementarity determining region” (“CDR”) to describe thenon-contiguous antigen combining sites found within the variable regionof both heavy and light chain polypeptides. This particular region hasbeen described by Kabat et al. (1983) U.S. Dept. of Health and HumanServices, “Sequences of Proteins of Immunological Interest” and byChothia and Lesk, J. Mol. Biol. 196:901-917 (1987), which areincorporated herein by reference, where the definitions includeoverlapping or subsets of amino acid residues when compared against eachother. Nevertheless, application of either definition to refer to a CDRof an antibody or variants thereof is intended to be within the scope ofthe term as defined and used herein. The appropriate amino acid residuesthat encompass the CDRs as defined by each of the above cited referencesare set forth below in Table 1 as a comparison. The exact residuenumbers that encompass a particular CDR will vary depending on thesequence and size of the CDR. Those skilled in the art can routinelydetermine which residues comprise a particular CDR given the variableregion amino acid sequence of the antibody.

TABLE 1 CDR Definitions¹ Kabat Chothia VH CDR1 31-35 26-32 VH CDR2 50-6552-58 VH CDR3  95-102  95-102 VL CDR1 24-34 26-32 VL CDR2 50-56 50-52 VLCDR3 89-97 91-96 ¹Numbering of all CDR definitions in Table 1 isaccording to the numbering conventions set forth by Kabat et al. (seebelow).

Kabat et al. also defined a numbering system for variable domainsequences that is applicable to any antibody. One of ordinary skill inthe art can unambiguously assign this system of “Kabat numbering” to anyvariable domain sequence, without reliance on any experimental databeyond the sequence itself. As used herein, “Kabat numbering” refers tothe numbering system set forth by Kabat et al. (1983) U.S. Dept. ofHealth and Human Services, “Sequence of Proteins of ImmunologicalInterest.” Unless otherwise specified, references to the numbering ofspecific amino acid residue positions in an anti-IL-33 antibody orantigen-binding fragment, variant, or derivative thereof of the presentdisclosure are according to the Kabat numbering system.

Antibodies or antigen-binding fragments, variants, or derivativesthereof of the disclosure include, but are not limited to, polyclonal,monoclonal, multispecific, mouse, human, humanized, primatized, orchimeric antibodies, single-chain antibodies, epitope-binding fragments,e.g., Fab, Fab′ and F(ab′)₂, Fd, Fvs, single-chain Fvs (scFv),disulfide-linked Fvs (sdFv), fragments comprising either a VL or VHdomain, fragments produced by a Fab expression library, andanti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodiesto anti-IL-33 antibodies disclosed herein). ScFv molecules are known inthe art and are described, e.g., in U.S. Pat. No. 5,892,019.Immunoglobulin or antibody molecules of the disclosure can be of anytype (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG 1, IgG2,IgG3, IgG4, IgA1, and IgA2, etc.), or subclass of immunoglobulinmolecule.

As used herein, the term “heavy chain portion” includes amino acidsequences derived from an immunoglobulin heavy chain. A polypeptidecomprising a heavy chain portion comprises at least one of: a CH1domain, a hinge (e.g., upper, middle, and/or lower hinge region) domain,a CH2 domain, a CH3 domain, or a variant or fragment thereof. Forexample, a binding polypeptide for use in the disclosure may comprise apolypeptide chain comprising a CH1 domain; a polypeptide chaincomprising a CH1 domain, at least a portion of a hinge domain, and a CH2domain; a polypeptide chain comprising a CH1 domain and a CH3 domain; apolypeptide chain comprising a CH1 domain, at least a portion of a hingedomain, and a CH3 domain, or a polypeptide chain comprising a CH1domain, at least a portion of a hinge domain, a CH2 domain, and a CH3domain. In another embodiment, a polypeptide of the disclosure comprisesa polypeptide chain comprising a CH3 domain. Further, a bindingpolypeptide for use in the disclosure may lack at least a portion of aCH2 domain (e.g., all or part of a CH2 domain). As set forth above, itwill be understood by one of ordinary skill in the art that thesedomains (e.g., the heavy chain portions) may be modified such that theyvary in amino acid sequence from the naturally occurring immunoglobulinmolecule.

In certain anti-IL-33 antibodies, or antigen-binding fragments,variants, or derivatives thereof disclosed herein, the heavy chainportions of one polypeptide chain of a multimer are identical to thoseon a second polypeptide chain of the multimer. Alternatively, heavychain portion-containing monomers of the disclosure are not identical.For example, each monomer may comprise a different target binding site,forming, for example, a bispecific antibody.

The heavy chain portions of a binding molecule for use in the diagnosticand treatment methods disclosed herein may be derived from differentimmunoglobulin molecules. For example, a heavy chain portion of apolypeptide may comprise a C_(H1) domain derived from an IgG1 moleculeand a hinge region derived from an IgG3 molecule. In another example, aheavy chain portion can comprise a hinge region derived, in part, froman IgG1 molecule and, in part, from an IgG3 molecule. In anotherexample, a heavy chain portion can comprise a chimeric hinge derived, inpart, from an IgG1 molecule and, in part, from an IgG4 molecule.

As used herein, the term “light chain portion” includes amino acidsequences derived from an immunoglobulin light chain, e.g., a kappa orlambda light chain. Preferably, the light chain portion comprises atleast one of a VL or CL domain.

Anti-IL-33 antibodies, or antigen-binding fragments, variants, orderivatives thereof disclosed herein may be described or specified interms of the epitope(s) or portion(s) of an antigen, e.g., a targetpolypeptide disclosed herein (e.g., full length or mature IL-33) thatthey recognize or specifically bind. The portion of a target polypeptidethat specifically interacts with the antigen binding domain of anantibody is an “epitope,” or an “antigenic determinant.” A targetpolypeptide may comprise a single epitope, but typically comprises atleast two epitopes, and can include any number of epitopes, depending onthe size, conformation, and type of antigen. Furthermore, it should benoted that an “epitope” on a target polypeptide may be or may includenon-polypeptide elements, e.g., an epitope may include a carbohydrateside chain.

The minimum size of a peptide or polypeptide epitope for an antibody isthought to be about four to five amino acids. Peptide or polypeptideepitopes preferably contain at least seven, more preferably at leastnine and most preferably between at least about 15 to about 30 aminoacids. Since a CDR can recognize an antigenic peptide or polypeptide inits tertiary form, the amino acids comprising an epitope need not becontiguous, and in some cases, may not even be on the same peptidechain. A peptide or polypeptide epitope recognized by anti-IL-33antibodies of the present disclosure may contain a sequence of at least4, at least 5, at least 6, at least 7, more preferably at least 8, atleast 9, at least 10, at least 15, at least 20, at least 25, or betweenabout 15 to about 30 contiguous or non-contiguous amino acids of IL-33.

By “specifically binds,” it is generally meant that an antibody binds toan epitope via its antigen binding domain, and that the binding entailssome complementarity between the antigen binding domain and the epitope.According to this definition, an antibody is said to “specifically bind”to an epitope when it binds to that epitope, via its antigen bindingdomain more readily than it would bind to a random, unrelated epitope.The term “specificity” is used herein to qualify the relative affinityby which a certain antibody binds to a certain epitope. For example,antibody “A” may be deemed to have a higher specificity for a givenepitope than antibody “B,” or antibody “A” may be said to bind toepitope “C” with a higher specificity than it has for related epitope“D.”

In one embodiment an antibody or binding fragment thereof preferentiallybinds IL-33. By “preferentially binds,” it is meant that the antibodyspecifically binds to an epitope more readily than it would bind to arelated, similar, homologous, or analogous epitope. Thus, an antibodythat “preferentially binds” to a given epitope would more likely bind tothat epitope than to a related epitope, even though such an antibody maycross-react with the related epitope.

By way of non-limiting example, an antibody may be considered to bind afirst epitope preferentially if it binds said first epitope with adissociation constant (K_(D)) that is less than the antibody's K_(D) forthe second epitope. In another non-limiting example, an antibody may beconsidered to bind a first antigen preferentially if it binds the firstepitope with an affinity that is at least one order of magnitude lessthan the antibody's K_(D) for the second epitope. In anothernon-limiting example, an antibody may be considered to bind a firstepitope preferentially if it binds the first epitope with an affinitythat is at least two orders of magnitude less than the antibody's K_(D)for the second epitope.

In another non-limiting example, an antibody may be considered to bind afirst epitope preferentially if it binds the first epitope with an offrate (k(off)) that is less than the antibody's k(off) for the secondepitope. In another non-limiting example, an antibody may be consideredto bind a first epitope preferentially if it binds the first epitopewith an affinity that is at least one order of magnitude less than theantibody's k(off) for the second epitope. In another non-limitingexample, an antibody may be considered to bind a first epitopepreferentially if it binds the first epitope with an affinity that is atleast two orders of magnitude less than the antibody's k(off) for thesecond epitope.

In one embodiment an antibody or antigen-binding fragment, variant, orderivative thereof according to the present disclosure may be said tobind a target polypeptide disclosed herein (e.g., IL-33, e.g., human,primate, murine, or any combination of human, primate and murine IL-33)or a fragment or variant thereof with an off rate (k(off)) of less thanor equal to 5×10⁻¹ sec⁻¹, 10⁻¹ sec⁻¹, 5×10⁻² sec⁻¹, 10⁻² sec⁻¹, 5×10⁻³sec⁻¹ or 10⁻³ sec⁻¹. For example, an antibody of the disclosure may besaid to bind a target polypeptide disclosed herein (e.g., IL-33, e.g.,human, primate, murine, or any combination of human, primate and murineIL-33) or a fragment or variant thereof with an off rate (k(off)) lessthan or equal to 5×10⁻⁴ sec⁻¹, 10⁻⁴ sec⁻¹, 5×10⁻⁵ sec⁻¹, or 10⁻⁵ sec⁻¹,5×10⁻⁶ sec⁻¹, 10⁻⁶ sec, 5×10⁻⁷ sec⁻¹ or 10⁻⁷ sec⁻¹.

In one embodiment an antibody or antigen-binding fragment, variant, orderivative thereof disclosed herein may be said to bind a targetpolypeptide disclosed herein (e.g., IL-33, e.g., human, primate, murine,or any combination of human, primate and murine IL-33) or a fragment orvariant thereof with an on rate (k(on)) of greater than or equal to 10³M⁻¹ sec⁻¹, 5×10³ M⁻¹ sec⁻¹, 10⁴ M⁻¹ sec⁻¹ or 5×10⁴ M⁻¹ sec⁻¹. Forexample, an antibody of the disclosure may be said to bind a targetpolypeptide disclosed herein (e.g., IL-33, e.g., human, primate, murine,or any combination of human, primate and murine IL-33) or a fragment orvariant thereof with an on rate (k(on)) greater than or equal to 10⁵ M⁻¹sec⁻¹, 5×10⁵ M⁻¹ sec⁻¹, 10⁶ M⁻¹ sec⁻¹, or 5×10⁶ M⁻¹ sec⁻¹ or 10⁷ M⁻¹sec⁻¹.

Cross-reactivity as employed herein intended to refer to where bindingmolecules, for example antibodies or binding fragments thereof bind thesame epitope or overlapping epitopes. Competively inhibiting binding asemployed herein is a form of cross-reactivity.

An antibody is said to competitively inhibit binding of a referenceantibody to a given epitope if it preferentially binds to that epitopeto the extent that it blocks, to some degree, binding of the referenceantibody to the epitope. Competitive inhibition may be determined by anymethod known in the art, for example, solid phase assays such ascompetition ELISA assays, Dissociation-Enhanced Lanthanide FluorescentImmunoassays (DELFIA®, Perkin Elmer), and radioligand binding assays. Anantibody may be said to competitively inhibit binding of the referenceantibody to a given epitope by at least 90%, at least 80%, at least 70%,at least 60%, or at least 50%.

As used herein, the term “affinity” refers to a measure of the strengthof the binding of an individual epitope with the CDR of animmunoglobulin molecule. See, e.g., Harlow et al. (1988) Antibodies: ALaboratory Manual (Cold Spring Harbor Laboratory Press, 2nd ed.) pages27-28. As used herein, the term “avidity” refers to the overallstability of the complex between a population of immunoglobulins and anantigen, that is, the functional combining strength of an immunoglobulinmixture with the antigen. See, e.g., Harlow at pages 29-34. Avidity isrelated to both the affinity of individual immunoglobulin molecules inthe population with specific epitopes, and also the valencies of theimmunoglobulins and the antigen. For example, the interaction between abivalent monoclonal antibody and an antigen with a highly repeatingepitope structure, such as a polymer, would be one of high avidity.

Anti-IL-33 antibodies or antigen-binding fragments, variants, orderivatives thereof of the disclosure may also be described or specifiedin terms of their cross-reactivity. As used herein, the term“cross-reactivity” refers to the ability of an antibody, specific forone antigen, to react with a second antigen; a measure of relatednessbetween two different antigenic substances. Thus, an antibody is crossreactive if it binds to an epitope other than the one that induced itsformation. The cross reactive epitope generally contains many of thesame complementary structural features as the inducing epitope, and insome cases, may actually fit better than the original.

For example, certain antibodies have some degree of cross-reactivity, inthat they bind related, but non-identical epitopes, e.g., epitopes withat least 95%, at least 90%, at least 85%, at least 80%, at least 75%, atleast 70%, at least 65%, at least 60%, at least 55%, and at least 50%identity (as calculated using methods known in the art and describedherein) to a reference epitope. An antibody may be said to have littleor no cross-reactivity if it does not bind epitopes with less than 95%,less than 90%, less than 85%, less than 80%, less than 75%, less than70%, less than 65%, less than 60%, less than 55%, and less than 50%identity (as calculated using methods known in the art and describedherein) to a reference epitope. An antibody may be deemed “highlyspecific” for a certain epitope, if it does not bind any other analog,ortholog, or homolog of that epitope.

Anti-IL-33 binding molecules, e.g., antibodies or antigen-bindingfragments, variants or derivatives thereof of the disclosure may also bedescribed or specified in terms of their binding affinity to apolypeptide of the disclosure, e.g., IL-33, e.g., human, primate,murine, or any combination of human, primate and murine IL-33. Preferredbinding affinities include those with a dissociation constant or Kd lessthan 5×10⁻² M, 10⁻² M, 5×10⁻³ M, 10⁻³ M, 5×10⁻⁴ M, 10⁻⁴ M, 5×10⁻⁵ M,10⁻⁵ M, 5×10⁻⁶ M, 10⁻⁶ M, 5×10⁻⁷ M, 10⁻⁷ M, 5×10⁻⁸ M, 10⁻⁸ M, 5×10⁻⁹ M,10⁻⁹ M, 5×10⁻¹⁰ M, 10 ⁻¹⁰ M, 5×10⁻¹¹ M, 5×10⁻¹² M, 10⁻¹² M, 5×10⁻¹³ M,10⁻¹³ M, 5×10⁻¹⁴ M, 10⁻¹⁴ M, 5×10⁻¹⁵ M, or 10⁻¹⁵ M.

Anti-IL-33 antibodies or antigen-binding fragments, variants orderivatives thereof of the disclosure may be “multispecific,” e.g.,bispecific, trispecific, or of greater multispecificity, meaning that itrecognizes and binds to two or more different epitopes present on one ormore different antigens (e.g., proteins) at the same time. Thus, whetheran anti-IL-33 antibody is “monospecific” or “multispecific,” e.g.,“bispecific,” refers to the number of different epitopes with which abinding polypeptide reacts. Multispecific antibodies may be specific fordifferent epitopes of a target polypeptide described herein or may bespecific for a target polypeptide as well as for a heterologous epitope,such as a heterologous polypeptide or solid support material.

As used herein the term “valency” refers to the number of potentialbinding domains, e.g., antigen binding domains present in a bindingpolypeptide or IL-33 binding molecule, e.g., an antibody or antigenbinding fragment thereof. Each binding domain specifically binds oneepitope. When a binding polypeptide or IL-33 binding molecule comprisesmore than one binding domain, each binding domain may specifically bindthe same epitope, for an antibody with two binding domains, termed“bivalent monospecific,” or to different epitopes, for an antibody withtwo binding domains, termed “bivalent bispecific.” An antibody orantigen binding fragment thereof may also be bispecific and bivalent foreach specificity (termed “bispecific tetravalent antibodies”). Inanother embodiment, tetravalent minibodies or domain deleted antibodiescan be made.

Bispecific bivalent antibodies, and methods of making them, aredescribed, for instance in U.S. Pat. Nos. 5,731,168; 5,807,706;5,821,333; and U.S. Patent Appl. Publ. Nos. 2003/020734 and2002/0155537, the disclosures of all of which are incorporated byreference herein. Bispecific tetravalent antibodies, and methods ofmaking them are described, for instance, in WO 02/096948 and WO00/44788, the disclosures of both of which are incorporated by referenceherein. See generally, PCT publications WO 93/17715; WO 92/08802; WO91/00360; WO 92/05793; Tutt et al., J. Immunol. 147:60-69 (1991); U.S.Pat. Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819;Kostelny et al., J. Immunol. 148: 1547-1553 (1992).

As previously indicated, the subunit structures and three dimensionalconfiguration of the constant regions of the various immunoglobulinclasses are well known. As used herein, the term “VH domain” includesthe amino terminal variable domain of an immunoglobulin heavy chain andthe term “CH1 domain” includes the first (most amino terminal) constantregion domain of an immunoglobulin heavy chain. The CH1 domain isadjacent to the VH domain and is amino terminal to the hinge region ofan immunoglobulin heavy chain molecule.

As used herein the term “CH2 domain” includes the portion of a heavychain molecule that extends, e.g., from about residue 244 to residue 360of an antibody using conventional numbering schemes (residues 244 to360, Kabat numbering system; and residues 231-340, EU numbering system;see Kabat E A et al.). The CH2 domain is unique in that it is notclosely paired with another domain. Rather, two N-linked branchedcarbohydrate chains are interposed between the two CH2 domains of anintact native IgG molecule. It is also well documented that the CH3domain extends from the CH2 domain to the C-terminal of the IgG moleculeand comprises approximately 108 residues.

As used herein, the term “hinge region” includes the portion of a heavychain molecule that joins the CH1 domain to the CH2 domain. This hingeregion comprises approximately 25 residues and is flexible, thusallowing the two N-terminal antigen binding regions to moveindependently. Hinge regions can be subdivided into three distinctdomains: upper, middle, and lower hinge domains (Roux et al., J.Immunol. 161:4083 (1998)).

As used herein the term “disulfide bond” includes the covalent bondformed between two sulfur atoms. The amino acid cysteine comprises athiol group that can form a disulfide bond or bridge with a second thiolgroup. In most naturally occurring IgG molecules, the CH1 and CL regionsare linked by a disulfide bond and the two heavy chains are linked bytwo disulfide bonds at positions corresponding to 239 and 242 using theKabat numbering system (position 226 or 229, EU numbering system).

As used herein, the term “chimeric antibody” will be held to mean anyantibody wherein the immunoreactive region or site is obtained orderived from a first species and the constant region (which may beintact, partial or modified in accordance with the instant disclosure)is obtained from a second species. In certain embodiments the targetbinding region or site will be from a non-human source (e.g., mouse orprimate) and the constant region is human.

As used herein, the term “engineered antibody” will refer to a humanantibody in which the variable domain in either the heavy or light chainor both is altered by at least one amino acid replacement. In oneembodiment amino acid replacement of framework residues will reducepotential immunogenicity by changing the framework residue to germline.In another embodiment, amino acid replacement of either framework or CDRresidues may remove potential structural liabilities that may result ininstability, aggregation or heterogeneity of product. Examples ofundesirable liabilities include unpaired cysteines (which may lead todisulfide bond scrambling, or variable sulfhydryl adduct formation),N-linked glycosylation sites (resulting in heterogeneity of structureand activity), as well as deamidation (e.g. NG, NS), isomerization (DG),oxidation (exposed methionine), and hydrolysis (DP) sites. In anotherembodiment, amino acid replacement of CDR and framework residues byeither a targeted or random mutagenesis approach may result inantibodies with enhanced binding, potency or specificitycharacteristics. In another embodiment, “engineered antibody” refers toan antibody in which the variable domain in either the heavy or lightchain or both is altered by at least partial replacement of one or moreCDRs from an antibody of known specificity and, if necessary, by partialframework region replacement and sequence changing. Although the CDRsmay be derived from an antibody of the same class or even subclass asthe antibody from which the framework regions are derived, it isenvisaged that the CDRs will be derived from an antibody of differentclass and preferably from an antibody from a different species.

As used herein, the term “humanized antibody” will refer to an antibodymolecule derived from a non-human species antibody (also referred toherein as a donor antibody) that bind the desired antigen having one ormore complementarity determining regions (CDRs) from the non-humanspecies and a framework region from a human immunoglobulin molecule(also referred to herein as an acceptor antibody). It may not benecessary to replace all of the CDRs with the complete CDRs from thedonor variable domain to transfer the antigen binding capacity of onevariable domain to another. Rather, it may only be necessary to transferthose residues that are necessary to maintain the activity of the targetbinding site.

It is further recognized that the framework regions within the variabledomain in a heavy or light chain, or both, of a humanized antibody maycomprise solely residues of human origin, in which case these frameworkregions of the humanized antibody are referred to as “fully humanframework regions.” Alternatively, one or more residues of the frameworkregion(s) of the donor variable domain can be engineered within thecorresponding position of the human framework region(s) of a variabledomain in a heavy or light chain, or both, of a humanized antibody ifnecessary to maintain proper binding or to enhance binding to the IL-33antigen. A human framework region that has been engineered in thismanner would thus comprise a mixture of human and donor frameworkresidues, and is referred to herein as a “partially human frameworkregion.”

For example, humanization of an anti-IL-33 antibody can be essentiallyperformed by methods known in the art (e.g., the method of Winter andco-workers (Jones et al., Nature 321:522-525 (1986); Riechmann et al.,Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536(1988)), by substituting rodent or mutant rodent CDRs or CDR sequencesfor the corresponding sequences of a human anti-IL-33 antibody. See alsoU.S. Pat. Nos. 5,225,539; 5,585,089; 5,693,761; 5,693,762; 5,859,205;herein incorporated by reference. The resulting humanized anti-IL-33antibody would comprise at least one rodent or mutant rodent CDR withinthe fully human framework regions of the variable domain of the heavyand/or light chain of the humanized antibody. In some instances,residues within the framework regions of one or more variable domains ofthe humanized anti-IL-33 antibody are replaced by correspondingnon-human (for example, rodent) residues (see, for example, U.S. Pat.Nos. 5,585,089; 5,693,761; 5,693,762; and 6,180,370), in which case theresulting humanized anti-IL-33 antibody would comprise partially humanframework regions within the variable domain of the heavy and/or lightchain.

Furthermore, humanized antibodies may comprise residues that are notfound in the recipient antibody or in the donor antibody. Thesemodifications are made to further refine antibody performance (e.g., toobtain desired affinity). In general, the humanized antibody willcomprise substantially all of at least one, and typically two, variabledomains, in which all or substantially all of the CDRs correspond tothose of a non-human immunoglobulin and all or substantially all of theframework regions are those of a human immunoglobulin sequence. Thehumanized antibody optionally also will comprise at least a portion ofan immunoglobulin constant region (Fc), typically that of a humanimmunoglobulin. For further details see Jones et al., Nature 321:522-525(1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr.Op. Struct. Biol. 2:593-596 (1992); herein incorporated by reference.Accordingly, such “humanized” antibodies may include antibodies whereinsubstantially less than an intact human variable domain has beensubstituted by the corresponding sequence from a non-human species. Inpractice, humanized antibodies are typically human antibodies in whichsome CDR residues and possibly some framework residues are substitutedby residues from analogous sites in rodent antibodies. See, for example,U.S. Pat. Nos. 5,225,539; 5,585,089; 5,693,761; 5,693,762; 5,859,205.See also U.S. Pat. No. 6,180,370, and International Publication No. WO01/27160, where humanized antibodies and techniques for producinghumanized antibodies having improved affinity for a predeterminedantigen are disclosed.

As used herein, the terms “linked,” “fused,” or “fusion” are usedinterchangeably. These terms refer to the joining together of two moreelements or components, by whatever means including chemical conjugationor recombinant means. An “in-frame fusion” refers to the joining of twoor more polynucleotide open reading frames (ORFs) to form a continuouslonger ORF, in a manner that maintains the correct translational readingframe of the original ORFs. Thus, a recombinant fusion protein is asingle protein containing two or more segments that correspond topolypeptides encoded by the original ORFs (which segments are notnormally so joined in nature). Although the reading frame is thus madecontinuous throughout the fused segments, the segments may be physicallyor spatially separated by, for example, in-frame linker sequence. Forexample, polynucleotides encoding the CDRs of an immunoglobulin variableregion may be fused, in-frame, but be separated by a polynucleotideencoding at least one immunoglobulin framework region or additional CDRregions, as long as the “fused” CDRs are co-translated as part of acontinuous polypeptide.

In the context of polypeptides, a “linear sequence” or a “sequence” isan order of amino acids in a polypeptide in an amino to carboxylterminal direction in which residues that neighbor each other in thesequence are contiguous in the primary structure of the polypeptide.

The term “expression” as used herein refers to a process by which a geneproduces a biochemical, for example, a polypeptide. The process includesany manifestation of the functional presence of the gene within the cellincluding, without limitation, gene knockdown as well as both transientexpression and stable expression. It includes without limitationtranscription of the gene into messenger RNA (mRNA), and the translationof such mRNA into polypeptide(s). If the final desired product is abiochemical, expression includes the creation of that biochemical andany precursors. Expression of a gene produces a “gene product.” As usedherein, a gene product can be either a nucleic acid, e.g., a messengerRNA produced by transcription of a gene, or a polypeptide which istranslated from a transcript. Gene products described herein furtherinclude nucleic acids with post transcriptional modifications, e.g.,polyadenylation, or polypeptides with post translational modifications,e.g., methylation, glycosylation, the addition of lipids, associationwith other protein subunits, proteolytic cleavage, and the like.

As used herein, the terms “treat” or “treatment” refer to boththerapeutic treatment and prophylactic or preventative measures, whereinthe object is to prevent or slow down (lessen) an undesiredphysiological change or disorder, such as the progression of aninflammatory condition. Beneficial or desired clinical results include,but are not limited to, alleviation of symptoms, diminishment of extentof disease, stabilized (i.e., not worsening) state of disease, delay orslowing of disease progression, amelioration or palliation of thedisease state, and remission (whether partial or total), whetherdetectable or undetectable. “Treatment” can also mean prolongingsurvival as compared to expected survival if not receiving treatment.Those in need of treatment include those already with the condition ordisorder as well as those prone to have the condition or disorder orthose in which the condition or disorder is to be prevented.

By “subject” or “individual” or “animal” or “patient” or “mammal,” ismeant any subject, particularly a mammalian subject, for whom diagnosis,prognosis, or therapy is desired. Mammalian subjects include humans;domestic animals; farm animals; and zoo, sports, or pet animals such asdogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, andso on.

As used herein, phrases such as “a subject that would benefit fromadministration of an anti-IL-33 antibody” and “an animal in need oftreatment” includes subjects, such as mammalian subjects, that wouldbenefit from administration of an anti-IL-33 antibody used, e.g., fordetection of an anti-IL-33 polypeptide (e.g., for a diagnosticprocedure) and/or from treatment, i.e., palliation or prevention of adisease, with an anti-IL-33 antibody.

II. Target Polypeptide Description

As used herein, the terms “IL-33” and “IL-33 polypeptide” are usedinterchangably. In certain embodiments, IL-33 is full length. In anotherembodiment, IL-33 is mature, truncated IL-33 (amino acids 112-270).Recent studies suggest full length IL-33 is active (Cayrol and Girard,Proc Natl Acad Sci USA 106(22):9021-6 (2009); Hayakawa et al., BiochemBiophys Res Commun 387(1):218-22 (2009); Talabot-Ayer et al., J BiolChem. 284(29):19420-6 (2009)). However, N-terminally processed ortruncated IL-33 including but not limited to aa 72-270, 79-270, 95-270,99-270, 107-270, 109-270, 111-270, 112-270 may have enhanced activity(Lefrancais 2012, 2014). In another embodiments, IL-33 may include afull length IL-33, a fragment thereof, or an IL-33 mutant or variantpolypeptide, wherein the fragment of IL-33 or IL-33 variant polypeptideretains some or all functional properties of active IL-33.

Human IL-33 is a 270 amino acid protein (Accession No. 095760),consisting of two domains: a homeodomain and a cytokine (IL-1-like)domain. The homeodomain contains a nuclear localization signal (NLS).IL-33 was originally identified as “DVS27” gene which was upregulated invasospastic cerebral arteries after subarachnoid hemorrhage (Onda etal., J. Cereb. Blood Flow Metab. 19:1279-88 (1999)), and as a “nuclearfactor from high endothelial venules (NF-HEV),” which is expressed inendothelial cell nuclei (Baekkevold et al., Am. J. Pathol 163:69-79(2003)). IL-33 (also called IL-1F11) is now regarded as the 11^(th)member in the IL-1 family for cytokines, which also includes IL-α, IL1β,and IL-18. See Oboki et al., Allergology International 59:143-160(2010).

Schmitz et al. first identified IL-33 as the ligand for the orphanreceptor ST2 (also called IL-1R4) (Schmitz et al., Immunity 23(5):479-90(2005)). The only known ligand of the ST2 receptor is IL-33 (Schmitz etal. (2005)). IL-33 receptor is formed from heterodimeric molecules,consisting of ST2 and IL-1R accessory protein (IL-1RAcP). IL-1RAcP is ashared component of receptors for IL-1α, IL-1β, IL-1F6, IL1F8, andIL1F9. IL-33 binds to IL-33 receptor, which is a dimer of ST2 andIL-1RAcP. IL-1RAcP is not required for binding, but is critical forsignaling. The TIR-domain of IL-33 receptor recruits MyD88 and TRAF6,and the receptor signal results in activation of NFκB and MAP Kinasepathways (Oboki et al. (2010)). The IL-33 receptor may potentiallyassociate with other receptors and has been reported to cross activatethe receptor tyrosine kinase c-Kit in human and mouse mast cells (Drubeet al., Blood 115:3899-906 (2010)). The structural basis for thiscross-activation is the complex formation between c-Kit, ST2, andIL-1RAcP. C-Kit and IL-1RAcP interact constitutively and ST2 joins thiscomplex upon ligand binding.

Recently, IL-33 has been shown to bind a second IL-33 receptorheterodimeric complex. ST2 forms a complex with another IL1R familymolecule, “single Ig IL-1R-related molecule” (SIGIRR) (also called TollIL-1R8 (TIRE)). SIGIRR/TIR8 is considered to act as a negative regulatorof IL-1R and Toll-like receptor (TLR)-mediated immune responses(Garlanda et al., Trends Immunol. 30:439-46 (2009)). In contrast toST2:IL-1RAcP, ST2:SIGIRR seems to act as a negative regulator of IL-33.

ST2 is expressed at baseline by Th2 cells and mast cells, both celltypes known to be important mediators of allergic asthma. IL-33 is ableto stimulate these (and various other cells) to produce a range offunctional responses including cytokines and chemokines.

Anti-IL-33 Antibodies

In certain embodiments, the binding molecules, e.g., antibodies orantigen-binding fragments, variants, or derivatives thereof, of thedisclosure, e.g., antibodies IL330065, IL330099, IL330101, IL330107,IL33149, and IL330180, and 33_640076-4B, 33_640081-AB; 33_640082-6B,33_640082-7B, 33_640084-2B, 33_640086-6B, 33_640087-7B, 33_640201-2B,and 33_640237-2B, bind to IL-33 and inhibit the IL-33-driven cytokinerelease from mast cells, endothelial cells and proliferation of TF-1cells.

In certain embodiments, the antibodies of the disclosure compriseanti-IL-33 antibodies or antigen-binding fragments, variants, orderivatives thereof that bind to IL-33, e.g., antibodies IL330065,IL330099, IL330101, IL330107, IL33149, and IL330180 and 33_640076-4B,33_640081-AB; 33_640082-6B, 33_640082-7B, 33_640084-2B, 33_640086-6B,33_640087-7B, 33_640201-2B, and 33_640237-2B. In certain embodiments theanti-IL-33 antibodies bind human, primate, murine, or any combination ofhuman, primate and murine IL-33. In certain embodiments, the anti-IL-33antibodies inhibit IL-33 driven cytokine production.

In one embodiment, the present disclosure provides an isolated bindingmolecule, e.g., an antibody or antigen-binding fragment thereof, whichspecifically binds to the same IL-33 epitope as antibody IL330065,IL330099, IL330101, IL330107, IL33149, or IL330180 and 33_640076-4B,33_640081-AB; 33_640082-6B, 33_640082-7B, 33_640084-2B, 33_640086-6B,33_640087-7B, 33_640201-2B, and 33_640237-2B. In another embodiment, thepresent disclosure provides an isolated binding molecule, e.g., anantibody or antigen-binding fragment thereof, which specifically bindsto IL-33, and competitively inhibits antibody IL330065, IL330099,IL330101, IL330107, IL33149, or IL330180 and 33_640076-4B, 33_640081-AB;33_640082-6B, 33_640082-7B, 33_640084-2B, 33_640086-6B, 33_640087-7B,33_640201-2B, and 33_640237-2B from specifically binding to IL-33, e.g.,human, primate, murine, or any combination of human, primate, and murineIL-33.

In certain embodiments, the binding molecule of the disclosure has anamino acid sequence that has at least 75%, 80%, 85%, 88%, 89%, 90%, 91%,92%, 93%, 94%, or 95% sequence identity to the amino acid sequence forthe reference anti-IL-33 antibody molecule. In a further embodiment, thebinding molecule shares at least 96%, 97%, 98%, 99%, or 100% sequenceidentity to the reference antibody. In certain embodiments, thereference antibody is IL330065, IL330099, IL330101, IL330107, IL33149,or IL330180 and 33_640076-4B, 33_640081-AB; 33_640082-6B, 33_640082-7B,33_640084-2B, 33_640086-6B, 33_640087-7B, 33_640201-2B, and33_640237-2B.

In another embodiment, the present disclosure provides an isolatedantibody or antigen-binding fragment thereof comprising, consistingessentially of, or consisting of an immunoglobulin heavy chain variabledomain (VH domain), where at least one of the CDRs of the VH domain hasan amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%,97%, 98%, 99%, or identical to a CDR1, CDR2 or CDR3 region from to theVH CDRs disclosed above, wherein an antibody or antigen-binding fragmentthereof comprising the encoded VH domain specifically or preferentiallybinds to IL-33. In certain embodiments, the antibody or antigen-bindingfragment thereof inhibits IL-33 driven cytokine production.

In another embodiment, the present disclosure provides an isolatedantibody or antigen-binding fragment thereof comprising, consistingessentially of, or consisting of an immunoglobulin heavy chain variabledomain (VH domain), where at least one of the CDRs of the VH domain hasan amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%,97%, 98%, 99%, or identical to to the VH CDRs disclosed above, whereinan antibody or antigen-binding fragment thereof comprising the encodedVH domain specifically or preferentially binds to IL-33. In certainembodiments, the isolated antibody further comprises a immunoglobulinlight chain variable domain (VL domain). In certain embodiments, theantibody or antigen-binding fragment thereof inhibits IL-33 drivencytokine production.

In another embodiment, the present disclosure provides an isolatedantibody or antigen-binding fragment thereof comprising, consistingessentially of, or consisting of an immunoglobulin heavy chain variabledomain (VH domain), where at least one of the CDRs of the VH domain hasan amino acid sequence identical, except for 1, 2, 3, 4, or 5conservative amino acid substitutions, to the VH CDRs disclosed above,wherein an antibody or antigen-binding fragment thereof comprising theencoded VH domain specifically or preferentially binds to IL-33. Incertain embodiments, the isolated antibody further comprises a VLdomain. In certain embodiments, the antibody or antigen-binding fragmentthereof inhibits IL-33 driven cytokine production.

In another embodiment, the present disclosure provides an isolatedantibody or antigen-binding fragment thereof comprising, consistingessentially of, or consisting of a VH domain that has an amino acidsequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99%, or 100% identical to a VH amino acid sequence of SEQID NO: 2, 12, 22, 32, 42, or 52, wherein an antibody or antigen-bindingfragment thereof comprising the encoded VH domain specifically orpreferentially binds to IL-33. In certain embodiments, the isolatedantibody further comprises a VL domain. In certain embodiments, theantibody or antigen-binding fragment thereof inhibits IL-33 drivencytokine production.

In another embodiment, the present disclosure provides an isolatedantibody or antigen-binding fragment thereof comprising, consistingessentially of, or consisting of an immunoglobulin light chain variabledomain (VL domain), where at least one of the CDRs of the VL domain hasan amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%,97%, 98%, 99%, or identical to a CDR1, CDR2 or CDR3 region from VH aminoacid sequences SEQ disclosed above., wherein an antibody orantigen-binding fragment thereof comprising the encoded VL domainspecifically or preferentially binds to IL-33. In certain embodiments,the isolated antibody further comprises a VH domain. In certainembodiments, the antibody or antigen-binding fragment thereof inhibitsIL-33 driven cytokine production.

In another embodiment, the present disclosure provides an isolatedantibody or antigen-binding fragment thereof comprising, consistingessentially of, or consisting of an immunoglobulin light chain variabledomain (VL domain), where at least one of the CDRs of the VL domain hasan amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%,97%, 98%, 99%, or identical to the VL CDRs disclosed above, wherein anantibody or antigen-binding fragment thereof comprising the encoded VLdomain specifically or preferentially binds to IL-33. In certainembodiments, the isolated antibody further comprises a VH domain. Incertain embodiments, the antibody or antigen-binding fragment thereofinhibits IL-33 driven cytokine production.

In another embodiment, the present disclosure provides an isolatedantibody or antigen-binding fragment thereof comprising, consistingessentially of, or consisting of an immunoglobulin light chain variabledomain (VL domain), where at least one of the CDRs of the VL domain hasan amino acid sequence identical, except for 1, 2, 3, 4, or 5conservative amino acid substitutions, to the VL CDRs disclosed above,wherein an antibody or antigen-binding fragment thereof comprising theencoded VL domain specifically or preferentially binds to IL-33. Incertain embodiments, the isolated antibody further comprises a VHdomain. In certain embodiments, the antibody or antigen-binding fragmentthereof inhibits IL-33 driven cytokine production.

In a further embodiment, the present disclosure includes an isolatedantibody or antigen-binding fragment thereof comprising, consistingessentially of, or consisting of a VL domain that has an amino acidsequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99%, or 100% identical to a VL amino acid sequencedisclosed above, wherein an antibody or antigen-binding fragment thereofcomprising the encoded VL domain specifically or preferentially binds toIL-33. In certain embodiments, the isolated antibody further comprises aVH domain. In certain embodiments, the antibody or antigen-bindingfragment thereof inhibits IL-33 driven cytokine production.

Suitable biologically active variants of the anti-IL-33 antibodies ofthe disclosure can be used in the methods of the present disclosure.Such variants will retain the desired binding properties of the parentanti-IL-33 antibody. Methods for making antibody variants are generallyavailable in the art.

Methods for mutagenesis and nucleotide sequence alterations are wellknown in the art. See, for example, Walker and Gaastra, eds. (1983)Techniques in Molecular Biology (MacMillan Publishing Company, NewYork); Kunkel, Proc. Natl. Acad. Sci. USA 82:488-492 (1985); Kunkel etal., Methods Enzymol. 154:367-382 (1987); Sambrook et al. (1989)Molecular Cloning: A Laboratory Manual (Cold Spring Harbor, N.Y.); U.S.Pat. No. 4,873,192; and the references cited therein; hereinincorporated by reference. Guidance as to appropriate amino acidsubstitutions that do not affect biological activity of the polypeptideof interest may be found in the model of Dayhoff et al. (1978) in Atlasof Protein Sequence and Structure (Natl. Biomed. Res. Found.,Washington, D.C.), pp. 345-352, herein incorporated by reference in itsentirety. The model of Dayhoff et al. uses the Point Accepted Mutation(PAM) amino acid similarity matrix (PAM 250 matrix) to determinesuitable conservative amino acid substitutions. Conservativesubstitutions, such as exchanging one amino acid with another havingsimilar properties, may be preferred. Examples of conservative aminoacid substitutions as taught by the PAM 250 matrix of the Dayhoff et al.model include, but are not limited to, Gly↔Ala, Val↔Ile↔Leu, Asp↔Glu,Lys↔Arg, Asn↔Gln, and Phe↔Trp↔Tyr.

In constructing variants of an anti-IL-33 binding molecule, e.g., anantibody or antigen-binding fragment thereof, polypeptides of interest,modifications are made such that variants continue to possess thedesired properties, e.g., being capable of specifically binding to aIL-33, and in certain embodiments not blocking binding of IL-33 to ST2.Obviously, any mutations made in the DNA encoding the variantpolypeptide must not place the sequence out of reading frame andpreferably will not create complementary regions that could producesecondary mRNA structure.

Methods for measuring anti-IL-33 binding molecule, e.g., an antibody orantigen-binding fragment thereof, binding specificity include, but arenot limited to, standard competitive binding assays, ELISA assays,BIACORE assays, functional assays such as proliferation or factorrelease and the like. See, for example, such assays disclosed in WO93/14125; Shi et al., Immunity 13:633-642 (2000); Kumanogoh et al., JImmunol 169:1375-1381 (2002); Watanabe et al., J Immunol 167:4321-4328(2001); Wang et al., Blood 97:3498-3504 (2001); and Giraudon et al., JImmunol 172(2):1246-1255 (2004), all of which are herein incorporated byreference.

As discussed herein, where any particular polypeptide, including theconstant regions, CDRs, VH domains, or VL domains disclosed herein, isat least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99%, or even 100% identical to another polypeptide, the %identity can be determined using methods and computer programs/softwareknown in the art such as, but not limited to, the BESTFIT program(Wisconsin Sequence Analysis Package, Version 8 for Unix, GeneticsComputer Group, University Research Park, 575 Science Drive, Madison,Wis. 53713). BESTFIT uses the local homology algorithm of Smith andWaterman (1981) Adv. Appl. Math. 2:482-489, to find the best segment ofhomology between two sequences. When using BESTFIT or any other sequencealignment program to determine whether a particular sequence is, forexample, 95% identical to a reference sequence according to the presentdisclosure, the parameters are set, of course, such that the percentageof identity is calculated over the full length of the referencepolypeptide sequence and that gaps in homology of up to 5% of the totalnumber of amino acids in the reference sequence are allowed.

For the purposes of the present disclosure, percent sequence identitymay be determined using the Smith-Waterman homology search algorithmusing an affine gap search with a gap open penalty of 12 and a gapextension penalty of 2, BLOSUM matrix of 62. The Smith-Waterman homologysearch algorithm is taught in Smith and Waterman (1981) Adv. Appl. Math.2:482-489. A variant may, for example, differ from a referenceanti-IL-33 antibody (e.g., IL330065, IL330099, IL330101, IL330107,IL33149, or IL330180) by as few as 1 to 30 amino acid residues, as fewas 1 to 15 amino acid residues, as few as 1 to 10 amino acid residues,such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acidresidue.

The precise chemical structure of a polypeptide capable of specificallybinding IL-33 and retaining the desired activity depends on a number offactors. As ionizable amino and carboxyl groups are present in themolecule, a particular polypeptide may be obtained as an acidic or basicsalt, or in neutral form. All such preparations that retain theirbiological activity when placed in suitable environmental conditions areincluded in the definition of anti-IL-33 antibodies as used herein.Further, the primary amino acid sequence of the polypeptide may beaugmented by derivatization using sugar moieties (glycosylation) or byother supplementary molecules such as lipids, phosphate, acetyl groupsand the like. It may also be augmented by conjugation with saccharides.Certain aspects of such augmentation are accomplished throughpost-translational processing systems of the producing host; other suchmodifications may be introduced in vitro. In any event, suchmodifications are included in the definition of an anti-IL-33 antibodyused herein so long as the desired properties of the anti-IL-33 antibodyare not destroyed. It is expected that such modifications mayquantitatively or qualitatively affect the activity, either by enhancingor diminishing the activity of the polypeptide, in the various assays.Further, individual amino acid residues in the chain may be modified byoxidation, reduction, or other derivatization, and the polypeptide maybe cleaved to obtain fragments that retain activity. Such alterationsthat do not destroy the desired properties (e.g., binding specificityfor IL-33, binding affinity, and associated activity, e.g., ability toinhibit the IL-33-driven cytokine release from mast cells, endothelialcells and proliferation of TF-1 cells) do not remove the polypeptidesequence from the definition of anti-IL-33 antibodies of interest asused herein.

The art provides substantial guidance regarding the preparation and useof polypeptide variants. In preparing the anti-IL-33 binding molecule,e.g., an antibody or antigen-binding fragment thereof, variants, one ofskill in the art can readily determine which modifications to the nativeprotein's nucleotide or amino acid sequence will result in a variantthat is suitable for use as a therapeutically active component of apharmaceutical composition used in the methods of the presentdisclosure.

It is known that variants of the Fc region (e.g., amino acidsubstitutions and/or additions and/or deletions) can enhance or diminisheffector function of an antibody and may alter the pharmacokineticproperties (e.g., half-life) of the antibody. For example, see U.S. Pat.No. 6,737,056B1 and U.S. Patent Application Publication No.2004/0132101A1, which disclose Fc mutations that optimize antibodybinding to Fc receptors.

In certain anti-IL-33 antibodies, the Fc portion may be mutated todecrease effector function using techniques known in the art. Forexample, alteration of a constant region domain e.g. by point mutationsor amino acid substitutions may reduce Fc receptor binding of thecirculating modified antibody thereby minimizing effector cell orcomplement-mediated clearance or damage to cells expressing orpresenting the target. For example, one particular set of substitutions,the triple mutation L234F/L235E/P331S (‘TM’) causes a profound decreasein the binding activity of human IgG1 molecules to human Clq, CD64,CD32A and CD16. See, e.g., Oganesyan et al., Acta Crystallogr D BiolCrystallogr. 64:700-704 (2008).

In other cases it may be that constant region modifications consistentwith the instant disclosure increases serum half-life. The serumhalf-life of proteins comprising Fc regions may be increased byincreasing the binding affinity of the Fc region for FcRn. The term“antibody half-life” as used herein means a pharmacokinetic property ofan antibody that is a measure of the mean survival time of antibodymolecules following their administration. Antibody half-life can beexpressed as the time required to eliminate 50 percent of a knownquantity of immunoglobulin from the patient's body (or other mammal) ora specific compartment thereof, for example, as measured in serum, i.e.,circulating half-life, or in other tissues. Half-life may vary from oneimmunoglobulin or class of immunoglobulin to another. In general, anincrease in antibody half-life results in an increase in mean residencetime in circulation for the antibody administered.

An increase in half-life allows for the reduction in amount of druggiven to a patient as well as reducing the frequency of administration.To increase the serum half life of the antibody, one may incorporate asalvage receptor binding epitope into the antibody (especially anantibody fragment) as known in the art. As used herein, the term“salvage receptor binding epitope” refers to an epitope of the Fc regionof an IgG molecule (e.g., IgG1, IgG2, IgG3, or IgG4) that is responsiblefor increasing the in vivo serum half-life of the IgG molecule.Antibodies with increased half-lives may also be generated by modifyingamino acid residues identified as involved in the interaction betweenthe Fc and the FcRn receptor. For example, the introduction of thetriple mutation M252Y/S254T/T256E (‘YTE’) into the CH2 domain of humanimmunoglobulin G (IgG) molecules causes an increase in their binding tothe human neonatal Fc receptor (FcRn). See U.S. Pat. No. 7,083,784, thecontents of which are herein incorporated by reference in its entirety.

In addition, in some embodiments, the Fc region comprises a modification(e.g., amino acid substitutions, amino acid insertions, amino aciddeletions) at one or more positions selected from the group consistingof 234, 235, 236, 237, 238, 239, 240, 241, 243, 244, 245, 247, 251, 252,254, 255, 256, 262, 263, 264, 265, 266, 267, 268, 269, 279, 280, 284,292, 296, 297, 298, 299, 305, 313, 316, 325, 326, 327, 328, 329, 330,331, 332, 333, 334, 339, 341, 343, 370, 373, 378, 392, 416, 419, 421,440 and 443 as numbered by the EU index as set forth in Kabat.Optionally, the Fc region may comprise a non naturally occurring aminoacid residue at additional and/or alternative positions known in theart.

In other embodiments, the Fc region comprises at least one substitutionselected from the group consisting of 234D, 234E, 234N, 234Q, 234T,234H, 234Y, 234I, 234V, 234F, 235A, 235D, 235R, 235W, 235P, 235S, 235N,235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 236E, 239D, 239E, 239N, 239Q,239F, 239T, 239H, 239Y, 240I, 240A, 240T, 240M, 241W, 241 L, 241Y, 241E,241R. 243W, 243L 243Y, 243R, 243Q, 244H, 245A, 247L, 247V, 247G, 251F,252Y, 254T, 255L, 256E, 256M, 262I, 262A, 262T, 262E, 263I, 263A, 263T,263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N,265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M,267Q, 267L, 268E, 269H, 269Y, 269F, 269R, 270E, 280A, 284M, 292P, 292L,296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 269G, 297S, 297D,297E, 298H, 298I, 298T, 298F, 2991, 299L, 299A, 299S, 299V, 299H, 299F,299E, 305I, 313F, 316D, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V,325H, 327G, 327W, 327N, 327L, 328S, 328M, 328D, 328E, 328N, 328Q, 328F,328I, 328V, 328T, 328H, 328A, 329F, 329H, 329Q, 330K, 330G, 330T, 330C,330L, 330Y, 330V, 330I, 330F, 330R, 330H, 331G, 331A, 331L, 331M, 331F,331W, 331K, 331Q, 331E, 331S, 331V, 331I, 331C, 331Y, 331H, 331R, 331N,331D, 331T, 332D, 332S, 332W, 332F, 332E, 332N, 332Q, 332T, 332H, 332Y,332A, 339T, 370E, 370N, 378D, 392T, 396L, 416G, 419H, 421K, 440Y and434W as numbered by the EU index as set forth in Kabat. Optionally, theFc region may comprise additional and/or alternative non-naturallyoccurring amino acid residues known in the art.

In additional embodiments, the Fc region comprises at least onemodification (e.g., amino acid substitutions, amino acid insertions,amino acid deletions) at one or more positions selected from the groupconsisting of 234, 235 and 331. In some embodiments, the non-naturallyoccurring amino acids are selected from the group consisting of 234F,235F, 235Y, and 331S. Provided herein is an Fc variant, where the Fcregion comprises at least one non-naturally occurring amino acid at oneor more positions selected from the group consisting of 239, 330 and332. In some embodiments, the non-naturally occurring amino acids areselected from the group consisting of 239D, 330L and 332E.

In other embodiments, the Fc region comprises at least one non-naturallyoccurring amino acid at one or more positions selected from the groupconsisting of 252, 254, and 256. In certain embodiments, thenon-naturally occurring amino acids are selected from the groupconsisting of 252Y, 254T and 256E, described in U.S. Pat. No. 7,083,784,the contents of which are herein incorporated by reference in itsentirety.

Yet other modifications of the constant region may be used to modifydisulfide linkages or oligosaccharide moieties that allow for enhancedlocalization due to increased antigen specificity or antibodyflexibility. The resulting physiological profile, bioavailability andother biochemical effects of the modifications, such as biodistributionand serum half-life, may easily be measured and quantified using wellknown immunological techniques without undue experimentation.

Anti-IL-33 antibodies of the disclosure also include derivatives thatare modified, e.g., by the covalent attachment of any type of moleculeto the antibody such that covalent attachment does not prevent theantibody from specifically binding to its cognate epitope. For example,but not by way of limitation, the antibody derivatives includeantibodies that have been modified, e.g., by glycosylation, acetylation,pegylation, phosphorylation, amidation, derivatization by knownprotecting/blocking groups, proteolytic cleavage, linkage to a cellularligand or other protein, etc. Any of numerous chemical modifications maybe carried out by known techniques, including, but not limited tospecific chemical cleavage, acetylation, formylation, etc. Additionally,the derivative may contain one or more non-classical amino acids.

A “conservative amino acid substitution” is one in which the amino acidresidue is replaced with an amino acid residue having a side chain witha similar charge. Families of amino acid residues having side chainswith similar charges have been defined in the art. These familiesinclude amino acids with basic side chains (e.g., lysine, arginine,histidine), acidic side chains (e.g., aspartic acid, glutamic acid),uncharged polar side chains (e.g., glycine, asparagine, glutamine,serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g.,alanine, valine, leucine, isoleucine, proline, phenylalanine,methionine, tryptophan), beta-branched side chains (e.g., threonine,valine, isoleucine) and aromatic side chains (e.g., tyrosine,phenylalanine, tryptophan, histidine). Alternatively, mutations can beintroduced randomly along all or part of the coding sequence, such as bysaturation mutagenesis, and the resultant mutants can be screened forbiological activity to identify mutants that retain activity (e.g., theability to bind an anti-IL-33 polypeptide).

For example, it is possible to introduce mutations only in frameworkregions or only in CDR regions of an antibody molecule. Introducedmutations may be silent or neutral missense mutations, i.e., have no, orlittle, effect on an antibody's ability to bind antigen. These types ofmutations may be useful to optimize codon usage, or improve ahybridoma's antibody production. Alternatively, non-neutral missensemutations may alter an antibody's ability to bind an antigen. Thelocation of most silent and neutral missense mutations is likely to bein the framework regions, while the location of most non-neutralmissense mutations is likely to be in CDR, though this is not anabsolute requirement. One of skill in the art would be able to designand test mutant molecules with desired properties such as no alterationin antigen binding activity or alteration in binding activity (e.g.,improvements in antigen binding activity or change in antibodyspecificity or enhanced stability/homogeneity of the final molecule).Following mutagenesis, the encoded protein may routinely be expressedand the functional and/or biological activity of the encoded protein,(e.g., ability to immunospecifically bind at least one epitope of anIL-33 polypeptide) can be determined using techniques described hereinor by routinely modifying techniques known in the art.

In certain embodiments, antibodies of the disclosure can be optimized bymodifying framework residues located in the vernier region/zone orresidues proposed to support the structure of the CDR regions (see,e.g., Foote, J. and G. Winter, J Mol. Biol. 224.2: 487-99 (1992);Padlan, E. A., Mol. Immunol 31.3: 169-217 (1994)). In some embodiments,these modifications may be constructed by using PCR mediatedsite-directed mutagenesis using standard molecular biology methods. Themodified antibodies can be tested for binding affinity as disclosedherein. In another embodiment, further optimization, e.g., backmutations or affinity maturation by introducing amino acid substitutionsin the CDR regions or by site directed mutagenesis can also beperformed.

In certain embodiments, the anti-IL-33 antibodies of the disclosurecomprise at least one optimized complementarity-determining region(CDR). By “optimized CDR” is intended that the CDR has been modified andoptimized sequences selected based on the sustained or improved bindingaffinity and/or anti-IL-33 activity that is imparted to an anti-IL-33antibody comprising the optimized CDR. “Anti-IL-33 activity” caninclude, for example activity which modulates one or more of thefollowing activities associated with IL-33, e.g., IL-33-driven cytokinerelease from mast cells, endothelial cells, and proliferation of TF-1cells; mediator (e.g., cytokine or chemokine) release from basophils,eosinophils, Th2 cells, NK, NKT cells, macrophages, or dendritic cells;modulation of cell surface receptors; modulation of antigenpresentation; or any other activity association with IL-33. Anti-IL-33activity can also be attributed to a decrease in incidence or severityof diseases associated with IL-33 expression and/or release, including,but not limited to, certain types of inflammatory conditions, e.g., anallergic disorder such as asthma or other inflammatory response in theairway of a subject. The modifications may involve replacement of aminoacid residues within the CDR such that an anti-IL-33 antibody retainsspecificity for the IL-33 antigen and has improved binding affinityand/or improved anti-IL-33 activity.

IV. Polynucleotides Encoding Anti-IL-33 Antibodies

The present disclosure also provides for nucleic acid molecules encodinganti-IL-33 antibodies of the disclosure, or antigen-binding fragments,variants, or derivatives thereof.

In one embodiment, the present disclosure provides an isolatedpolynucleotide comprising, consisting essentially of, or consisting of anucleic acid encoding an immunoglobulin heavy chain variable domain (VHdomain), where at least one of the CDRs of the VH domain is encoded by anucleic acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%,97%, 98%, 99%, or identical to a CDRH 1, 2, or 3 polynucleotide sequenceof a VH-encoding sequence selected from the group consisting of SEQ IDNO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151,161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291,301, 311, 321, 331, 341, 351, 361, 371, 381, 391, 401, 411, 421, 431,441, 451, 461, 471, 481, 491, 501, 511, 5421, 531, 541, 551, 561, 571,and 581. In certain embodiments, the antibody or antigen-bindingfragment thereof inhibits IL-33 driven cytokine production.

In other embodiments, the present disclosure provides an isolatedpolynucleotide comprising, consisting essentially of, or consisting of anucleic acid encoding an immunoglobulin VH domain, where the sequence ofat least one of the CDRs of the VH domain is selected from the groupconsisting of: (a) a CDRH1 sequence comprising the amino acid sequenceset forth in SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113,123, 133, 143, 153, 163, 173, 183, 193, 203, 213, 223, 233, 243, 253,263, 273, 283, 293, 303, 313, 323, 333, 343, 353, 363, 373, 383, 393,403, 413, 423, 433, 443, 453, 463, 473, 483, 493, 503, 513, 5423, 533,543, 553, 563, 573 and 583; (b) a CDRH2 sequence comprising the aminoacid sequence set forth in SEQ ID NO: 4, 14, 24, 34, 44, 54, 64, 74, 84,94, 104, 114, 124, 134, 144, 154, 164, 174, 184, 194, 204, 214, 224,234, 244, 254, 264, 274, 284, 294, 304, 314, 324, 334, 344, 354, 364,374, 384, 394, 404, 414, 424, 434, 444, 454, 464, 474, 484, 494, 504,514, 5424, 534, 544, 554, 564, 574; and 584, and (c) a CDRH3 sequencecomprising the amino acid sequence set forth in SEQ ID NO: 5, 15, 25,35, 45, 55, 65, 75, 85, 95, 105, 115, 125, 135, 145, 155, 165, 175, 185,195, 205, 215, 225, 235, 245, 255, 265, 275, 285, 295, 305, 315, 325,335, 345, 355, 365, 375, 385, 395, 405, 415, 425, 435, 445, 455, 465,475, 485, 495, 505, 515, 5425, 535, 545, 555, 565, 575 and 585. Incertain embodiments, the antibody or antigen-binding fragment thereofinhibits IL-33 driven cytokine production.

In a further embodiment, the present disclosure includes an isolatedpolynucleotide comprising, consisting essentially of, or consisting of anucleic acid encoding a VH domain that has an amino acid sequence thatis at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99%, or 100% identical to a reference VH domain polypeptide sequencecomprising SEQ ID NO: 2, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112,122, 132, 142, 152, 162, 172, 182, 192, 202, 212, 222, 232, 242, 252,262, 272, 282, 292, 302, 312, 322, 332, 342, 352, 362, 372, 382, 392,402, 412, 422, 432, 442, 452, 462, 472, 482, 492, 502, 512, 5422, 532,542, 552, 562, 572, and 582, wherein an anti-IL-33 antibody comprisingthe encoded VH domain specifically or preferentially binds to IL-33. Incertain embodiments, the antibody or antigen-binding fragment thereofinhibits IL-33 driven cytokine production.

In one embodiment, the present disclosure provides an isolatedpolynucleotide comprising, consisting essentially of, or consisting of anucleic acid encoding an immunoglobulin light chain variable domain (VLdomain), where at least one of the CDRs of the VL domain is encoded by anucleic acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%,97%, 98%, 99%, or identical to a CDRL 1, 2, or 3 polynucleotide sequenceof a VL-encoding sequence selected from the group consisting of SEQ IDNO: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156,166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296,306, 316, 326, 336, 346, 356, 366, 376, 386, 396, 406, 416, 426, 436,446, 456, 466, 476, 486, 496, 506, 516, 5426, 536, 546, 556, 566, 576,and 586. In certain embodiments, the antibody or antigen-bindingfragment thereof inhibits IL-33 driven cytokine production.

In other embodiments, the present disclosure provides an isolatedpolynucleotide comprising, consisting essentially of, or consisting of anucleic acid encoding an immunoglobulin VL domain, where the sequence ofat least one of the CDRs of the VL domain is selected from the groupconsisting of: (a) a CDRL1 sequence comprising the amino acid sequenceset forth in SEQ ID NO: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 118,128, 138, 148, 158, 168, 178, 188, 198, 208, 218, 228, 238, 248, 258,268, 278, 288, 298, 308, 318, 328, 338, 348, 358, 368, 378, 388, 398,408, 418, 428, 438, 448, 458, 468, 478, 488, 498, 508, 518, 5428, 538,548, 558, 568, 578, and 588, (b) a CDRL2 sequence comprising the aminoacid sequence set forth in SEQ ID NO: 9, 19, 29, 39, 49, 59, 69, 79, 89,99, 109, 119, 129, 139, 149, 159, 169, 179, 189, 199, 209, 219, 229,239, 249, 259, 269, 279, 289, 299, 309, 319, 329, 339, 349, 359, 369,379, 389, 399, 409, 419, 429, 439, 449, 459, 469, 479, 489, 499, 509,519, 5429, 539, 549, 559, 569, 579, and 589, and (c) a CDRL3 sequencecomprising the amino acid sequence set forth in SEQ ID NO: 10, 20, 30,40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180,190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320,330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460,470, 480, 490, 500, 510, 5420, 530, 540, 550, 560, 570, 580 and 590. Incertain embodiments, the antibody or antigen-binding fragment thereofinhibits IL-33 driven cytokine production.

In a further embodiment, the present disclosure includes an isolatedpolynucleotide comprising, consisting essentially of, or consisting of anucleic acid encoding a VL domain that has an amino acid sequence thatis at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,99%, or 100% identical to a reference VL domain polypeptide sequencecomprising SEQ ID NO: 7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117,127, 137, 147, 157, 167, 177, 187, 197, 207, 217, 227, 237, 247, 257,267, 277, 287, 297, 307, 317, 327, 337, 347, 357, 367, 377, 387, 397,407, 417, 427, 437, 447, 457, 467, 477, 487, 497, 507, 517, 5427, 537,547, 557, 567, 577, and 587, wherein an anti-IL-33 antibody comprisingthe encoded VL domain specifically or preferentially binds to IL-33. Incertain embodiments, the antibody or antigen-binding fragment thereofinhibits IL-33 driven cytokine production.

Any of the polynucleotides described above may further includeadditional nucleic acids, encoding, e.g., a signal peptide to directsecretion of the encoded polypeptide, antibody constant regions asdescribed herein, or other heterologous polypeptides as describedherein. Also, as described in more detail elsewhere herein, the presentdisclosure includes compositions comprising one or more of thepolynucleotides described above.

In one embodiment, the disclosure includes compositions comprising afirst polynucleotide and second polynucleotide wherein said firstpolynucleotide encodes a VH domain as described herein and wherein saidsecond polynucleotide encodes a VL domain as described herein.Specifically a composition which comprises, consists essentially of, orconsists of a VH domain-encoding polynucleotide, as set forth in SEQ IDNO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151,161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291,301, 311, 321, 331, 341, 351, 361, 371, 381, 391, 401, 411, 421, 431,441, 451, 461, 471, 481, 491, 501, 511, 5421, 531, 541, 551, 561, 571,or 581, and a VL domain-encoding polynucleotide, for example, apolynucleotide encoding the VL domain as set forth in SEQ ID NO: 66, 16,26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176,186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316,326, 336, 346, 356, 366, 376, 386, 396, 406, 416, 426, 436, 446, 456,466, 476, 486, 496, 506, 516, 5426, 536, 546, 556, 566, 576, or 586.

The present disclosure also includes fragments of the polynucleotides ofthe disclosure, as described elsewhere. Additionally polynucleotidesthat encode fusion polypolypeptides, Fab fragments, and otherderivatives, as described herein, are also contemplated by thedisclosure.

The polynucleotides may be produced or manufactured by any method knownin the art. For example, if the nucleotide sequence of the antibody isknown, a polynucleotide encoding the antibody may be assembled fromchemically synthesized oligonucleotides (e.g., as described in Kutmeieret al., Bio Techniques 17:242 (1994)), which, briefly, involves thesynthesis of overlapping oligonucleotides containing portions of thesequence encoding the antibody, annealing and ligating of thoseoligonucleotides, and then amplification of the ligated oligonucleotidesby PCR.

Alternatively, a polynucleotide encoding an anti-IL-33 antibody, orantigen-binding fragment, variant, or derivative thereof of thedisclosure, may be generated from nucleic acid from a suitable source.If a clone containing a nucleic acid encoding a particular antibody isnot available, but the sequence of the antibody molecule is known, anucleic acid encoding the antibody may be chemically synthesized orobtained from a suitable source (e.g., an antibody cDNA library, or acDNA library generated from, or nucleic acid, preferably poly A+RNA,isolated from, any tissue or cells expressing the antibody or otheranti-IL-33 antibody, such as hybridoma cells selected to express anantibody) by PCR amplification using synthetic primers hybridizable tothe 3′ and 5′ ends of the sequence or by cloning using anoligonucleotide probe specific for the particular gene sequence toidentify, e.g., a cDNA clone from a cDNA library that encodes theantibody or other anti-IL-33 antibody. Amplified nucleic acids generatedby PCR may then be cloned into replicable cloning vectors using anymethod well known in the art.

Once the nucleotide sequence and corresponding amino acid sequence ofthe anti-IL-33 antibody, or antigen-binding fragment, variant, orderivative thereof is determined, its nucleotide sequence may bemanipulated using methods well known in the art for the manipulation ofnucleotide sequences, e.g., recombinant DNA techniques, site directedmutagenesis, PCR, etc. (see, for example, the techniques described inSambrook et al. (1990) Molecular Cloning, A Laboratory Manual (2nd ed.;Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) and Ausubel etal., eds. (1998) Current Protocols in Molecular Biology (John Wiley &Sons, NY), which are both incorporated by reference herein in theirentireties), to generate antibodies having a different amino acidsequence, for example to create amino acid substitutions, deletions,and/or insertions.

A polynucleotide encoding an anti-IL-33 binding molecule, e.g., anantibody, or antigen-binding fragment, variant, or derivative thereof,can be composed of any polyribonucleotide or polydeoxyribonucleotide,which may be unmodified RNA or DNA or modified RNA or DNA. For example,a polynucleotide encoding anti-IL-33 antibody, or antigen-bindingfragment, variant, or derivative thereof can be composed of single- anddouble-stranded DNA, DNA that is a mixture of single- anddouble-stranded regions, single- and double-stranded RNA, and RNA thatis mixture of single- and double-stranded regions, hybrid moleculescomprising DNA and RNA that may be single-stranded or, more typically,double-stranded or a mixture of single- and double-stranded regions. Inaddition, a polynucleotide encoding an anti-IL-33 binding molecule,e.g., an antibody, or antigen-binding fragment, variant, or derivativethereof can be composed of triple-stranded regions comprising RNA or DNAor both RNA and DNA. A polynucleotide encoding an anti-IL-33 bindingmolecule, e.g., antibody, or antigen-binding fragment, variant, orderivative thereof, may also contain one or more modified bases or DNAor RNA backbones modified for stability or for other reasons. “Modified”bases include, for example, tritylated bases and unusual bases such asinosine. A variety of modifications can be made to DNA and RNA; thus,“polynucleotide” embraces chemically, enzymatically, or metabolicallymodified forms.

An isolated polynucleotide encoding a non-natural variant of apolypeptide derived from an immunoglobulin (e.g., an immunoglobulinheavy chain portion or light chain portion) can be created byintroducing one or more nucleotide substitutions, additions or deletionsinto the nucleotide sequence of the immunoglobulin such that one or moreamino acid substitutions, additions or deletions are introduced into theencoded protein. Mutations may be introduced by standard techniques,such as site-directed mutagenesis and PCR-mediated mutagenesis.Preferably, conservative amino acid substitutions are made at one ormore non-essential amino acid residues.

V. Fusion Proteins and Antibody Conjugates

As discussed in more detail elsewhere herein, anti-IL-33 bindingmolecules, e.g., antibodies of the disclosure, or antigen-bindingfragments, variants, or derivatives thereof, may further berecombinantly fused to a heterologous polypeptide at the N- orC-terminus or chemically conjugated (including covalent and non-covalentconjugations) to polypeptides or other compositions. For example,anti-IL-33 antibodies may be recombinantly fused or conjugated tomolecules useful as labels in detection assays and effector moleculessuch as heterologous polypeptides, drugs, radionuclides, or toxins. See,e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Pat.No. 5,314,995; and EP 396,387.

Anti-IL-33 antibodies of the disclosure, or antigen-binding fragments,variants, or derivatives thereof, may include derivatives that aremodified, i.e., by the covalent attachment of any type of molecule tothe antibody such that covalent attachment does not prevent the antibodyfrom binding to IL-33. For example, but not by way of limitation, theantibody derivatives include antibodies that have been modified, e.g.,by glycosylation, acetylation, pegylation, phosphorylation, amidation,derivatization by known protecting/blocking groups, proteolyticcleavage, linkage to a cellular ligand or other protein, etc. Any ofnumerous chemical modifications may be carried out by known techniques,including, but not limited to specific chemical cleavage, acetylation,formylation, etc. Additionally, the derivative may contain one or morenon-classical amino acids.

Anti-IL-33 binding molecules, e.g., antibodies of the disclosure, orantigen-binding fragments, variants, or derivatives thereof, can becomposed of amino acids joined to each other by peptide bonds ormodified peptide bonds, i.e., peptide isosteres, and may contain aminoacids other than the 20 gene-encoded amino acids. For example,anti-IL-33 antibodies may be modified by natural processes, such aspost-translational processing, or by chemical modification techniquesthat are well known in the art. Such modifications are well described inbasic texts and in more detailed monographs, as well as in a voluminousresearch literature. Modifications can occur anywhere in the anti-IL-33binding molecule, including the peptide backbone, the amino acidside-chains and the amino or carboxyl termini, or on moieties such ascarbohydrates. It will be appreciated that the same type of modificationmay be present in the same or varying degrees at several sites in agiven anti-IL-33 binding molecule. Also, a given anti-IL-33 bindingmolecule may contain many types of modifications. Anti-IL-33 bindingmolecules may be branched, for example, as a result of ubiquitination,and they may be cyclic, with or without branching. Cyclic, branched, andbranched cyclic anti-IL-33 binding molecule may result fromposttranslation natural processes or may be made by synthetic methods.Modifications include acetylation, acylation, ADP-ribosylation,amidation, covalent attachment of flavin, covalent attachment of a hememoiety, covalent attachment of a nucleotide or nucleotide derivative,covalent attachment of a lipid or lipid derivative, covalent attachmentof phosphotidylinositol, cross-linking, cyclization, disulfide bondformation, demethylation, formation of covalent cross-links, formationof cysteine, formation of pyroglutamate, formylation,gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation,iodination, methylation, myristoylation, oxidation, pegylation,proteolytic processing, phosphorylation, prenylation, racemization,selenoylation, sulfation, transfer-RNA mediated addition of amino acidsto proteins such as arginylation, and ubiquitination. (See, forinstance, Proteins—Structure and Molecular Properties, T. E. Creighton,W. H. Freeman and Company, NY; 2nd ed. (1993); Johnson, ed. (1983)Posttranslational Covalent Modification of Proteins (Academic Press,NY), pgs. 1-12; Seifter et al., Meth. Enzymol. 182:626-646 (1990);Rattan et al., Ann. NY Acad. Sci. 663:48-62 (1992)).

The present disclosure also provides for fusion proteins comprising ananti-IL-33 antibody, or antigen-binding fragment, variant, or derivativethereof, and a heterologous polypeptide. The heterologous polypeptide towhich the antibody is fused may be useful for function or is useful totarget the anti-IL-33 polypeptide expressing cells.

In one embodiment, a fusion protein of the disclosure comprises,consists essentially of, or consists of, a polypeptide having the aminoacid sequence of any one or more of the VH domains of an antibody of thedisclosure or the amino acid sequence of any one or more of the VLdomains of an antibody of the disclosure or fragments or variantsthereof, and a heterologous polypeptide sequence.

In another embodiment, a fusion protein for use in the diagnostic andtreatment methods disclosed herein comprises, consists essentially of,or consists of a polypeptide having the amino acid sequence of any one,two, three of the CDRs of the VH domain of an anti-IL-33 antibody, orfragments, variants, or derivatives thereof, or the amino acid sequenceof any one, two, three of the CDRs of the VL domain an anti-IL-33antibody, or fragments, variants, or derivatives thereof, and aheterologous polypeptide sequence.

In one embodiment, a fusion protein comprises a polypeptide having theamino acid sequence of at least one VH domain of an anti-IL-33 antibodyof the disclosure and the amino acid sequence of at least one VL domainof an anti-IL-33 antibody of the disclosure or fragments, derivatives orvariants thereof, and a heterologous polypeptide sequence. Preferably,the VH and VL domains of the fusion protein correspond to a singlesource antibody (or scFv or Fab fragment) that specifically binds atleast one epitope of IL-33.

In yet another embodiment, a fusion protein for use in the diagnosticand treatment methods disclosed herein comprises a polypeptide havingthe amino acid sequence of any one, two, three or more of the CDRs ofthe VH domain of an anti-IL-33 antibody and the amino acid sequence ofany one, two, three or more of the CDRs of the VL domain of ananti-IL-33 antibody, or fragments or variants thereof, and aheterologous polypeptide sequence. Preferably, two, three, four, five,six, or more of the CDR(s) of the VH domain or VL domain correspond tosingle source antibody (or scFv or Fab fragment) of the disclosure.Nucleic acid molecules encoding these fusion proteins are alsoencompassed by the disclosure.

Exemplary fusion proteins reported in the literature include fusions ofthe T cell receptor (Gascoigne et al., Proc. Natl. Acad. Sci. USA84:2936-2940 (1987)); CD4 (Capon et al., Nature 337:525-531 (1989);Traunecker et al., Nature 339:68-70 (1989); Zettmeissl et al., DNA CellBiol. USA 9:347-353 (1990); and Byrn et al., Nature 344:667-670(1990));L-selectin (homing receptor) (Watson et al., J. Cell. Biol.130:2221-2229 (1990); and Watson et al., Nature 349:164-167 (1991));CD44 (Aruffo et al., Cell 61:1303-1313 (1990)); CD28 and B7 (Linsley etal., J. Exp. Med. 173:721-730 (1991)); CTLA-4 (Lisley et al., J. Exp.Med. 174:561-569 (1991)); CD22 (Stamenkovic et al., Cell 66:1333-1344(1991)); TNF receptor (Ashkenazi et al., Proc. Natl. Acad. Sci. USA88:10535-10539 (1991); Lesslauer et al., Eur. J. Immunol. 27:2883-2886(1991); and Peppel et al., J. Exp. Med. 174:1483-1489 (1991)); and IgEreceptor a (Ridgway and Gorman, J. Cell. Biol. Vol. 135, Abstract No.1448 (1991)).

As discussed elsewhere herein, anti-IL-33 binding molecules, e.g.,antibodies of the disclosure, or antigen-binding fragments, variants, orderivatives thereof, may be fused to heterologous polypeptides toincrease the in vivo half life of the polypeptides or for use inimmunoassays using methods known in the art. For example, in oneembodiment, PEG can be conjugated to the anti-IL-33 antibodies of thedisclosure to increase their half-life in vivo. See Leong et al.,Cytokine 16:106 (2001); Adv. in Drug Deliv. Rev. 54:531 (2002); or Weiret al., Biochem. Soc. Transactions 30:512 (2002).

Moreover, anti-IL-33 binding molecules, e.g., antibodies of thedisclosure, or antigen-binding fragments, variants, or derivativesthereof, can be fused to marker sequences, such as a peptide tofacilitate their purification or detection. In preferred embodiments,the marker amino acid sequence is a hexa-histidine peptide, such as thetag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue,Chatsworth, Calif., 91313), among others, many of which are commerciallyavailable. As described in Gentz et al., Proc. Natl. Acad. Sci. USA86:821-824 (1989), for instance, hexa-histidine provides for convenientpurification of the fusion protein. Other peptide tags useful forpurification include, but are not limited to, the “HA” tag, whichcorresponds to an epitope derived from the influenza hemagglutininprotein (Wilson et al., Cell 37:767 (1984)) and the “flag” tag.

Fusion proteins can be prepared using methods that are well known in theart (see for example U.S. Pat. Nos. 5,136,964 and 5,225,538). Theprecise site at which the fusion is made may be selected empirically tooptimize the secretion or binding characteristics of the fusion protein.DNA encoding the fusion protein is then transfected into a host cell forexpression.

Anti-IL-33 binding molecules, e.g., antibodies of the presentdisclosure, or antigen-binding fragments, variants, or derivativesthereof, may be used in non-conjugated form or may be conjugated to atleast one of a variety of molecules, e.g., to improve the therapeuticproperties of the molecule, to facilitate target detection, or forimaging or therapy of the patient. Anti-IL-33 binding molecules, e.g.,antibodies of the disclosure, or antigen-binding fragments, variants, orderivatives thereof, can be labeled or conjugated either before or afterpurification, or when purification is performed.

In particular, anti-IL-33 antibodies of the disclosure, orantigen-binding fragments, variants, or derivatives thereof, may beconjugated to therapeutic agents, prodrugs, peptides, proteins, enzymes,viruses, lipids, biological response modifiers, pharmaceutical agents,or PEG.

Those skilled in the art will appreciate that conjugates may also beassembled using a variety of techniques depending on the selected agentto be conjugated. For example, conjugates with biotin are prepared,e.g., by reacting a binding polypeptide with an activated ester ofbiotin such as the biotin N-hydroxysuccinimide ester. Similarly,conjugates with a fluorescent marker may be prepared in the presence ofa coupling agent, e.g., those listed herein, or by reaction with anisothiocyanate, preferably fluorescein-isothiocyanate. Conjugates of theanti-IL-33 antibodies of the disclosure, or antigen-binding fragments,variants, or derivatives thereof, are prepared in an analogous manner.

The present disclosure further encompasses anti-IL-33 binding molecules,e.g., antibodies of the disclosure, or antigen-binding fragments,variants, or derivatives thereof, conjugated to a diagnostic ortherapeutic agent. The anti-IL-33 antibodies, including antigen-bindingfragments, variants, and derivatives thereof, can be used diagnosticallyto, for example, monitor the development or progression of a disease aspart of a clinical testing procedure to, e.g., determine the efficacy ofa given treatment and/or prevention regimen. For example, detection canbe facilitated by coupling the anti-IL-33 antibody, or antigen-bindingfragment, variant, or derivative thereof, to a detectable substance.Examples of detectable substances include various enzymes, prostheticgroups, fluorescent materials, luminescent materials, bioluminescentmaterials, radioactive materials, positron emitting metals using variouspositron emission tomographies, and nonradioactive paramagnetic metalions. See, for example, U.S. Pat. No. 4,741,900 for metal ions which canbe conjugated to antibodies for use as diagnostics according to thepresent disclosure. Examples of suitable enzymes include horseradishperoxidase, alkaline phosphatase, β-galactosidase, oracetylcholinesterase; examples of suitable prosthetic group complexesinclude streptavidin/biotin and avidin/biotin; examples of suitablefluorescent materials include umbelliferone, fluorescein, fluoresceinisothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansylchloride or phycoerythrin; an example of a luminescent material includesluminol; examples of bioluminescent materials include luciferase,luciferin, and aequorin; and examples of suitable radioactive materialinclude ¹²⁵I, ¹³¹I, ¹³¹In, ⁹⁰Y, or ⁹⁹Tc.

An anti-IL-33 binding molecule, e.g., an antibody, or antigen-bindingfragment, variant, or derivative thereof, also can be detectably labeledby coupling it to a chemiluminescent compound. The presence of thechemiluminescent-tagged anti-IL-33 binding molecule is then determinedby detecting the presence of luminescence that arises during the courseof a chemical reaction. Examples of particularly useful chemiluminescentlabeling compounds are luminol, isoluminol, theromatic acridinium ester,imidazole, acridinium salt and oxalate ester.

One of the ways in which an anti-IL-33 antibody, or antigen-bindingfragment, variant, or derivative thereof, can be detectably labeled isby linking the same to an enzyme and using the linked product in anenzyme immunoassay (EIA) (Voller, A., “The Enzyme Linked ImmunosorbentAssay (ELISA)” Microbiological Associates Quarterly Publication,Walkersville, Md.; Diagnostic Horizons 2:1-7 (1978); Voller et al., J.Clin. Pathol. 31:507-520 (1978); Butler, Meth. Enzymol. 73:482-523(1981); Maggio, ed. (1980) Enzyme Immunoassay, CRC Press, Boca Raton,Fla.; Ishikawa et al., eds. (1981) Enzyme Immunoassay (Kgaku Shoin,Tokyo). The enzyme, which is bound to the anti-IL-33 antibody will reactwith an appropriate substrate, preferably a chromogenic substrate, insuch a manner as to produce a chemical moiety which can be detected, forexample, by spectrophotometric, fluorimetric or by visual means. Enzymeswhich can be used to detectably label the antibody include, but are notlimited to, malate dehydrogenase, staphylococcal nuclease,delta-5-steroid isomerase, yeast alcohol dehydrogenase,alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase,horseradish peroxidase, alkaline phosphatase, asparaginase, glucoseoxidase, beta-galactosidase, ribonuclease, urease, catalase,glucose-6-phosphate dehydrogenase, glucoamylase andacetylcholinesterase. Additionally, the detection can be accomplished bycolorimetric methods which employ a chromogenic substrate for theenzyme. Additionally, the detection can be accomplished by fluorescentmethods, whereby a fluorescence emitting metals such as 152Eu, or othersof the lanthanide series is bound directly or indirectly to theanti-IL-33 antibody. Detection may also be accomplished by visualcomparison of the extent of enzymatic reaction of a substrate incomparison with similarly prepared standards.

Detection may also be accomplished using any of a variety of otherimmunoassays. For example, by radioactively labeling the anti-IL-33binding molecule, e.g., antibody, or antigen-binding fragment, variant,or derivative thereof, it is possible to detect the binding moleculethrough the use of a radioimmunoassay (RIA) (see, for example, Weintraub(March, 1986) Principles of Radioimmunoassays, Seventh Training Courseon Radioligand Assay Techniques (The Endocrine Society), which isincorporated by reference herein). The radioactive isotope can bedetected by means including, but not limited to, a gamma counter, ascintillation counter, or autoradiography.

An anti-IL-33 binding molecule, e.g., antibody, or antigen-bindingfragment, variant, or derivative thereof, can also be detectably labeledusing fluorescence emitting metals such as 152Eu, or others of thelanthanide series. These metals can be attached to the binding moleculeusing such metal chelating groups as diethylenetriaminepentacetic acid(DTPA) or ethylenediaminetetraacetic acid (EDTA).

Techniques for conjugating various moieties to an antibody (e.g., ananti-IL-33 antibody), or antigen-binding fragment, variant, orderivative thereof, are well known, see, e.g., Amon et al. (1985)“Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy,”in Monoclonal Antibodies and Cancer Therapy, ed. Reisfeld et al. (AlanR. Liss, Inc.), pp. 243-56; Hellstrom et al. (1987) “Antibodies for DrugDelivery,” in Controlled Drug Delivery, ed. Robinson et al. (2nd ed.;Marcel Dekker, Inc.), pp. 623-53); Thorpe (1985) “Antibody Carriers ofCytotoxic Agents in Cancer Therapy: A Review,” in Monoclonal Antibodies'84: Biological and Clinical Applications, ed. Pinchera et al., pp.475-506; “Analysis, Results, and Future Prospective of the TherapeuticUse of Radiolabeled Antibody in Cancer Therapy,” in MonoclonalAntibodies for Cancer Detection and Therapy, ed. Baldwin et al.,Academic Press, pp. 303-16 (1985); and Thorpe et al. (1982) “ThePreparation and Cytotoxic Properties of Antibody-Toxin Conjugates,”Immunol. Rev. 62:139-58.

VI. Expression of Antibody Polypeptides

DNA sequences that encode the light and the heavy chains of the antibodymay be made, either simultaneously or separately, using reversetranscriptase and DNA polymerase in accordance with well known methods.PCR may be initiated by consensus constant region primers or by morespecific primers based on the published heavy and light chain DNA andamino acid sequences. As discussed above, PCR also may be used toisolate DNA clones encoding the antibody light and heavy chains. In thiscase the libraries may be screened by consensus primers or largerhomologous probes, such as mouse constant region probes.

DNA, typically plasmid DNA, may be isolated from the cells usingtechniques known in the art, restriction mapped and sequenced inaccordance with standard, well known techniques set forth in detail,e.g., in the foregoing references relating to recombinant DNAtechniques. Of course, the DNA may be synthetic according to the presentdisclosure at any point during the isolation process or subsequentanalysis.

Following manipulation of the isolated genetic material to provideanti-IL-33 antibodies, or antigen-binding fragments, variants, orderivatives thereof, of the disclosure, the polynucleotides encoding theanti-IL-33 antibodies are typically inserted in an expression vector forintroduction into host cells that may be used to produce the desiredquantity of anti-IL-33 antibody.

Recombinant expression of an antibody, or fragment, derivative or analogthereof, e.g., a heavy or light chain of an antibody that binds to atarget molecule described herein, e.g., IL-33, requires construction ofan expression vector containing a polynucleotide that encodes theantibody. Once a polynucleotide encoding an antibody molecule or a heavyor light chain of an antibody, or portion thereof (preferably containingthe heavy or light chain variable domain), of the disclosure has beenobtained, the vector for the production of the antibody molecule may beproduced by recombinant DNA technology using techniques well known inthe art. Thus, methods for preparing a protein by expressing apolynucleotide containing an antibody encoding nucleotide sequence aredescribed herein. Methods that are well known to those skilled in theart can be used to construct expression vectors containing antibodycoding sequences and appropriate transcriptional and translationalcontrol signals. These methods include, for example, in vitrorecombinant DNA techniques, synthetic techniques, and in vivo geneticrecombination. The disclosure, thus, provides replicable vectorscomprising a nucleotide sequence encoding an antibody molecule of thedisclosure, or a heavy or light chain thereof, or a heavy or light chainvariable domain, operably linked to a promoter. Such vectors may includethe nucleotide sequence encoding the constant region of the antibodymolecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO89/01036; and U.S. Pat. No. 5,122,464) and the variable domain of theantibody may be cloned into such a vector for expression of the entireheavy or light chain.

The term “vector” or “expression vector” is used herein to mean vectorsused in accordance with the present disclosure as a vehicle forintroducing into and expressing a desired gene in a host cell. As knownto those skilled in the art, such vectors may easily be selected fromthe group consisting of plasmids, phages, viruses and retroviruses. Ingeneral, vectors compatible with the instant disclosure will comprise aselection marker, appropriate restriction sites to facilitate cloning ofthe desired gene and the ability to enter and/or replicate in eukaryoticor prokaryotic cells.

For the purposes of this disclosure, numerous expression vector systemsmay be employed. For example, one class of vector utilizes DNA elementsthat are derived from animal viruses such as bovine papilloma virus,polyoma virus, adenovirus, vaccinia virus, baculovirus, retroviruses(RSV, MMTV or MOMLV) or SV40 virus. Others involve the use ofpolycistronic systems with internal ribosome binding sites.Additionally, cells that have integrated the DNA into their chromosomesmay be selected by introducing one or more markers which allow selectionof transfected host cells. The marker may provide for prototrophy to anauxotrophic host, biocide resistance (e.g., antibiotics) or resistanceto heavy metals such as copper. The selectable marker gene can either bedirectly linked to the DNA sequences to be expressed, or introduced intothe same cell by cotransformation. Additional elements may also beneeded for optimal synthesis of mRNA. These elements may include signalsequences, splice signals, as well as transcriptional promoters,enhancers, and termination signals.

In particularly preferred embodiments the cloned variable region genesare inserted into an expression vector along with the heavy and lightchain constant region genes (preferably human) synthesized as discussedabove. Of course, any expression vector that is capable of elicitingexpression in eukaryotic cells may be used in the present disclosure.Examples of suitable vectors include, but are not limited to plasmidspcDNA3, pHCMV/Zeo, pCR3.1, pEF 1/His, pIND/GS, pRc/HCMV2, pSV40/Zeo2,pTRACER-HCMV, pUB6/V5-His, pVAX1, and pZeoSV2 (available fromInvitrogen, San Diego, Calif.), and plasmid pCI (available from Promega,Madison, Wis.). In general, screening large numbers of transformed cellsfor those that express suitably high levels of immunoglobulin heavy andlight chains is routine experimentation that can be carried out, forexample, by robotic systems.

More generally, once the vector or DNA sequence encoding a monomericsubunit of the anti-IL-33 antibody has been prepared, the expressionvector may be introduced into an appropriate host cell. Introduction ofthe plasmid into the host cell can be accomplished by various techniqueswell known to those of skill in the art. These include, but are notlimited to, transfection (including electrophoresis andelectroporation), protoplast fusion, calcium phosphate precipitation,cell fusion with enveloped DNA, microinjection, and infection withintact virus. See, Ridgway (1988) “Mammalian Expression Vectors” inVectors, ed. Rodriguez and Denhardt (Butterworths, Boston, Mass.),Chapter 24.2, pp. 470-472. Typically, plasmid introduction into the hostis via electroporation. The host cells harboring the expressionconstruct are grown under conditions appropriate to the production ofthe light chains and heavy chains, and assayed for heavy and/or lightchain protein synthesis. Exemplary assay techniques includeenzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), orfluorescence-activated cell sorter analysis (FACS), immunohistochemistryand the like.

The expression vector is transferred to a host cell by conventionaltechniques, and the transfected cells are then cultured by conventionaltechniques to produce an antibody for use in the methods describedherein. Thus, the disclosure includes host cells containing apolynucleotide encoding an antibody of the disclosure, or a heavy orlight chain thereof, operably linked to a heterologous promoter. Inpreferred embodiments for the expression of double-chained antibodies,vectors encoding both the heavy and light chains may be co-expressed inthe host cell for expression of the entire immunoglobulin molecule, asdetailed below.

As used herein, “host cells” refers to cells that harbor vectorsconstructed using recombinant DNA techniques and encoding at least oneheterologous gene. In descriptions of processes for isolation ofantibodies from recombinant hosts, the terms “cell” and “cell culture”are used interchangeably to denote the source of antibody unless it isclearly specified otherwise. In other words, recovery of polypeptidefrom the “cells” may mean either from spun down whole cells, or from thecell culture containing both the medium and the suspended cells.

A variety of host-expression vector systems may be utilized to expressantibody molecules for use in the methods described herein. Suchhost-expression systems represent vehicles by which the coding sequencesof interest may be produced and subsequently purified, but alsorepresent cells that may, when transformed or transfected with theappropriate nucleotide coding sequences, express an antibody molecule ofthe disclosure in situ. These include, but are not limited to,microorganisms such as bacteria (e.g., E. coli, B. subtilis) transformedwith recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expressionvectors containing antibody coding sequences; yeast (e.g.,Saccharomyces, Pichia) transformed with recombinant yeast expressionvectors containing antibody coding sequences; insect cell systemsinfected with recombinant virus expression vectors (e.g., baculovirus)containing antibody coding sequences; plant cell systems infected withrecombinant virus expression vectors (e.g., cauliflower mosaic virus,CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmidexpression vectors (e.g., Ti plasmid) containing antibody codingsequences; or mammalian cell systems (e.g., COS, CHO, BLK, 293, 3T3cells) harboring recombinant expression constructs containing promotersderived from the genome of mammalian cells (e.g., metallothioneinpromoter) or from mammalian viruses (e.g., the adenovirus late promoter;the vaccinia virus 7.5K promoter). Preferably, bacterial cells such asEscherichia coli, and more preferably, eukaryotic cells, especially forthe expression of whole recombinant antibody molecule, are used for theexpression of a recombinant antibody molecule. For example, mammaliancells such as Chinese hamster ovary cells (CHO), in conjunction with avector such as the major intermediate early gene promoter element fromhuman cytomegalovirus is an effective expression system for antibodies(Foecking et al., Gene 45:101 (1986); Cockett et al., Bio/Technology 8:2(1990)).

The host cell line used for protein expression is often of mammalianorigin; those skilled in the art are credited with ability topreferentially determine particular host cell lines that are best suitedfor the desired gene product to be expressed therein. Exemplary hostcell lines include, but are not limited to, CHO (Chinese Hamster Ovary),DG44 and DUXB 13 (Chinese Hamster Ovary lines, DHFR minus), HELA (humancervical carcinoma), CVI (monkey kidney line), COS (a derivative of CVIwith SV40 T antigen), VERY, BHK (baby hamster kidney), MDCK, 293, WI38,R1610 (Chinese hamster fibroblast) BALBC/3T3 (mouse fibroblast), HAK(hamster kidney line), SP2/O (mouse myeloma), P3.times.63-Ag3.653 (mousemyeloma), BFA-1c1BPT (bovine endothelial cells), RAJI (human lymphocyte)and 293 (human kidney). Host cell lines are typically available fromcommercial services, the American Tissue Culture Collection or frompublished literature.

In addition, a host cell strain may be chosen that modulates theexpression of the inserted sequences, or modifies and processes the geneproduct in the specific fashion desired. Such modifications (e.g.,glycosylation) and processing (e.g., cleavage) of protein products maybe important for the function of the protein. Different host cells havecharacteristic and specific mechanisms for the post-translationalprocessing and modification of proteins and gene products. Appropriatecell lines or host systems can be chosen to ensure the correctmodification and processing of the foreign protein expressed. To thisend, eukaryotic host cells that possess the cellular machinery forproper processing of the primary transcript, glycosylation, andphosphorylation of the gene product may be used.

For long-term, high-yield production of recombinant proteins, stableexpression is preferred. For example, cell lines that stably express theantibody molecule may be engineered. Rather than using expressionvectors that contain viral origins of replication, host cells can betransformed with DNA controlled by appropriate expression controlelements (e.g., promoter, enhancer, sequences, transcriptionterminators, polyadenylation sites, etc.), and a selectable marker.Following the introduction of the foreign DNA, engineered cells may beallowed to grow for 1-2 days in an enriched media, and then are switchedto a selective media. The selectable marker in the recombinant plasmidconfers resistance to the selection and allows cells to stably integratethe plasmid into their chromosomes and grow to form foci which in turncan be cloned and expanded into cell lines. This method mayadvantageously be used to engineer cell lines which stably express theantibody molecule.

A number of selection systems may be used, including, but not limitedto, the herpes simplex virus thymidine kinase (Wigler et al., Cell13:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase(Szybalska and Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), andadenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980))genes can be employed in tk-, hgprt- or aprt-cells, respectively. Also,antimetabolite resistance can be used as the basis of selection for thefollowing genes: dhfr, which confers resistance to methotrexate (Wigleret al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl.Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance tomycophenolic acid (Mulligan and Berg, Proc. Natl. Acad. Sci. USA 78:2072(1981)); neo, which confers resistance to the aminoglycoside G-418Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991);Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan,Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem.62:191-217 (1993); TIB TECH 13(5):155-215 (May, 1993); and hygro, whichconfers resistance to hygromycin (Santerre et al., Gene 30:147 (1984).Methods commonly known in the art of recombinant DNA technology whichcan be used are described in Ausubel et al. (1993) Current Protocols inMolecular Biology (John Wiley & Sons, NY); Kriegler (1990) “GeneTransfer and Expression” in A Laboratory Manual (Stockton Press, NY);Dracopoli et al. (eds) (1994) Current Protocols in Human Genetics (JohnWiley & Sons, NY) Chapters 12 and 13; Colberre-Garapin et al. (1981) J.Mol. Biol. 150:1, which are incorporated by reference herein in theirentireties.

The expression levels of an antibody molecule can be increased by vectoramplification (for a review, see Bebbington and Hentschel (1987) “TheUse of Vectors Based on Gene Amplification for the Expression of ClonedGenes in Mammalian Cells in DNA Cloning” (Academic Press, NY) Vol. 3.When a marker in the vector system expressing antibody is amplifiable,increase in the level of inhibitor present in culture of host cell willincrease the number of copies of the marker gene. Since the amplifiedregion is associated with the antibody gene, production of the antibodywill also increase (Crouse et al., Mol. Cell. Biol. 3:257 (1983)).

In vitro production allows scale-up to give large amounts of the desiredpolypeptides. Techniques for mammalian cell cultivation under tissueculture conditions are known in the art and include homogeneoussuspension culture, e.g. in an airlift reactor or in a continuousstirrer reactor, or immobilized or entrapped cell culture, e.g. inhollow fibers, microcapsules, on agarose microbeads or ceramiccartridges. If necessary and/or desired, the solutions of polypeptidescan be purified by the customary chromatography methods, for example gelfiltration, ion-exchange chromatography, chromatography overDEAE-cellulose or (immuno-)affinity chromatography, e.g., afterpreferential biosynthesis of a synthetic hinge region polypeptide orprior to or subsequent to the HIC chromatography step described herein.

Genes encoding anti-IL-33 antibodies, or antigen-binding fragments,variants, or derivatives thereof of the disclosure can also be expressedin non-mammalian cells such as insect, bacteria or yeast or plant cells.Bacteria that readily take up nucleic acids include members of theenterobacteriaceae, such as strains of Escherichia coli or Salmonella;Bacillaceae, such as Bacillus subtilis; Pneumococcus; Streptococcus, andHaemophilus influenzae. It will further be appreciated that, whenexpressed in bacteria, the heterologous polypeptides typically becomepart of inclusion bodies. The heterologous polypeptides must beisolated, purified and then assembled into functional molecules. Wheretetravalent forms of antibodies are desired, the subunits will thenself-assemble into tetravalent antibodies (WO 02/096948A2).

In bacterial systems, a number of expression vectors may beadvantageously selected depending upon the use intended for the antibodymolecule being expressed. For example, when a large quantity of such aprotein is to be produced, for the generation of pharmaceuticalcompositions of an antibody molecule, vectors which direct theexpression of high levels of fusion protein products that are readilypurified may be desirable. Such vectors include, but are not limited, tothe E. coli expression vector pUR278 (Ruther et al., EMBO J. 2:1791(1983)), in which the antibody coding sequence may be ligatedindividually into the vector in frame with the lacZ coding region sothat a fusion protein is produced; pIN vectors (Inouye and Inouye,Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke and Schuster, J. Biol.Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be usedto express foreign polypeptides as fusion proteins with glutathioneS-transferase (GST). In general, such fusion proteins are soluble andcan easily be purified from lysed cells by adsorption and binding to amatrix glutathione-agarose beads followed by elution in the presence offree glutathione. The pGEX vectors are designed to include thrombin orfactor Xa protease cleavage sites so that the cloned target gene productcan be released from the GST moiety.

In addition to prokaryotes, eukaryotic microbes may also be used.Saccharomyces cerevisiae, or common baker's yeast, is the most commonlyused among eukaryotic microorganisms although a number of other strainsare commonly available, e.g., Pichia pastoris.

For expression in Saccharomyces, the plasmid YRp7, for example,(Stinchcomb et al., Nature 282:39 (1979); Kingsman et al., Gene 7:141(1979); Tschemper et al., Gene 10:157 (1980)) is commonly used. Thisplasmid already contains the TRP1 gene, which provides a selectionmarker for a mutant strain of yeast lacking the ability to grow intryptophan, for example ATCC No. 44076 or PEP4-1 (Jones, Genetics 85:12(1977)). The presence of the trp1 lesion as a characteristic of theyeast host cell genome then provides an effective environment fordetecting transformation by growth in the absence of tryptophan.

In an insect system, Autographa californica nuclear polyhedrosis virus(AcNPV) is typically used as a vector to express foreign genes. Thevirus grows in Spodoptera frugiperda cells. The antibody coding sequencemay be cloned individually into non-essential regions (for example thepolyhedrin gene) of the virus and placed under control of an AcNPVpromoter (for example the polyhedrin promoter).

Once a binding molecule of the disclosure has been recombinantlyexpressed, it may be purified by any method known in the art forpurification of an immunoglobulin molecule, for example, bychromatography (e.g., ion exchange, affinity, particularly by affinityfor the specific antigen after Protein A, and sizing columnchromatography), centrifugation, differential solubility, or by anyother standard technique for the purification of proteins.Alternatively, a preferred method for increasing the affinity ofantibodies of the disclosure is disclosed in U.S. Patent ApplicationPublication No. 2002 0123057 A1.

VII. Treatment Methods Using Therapeutic Anti-IL-33 Antibodies

Methods of the disclosure are directed to the use of anti-IL-33 bindingmolecules, e.g., antibodies, including antigen-binding fragments,variants, and derivatives thereof, to treat patients having a diseaseassociated with IL-33 expression or IL-33-expressing cells. By“IL-33-expressing cell” is intended cells expressing IL-33 antigen.Methods for detecting IL-33 expression in cells are well known in theart and include, but are not limited to, PCR techniques,immunohistochemistry, flow cytometry, Western blot, ELISA, and the like.

Though the following discussion refers to diagnostic methods andtreatment of various diseases and disorders with an anti-IL-33 antibodyof the disclosure, the methods described herein are also applicable tothe antigen-binding fragments, variants, and derivatives of theseanti-IL-33 antibodies that retain the desired properties of theanti-IL-33 antibodies of the disclosure, e.g., capable of specificallybinding IL-33 and neutralizing IL-33 pathogenic activity.

In one embodiment, treatment includes the application or administrationof an anti-IL-33 binding molecule, e.g., an antibody or antigen bindingfragment thereof, of the current disclosure to a subject or patient, orapplication or administration of the anti-IL-33 binding molecule to anisolated tissue or cell line from a subject or patient, where thesubject or patient has a disease, a symptom of a disease, or apredisposition toward a disease. In another embodiment, treatment isalso intended to include the application or administration of apharmaceutical composition comprising the anti-IL-33 binding molecule,e.g., an antibody or antigen binding fragment thereof, of the currentdisclosure to a subject or patient, or application or administration ofa pharmaceutical composition comprising the anti-IL-33 binding moleculeto an isolated tissue or cell line from a subject or patient, who has adisease, a symptom of a disease, or a predisposition toward a disease.

The anti-IL-33 binding molecules, e.g., antibodies or binding fragmentsthereof, of the present disclosure are useful for the treatment ofvarious inflammatory conditions. By “anti-inflammatory activity” isintended a reduction in the rate of inflammatory response in anIL-33-expressing cell, and hence a decline in inflammation in a tissuethat arises during therapy. For example, therapy with at least oneanti-IL-33 antibody causes a physiological response, for example, areduction in inflammatory response that is beneficial with respect totreatment of disease states associated with IL-33-expressing cells in ahuman.

In one embodiment, the disclosure relates to anti-IL-33 bindingmolecules, e.g., antibodies or binding fragments thereof, according tothe present disclosure for use as a medicament, in particular for use inthe treatment or prophylaxis of an inflammatory response or for use intreatment of an inflammatory condition e.g., asthma or COPD. In certainembodiments, an anti-IL-33 binding molecule, e.g., an antibody orbinding-fragment thereof, of the disclosure is used for the treatment ofan allergic disorder. In certain embodiments, an anti-IL-33 bindingmolecule, e.g., an antibody or binding-fragment thereof, of thedisclosure is used for the treatment of an inflammatory response in theairway of a subject or patient.

In accordance with the methods of the present disclosure, at least oneanti-IL-33 binding molecule, e.g., an antibody or antigen bindingfragment thereof, as defined elsewhere herein is used to promote apositive therapeutic response with respect to an inflammatory response.By “positive therapeutic response” with respect to inflammationtreatment is intended an improvement in the disease in association withthe anti-inflammatory activity of these binding molecules, e.g.,antibodies or fragments thereof, and/or an improvement in the symptomsassociated with the disease. That is, an anti-inflammatory effect, theprevention of further inflammation and/or a reduction in existinginflammation, and/or a decrease in one or more symptoms associated withthe disease can be observed. Thus, for example, an improvement in thedisease may be characterized as a complete response. By “completeresponse” is intended an absence of clinically detectable disease withnormalization of any previous test results. Such a response must persistfor at least one month following treatment according to the methods ofthe disclosure. Alternatively, an improvement in the disease may becategorized as being a partial response.

The anti-IL-33 binding molecules, e.g., antibodies or antigen bindingfragments thereof, described herein may also find use in the treatmentof inflammatory diseases and deficiencies or disorders of the immunesystem that are associated with IL-33 expressing cells. Inflammatorydiseases are characterized by inflammation and tissue destruction, or acombination thereof. By “anti-inflammatory activity” is intended areduction or prevention of inflammation. “Inflammatory disease” includesany inflammatory immune-mediated process where the initiating event ortarget of the immune response involves non-self antigen(s), including,for example, alloantigens, xenoantigens, viral antigens, bacterialantigens, unknown antigens, or allergens. In one embodiment, theinflammatory disease is an inflammatory disorder of the airway, e.g.,asthma or COPD.

Asthma is considered a common inflammatory disease of the airwayscharacterized, e.g., by variable and recurring symptoms, reversibleairflow obstruction, and bronchospasm. Asthma symptoms can includewheezing, coughing, chest tightness, and shortness of breath. Symptomscan be triggered by exposure to allergens or irritants. Asthma may beclassified as atopic (extrinsic) or non-atopic (intrinsic), based onwhether symptoms are precipitated by allergens (atopic) or not(non-atopic). An acute asthma exacerbation is commonly referred to as an“asthma attack”. Further signs which can occur during an asthma attackinclude the use of accessory muscles of respiration (sternocleidomastoidand scalene muscles of the neck), there may be a paradoxical pulse (apulse that is weaker during inhalation and stronger during exhalation),and over-inflation of the chest. A blue color of the skin and nails mayoccur from lack of oxygen.

In accordance with the methods of the present disclosure, at least oneanti-IL-33 binding molecule, e.g., an antibody or antigen bindingfragment thereof, as defined elsewhere herein is used to promote apositive therapeutic response with respect to treatment or prevention ofan inflammatory disease. By “positive therapeutic response” with respectto an inflammatory disease is intended an improvement in the disease inassociation with the anti-inflammatory activity, or the like, of theseantibodies, and/or an improvement in the symptoms associated with thedisease. That is, a reduction in the inflammatory response including butnot limited to reduced secretion of inflammatory cytokines, adhesionmolecules, proteases, immunoglobulins, combinations thereof, and thelike, increased production of anti-inflammatory proteins, a reduction inthe number of autoreactive cells, an increase in immune tolerance,inhibition of autoreactive cell survival, reduction in apoptosis,reduction in endothelial cell migration, increase in spontaneousmonocyte migration, reduction in and/or a decrease in one or moresymptoms mediated by stimulation of IL-33-expressing cells can beobserved. Such positive therapeutic responses are not limited to theroute of administration.

Clinical response can be assessed using screening techniques such asmagnetic resonance imaging (MRI) scan, x-radiographic imaging, computedtomographic (CT) scan, flow cytometry or fluorescence-activated cellsorter (FACS) analysis, histology, gross pathology, and blood chemistry,including but not limited to changes detectable by ELISA, RIA,chromatography, and the like. In addition to these positive therapeuticresponses, the subject undergoing therapy with the anti-IL-33 bindingmolecule, e.g., an antibody or antigen-binding fragment thereof, mayexperience the beneficial effect of an improvement in the symptomsassociated with the disease.

The anti-IL-33 binding molecules, e.g., antibodies or binding fragmentsthereof, of the disclosure can be used in combination with any knowntherapies for inflammatory diseases, including any agent or combinationof agents that are known to be useful, or which have been used or arecurrently in use, for treatment of inflammatory diseases, e.g., asthmaor COPD. Agents used to treat asthma are divided into two generalclasses: quick-relief medications used to treat acute symptoms; andlong-term control medications used to prevent further exacerbation. Fastacting treatments include, e.g., short-acting beta-2 adrenoceptoragonist (SABA) (e.g., salbutamol); anticholinerginic medications (e.g.,ipratropium bromide), adrenergic agonists (e.g., epinephrine). Long termcontrol treatments include, e.g., glucocorticoids (e.g., fluticasonepropionate); long-acting beta-2 adrenoceptor agonist (LABA); leukotrieneantagonists (e.g., zafirlukast); and mast cell stabilizers (e.g.,cromolyn sodium). Fast acting and long term control treatments are oftenadministered by inhalation.

Thus, where the combined therapies comprise administration of ananti-IL-33 binding molecule in combination with administration ofanother therapeutic agent, the methods of the disclosure encompasscoadministration, using separate formulations or a single pharmaceuticalformulation, and consecutive administration in either order. In someembodiments of the disclosure, the anti-IL-33 antibodies describedherein are administered in combination with anti-inflammatory drugs,wherein the antibody or antigen-binding fragment thereof and thetherapeutic agent(s) may be administered sequentially, in either order,or simultaneously (i.e., concurrently or within the same time frame).

A further embodiment of the disclosure is the use of anti-IL-33 bindingmolecule, e.g., antibodies or antigen binding fragments thereof, fordiagnostic monitoring of protein levels in tissue as part of a clinicaltesting procedure, e.g., to determine the efficacy of a given treatmentregimen. For example, detection can be facilitated by coupling theantibody to a detectable substance. Examples of detectable substancesinclude various enzymes, prosthetic groups, fluorescent materials,luminescent materials, bioluminescent materials, and radioactivematerials. Examples of suitable enzymes include horseradish peroxidase,alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examplesof suitable prosthetic group complexes include streptavidin/biotin andavidin/biotin; examples of suitable fluorescent materials includeumbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine,dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; anexample of a luminescent material includes luminol; examples ofbioluminescent materials include luciferase, luciferin, and aequorin;and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S,or ³H.

VIII. Pharmaceutical Compositions and Administration Methods

Methods of preparing and administering the anti-IL-33 binding molecule,e.g., antibodies, or antigen-binding fragments, variants, or derivativesthereof, of the disclosure to a subject in need thereof are well knownto or are readily determined by those skilled in the art. The route ofadministration of the anti-IL-33 binding molecule, e.g, antibody, orantigen-binding fragment, variant, or derivative thereof, may be, forexample, oral, parenteral, by inhalation or topical. The term parenteralas used herein includes, e.g., intravenous, intraarterial,intraperitoneal, intramuscular, subcutaneous, rectal, or vaginaladministration. While all these forms of administration are clearlycontemplated as being within the scope of the disclosure, anotherexample of a form for administration would be a solution for injection,in particular for intravenous or intraarterial injection or drip.Usually, a suitable pharmaceutical composition of the disclosure maycomprise a buffer (e.g. acetate, phosphate or citrate buffer), asurfactant (e.g. a polysorbate), optionally a stabilizer agent (e.g.human albumin), etc. However, in other methods compatible with theteachings herein, anti-IL-33 binding molecules, e.g., antibodies, orantigen-binding fragments, variants, or derivatives thereof, of thedisclosure can be delivered directly to the site of the adverse cellularpopulation thereby increasing the exposure of the diseased tissue to thetherapeutic agent. In one embodiment, the administration is directly tothe airway, e.g., by inhalation or intranasal administration.

As discussed herein, anti-IL-33 binding molecules, e.g., antibodies, orantigen-binding fragments, variants, or derivatives thereof, of thedisclosure may be administered in a pharmaceutically effective amountfor the in vivo treatment of IL-33-expressing cell-mediated diseasessuch as certain types of inflammatory diseases. In this regard, it willbe appreciated that the disclosed binding molecules of the disclosurewill be formulated so as to facilitate administration and promotestability of the active agent. Preferably, pharmaceutical compositionsin accordance with the present disclosure comprise a pharmaceuticallyacceptable, non-toxic, sterile carrier such as physiological saline,non-toxic buffers, preservatives and the like. For the purposes of theinstant application, a pharmaceutically effective amount of ananti-IL-33 binding molecule, e.g., an antibody, or antigen-bindingfragment, variant, or derivative thereof, conjugated or unconjugated,shall be held to mean an amount sufficient to achieve effective bindingto a target and to achieve a benefit, e.g., to ameliorate symptoms of adisease or condition or to detect a substance or a cell.

The pharmaceutical compositions used in this disclosure may comprisepharmaceutically acceptable carriers, including, e.g., water, ionexchangers, alumina, aluminum stearate, lecithin, serum proteins, suchas human serum albumin, buffer substances such as phosphates, glycine,sorbic acid, potassium sorbate, partial glyceride mixtures of saturatedvegetable fatty acids, water, salts or electrolytes, such as protaminesulfate, disodium hydrogen phosphate, potassium hydrogen phosphate,sodium chloride, zinc salts, colloidal silica, magnesium trisilicate,polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol,sodium carboxymethylcellulose, polyacrylates, waxes,polyethylene-polyoxypropylene-block polymers, polyethylene glycol, andwool fat.

Preparations for administration include sterile aqueous or non-aqueoussolutions, suspensions, and emulsions. Examples of non-aqueous solventsare propylene glycol, polyethylene glycol, vegetable oils such as oliveoil, and injectable organic esters such as ethyl oleate. Aqueouscarriers include, e.g., water, alcoholic/aqueous solutions, emulsions orsuspensions, including saline and buffered media. In the presentdisclosure, pharmaceutically acceptable carriers include, but are notlimited to, 0.01-0.1 M and preferably 0.05 M phosphate buffer or 0.8%saline. Other common parenteral vehicles include sodium phosphatesolutions, Ringer's dextrose, dextrose and sodium chloride, lactatedRinger's, or fixed oils. Intravenous vehicles include fluid and nutrientreplenishers, electrolyte replenishers, such as those based on Ringer'sdextrose, and the like. Preservatives and other additives may also bepresent such as, for example, antimicrobials, antioxidants, chelatingagents, and inert gases and the like.

More particularly, pharmaceutical compositions suitable for injectableuse include sterile aqueous solutions (where water soluble) ordispersions and sterile powders for the extemporaneous preparation ofsterile injectable solutions or dispersions. In such cases, thecomposition must be sterile and should be fluid to the extent that easysyringability exists. It should be stable under the conditions ofmanufacture and storage and will preferably be preserved against thecontaminating action of microorganisms, such as bacteria and fungi. Thecarrier can be a solvent or dispersion medium containing, for example,water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquidpolyethylene glycol, and the like), and suitable mixtures thereof. Theproper fluidity can be maintained, for example, by the use of a coatingsuch as lecithin, by the maintenance of the required particle size inthe case of dispersion and by the use of surfactants. Suitableformulations for use in the therapeutic methods disclosed herein aredescribed in Remington's Pharmaceutical Sciences (Mack Publishing Co.)16th ed. (1980).

Prevention of the action of microorganisms can be achieved by variousantibacterial and antifungal agents, for example, parabens,chlorobutanol, phenol, ascorbic acid, thimerosal and the like. In manycases, it will be preferable to include isotonic agents, for example,sugars, polyalcohols, such as mannitol, sorbitol, or sodium chloride inthe composition. Prolonged absorption of the injectable compositions canbe brought about by including in the composition an agent which delaysabsorption, for example, aluminum monostearate and gelatin.

In any case, sterile injectable solutions can be prepared byincorporating an active compound (e.g., an anti-IL-33 antibody, orantigen-binding fragment, variant, or derivative thereof, by itself orin combination with other active agents) in the required amount in anappropriate solvent with one or a combination of ingredients enumeratedherein, as required, followed by filtered sterilization. Generally,dispersions are prepared by incorporating the active compound into asterile vehicle, which contains a basic dispersion medium and therequired other ingredients from those enumerated above. In the case ofsterile powders for the preparation of sterile injectable solutions, thepreferred methods of preparation are vacuum drying and freeze-drying,which yields a powder of an active ingredient plus any additionaldesired ingredient from a previously sterile-filtered solution thereof.The preparations for injections are processed, filled into containerssuch as ampoules, bags, bottles, syringes or vials, and sealed underaseptic conditions according to methods known in the art. Further, thepreparations may be packaged and sold in the form of a kit. Sucharticles of manufacture will preferably have labels or package insertsindicating that the associated compositions are useful for treating asubject suffering from, or predisposed to a disease or disorder.

Parenteral formulations may be a single bolus dose, an infusion or aloading bolus dose followed with a maintenance dose. These compositionsmay be administered at specific fixed or variable intervals, e.g., oncea day, or on an “as needed” basis.

Certain pharmaceutical compositions used in this disclosure may beorally administered in an acceptable dosage form including, e.g.,capsules, tablets, aqueous suspensions or solutions. Certainpharmaceutical compositions also may be administered by nasal aerosol orinhalation. Such compositions may be prepared as solutions in saline,employing benzyl alcohol or other suitable preservatives, absorptionpromoters to enhance bioavailability, and/or other conventionalsolubilizing or dispersing agents.

The amount of an anti-IL-33 binding molecule, e.g., antibody, orfragment, variant, or derivative thereof that may be combined with thecarrier materials to produce a single dosage form will vary dependingupon the subject treated and the particular mode of administration. Thecomposition may be administered as a single dose, multiple doses or overan established period of time in an infusion. Dosage regimens also maybe adjusted to provide the optimum desired response (e.g., a therapeuticor prophylactic response).

In keeping with the scope of the present disclosure, anti-IL-33antibodies, or antigen-binding fragments, variants, or derivativesthereof of the disclosure may be administered to a human or other animalin accordance with the aforementioned methods of treatment in an amountsufficient to produce a therapeutic effect. The anti-IL-33 antibodies,or antigen-binding fragments, variants or derivatives thereof of thedisclosure can be administered to such human or other animal in aconventional dosage form prepared by combining the antibody orantigen-binding fragment thereof of the disclosure with a conventionalpharmaceutically acceptable carrier or diluent according to knowntechniques. It will be recognized by one of skill in the art that theform and character of the pharmaceutically acceptable carrier or diluentis dictated by the amount of active ingredient with which it is to becombined, the route of administration and other well-known variables.Those skilled in the art will further appreciate that a cocktailcomprising one or more species of anti-IL-33 binding molecules, e.g.,antibodies, or antigen-binding fragments, variants, or derivativesthereof, of the disclosure may prove to be particularly effective.

By “therapeutically effective dose or amount” or “effective amount” isintended an amount of anti-IL-33 binding molecule, e.g., antibody orantigen binding fragment thereof, that when administered brings about apositive therapeutic response with respect to treatment of a patientwith a disease or condition to be treated.

The present disclosure also provides for the use of an anti-IL-33binding molecule, e.g., an antibody or antigen-binding fragment,variant, or derivative thereof, in the manufacture of a medicament fortreating an inflammatory disease, including, e.g., asthma or COPD.

The disclosure also provides for the use of an anti-IL-33 bindingmolecule, e.g., antibody of the disclosure, or antigen-binding fragment,variant, or derivative thereof, in the manufacture of a medicament fortreating a subject for treating an inflammatory disease, wherein themedicament is used in a subject that has been pretreated with at leastone other therapy. By “pretreated” or “pretreatment” is intended thesubject has received one or more other therapies (e.g., been treatedwith at least one other anti-inflammatory therapy) prior to receivingthe medicament comprising the anti-IL-33 binding molecule, e.g.,antibody or antigen-binding fragment, variant, or derivative thereof.“Pretreated” or “pretreatment” includes subjects that have been treatedwith at least one other therapy within 2 years, within 18 months, within1 year, within 6 months, within 2 months, within 6 weeks, within 1month, within 4 weeks, within 3 weeks, within 2 weeks, within 1 week,within 6 days, within 5 days, within 4 days, within 3 days, within 2days, or even within 1 day prior to initiation of treatment with themedicament comprising the anti-IL-33 binding molecule, for example, anantibody or antigen-binding fragment, variant, or derivative thereof. Itis not necessary that the subject was a responder to pretreatment withthe prior therapy or therapies. Thus, the subject that receives themedicament comprising the anti-IL-33 binding molecule, e.g., an antibodyor antigen-binding fragment, variant, or derivative thereof could haveresponded, or could have failed to respond to pretreatment with theprior therapy, or to one or more of the prior therapies wherepretreatment comprised multiple therapies.

IX. Diagnostics

The disclosure further provides a diagnostic method useful duringdiagnosis of IL-33-expressing cell-mediated diseases such as certaintypes of inflammatory diseases including, e.g., asthma, which involvesmeasuring the expression level of IL-33 protein or transcript in tissueor other cells or body fluid from an individual and comparing themeasured expression level with a standard IL-33 expression level innormal tissue or body fluid, whereby an increase in the expression levelcompared to the standard is indicative of a disorder.

The anti-IL-33 antibodies of the disclosure and antigen-bindingfragments, variants, and derivatives thereof, can be used to assay IL-33protein levels in a biological sample using classical immunohistologicalmethods known to those of skill in the art (e.g., see Jalkanen, et al.,J. Cell. Biol. 101 :976-985 (1985); Jalkanen et al., J. Cell Biol.105:3087-3096 (1987)). Other antibody-based methods useful for detectingIL-33 protein expression include immunoassays, such as the enzyme linkedimmunosorbent assay (ELISA), immunoprecipitation, or Western blotting.Suitable assays are described in more detail elsewhere herein.

By “assaying the expression level of IL-33 polypeptide” is intendedqualitatively or quantitatively measuring or estimating the level ofIL-33 polypeptide in a first biological sample either directly (e.g., bydetermining or estimating absolute protein level) or relatively (e.g.,by comparing to the disease associated polypeptide level in a secondbiological sample). Preferably, IL-33 polypeptide expression level inthe first biological sample is measured or estimated and compared to astandard IL-33 polypeptide level, the standard being taken from a secondbiological sample obtained from an individual not having the disorder orbeing determined by averaging levels from a population of individualsnot having the disorder. As will be appreciated in the art, once the“standard” IL-33 polypeptide level is known, it can be used repeatedlyas a standard for comparison.

By “biological sample” is intended any biological sample obtained froman individual, cell line, tissue culture, or other source of cellspotentially expressing IL-33. Methods for obtaining tissue biopsies andbody fluids from mammals are well known in the art.

X. Immunoassays

Anti-IL-33 binding molecules, e.g., antibodies, or antigen-bindingfragments, variants, or derivatives thereof of the disclosure may beassayed for immunospecific binding by any method known in the art.Binding assays may be performed as direct binding assays or ascompetition-binding assays. Immunoassays that can be used include butare not limited to ELISA (enzyme linked immunosorbent assay), westernblotting, immunocytochemistry, immunoprecipitation, affinitychromotography, Bio-Layer Interferometry, Octet, ForteBio) andbiochemical assays such as Dissociation-Enhanced Lanthanide FluorescentImmunoassays (DELFIA®, Perkin Elmer), Förster resonance energy transfer(FRET) assays (e.g. homogeneous time resolved fluorescence (HTRF®, CisBiointernational), and radioligand binding assays to name but a few.Binding can also be detected in cell assays, for example, by flowcytometry and Fluorescent Microvolumetric Assay Technology (FMAT®,Applied Biosystems). In a direct binding assay, a candidate antibody istested for binding to IL-33 antigen. Competition binding assays, on theother hand, assess the ability of a candidate antibody to compete with aknown anti-IL-33 antibody or fragment or other compound, such as ST2,that binds to IL-33. Such assays are routine and well known in the art(see, e.g., Ausubel et al., eds, (1994) Current Protocols in MolecularBiology (John Wiley & Sons, Inc., NY) Vol. 1, which is incorporated byreference herein in its entirety). Exemplary immunoassays are describedbriefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population ofcells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X-100,1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphateat pH 7.2, 1% Trasylol) supplemented with protein phosphatase and/orprotease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate),adding the antibody of interest to the cell lysate, incubating for aperiod of time (e.g., 1-4 hours) at 4° C., adding protein A and/orprotein G sepharose beads to the cell lysate, incubating for about anhour or more at 4° C., washing the beads in lysis buffer andresuspending the beads in SDS/sample buffer. The ability of the antibodyof interest to immunoprecipitate a particular antigen can be assessedby, e.g., Western blot analysis. One of skill in the art would beknowledgeable as to the parameters that can be modified to increase thebinding of the antibody to an antigen and decrease the background (e.g.,pre-clearing the cell lysate with sepharose beads). For furtherdiscussion regarding immunoprecipitation protocols see, e.g., Ausubel etal., eds, (1994) Current Protocols in Molecular Biology (John Wiley &Sons, Inc., NY) Vol. 1 at 10.16.1.

Western blot analysis generally comprises preparing protein samples,electrophoresis of the protein samples in a polyacrylamide gel (e.g.,8%-20% SDS-PAGE depending on the molecular weight of the antigen),transferring the protein sample from the polyacrylamide gel to amembrane such as nitrocellulose, PVDF or nylon, blocking the membrane inblocking solution (e.g., PBS with 3% BSA or non-fat milk), washing themembrane in washing buffer (e.g., PBS-Tween 20), blocking the membranewith primary antibody (the antibody of interest) diluted in blockingbuffer, washing the membrane in washing buffer, blocking the membranewith a secondary antibody (which recognizes the primary antibody, e.g.,an anti-human antibody) conjugated to an enzymatic substrate (e.g.,horseradish peroxidase or alkaline phosphatase) or radioactive molecule(e.g., ³²P or ¹²⁵I) diluted in blocking buffer, washing the membrane inwash buffer, and detecting the presence of the antigen. One of skill inthe art would be knowledgeable as to the parameters that can be modifiedto increase the signal detected and to reduce the background noise. Forfurther discussion regarding Western blot protocols see, e.g., Ausubelet al., eds, (1994) Current Protocols in Molecular Biology (John Wiley &Sons, Inc., NY) Vol. 1 at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96-wellmicrotiter plate with the antigen, adding the antibody of interestconjugated to a detectable compound such as an enzymatic substrate(e.g., horseradish peroxidase or alkaline phosphatase) to the well andincubating for a period of time, and detecting the presence of theantigen. In ELISAs the antibody of interest does not have to beconjugated to a detectable compound; instead, a second antibody (whichrecognizes the antibody of interest) conjugated to a detectable compoundmay be added to the well. Further, instead of coating the well with theantigen, the antibody may be coated to the well. In this case, a secondantibody conjugated to a detectable compound may be added following theaddition of the antigen of interest to the coated well. One of skill inthe art would be knowledgeable as to the parameters that can be modifiedto increase the signal detected as well as other variations of ELISAsknown in the art. For further discussion regarding ELISAs see, e.g.,Ausubel et al., eds, (1994) Current Protocols in Molecular Biology (JohnWiley & Sons, Inc., NY) Vol. 1 at 13.2.1.

Anti-IL-33 antibodies, or antigen-binding fragments, variants, orderivatives thereof of the disclosure, additionally, can be employedhistologically, as in immunofluorescence, immunoelectron microscopy ornon-immunological assays, for in situ detection of IL-33 protein orconserved variants or peptide fragments thereof. In situ detection maybe accomplished by removing a histological specimen from a patient, andapplying thereto a labeled anti-IL-33 antibody, or antigen-bindingfragment, variant, or derivative thereof, preferably applied byoverlaying the labeled antibody (or fragment) onto a biological sample.Through the use of such a procedure, it is possible to determine notonly the presence of IL-33 protein, or conserved variants or peptidefragments, but also its distribution in the examined tissue. Using thepresent disclosure, those of ordinary skill will readily perceive thatany of a wide variety of histological methods (such as stainingprocedures) can be modified in order to achieve such in situ detection.

Immunoassays and non-immunoassays for IL-33 gene products or conservedvariants or peptide fragments thereof will typically comprise incubatinga sample, such as a biological fluid, a tissue extract, freshlyharvested cells, or lysates of cells which have been incubated in cellculture, in the presence of a detectably labeled antibody capable ofbinding to IL-33 or conserved variants or peptide fragments thereof, anddetecting the bound antibody by any of a number of techniques well knownin the art.

The biological sample can be brought in contact with and immobilizedonto a solid phase support or carrier such as nitrocellulose, or othersolid support which is capable of immobilizing cells, cell particles orsoluble proteins. The support may then be washed with suitable buffersfollowed by treatment with the detectably labeled anti-IL-33 antibody,or antigen-binding fragment, variant, or derivative thereof. The solidphase support may then be washed with the buffer a second time to removeunbound antibody. Optionally the antibody is subsequently labeled. Theamount of bound label on solid support may then be detected byconventional means.

By “solid phase support or carrier” is intended any support capable ofbinding an antigen or an antibody. Well-known supports or carriersinclude glass, polystyrene, polypropylene, polyethylene, dextran, nylon,amylases, natural and modified celluloses, polyacrylamides, gabbros, andmagnetite. The nature of the carrier can be either soluble to someextent or insoluble for the purposes of the present disclosure. Thesupport material may have virtually any possible structuralconfiguration so long as the coupled molecule is capable of binding toan antigen or antibody. Thus, the support configuration may bespherical, as in a bead, or cylindrical, as in the inside surface of atest tube, or the external surface of a rod. Alternatively, the surfacemay be flat such as a sheet, test strip, etc. Preferred supports includepolystyrene beads. Those skilled in the art will know many othersuitable carriers for binding antibody or antigen, or will be able toascertain the same by use of routine experimentation.

Solution phase binding assays may also be performed using suitablemethods known in the art, by way of example but not limited to Försterresonance energy transfer (FRET) assays (e.g. homogeneous time resolvedfluorescence (HTRF®, Cis Biointernational). An HTRF® assay is ahomogeneous assay technology that utilizes fluorescence resonance energytransfer between a donor and acceptor fluorophore that are in closeproximity (Mathis, G., Clin Chem 41(9):1391-7 (1995)). The assay can beused to measure macromolecular interactions by directly or indirectlycoupling one of the molecules of interest to a donor fluorophore, e.g.europium (Eu3+) cryptate, and coupling the other molecule of interest toan acceptor fluorophore, e.g. XL665 (a stable cross linkedallophycocyanin). Excitation of the donor molecule results influorescence emission. The energy from this emission can be transferredto the acceptor fluorophore, when in close proximity to the donorfluorophore, resulting in the emission of a specific long-livedfluorescence.

The binding activity of a given lot of anti-IL-33 antibody, orantigen-binding fragment, variant, or derivative thereof may bedetermined according to well known methods. Those skilled in the artwill be able to determine operative and optimal assay conditions foreach determination by employing routine experimentation.

There are a variety of methods available for measuring the affinity ofan antibody-antigen interaction, but relatively few for determining rateconstants. Most of the methods rely on either labeling antibody orantigen, which inevitably complicates routine measurements andintroduces uncertainties in the measured quantities.

The binding affinity of an antibody to an antigen and the off-rate of anantibody-antigen interaction can be determined by competitive bindingassays. One example of a competitive binding assay is a radioimmunoassaycomprising the incubation of labeled antigen (e.g., ³H or ¹²⁵I) with theantibody of interest in the presence of increasing amounts of unlabeledantigen, and the detection of the antibody bound to the labeled antigen.The affinity of the antibody of interest for a particular antigen andthe binding off-rates can be determined from the data by scatchard plotanalysis. Competition with a second antibody can also be determinedusing radioimmunoassays. In this case, the antigen is incubated withantibody of interest is conjugated to a labeled compound (e.g., ³H or¹²⁵I) in the presence of increasing amounts of an unlabeled secondantibody

Surface plasmon reasonance (SPR) as performed on BIACORE® offers anumber of advantages over conventional methods of measuring the affinityof antibody-antigen interactions: (i) no requirement to label eitherantibody or antigen; (ii) antibodies do not need to be purified inadvance, cell culture supernatant can be used directly; (iii) real-timemeasurements, allowing rapid semi-quantitative comparison of differentmonoclonal antibody interactions, are enabled and are sufficient formany evaluation purposes; (iv) biospecific surface can be regenerated sothat a series of different monoclonal antibodies can easily be comparedunder identical conditions; (v) analytical procedures are fullyautomated, and extensive series of measurements can be performed withoutuser intervention. BIAapplications Handbook, version AB (reprinted1998), BIACORE® code No. BR-1001-86; BIAtechnology Handbook, version AB(reprinted 1998), BIACORE® code No. BR-1001-84. SPR based bindingstudies require that one member of a binding pair be immobilized on asensor surface. The binding partner immobilized is referred to as theligand. The binding partner in solution is referred to as the analyte.In some cases, the ligand is attached indirectly to the surface throughbinding to another immobilized molecule, which is referred as thecapturing molecule. SPR response reflects a change in mass concentrationat the detector surface as analytes bind or dissociate.

Based on SPR, real-time BIACORE® measurements monitor interactionsdirectly as they happen. The technique is well suited to determinationof kinetic parameters. Comparative affinity ranking is simple toperform, and both kinetic and affinity constants can be derived from thesensorgram data.

When an analyte is injected in a discrete pulse across a ligand surface,the resulting sensorgram can be divided into three essential phases: (i)Association of analyte with ligand during sample injection; (ii)Equilibrium or steady state during sample injection, where the rate ofanalyte binding is balanced by dissociation from the complex; (iii)Dissociation of analyte from the surface during buffer flow.

The association and dissociation phases provide information on thekinetics of analyte-ligand interaction (k_(a) and k_(d), the rates ofcomplex formation and dissociation, k_(d)/k_(a)=K_(D)). The equilibriumphase provides information on the affinity of the analyte-ligandinteraction (K_(D)).

BIAevaluation software provides comprehensive facilities for curvefitting using both numerical integration and global fitting algorithms.With suitable analysis of the data, separate rate and affinity constantsfor interaction can be obtained from simple BIACORE® investigations. Therange of affinities measurable by this technique is very broad rangingfrom mM to pM.

Another example of such a method includes measuring the equilibriumdissociation constant “K_(D)” using a Kinetic Exclusion Assay, which canbe carried out, for example, using a KinExa instrument (SapidyneInstruments). Briefly, the solution phase equilibrium dissociationconstant K_(D) of anti-IL33 antibodies can be determined by pre-mixingvarying concentrations of the antibody with IL-33 until equilibrium isreached. The amount of free antibody is then measured using the KinExaby capturing free antibody using IL-33 coated beads, washing awayunbound material and detecting bound antibody using a fluorescentlylabelled species specific antibody. The amount of free antibody detectedat each IL-33 concentration is plotted against the concentration ofIL-33 and the KinExa software is used to calculate the equilibriumdissociation constant (K_(D)).

Methods and reagents suitable for determination of bindingcharacteristics of an isolated antibody or antigen-binding fragmentthereof presented, or an altered/mutant derivative thereof (discussedbelow), are known in the art and/or are commercially available.Equipment and software designed for such kinetic analyses arecommercially available (e.g., BIAcore, BIAevaluation software, GEHealthcare; KinExa Software, Sapidyne Instruments).

Epitope specificity is an important characteristic of a monoclonalantibody. Epitope mapping with BIACORE®, in contrast to conventionaltechniques using radioimmunoas say, ELISA or other surface adsorptionmethods, does not require labeling or purified antibodies, and allowsmulti-site specificity tests using a sequence of several monoclonalantibodies. Additionally, large numbers of analyses can be processedautomatically.

Pair-wise binding experiments test the ability of two MAbs to bindsimultaneously to the same antigen. MAbs directed against separateepitopes will bind independently, whereas MAbs directed againstidentical or closely related epitopes will interfere with each other'sbinding. These binding experiments with BIACORE® are straightforward tocarry out.

For example, one can use a capture molecule to bind the first Mab,followed by addition of antigen and second MAb sequentially. Thesensorgrams will reveal: (1) how much of the antigen binds to first Mab,(2) to what extent the second MAb binds to the surface-attached antigen,(3) if the second MAb does not bind, whether reversing the order of thepair-wise test alters the results.

Peptide inhibition is another technique used for epitope mapping. Thismethod can complement pair-wise antibody binding studies, and can relatefunctional epitopes to structural features when the primary sequence ofthe antigen is known. Peptides or antigen fragments are tested forinhibition of binding of different MAbs to immobilized antigen. Peptidesthat interfere with binding of a given MAb are assumed to bestructurally related to the epitope defined by that MAb.

The practice of the present disclosure will employ, unless otherwiseindicated, conventional techniques of cell biology, cell culture,molecular biology, transgenic biology, microbiology, recombinant DNA,and immunology, which are within the skill of the art. Such techniquesare explained fully in the literature.

All of the references cited cited herein, are incorporated herein byreference in their entireties. The following examples are offered by wayof illustration and not by way of limitation.

DESCRIPTION OF THE FIGURES

FIG. 1 Shows a HTRF assay for human IL33-ST2 binding in the presence ofunpurified scFv periplasmic preparations. A well containing antibodyIL330004 is highlighted.

FIG. 2 Shows neutralization of human (A) and cynomolgus (B) IL33 bypurified scFv preparations in an IL33-ST2 HTRF assay.

FIG. 3 Shows neutralization of human (A) and cynomolgus (B) IL33 bypurified IgG preparations in an IL33-ST2 HTRF assay.

FIG. 4 Shows neutralization of human IL33 by purified IgG preparationsin a luciferase NFκB reporter assay (A) and a HUVEC NFκB translocationassay (B).

FIG. 5 Shows detection of endogenous IL-33 in bronchial smooth musclecells by immunofluorescence staining by IL-33 antibody IL330004 (rightpanel) compared to CAT-002 negative control (left panel).

FIG. 6 Shows binding data from a single plate screened against humanIL-33, cynomolgus IL-33 and insulin. One specific human/cynomolguscross-reactive IL-33 binder is shown in well C4, and wells A12 and B12contain control IL-33 binding clone.

FIG. 7 Shows neutralizing activity of antibodies in a TF-1 proliferationassay (A) and in a HUVEC IL-6 production assay (B).

FIG. 8 Shows neutralizing activity of antibodies in a mast cell IL-6(A), GM-CSF (B), IL-10 (C), IL-8 (D), IL-13 (E) and IL-5 (F) cytokineproduction assay.

FIG. 9 Shows binding of IL-33 antibodies (IL330065, IL330101, IL330107,and IL330149) to full length human IL-33 by Western blot.

FIG. 10 Shows neutralizing activity of anti-IL-33 antibodies IL330065and IL330101 on mast cell IL-6 (A) and IL-13 (B) production stimulatedby full length IL-33 cell lysates.

FIG. 11 Shows a HTRF® receptor-ligand competition assay in the presenceof antibodies IL330065, IL330099, IL330101, IL330107, IL33149, andIL330180 (A) and Huvec NFkB (p65/RelA) translocation assay in thepresence of antibodies IL330065, IL330099, IL330101, IL330107, andIL330149 (B).

FIG. 12 Shows competitive binding of purified scFv preparations with mAbIL330101 for binding to biotinylated human IL-33 (A) and competitivebinding of purified scFv preparations with mAb IL330180 for binding tobiotinylated human IL-33 (B).

FIG. 13 Shows competitive binding IL330259 scFv with mAb IL330101 forbinding to biotinylated human IL-33.

FIG. 14 Shows competitive binding IL330259 IgG with mAb IL330101 forbinding to biotinylated human IL-33 (A) and competitive bindingantibodies with mAb H338L293 for binding to biotinylated human IL-33(B).

FIG. 15 Shows neutralizing activity of antibodies in HUVEC (A) or mastcell (B) IL-6 production assays.

FIG. 16 Shows a Schild analysis of IL330388 and H338L293 in a mast cellIL-6 production assay.

FIG. 17 Shows the activity of human IL-33 (A), cysteine-biotinylatedIL-33 (B) or cell culture media-pretreated IL-33 (C), measured in HUVECsignaling assays (30 minutes) and IL-6 production assay (18-24 hours).

FIG. 18 Shows SDS-PAGE of: human IL-33 (BK349) before or after treatmentwith Iscoves Modified Dulbeccos Medium (IMDM) (A), of human IL-33 Flag®His, non-biotinylated versus biotinylated under non-reducing conditions(B), of the mouse IL-33 Flag® His after treatment with IMDM (C).

FIG. 19 Shows the purification of cell culture media-treated human IL-33by SEC.

FIG. 20 Shows the intact mass of PBS versus media-treated IL-33determined by LC-MS. IMDM-treated IL-33 displayed a 4 Da loss comparedwith PBS-treated compatible with the formation of two disulphide bonds.

FIG. 21 Shows the disulphide mapping of media-treated human IL-33. Datawere consistent with the formation of two disulphide bridges. A showscombined, deconvoluted mass spectra from non-reduced and reduced Lys-Cpeptide mapping analysis of DSB IL-33. B shows isolated spectra forcysteine containing peptides. C shows sequences of disulphide bondedpeptides identified by non-reduced and reduced Lys-C peptide mappinganalysis of disulphide bonded IL-33. Disulphide linkages are representedby two hyphens (--). Lys-C miscleavages are represented by squarebrackets.

FIG. 22 Shows SDS-PAGE analysis of high concentration redIL-33 and DSBIL-33 for NMR analysis (A), NMR heteronuclear multiple quantum coherence(HMQC) analysis with overlay of the ¹H-¹⁵N HMQC spectra for ¹⁵N-labeledhuman IL-33 for redIL-33 and DSB IL-33 (B), near-UV circular dichroism(CD) Spectrum (C), key features of IL-33 (Trp193, cysteines, and ST2binding site) indicated within the solved IL-33 structure (D) and Far-UVcircular dichroism (CD) Spectrum (E).

FIG. 23 Shows hydrogen-deuterium exchange analysis of redIL-33 and DSBIL-33. Differences in deuterium incorporation are mapped onto thepublished IL-33 structure. (A) shows the comparison of fractionalhydrogen exchange (for deuterium) in reduced IL-33 (left panel) and DSBIL-33 (right panel). (B) shows a structural model of differential HX-MSdata overlaid with the ST2 binding site (red and magenta).

FIG. 24 Shows redIL-33 (A) or DSB IL-33 (B) binding to ST2.

FIG. 25 Shows analysis of three commercial IL-33 ELISA assays fordetection of redIL-33 and DSB IL-33 forms. A and B show that twocommercial human IL-33 assays predominantly detect the disulphide-bondedform of IL-33 (IL33-DSB). C shows that the mouse IL-33 assay detectsboth reduced and oxidized forms of mouse IL-33.

FIG. 26 Shows ELISA assays that are specific for detection of redIL-33.(A) shows signal intensity as a function of DSB IL-33 or red-IL-33concentration using IL330004 as a capture probe and IL330425 as adetection probe. (B) shows signal intensity as a function of DSB IL-33or red-IL-33 concentration using IL330425 as a capture probe andbiotinylated sST2.Fc as a detection probe.

FIG. 27 Shows a time course of human IL-33 incubated in cell culturemedia (IMDM) or human serum. redIL-33 or DSB IL-33 forms are measured byELISA (A) or Western blot (B).

FIG. 28 Shows analysis of BALF from humanized IL-33 mice collected atvarying timepoints following Alternaria intranasal challenge, using acombination of multiple ELISA assays. (A) Millipore, (B) R&D systems and(C) IL330425/sST2-biotin assays were used to measure IL-33 in thepresence or absence of sST2 (left hand graphs). Signals in the presenceof sST2 (signal from the reduced IL-33 fraction eliminated) werecompared with a disulphide bonded IL-33 standard to quantify the levelsof disulphide bonded IL-33. The reduced IL-33 signal was calculated asthe difference in signal between IL-33 measurements in the presence andabsence of ST2, quantified against a reduced IL-33 standard. Estimationsfor reduced IL-33 are shown on the right hand graphs.

FIG. 29 Shows analysis of BALF from wild type BALB/c mice collected atvarying timepoints following Alternaria intranasal challenge. MouseIL-33 ELISA (R&D systems) was used to measure IL-33 in the presence orabsence of sST2 (media-treated mouse IL-33 used as standard curve) (A).Signals in the presence of sST2 (signal from the reduced IL-33 fractioneliminated) were compared with a media-treated mouse IL-33 standard toquantify the levels of oxidised IL-33. The reduced IL-33 signal wascalculated as the difference in signal between IL-33 measurements in thepresence and absence of ST2, quantified against a reduced mouse IL-33standard (B).

FIG. 30 Shows relative fluorescence units at 100 minutes followingincubation of 5 uM antibody with 20 uM IL33 at 25° C. in the presence of8×SYPRO orange dye. In the presence of IL-33 H338L293, but not IL330004or the control mAb, the increased fluorescent signal is indicative ofprotein unfolding (A). (B) shows relative fluorescence units over timefollowing incubation of varying concentrations of H338L293 with 20 uMIL33 at 25° C. in the presence of 8×SYPRO orange dye. Fluorescent signalincreased with increasing antibody concentration. (C) Shows SDS-PAGEanalysis of IL-33. Preincubation of IL-33 with H338L293, but not controlmAb or no mAb, increased the presence of the faster migrating, disulfidebonded form of IL-33 under non-reducing conditions.

FIG. 31 Shows a timecourse of neutralization of IL-33 stimulated NFkBsignaling in HUVECs with mAb H338L293. (A) shows NFkB signaling 30minutes following stimulation. (B) shows NFkB signaling 6 hoursfollowing stimulation.

FIG. 32 Shows the inhibition of the FRET signal, produced by human IL-33binding to human ST2 with increasing concentrations of H338L293 underdirectly competitive conditions (B) or following preincubation withIL-33 (C). A shows a schematic representation of the assay.

FIG. 33 Shows epitope mapping of H338L293. A shows SEC analysis ofIL33:IgG complexes with H338L293 pre and post digestion with trypsin. Bshows the truncate peptide that was determined to bind strongly toH338L293 coloured black within the IL-33 structure described by Lingelet al 2009.

FIG. 34 Shows NFkB signaling activity of wild type IL-33 (IL33-01-A) andIL-33 cysteine to serine mutants (IL33-02-B, IL33-03-C, IL33-04-D,IL33-05-E, IL33-06-F, IL33-07-G, IL33-08-H, IL33-09-I, IL33-10-J,IL33-11-K, IL33-12-L, IL33-13-M, IL33-14-N, IL33-15-O, IL33-16-P) beforeand after treatment for 18 hours with IMDM cell culture media.

FIG. 35 Shows that IL33-11 has greater potency than IL33-01 (WT) invitro (A) and in vivo (B).

FIG. 36 Shows overlay of the ¹H-¹⁵N HMQC spectra for 0.1 mM ¹⁵N-labeledIL33-01 and IL33-11 plotted in black and red, respectively. Assignmentfor relevant residues are indicated. Data show peak shifts around C208and C259 as expected. However, there are more more peak shifts thanexpected from T185 to A196 which might indicate a conformation change.

FIG. 37 Shows a timecourse of IL-33 neutralizing activity of 33v20064scFv in an IL33-ST2 HTRF binding assay. (A) shows the inhibition of theFRET signal after 1 hour incubation produced by human IL-33-01 bindingto human ST2 with increasing concentrations of IL-33 scFv antibody33v20064. (B) shows the inhibition of the FRET signal after 1 hourincubation produced by human IL-33-11 binding to human ST2 withincreasing concentrations of IL-33 scFv antibody 33v20064. (C) shows theinhibition of the FRET signal after overnight incubation produced byhuman IL-33-01 binding to human ST2 with increasing concentrations ofIL-33 scFv antibody 33v20064. (D) shows the inhibition of the FRETsignal after overnight incubation produced by human IL-33-11 binding tohuman ST2 with increasing concentrations of IL-33 scFv antibody33v20064.

FIG. 38 Shows a timecourse of IL-33 neutralizing activity of 33v20064IgG in an IL33-ST2 HTRF binding assay. (A) shows the inhibition of theFRET signal after 1 hour incubation, produced by human IL-33 binding tohuman ST2 with increasing concentrations of 33v20064 IgG1 antibody. (B)shows the inhibition of the FRET signal after overnight incubation,produced by human IL-33 binding to human ST2 with increasingconcentrations of 33v20064 IgG1 antibody.

FIG. 39 Shows antibody neutralization of IL-6 production in HUVECsstimulated by wild type (A) or mutant IL-33 (B).

FIG. 40 Shows the inhibition of the FRET signal, produced bybiotinylated human IL-33-01 binding to DyLight labelled 33v20064, withincreasing concentrations of mouse IL-33 FH and cyno IL-33 FH (A), humanIL-33 FH and B7H3 avi his (A and B), and human IL-1 beta and human IL-1alpha (B). Inhibition of the signal corresponds with relative bindingaffinity of 33v20064 to the test protein.

FIG. 41 Shows a timecourse of IL-33 neutralizing activity in an IL33-ST2HTRF binding assay of germline variant 33_640001 compared with parent33v20064 scFv. (A) shows the inhibition of the FRET signal after 1 hourincubation. (B) shows the inhibition of the FRET signal after overnightincubation.

FIG. 42 Shows antibody neutralization of IL-8 production in HUVECsstimulated by truncated (112-270) (A) or full length (1-270) IL-33 (B).

FIG. 43 Shows the effect of IL-33 binding proteins on conversion fromredIL-33 to DSB IL-33 in IMDM+1% BSA (A) or PBS+1% BSA (B).

FIG. 44 Shows the inhibition of the FRET signal, produced bybiotinylated human IL-33 after 1 hour incubation (A) or after overnightincubation (B), or cynomolgus IL-33 binding to 33_640117 mAb (C), withincreasing concentrations of test proteins. Inhibition of the signalcorresponds with relative binding affinity of 33v20064 to the testprotein.

FIG. 45 Shows antibody neutralization of IL-8 production in HUVECsstimulated by truncated (112-270) (A) or full length (1-270) IL-33 (B).

FIG. 46 Shows that H338L293 dose-dependently inhibits Alternaria(ALT)-induced BAL IL-5 and eosinophilia in wild type BALB/c mice. Testsubstances were dosed intranasally (10, 30 or 100 mg/kg as indicated inbrackets) at −2 hours prior to challenge with 25 ug of ALT. BALF washarvested at 24 hours post ALT challenge and analysed for presence ofIL-5 (A) and eosinophils (B). Significant effect of test substances wasdetermined using one-way ANOVA with Bonferroni's multiple comparisonstest. ***p<0.001, ˜˜p<0.01 compared to control mAb (n=4-8). Mouse IL-33Trap was used as a positive control.

FIG. 47 Shows that H338L293 (30 mg/kg) and mouse IL-33 Trap (10 mg/kg),but not IL330004 (30 mg/kg), inhibit ALT-induced BAL IL-5 in humanizedIL-33 mice. Test substances were dosed intranasally at −2 hours prior tochallenge with 25 ug of ALT. BALF was harvested at 24 hours post ALTchallenge and analysed for presence of IL-5. Significant effect of testsubstances was determined using one-way ANOVA with Bonferroni's multiplecomparisons test. ***p<0.001, **p<0.01 (n=4).

FIG. 48 Shows that 33_640050 dose dependently inhibitsAlternaria-induced BAL IL-5 in humanized IL-33 mice. Test substanceswere dosed intraperitoneally (0.3, 3 or 30 mg/kg as indicated inbrackets) at −24 hours prior to challenge with 25 ug of Alternaria. BALFwas harvested at 24 hours post ALT challenge and analysed for presenceof IL-5. Significant effect of test substances was determined usingone-way ANOVA with Bonferroni's multiple comparisons test. ***p<0.001,**p<0.01 (n=4-5).

FIG. 49 Shows effect of antibodies in an IL33-ST2 FRET binding assay (A)and on IL-33 stimulated IL-8 release from Huvecs (B).

FIG. 50 Shows mAb specificity for IL-33 from various species or otherIL-1 family members using a FRET assay based on (A) IL33/33_640087-7B or(B) 33_640237-2B.

FIG. 51 Shows effect of antibodies on IL-8 release from Huvecsstimulated by human lung lysate.

FIG. 52 Shows that 33_640087-7B dose dependently inhibitsAlternaria-induced BAL IL-5 in humanized IL-33 mice.

FIG. 53 Experimental design of a pilot in vivo study to investigate thepotential for activity IL-33 independent of ST2 (A). Analysis of humanIL-33 exposure in BAL fluid following repeated administration of humanIL-33 to BALB/c mice (B). Analysis of IL-33 exposure in plasma followinga single intraperitoneal administration of human IL-33 (10 μg) (C).Analysis of IL-33 exposure in plasma following repeated administrationof human IL-33 to BALB/c mice (D).

FIG. 54 Shows representative H&E stained paraffin sections of lungtissue from mice administered (A) PBS or (B) IL-33 intranasally for 6weeks.

FIG. 55 Shows (A) p-p38 MAPK or (B) p-STAT5 nuclear translocationactivity in Huvecs in response to reduced IL-33 or DSB IL-33 and Westernblot analysis of p-p38 MAPK, p-JAK2 and p-STAT5 in Huvecs stimulated for15 minutes with reduced IL-33 or DSB IL-33 (C).

FIG. 56 (A) Shows binding of RAGE-Fc to reduced or DSB IL-33 by ELISA.(B) Shows inhibition of the Huvec pSTAT5 response to DSB IL-33 withRAGE-Fc or anti-RAGE mAb. (C) Shows inhibition of the Huvec pSTAT5response to DSB IL-33 with anti-RAGE mAb.

FIG. 57 Shows the effect of anti-IL-33 versus anti-ST2 on the pSTAT5response in Huvecs.

FIG. 58 Shows the effect of anti-IL-33, anti-ST2 or anti-RAGE mAbs onIL-33 induced inhibition of A549 cell migration versus (A) reduced IL-33(B) DSB IL-33.

SUMMARY OF THE SEQUENCES

SEQ ID NO: Reference/Antibody Name Description 1 IL330002 VH DNA 2IL330002 VH PRT 3 IL330002 VH CDR1 PRT 4 IL330002 VH CDR2 PRT 5 IL330002VH CDR3 PRT 6 IL330002 VL DNA 7 IL330002 VL PRT 8 IL330002 VL CDR1 PRT 9IL330002 VL CDR2 PRT 10 IL330002 VL CDR3 PRT 11 IL330004 VH DNA 12IL330004 VH PRT 13 IL330004 VH CDR1 PRT 14 IL330004 VH CDR2 PRT 15IL330004 VH CDR3 PRT 16 IL330004 VL DNA 17 IL330004 VL PRT 18 IL330004VL CDR1 PRT 19 IL330004 VL CDR2 PRT 20 IL330004 VL CDR3 PRT 21 IL330020VH DNA 22 IL330020 VH PRT 23 IL330020 VH CDR1 PRT 24 IL330020 VH CDR2PRT 25 IL330020 VH CDR3 PRT 26 IL330020 VL DNA 27 IL330020 VL PRT 28IL330020 VL CDR1 PRT 29 IL330020 VL CDR2 PRT 30 IL330020 VL CDR3 PRT 31IL330071 VH DNA 32 IL330071 VH PRT 33 IL330071 VH CDR1 PRT 34 IL330071VH CDR2 PRT 35 IL330071 VH CDR3 PRT 36 IL330071 VL DNA 37 IL330071 VLPRT 38 IL330071 VL CDR1 PRT 39 IL330071 VL CDR2 PRT 40 IL330071 VL CDR3PRT 41 IL330125 VH DNA 42 IL330125 VH PRT 43 IL330125 VH CDR1 PRT 44IL330125 VH CDR2 PRT 45 IL330125 VH CDR3 PRT 46 IL330125 VL DNA 47IL330125 VL PRT 48 IL330125 VL CDR1 PRT 49 IL330125 VL CDR2 PRT 50IL330125 VL CDR3 PRT 51 IL330126 VH DNA 52 IL330126 VH PRT 53 IL330126VH CDR1 PRT 54 IL330126 VH CDR2 PRT 55 IL330126 VH CDR3 PRT 56 IL330126VL DNA 57 IL330126 VL PRT 58 IL330126 VL CDR1 PRT 59 IL330126 VL CDR2PRT 60 IL330126 VL CDR3 PRT 61 IL330425 VH DNA 62 IL330425 VH PRT 63IL330425 VH CDR1 PRT 64 IL330425 VH CDR2 PRT 65 IL330425 VH CDR3 PRT 66IL330425 VL DNA 67 IL330425 VL PRT 68 IL330425 VL CDR1 PRT 69 IL330425VL CDR2 PRT 70 IL330425 VL CDR3 PRT 71 IL330428 VH DNA 72 IL330428 VHPRT 73 IL330428 VH CDR1 PRT 74 IL330428 VH CDR2 PRT 75 IL330428 VH CDR3PRT 76 IL330428 VL DNA 77 IL330428 VL PRT 78 IL330428 VL CDR1 PRT 79IL330428 VL CDR2 PRT 80 IL330428 VL CDR3 PRT 81 IL330065 VH DNA 82IL330065 VH PRT 83 IL330065 VH CDR1 PRT 84 IL330065 VH CDR2 PRT 85IL330065 VH CDR3 PRT 86 IL330065 VL DNA 87 IL330065 VL PRT 88 IL330065VL CDR1 PRT 89 IL330065 VL CDR2 PRT 90 IL330065 VL CDR3 PRT 91 IL330099VH DNA 92 IL330099 VH PRT 93 IL330099 VH CDR1 PRT 94 IL330099 VH CDR2PRT 95 IL330099 VH CDR3 PRT 96 IL330099 VL DNA 97 IL330099 VL PRT 98IL330099 VL CDR1 PRT 99 IL330099 VL CDR2 PRT 100 IL330099 VL CDR3 PRT101 IL330101 VH DNA 102 IL330101 VH PRT 103 IL330101 VH CDR1 PRT 104IL330101 VH CDR2 PRT 105 IL330101 VH CDR3 PRT 106 IL330101 VL DNA 107IL330101 VL PRT 108 IL330101 VL CDR1 PRT 109 IL330101 VL CDR2 PRT 110IL330101 VL CDR3 PRT 111 IL330101_fgl VH DNA 112 IL330101_fgl VH PRT 113IL330101_fgl VH CDR1 PRT 114 IL330101_fgl VH CDR2 PRT 115 IL330101_fglVH CDR3 PRT 116 IL330101_fgl VL DNA 117 IL330101_fgl VL PRT 118IL330101_fgl VL CDR1 PRT 119 IL330101_fgl VL CDR2 PRT 120 IL330101_fglVL CDR3 PRT 121 IL330107 VH DNA 122 IL330107 VH PRT 123 IL330107 VH CDR1PRT 124 IL330107 VH CDR2 PRT 125 IL330107 VH CDR3 PRT 126 IL330107 VLDNA 127 IL330107 VL PRT 128 IL330107 VL CDR1 PRT 129 IL330107 VL CDR2PRT 130 IL330107 VL CDR3 PRT 131 IL330149 VH DNA 132 IL330149 VH PRT 133IL330149 VH CDR1 PRT 134 IL330149 VH CDR2 PRT 135 IL330149 VH CDR3 PRT136 IL330149 VL DNA 137 IL330149 VL PRT 138 IL330149 VL CDR1 PRT 139IL330149 VL CDR2 PRT 140 IL330149 VL CDR3 PRT 141 IL330180 VH DNA 142IL330180 VH PRT 143 IL330180 VH CDR1 PRT 144 IL330180 VH CDR2 PRT 145IL330180 VH CDR3 PRT 146 IL330180 VL DNA 147 IL330180 VL PRT 148IL330180 VL CDR1 PRT 149 IL330180 VL CDR2 PRT 150 IL330180 VL CDR3 PRT151 IL330259 VH DNA 152 IL330259 VH PRT 153 IL330259 VH CDR1 PRT 154IL330259 VH CDR2 PRT 155 IL330259 VH CDR3 PRT 156 IL330259 VL DNA 157IL330259 VL PRT 158 IL330259 VL CDR1 PRT 159 IL330259 VL CDR2 PRT 160IL330259 VL CDR3 PRT 161 IL330259_fgl VH DNA 162 IL330259_fgl VH PRT 163IL330259_fgl VH CDR1 PRT 164 IL330259_fgl VH CDR2 PRT 165 IL330259_fglVH CDR3 PRT 166 IL330259_fgl VL DNA 167 IL330259_fgl VL PRT 168IL330259_fgl VL CDR1 PRT 169 IL330259_fgl VL CDR2 PRT 170 IL330259_fglVL CDR3 PRT 171 H338L293 VH DNA 172 H338L293 VH PRT 173 H338L293 VH CDR1PRT 174 H338L293 VH CDR2 PRT 175 H338L293 VH CDR3 PRT 176 H338L293 VLDNA 177 H338L293 VL PRT 178 H338L293 VL CDR1 PRT 179 H338L293 VL CDR2PRT 180 H338L293 VL CDR3 PRT 181 H338L293_fgl VH DNA 182 H338L293_fgl VHPRT 183 H338L293_fgl VH CDR1 PRT 184 H338L293_fgl VH CDR2 PRT 185H338L293_fgl VH CDR3 PRT 186 H338L293_fgl VL DNA 187 H338L293_fgl VL PRT188 H338L293_fgl VL CDR1 PRT 189 H338L293_fgl VL CDR2 PRT 190H338L293_fgl VL CDR3 PRT 191 IL330377 VH DNA 192 IL330377 VH PRT 193IL330377 VH CDR1 PRT 194 IL330377 VH CDR2 PRT 195 IL330377 VH CDR3 PRT196 IL330377 VL DNA 197 IL330377 VL PRT 198 IL330377 VL CDR1 PRT 199IL330377 VL CDR2 PRT 200 IL330377 VL CDR3 PRT 201 IL330377_fgl VH DNA202 IL330377_fgl VH PRT 203 IL330377_fgl VH CDR1 PRT 204 IL330377_fgl VHCDR2 PRT 205 IL330377_fgl VH CDR3 PRT 206 IL330377_fgl VL DNA 207IL330377_fgl VL PRT 208 IL330377_fgl VL CDR1 PRT 209 IL330377_fgl VLCDR2 PRT 210 IL330377_fgl VL CDR3 PRT 211 IL330388 VH DNA 212 IL330388VH PRT 213 IL330388 VH CDR1 PRT 214 IL330388 VH CDR2 PRT 215 IL330388 VHCDR3 PRT 216 IL330388 VL DNA 217 IL330388 VL PRT 218 IL330388 VL CDR1PRT 219 IL330388 VL CDR2 PRT 220 IL330388 VL CDR3 PRT 221 IL330388_fglVH DNA 222 IL330388_fgl VH PRT 223 IL330388_fgl VH CDR1 PRT 224IL330388_fgl VH CDR2 PRT 225 IL330388_fgl VH CDR3 PRT 226 IL330388_fglVL DNA 227 IL330388_fgl VL PRT 228 IL330388_fgl VL CDR1 PRT 229IL330388_fgl VL CDR2 PRT 230 IL330388_fgl VL CDR3 PRT 231 IL330396 VHDNA 232 IL330396 VH PRT 233 IL330396 VH CDR1 PRT 234 IL330396 VH CDR2PRT 235 IL330396 VH CDR3 PRT 236 IL330396 VL DNA 237 IL330396 VL PRT 238IL330396 VL CDR1 PRT 239 IL330396 VL CDR2 PRT 240 IL330396 VL CDR3 PRT241 IL330396_fgl VH DNA 242 IL330396_fgl VH PRT 243 IL330396_fgl VH CDR1PRT 244 IL330396_fgl VH CDR2 PRT 245 IL330396_fgl VH CDR3 PRT 246IL330396_fgl VL DNA 247 IL330396_fgl VL PRT 248 IL330396_fgl VL CDR1 PRT249 IL330396_fgl VL CDR2 PRT 250 IL330396_fgl VL CDR3 PRT 251 IL330398VH DNA 252 IL330398 VH PRT 253 IL330398 VH CDR1 PRT 254 IL330398 VH CDR2PRT 255 IL330398 VH CDR3 PRT 256 IL330398 VL DNA 257 IL330398 VL PRT 258IL330398 VL CDR1 PRT 259 IL330398 VL CDR2 PRT 260 IL330398 VL CDR3 PRT261 IL330398_fgl VH DNA 262 IL330398_fgl VH PRT 263 IL330398_fgl VH CDR1PRT 264 IL330398_fgl VH CDR2 PRT 265 IL330398_fgl VH CDR3 PRT 266IL330398_fgl VL DNA 267 IL330398_fgl VL PRT 268 IL330398_fgl VL CDR1 PRT269 IL330398_fgl VL CDR2 PRT 270 IL330398_fgl VL CDR3 PRT 271 ZZ1EBX-E05(33v20064) VH DNA 272 ZZ1EBX-E05 (33v20064) VH PRT 273 ZZ1EBX-E05(33v20064) VH CDR1 PRT 274 ZZ1EBX-E05 (33v20064) VH CDR2 PRT 275ZZ1EBX-E05 (33v20064) VH CDR3 PRT 276 ZZ1EBX-E05 (33v20064) VL DNA 277ZZ1EBX-E05 (33v20064) VL PRT 278 ZZ1EBX-E05 (33v20064) VL CDR1 PRT 279ZZ1EBX-E05 (33v20064) VL CDR2 PRT 280 ZZ1EBX-E05 (33v20064) VL CDR3 PRT281 ZZ1I6V-H02 (33_640001) VH DNA 282 ZZ1I6V-H02 (33_640001) VH PRT 283ZZ1I6V-H02 (33_640001) VH CDR1 PRT 284 ZZ1I6V-H02 (33_640001) VH CDR2PRT 285 ZZ1I6V-H02 (33_640001) VH CDR3 PRT 286 ZZ1I6V-H02 (33_640001) VLDNA 287 ZZ1I6V-H02 (33_640001) VL PRT 288 ZZ1I6V-H02 (33_640001) VL CDR1PRT 289 ZZ1I6V-H02 (33_640001) VL CDR2 PRT 290 ZZ1I6V-H02 (33_640001) VLCDR3 PRT 291 ZZ1JRB-A03 (33_640027) VH DNA 292 ZZ1JRB-A03 (33_640027) VHPRT 293 ZZ1JRB-A03 (33_640027) VH CDR1 PRT 294 ZZ1JRB-A03 (33_640027) VHCDR2 PRT 295 ZZ1JRB-A03 (33_640027) VH CDR3 PRT 296 ZZ1JRB-A03(33_640027) VL DNA 297 ZZ1JRB-A03 (33_640027) VL PRT 298 ZZ1JRB-A03(33_640027) VL CDR1 PRT 299 ZZ1JRB-A03 (33_640027) VL CDR2 PRT 300ZZ1JRB-A03 (33_640027) VL CDR3 PRT 301 ZZ1F7Q-D10 (33_640050) VH DNA 302ZZ1F7Q-D10 (33_640050) VH PRT 303 ZZ1F7Q-D10 (33_640050) VH CDR1 PRT 304ZZ1F7Q-D10 (33_640050) VH CDR2 PRT 305 ZZ1F7Q-D10 (33_640050) VH CDR3PRT 306 ZZ1F7Q-D10 (33_640050) VL DNA 307 ZZ1F7Q-D10 (33_640050) VL PRT308 ZZ1F7Q-D10 (33_640050) VL CDR1 PRT 309 ZZ1F7Q-D10 (33_640050) VLCDR2 PRT 310 ZZ1F7Q-D10 (33_640050) VL CDR3 PRT 311 ZZ1F7P-E01(33_640047) VH DNA 312 ZZ1F7P-E01 (33_640047) VH PRT 313 ZZ1F7P-E01(33_640047) VH CDR1 PRT 314 ZZ1F7P-E01 (33_640047) VH CDR2 PRT 315ZZ1F7P-E01 (33_640047) VH CDR3 PRT 316 ZZ1F7P-E01 (33_640047) VL DNA 317ZZ1F7P-E01 (33_640047) VL PRT 318 ZZ1F7P-E01 (33_640047) VL CDR1 PRT 319ZZ1F7P-E01 (33_640047) VL CDR2 PRT 320 ZZ1F7P-E01 (33_640047) VL CDR3PRT 321 ZZ1IV4-H06 (33_640166) VH DNA 322 ZZ1IV4-H06 (33_640166) VH PRT323 ZZ1IV4-H06 (33_640166) VH CDR1 PRT 324 ZZ1IV4-H06 (33_640166) VHCDR2 PRT 325 ZZ1IV4-H06 (33_640166) VH CDR3 PRT 326 ZZ1IV4-H06(33_640166) VL DNA 327 ZZ1IV4-H06 (33_640166) VL PRT 328 ZZ1IV4-H06(33_640166) VL CDR1 PRT 329 ZZ1IV4-H06 (33_640166) VL CDR2 PRT 330ZZ1IV4-H06 (33_640166) VL CDR3 PRT 331 ZZ1IV4-G09 (33_640169) VH DNA 332ZZ1IV4-G09 (33_640169) VH PRT 333 ZZ1IV4-G09 (33_640169) VH CDR1 PRT 334ZZ1IV4-G09 (33_640169) VH CDR2 PRT 335 ZZ1IV4-G09 (33_640169) VH CDR3PRT 336 ZZ1IV4-G09 (33_640169) VL DNA 337 ZZ1IV4-G09 (33_640169) VL PRT338 ZZ1IV4-G09 (33_640169) VL CDR1 PRT 339 ZZ1IV4-G09 (33_640169) VLCDR2 PRT 340 ZZ1IV4-G09 (33_640169) VL CDR3 PRT 341 ZZ1K7Q-B11(33_640170) VH DNA 342 ZZ1K7Q-B11 (33_640170) VH PRT 343 ZZ1K7Q-B11(33_640170) VH CDR1 PRT 344 ZZ1K7Q-B11 (33_640170) VH CDR2 PRT 345ZZ1K7Q-B11 (33_640170) VH CDR3 PRT 346 ZZ1K7Q-B11 (33_640170) VL DNA 347ZZ1K7Q-B11 (33_640170) VL PRT 348 ZZ1K7Q-B11 (33_640170) VL CDR1 PRT 349ZZ1K7Q-B11 (33_640170) VL CDR2 PRT 350 ZZ1K7Q-B11 (33_640170) VL CDR3PRT 351 ZZ1KAD-C04 (33_640036) VH DNA 352 ZZ1KAD-C04 (33_640036) VH PRT353 ZZ1KAD-C04 (33_640036) VH CDR1 PRT 354 ZZ1KAD-C04 (33_640036) VHCDR2 PRT 355 ZZ1KAD-C04 (33_640036) VH CDR3 PRT 356 ZZ1KAD-C04(33_640036) VL DNA 357 ZZ1KAD-C04 (33_640036) VL PRT 358 ZZ1KAD-C04(33_640036) VL CDR1 PRT 359 ZZ1KAD-C04 (33_640036) VL CDR2 PRT 360ZZ1KAD-C04 (33_640036) VL CDR3 PRT 361 33_640117 VH DNA 362 33_640117 VHPRT 363 33_640117 VH CDR1 PRT 364 33_640117 VH CDR2 PRT 365 33_640117 VHCDR3 PRT 366 33_640117 VL DNA 367 33_640117 VL PRT 368 33_640117 VL CDR1PRT 369 33_640117 VL CDR2 PRT 370 33_640117 VL CDR3 PRT 371 ZZ1JLT-F06(33_640076) VH DNA 372 ZZ1JLT-F06 (33_640076) VH PRT 373 ZZ1JLT-F06(33_640076) VH CDR1 PRT 374 ZZ1JLT-F06 (33_640076) VH CDR2 PRT 375ZZ1JLT-F06 (33_640076) VH CDR3 PRT 376 ZZ1JLT-F06 (33_640076) VL DNA 377ZZ1JLT-F06 (33_640076) VL PRT 378 ZZ1JLT-F06 (33_640076) VL CDR1 PRT 379ZZ1JLT-F06 (33_640076) VL CDR2 PRT 380 ZZ1JLT-F06 (33_640076) VL CDR3PRT 381 ZZ1JMB-H05 (33_640081) VH DNA 382 ZZ1JMB-H05 (33_640081) VH PRT383 ZZ1JMB-H05 (33_640081) VH CDR1 PRT 384 ZZ1JMB-H05 (33_640081) VHCDR2 PRT 385 ZZ1JMB-H05 (33_640081) VH CDR3 PRT 386 ZZ1JMB-H05(33_640081) VL DNA 387 ZZ1JMB-H05 (33_640081) VL PRT 388 ZZ1JMB-H05(33_640081) VL CDR1 PRT 389 ZZ1JMB-H05 (33_640081) VL CDR2 PRT 390ZZ1JMB-H05 (33_640081) VL CDR3 PRT 391 ZZ1JMA-B04 (33_640082) VH DNA 392ZZ1JMA-B04 (33_640082) VH PRT 393 ZZ1JMA-B04 (33_640082) VH CDR1 PRT 394ZZ1JMA-B04 (33_640082) VH CDR2 PRT 395 ZZ1JMA-B04 (33_640082) VH CDR3PRT 396 ZZ1JMA-B04 (33_640082) VL DNA 397 ZZ1JMA-B04 (33_640082) VL PRT398 ZZ1JMA-B04 (33_640082) VL CDR1 PRT 399 ZZ1JMA-B04 (33_640082) VLCDR2 PRT 400 ZZ1JMA-B04 (33_640082) VL CDR3 PRT 401 ZZ1JLR-D06(33_640084) VH DNA 402 ZZ1JLR-D06 (33_640084) VH PRT 403 ZZ1JLR-D06(33_640084) VH CDR1 PRT 404 ZZ1JLR-D06 (33_640084) VH CDR2 PRT 405ZZ1JLR-D06 (33_640084) VH CDR3 PRT 406 ZZ1JLR-D06 (33_640084) VL DNA 407ZZ1JLR-D06 (33_640084) VL PRT 408 ZZ1JLR-D06 (33_640084) VL CDR1 PRT 409ZZ1JLR-D06 (33_640084) VL CDR2 PRT 410 ZZ1JLR-D06 (33_640084) VL CDR3PRT 411 ZZ1JMC-H09 (33_640086) VH DNA 412 ZZ1JMC-H09 (33_640086) VH PRT413 ZZ1JMC-H09 (33_640086) VH CDR1 PRT 414 ZZ1JMC-H09 (33_640086) VHCDR2 PRT 415 ZZ1JMC-H09 (33_640086) VH CDR3 PRT 416 ZZ1JMC-H09(33_640086) VL DNA 417 ZZ1JMC-H09 (33_640086) VL PRT 418 ZZ1JMC-H09(33_640086) VL CDR1 PRT 419 ZZ1JMC-H09 (33_640086) VL CDR2 PRT 420ZZ1JMC-H09 (33_640086) VL CDR3 PRT 421 ZZ1JMF-G02 (33_640087) VH DNA 422ZZ1JMF-G02 (33_640087) VH PRT 423 ZZ1JMF-G02 (33_640087) VH CDR1 PRT 424ZZ1JMF-G02 (33_640087) VH CDR2 PRT 425 ZZ1JMF-G02 (33_640087) VH CDR3PRT 426 ZZ1JMF-G02 (33_640087) VL DNA 427 ZZ1JMF-G02 (33_640087) VL PRT428 ZZ1JMF-G02 (33_640087) VL CDR1 PRT 429 ZZ1JMF-G02 (33_640087) VLCDR2 PRT 430 ZZ1JMF-G02 (33_640087) VL CDR3 PRT 431 33_640076_1 VH DNA432 33_640076_1 VH PRT 433 33_640076_1 VH CDR1 PRT 434 33_640076_1 VHCDR2 PRT 435 33_640076_1 VH CDR3 PRT 436 33_640076_1 VL DNA 43733_640076_1 VL PRT 438 33_640076_1 VL CDR1 PRT 439 33_640076_1 VL CDR2PRT 440 33_640076_1 VL CDR3 PRT 441 33_640081_A VH DNA 442 33_640081_AVH PRT 443 33_640081_A VH CDR1 PRT 444 33_640081_A VH CDR2 PRT 44533_640081_A VH CDR3 PRT 446 33_640081_A VL DNA 447 33_640081_A VL PRT448 33_640081_A VL CDR1 PRT 449 33_640081_A VL CDR2 PRT 450 33_640081_AVL CDR3 PRT 451 33_640082_2 VH DNA 452 33_640082_2 VH PRT 45333_640082_2 VH CDR1 PRT 454 33_640082_2 VH CDR2 PRT 455 33_640082_2 VHCDR3 PRT 456 33_640082_2 VL DNA 457 33_640082_2 VL PRT 458 33_640082_2VL CDR1 PRT 459 33_640082_2 VL CDR2 PRT 460 33_640082_2 VL CDR3 PRT 46133_640084_2 VH DNA 462 33_640084_2 VH PRT 463 33_640084_2 VH CDR1 PRT464 33_640084_2 VH CDR2 PRT 465 33_640084_2 VH CDR3 PRT 466 33_640084_2VL DNA 467 33_640084_2 VL PRT 468 33_640084_2 VL CDR1 PRT 46933_640084_2 VL CDR2 PRT 470 33_640084_2 VL CDR3 PRT 471 33_640086_2 VHDNA 472 33_640086_2 VH PRT 473 33_640086_2 VH CDR1 PRT 474 33_640086_2VH CDR2 PRT 475 33_640086_2 VH CDR3 PRT 476 33_640086_2 VL DNA 47733_640086_2 VL PRT 478 33_640086_2 VL CDR1 PRT 479 33_640086_2 VL CDR2PRT 480 33_640086_2 VL CDR3 PRT 481 33_640087_2 VH DNA 482 33_640087_2VH PRT 483 33_640087_2 VH CDR1 PRT 484 33_640087_2 VH CDR2 PRT 48533_640087_2 VH CDR3 PRT 486 33_640087_2 VL DNA 487 33_640087_2 VL PRT488 33_640087_2 VL CDR1 PRT 489 33_640087_2 VL CDR2 PRT 490 33_640087_2VL CDR3 PRT 491 33_640076_4 VH DNA 492 33_640076_4 VH PRT 49333_640076_4 VH CDR1 PRT 494 33_640076_4 VH CDR2 PRT 495 33_640076_4 VHCDR3 PRT 496 33_640076_4 VL DNA 497 33_640076_4 VL PRT 498 33_640076_4VL CDR1 PRT 499 33_640076_4 VL CDR2 PRT 500 33_640076_4 VL CDR3 PRT 50133_640082_4 VH DNA 502 33_640082_4 VH PRT 503 33_640082_4 VH CDR1 PRT504 33_640082_4 VH CDR2 PRT 505 33_640082_4 VH CDR3 PRT 506 33_640082_4VL DNA 507 33_640082_4 VL PRT 508 33_640082_4 VL CDR1 PRT 50933_640082_4 VL CDR2 PRT 510 33_640082_4 VL CDR3 PRT 511 33_640082_6 VHDNA 512 33_640082_6 VH PRT 513 33_640082_6 VH CDR1 PRT 514 33_640082_6VH CDR2 PRT 515 33_640082_6 VH CDR3 PRT 516 33_640082_6 VL DNA 51733_640082_6 VL PRT 518 33_640082_6 VL CDR1 PRT 519 33_640082_6 VL CDR2PRT 520 33_640082_6 VL CDR3 PRT 521 33_640082_7 VH DNA 522 33_640082_7VH PRT 523 33_640082_7 VH CDR1 PRT 524 33_640082_7 VH CDR2 PRT 52533_640082_7 VH CDR3 PRT 526 33_640082_7 VL DNA 527 33_640082_7 VL PRT528 33_640082_7 VL CDR1 PRT 529 33_640082_7 VL CDR2 PRT 530 33_640082_7VL CDR3 PRT 531 33_640086_6 VH DNA 532 33_640086_6 VH PRT 53333_640086_6 VH CDR1 PRT 534 33_640086_6 VH CDR2 PRT 535 33_640086_6 VHCDR3 PRT 536 33_640086_6 VL DNA 537 33_640086_6 VL PRT 538 33_640086_6VL CDR1 PRT 539 33_640086_6 VL CDR2 PRT 540 33_640086_6 VL CDR3 PRT 54133_640087_7 VH DNA 542 33_640087_7 VH PRT 543 33_640087_7 VH CDR1 PRT544 33_640087_7 VH CDR2 PRT 545 33_640087_7 VH CDR3 PRT 546 33_640087_7VL DNA 547 33_640087_7 VL PRT 548 33_640087_7 VL CDR1 PRT 54933_640087_7 VL CDR2 PRT 550 33_640087_7 VL CDR3 PRT 551 ZZ1JMY-H09(33_640201) VH DNA 552 ZZ1JMY-H09 (33_640201) VH PRT 553 ZZ1JMY-H09(33_640201) VH CDR1 PRT 554 ZZ1JMY-H09 (33_640201) VH CDR2 PRT 555ZZ1JMY-H09 (33_640201) VH CDR3 PRT 556 ZZ1JMY-H09 (33_640201) VL DNA 557ZZ1JMY-H09 (33_640201) VL PRT 558 ZZ1JMY-H09 (33_640201) VL CDR1 PRT 559ZZ1JMY-H09 (33_640201) VL CDR2 PRT 560 ZZ1JMY-H09 (33_640201) VL CDR3PRT 561 ZZ1M37-E06 (33_640237) VH DNA 562 ZZ1M37-E06 (33_640237) VH PRT563 ZZ1M37-E06 (33_640237) VH CDR1 PRT 564 ZZ1M37-E06 (33_640237) VHCDR2 PRT 565 ZZ1M37-E06 (33_640237) VH CDR3 PRT 566 ZZ1M37-E06(33_640237) VL DNA 567 ZZ1M37-E06 (33_640237) VL PRT 568 ZZ1M37-E06(33_640237) VL CDR1 PRT 569 ZZ1M37-E06 (33_640237) VL CDR2 PRT 570ZZ1M37-E06 (33_640237) VL CDR3 PRT 571 33_640201_2 VH DNA 57233_640201_2 VH PRT 573 33_640201_2 VH CDR1 PRT 574 33_640201_2 VH CDR2PRT 575 33_640201_2 VH CDR3 PRT 576 33_640201_2 VL DNA 577 33_640201_2VL PRT 578 33_640201_2 VL CDR1 PRT 579 33_640201_2 VL CDR2 PRT 58033_640201_2 VL CDR3 PRT 581 33_640237_2 VH DNA 582 33_640237_2 VH PRT583 33_640237_2 VH CDR1 PRT 584 33_640237_2 VH CDR2 PRT 585 33_640237_2VH CDR3 PRT 586 33_640237_2 VL DNA 587 33_640237_2 VL PRT 58833_640237_2 VL CDR1 PRT 589 33_640237_2 VL CDR2 PRT 590 33_640237_2 VLCDR3 PRT 591 33_640076_4B VH DNA 592 33_640076_4B VH PRT 59333_640076_4B VL DNA 594 33_640076_4B VL PRT 595 33_640081_AB VH DNA 59633_640081_AB VH PRT 597 33_640081_AB VL DNA 598 33_640081_AB VL PRT 59933_640082_6B VH DNA 600 33_640082_6B VH PRT 601 33_640082_6B VL DNA 60233_640082_6B VL PRT 603 33_640082_7B VH DNA 604 33_640082_7B VH PRT 60533_640082_7B VL DNA 606 33_640082_7B VL PRT 607 33_640084_2B VH DNA 60833_640084_2B VH PRT 609 33_640084_2B VL DNA 610 33_640084_2B VL PRT 61133_640086_6B VH DNA 612 33_640086_6B VH PRT 613 33_640086_6B VL DNA 61433_640086_6B VL PRT 615 33_640087_7B VH DNA 616 33_640087_7B VH PRT 61733_640087_7B VL DNA 618 33_640087_7B VL PRT 619 33_640201_2B VH DNA 62033_640201_2B VH PRT 621 33_640201_2B VL DNA 622 33_640201_2B VL PRT 62333_640237_2B VH DNA 624 33_640237_2B VH PRT 625 33_640237_2B VL DNA 62633_640237_2B VL PRT 627 Mature Human IL-33_FH a.a. 112-270 PRT 628Mature Mouse IL-33_FH a.a. 109-266 PRT 629 Mature Cynomolugus IL-33 a.a.112-270 PRT 630 Human ST2 ECD-Fc/his6 a.a. 1-328 PRT 631 Mouse ST2ECD-Fc/His6 a.a. 1-332 PRT 632 IL33-01 a.a. 112-270 PRT 633 Human 6HisTEV mature IL-33 WT a.a. 112-270 PRT 634 IL33-02 a.a. 112-270 PRT 635IL33-03 a.a. 112-270 PRT 636 IL33-04 a.a. 112-270 PRT 637 IL33-05 a.a.112-270 PRT 638 IL33-06 a.a. 112-270 PRT 639 IL33-07 a.a. 112-270 PRT640 IL33-08 a.a. 112-270 PRT 641 IL33-09 a.a. 112-270 PRT 642 IL33-10a.a. 112-270 PRT 643 IL33-11 a.a. 112-270 PRT 644 IL33-12 a.a. 112-270PRT 645 IL33-13 a.a. 112-270 PRT 646 IL33-14 a.a. 112-270 PRT 647IL33-15 a.a. 112-270 PRT 648 IL33-16 a.a. 112-270 PRT 649 Cynomolgus10His Avitag IL-33 a.a. 112-270 PRT 650 Human ST2 ECD-Flag-his10 a.a.1-328 PRT

EXAMPLES Example 1 Isolation of Antibodies to IL-33

Cloning, Expression and Purification of Mature IL-33 from Human, Mouseand Cynomolgus Monkey

Protein sequences for IL-1RAcP and ST2 were obtained from Swiss Prot.Isolation and identification of anti-IL-33 scFv antibodies cDNAmolecules encoding the mature component of IL-33 were synthesized byprimer extension PCR and cloned into pJexpress404 (DNA 2.0). Accessionnumbers corresponding to database sequence information for human andmouse IL-33 are shown in Table 2. No Cynomologus monkey sequences wereavailable so based on the high homology between Cynomolgus monkey andRhesus monkey, the sequence of Rhesus monkey (Accession No.ENSMMUT00000030043) was used to design primers capable of amplifying thecoding sequence of the IL-33 gene in Cynomolgus monkey. The Rhesus genesequence was aligned to the Humans IL-33 cDNA sequence (Accession No.NM_033439), this demonstrated that the Rhesus sequence was mis-assembledand was missing exon 1. A BLAST search was performed against the Rhesusgenomic sequence using the human exon 1, and the Rhesus sequencematching exon 1 was identified. Additional primers were designed toamplify exon 1.

The mature IL-33 coding sequence was modified to contain a FLAG® 10× hisepitope tag (DYKDDDDKAAHHHHHHHHHH; SEQ ID NO. 627) at the C-terminus ofthe protein. SEQ ID NOs corresponding to mature Flag® His-tagged human,cynomolgus and mouse IL-33 are shown in Table 2.

TABLE 2 Sequences for human, mouse and cynomolgus monkey mature IL-33Accession No. Flag ®His-tagged Species Amino acids (Swiss-Prot) IL-33Sequences Human 112-270 O95760 SEQ ID NO. 627 Mouse 109-266 Q8BVZ5 SEQID NO. 628 Cynomolgus 112-270 Not Available SEQ ID NO. 629

Vectors were transformed into BL21(DE3) competent cells (MerckBiosciences, 69450) and expression induced with 1 mM IPTG. Harvestedcells were lysed with Bugbuster (Merck Biosciences, 70584) and expressedprotein was purified using Ni-NTA affinity chromatography (Histrap HPcolumn: GE Healthcare, 17-5248-02) followed by Size Exclusionchromatography (Superdex 75 column: GE Healthcare, 17-1068-01).

Protein Modifications

IgGs and modified receptor proteins used herein were biotinylated viafree amines using EZ link Sulfo-NHS-LC-Biotin (Thermo/Pierce, 21335) Thebiotin reagent was dissolved in anhydrous dimethylformamide and PBSbased protein solutions were adjusted to pH ˜8 with 1 M NaHCO₃ in D-PBS(Dulbecco's phosphate buffered saline). IL-33 proteins used herein werebiotinylated via free cysteines using EZ link Biotin-BMCC(Perbio/Pierce, product no. 21900). The biotin reagent was dissolved inanhydrous dimethylformamide and mixed PBS protein solutions. Labelincorporations were assessed by MALDI-TOF mass spectrometry in all casesand unreacted reagents were cleared by buffer exchange using PBSequilibrated disposable Sephadex G25 columns. For biotinylation, thefinal protein concentrations were determined by 280 nm absorbance usingextinction coefficients calculated from amino acid sequences.

Selections

A large single chain Fv (scFv) human antibody library, based uponvariable (V) genes isolated from human B-cells from adult naïve donorsand cloned into a phagemid vector based on filamentous phage M13 wasused for selections (Hutchings, C., “Generation of Naïve Human AntibodyLibraries” in Antibody Engineering, Dubel. Berlin, Springer LaboratoryManuals: p. 93 (2001); Lloyd et al., Protein Eng. Des. Sel. 22(3):159-68(2009)). IL-33-specific scFv antibodies were isolated from the phagedisplay library in a series of repeated selection cycles on recombinanthuman and/or mouse IL-33 essentially as described in Vaughan et al.(Nat. Biotechnol. 14(3):309-14 (1996)). A list of IL-33 reagents usedherein is shown in Table 3.

TABLE 3 ELISA Binding Assay Reagents Catalogue Number/ ELISA ReagentSupplier Designation assay Human IL-33 Axxora/Adipogen AG-40B-0038Phage/IgG Human IL-33 Axxora/Alexis ALX-522-098 Phage Human IL-33Flag ®His In house PS-295 Phage/IgG Human IL-33 Peprotech 200-33 PhageMouse IL-33 Peprotech 210-33 Phage Mouse IL-33 Axxora/Alexis ALX-522-101Phage Mouse IL-33 Flag ®His In house PS-296 Phage/IgG Cynomologus IL-33In house PS-368 Phage/IgG Flag ®His IL-4Rα Flag ®His In house 020629080Phage/IgG Bovine insulin - biotin Sigma I2258 Phage/IgG

In brief, the scFv-phage particles were incubated with biotinylatedrecombinant IL-33 in solution (biotinylated via free cysteines using EZlink Biotin-BMCC (Perbio/Pierce, product no. 21900)). Particles wereincubated with 100 nM biotinylated recombinant IL-33 for 2 hours. ScFvbound to antigen were then captured on streptavidin-coated paramagneticbeads (Dynabeads®, M-280) following manufacturer's recommendations.Unbound phage was washed away in a series of wash cycles usingPBS-Tween. The phage particles retained on the antigen were eluted,infected into bacteria and rescued for the next round of selection.Typically two or three rounds of selection were performed in this way.

Identification of IL-33 Specific Binders by Phage ELISA

A representative number of individual clones from the selection outputsafter two or three rounds of selection described above were grown up in96-well plates. Single-chain Fv fragments were displayed on phageparticles and tested in a binding assay to determine cross-reactivityand specificity to a panel of recombinant human, mouse and cynomolgusIL-33 antigens. Phage-displayed scFv supernatant samples were generatedin 96-well deep well plates as follows. 5 μl of culture from each wellof a 96-well master plate was transferred into a Greiner deep wellculture plate containing 500 μl of 2TYAG (2TY+100 μg/ml ampicillin+2%glucose) media and incubated for 5 hours at 37° C., 280 rpm. K07 M13helper phage (diluted to 1.5×10¹¹ pfu/ml in 2TYAG) was then added at 100μl/well and the plate incubated at 37° C., 150 rpm to allow infection.The plate was spun down at 3200 rpm for 10 minutes and the supernatantremoved. Bacterial pellets were resuspended in 500 μl/well 2TYAK(2TY+100 μg/ml ampicillin+50 μg/ml kanamycin) and the plate incubatedovernight at 25° C., 280 rpm. In the morning, 500 μl of 6% (w/v) skimmedmilk powder in 2×PBS was added to each well and the plate incubated for1 hour at room temperature. The plate was then centrifuged at 3200 rpmfor 10 minutes and the blocked phage-displayed scFv supernatants wereused directly in ELISA experiments.

For EC50 determinations, typically purified IgGs were diluted 3-fold in3% (w/v) dried-milk powder in PBS (PBS-M), to give 11 concentrationpoints. 96-well Greiner polypropylene plates (Greiner, 650201) were usedfor dilution preparation. Generally, each dilution was prepared induplicate. IgG dilutions were allowed to block in PBS-M for 1 hour atroom temperature before being used directly in ELISA experiments.

The IL-33 binding assays were plate-based ELISAs performed essentiallyas follows. Table 3 above shows the antigens used for these experiments.Not all antigens were used in every experiment, but in all cases ahuman, a mouse, and a cynomolgus IL-33 antigen was tested. Relevantcontrol antigens (bovine insulin plus IL-4Rα FLAG® His, if appropriate)were also used to test for non-specific binding. With the exception ofbovine insulin, all antigens were biotinylated (see subsection 1.1.above) and all were generated using bacterial expression. The method forgeneration of IL-4Rα FLAG® His, which was used as a control antigen, isdescribed in WO/2010/070346.

Streptavidin plates (Thermo Scientific, AB-1226) were coated withbiotinylated antigen at 0.5 μg/ml in PBS and incubated overnight at 4°C. Plates were washed 3× with PBS and blocked with 300 μl/well blockingbuffer (PBS-M) for 1 hour. Plates were washed 1× with PBS and blockedsamples added, 50 μl/well for 1 hour at room temperature. Plates werewashed 3× with PBS-T (PBS+1% (v/v) Tween-20) and detection reagents[anti-human IgG HRP (Sigma, A0170) or anti-M13-HRP antibody (Amersham,27-9421-01) for detection of IgG or phage-displayed scFv, respectively]at 1:5000 dilutions were added at 50 μl/well in PBS-M for 1 hour at roomtemperature. Plates were washed 3× with PBS-T and developed with TMB, 50μl/well (Sigma, T0440). The reaction was quenched with 50 μl/well 0.1MH₂SO₄ before reading on an EnVision™ plate reader, or similar equipment,at 450 nm.

Dose response curves were plotted for IgG titrations using Prism(Graphpad) curve-fitting software. Phage-displayed scFv were consideredto bind the IL-33 antigen if the absorbance 450 nm was >0.5, and <0.2for the same sample on controls (insulin and IL-4Rα Flag® His).

Cloning, Expression and Purification of ST2 ECD from Human and Mouse

cDNA molecules encoding the extracellular domains (ECDs) of ST2 fromhuman and mouse were synthesized by primer extension PCR cloning andcloned into pDONR221 (Invitrogen, 12536-017). Database sequences forhuman and mouse ST2 were used (see Table 4). ST2 ECD cDNA clones inpDONR221 were transferred to mammalian expression vector pDEST12.2 usingLR Gateway Clonase II enzyme according to the manufacturer'sinstructions. The pDEST12.2 vector had been modified to contain thehuman IgG1 Fc coding region, polyhistidine (His6) tag in-frame with theinserted gene of interest, and also by insertion of the oriP origin ofreplication from the pCEP4 vector allowing episomal plasmid replicationupon transfection into cell lines expressing the EBNA-1 gene product(such as HEK293-EBNA cells).

TABLE 4 Amino acids and accession numbers for human and mouse ST2extracellular domain Accession number EDC-Fc-His6 Species Amino acids(Swiss-Prot) Sequences Human 1-328 Q01638 SEQ ID NO: 630 Mouse 1-332P14719 SEQ ID NO: 631

Expressed ST2.Fc proteins in HEK293-EBNA supernatants were purifiedusing Protein A affinity chromatography (HiTrap Protein A column (GEHealthcare, 17-0402-01)) followed by Size Exclusion chromatography(Superdex 200 column (GE Healthcare, 17-1069-01)).

Inhibition of IL-33 binding to ST2 by unpurified scFv

A representative number of individual clones from the selection outputsafter two or three rounds of selection described above were grown up in96-well plates. ScFv were expressed in the bacterial periplasm(Kipriyanov, et al. J Immunol Methods 200(1-2): 69-77 (1997)) andscreened for their inhibitory activity in a homogeneous FRET(fluorescence resonance energy transfer) HTRF® (HomogeneousTime-Resolved Fluorescence, Cisbio International) basedIL-33:ST2-binding assay. In this assay, samples competed with human ormouse ST2.Fc for binding to FLAG® His-tagged human, cynomolgus or mouseIL-33.

An HTRF® assay is a homogeneous assay technology that utilisesfluorescence resonance energy transfer between a donor and acceptorfluorophore that are in close proximity (Mathis, et al. Clin Chem 41(9):1391-7 (1995)). This assay was used to measure macromolecularinteractions by directly or indirectly coupling one of the molecules ofinterest to a donor fluorophore, europium (Eu3+) cryptate, and couplingthe other molecule of interest to an acceptor fluorophore XL665, (astable cross linked allophycocyanin). Excitation of the cryptatemolecule (at 337 nm) resulted in fluorescence emission at 620 nm. Theenergy from this emission was transferred to XL665 in close proximity tothe cryptate, resulting in the emission of a specific long-livedfluorescence (at 665 nm) from the XL665. The specific signals of boththe donor (at 620 nm) and the acceptor (at 665 nm) were measured,allowing the calculation of a 665/620 nm ratio that compensates for thepresence of colored compounds in the assay.

Unpurified anti-IL-33 scFv samples were tested for inhibition ofFLAG®-His tagged IL-33 binding ST2-Fc by adding 10 microlitres of eachdilution of antibody test sample to a 384 well low volume assay plate(Costar, 3676). Next, a solution containing 2 nM human or mouse ST2-Fcand 3 nM anti-human Fc cryptate detection (Cisbio International,61HFCKLB) was prepared and 5 microlitres of the mix added to the assayplate. This was followed by the addition of 5 microlitres of a solutioncontaining 1.2 nM FLAG®-His tagged human, cynomolgus or mouse IL-33combined with 20 nM anti-FLAG® XL665 detection (Cisbio International,61FG2XLB). All dilutions were performed in assay buffer containing 0.8 Mpotassium fluoride (BDH 103444T) and 0.1% bovine serum albumin (BSA,Sigma A9576) in Dulbeccos PBS (Invitrogen, 14190185). Assay plates wereincubated for 1 hour at room temperature followed by 16 hour at 4° C.before reading time resolved fluorescence at 620 nm and 665 nm emissionwavelengths using an EnVision plate reader (Perkin Elmer).

Data were analysed by calculating the 665/620 nm ratio followed by the %Delta F values for each sample. The 665/620 nm ratio was used to correctfor sample interference using Equation 1:

${665/620{nm}{ratio}} = {\left( \frac{665{nm}{signal}}{620{nm}{signal}} \right) \times 10,000}$

The % Delta F for each sample was then calculated using Equation 2:

${{Delta}{}F(\%)} = {\left( \frac{{{sample}665/620{nm}{ratio}} - {{negative}{control}{}665/620{nm}{ratio}}}{{negative}{control}665/620{nm}{ratio}} \right) \times 100}$

The negative control (non-specific binding) was defined by replacingtest sample with 150 nM non-tagged human or mouse IL-33 (Axxora, humanALX522-098, mouse ALX-522-101) prepared in a dilution buffer comprisedof Dulbeccos PBS (Invitrogen, 14190185) containing 0.1% bovine serumalbumin (BSA, Sigma A9576).

The % Delta F values were subsequently used to calculate % specificbinding as described in Equation 3:

${\%{specific}{binding}} = {\left( \frac{\left( {{{Sample}{Delta}F\%} - {{NSB}{Delta}F\%}} \right)}{\left( {{{Total}{binding}{Delta}F\%} - {{NSB}{Delta}F\%}} \right)} \right) \times 100}$

IC₅₀ values were determined using GraphPad Prism software by curvefitting using a four-parameter logistic equation (Equation 4).

Y=Bottom+(Top−Bottom)/(1+10{circumflex over ( )}((LogEC50−X)*HillSlope))  Equation 4:

-   -   X is the logarithm of concentration.    -   Y is specific binding    -   Y starts at Bottom and goes to Top with a sigmoid shape.

FIG. 1 shows the inhibition of the FRET signal, produced by human IL-33binding to human ST2, by unpurified scFv periplasmic extracts in asingle point screen. The final concentration of the periplasmic extractwas 50% v/v. Well B04 (unpurified IL330004 scFv) shows an example ‘hit’and column 12 contains control wells as indicated.

Inhibition of IL-33 Binding to ST2 by Purified scFv

Single chain Fv clones which showed an inhibitory effect on IL-33:ST2interaction as unpurified periplasmic extracts or demonstrated adesirable species cross-reactivity and specificity profile by phagebinding experiments above, were subjected to DNA sequencing (Osbourn, etal. Immunotechnology 2(3):181-96 (1996); Vaughan, et al. Nat Biotechnol14(3):309-14 (1996).). Unique scFv were expressed again in bacteria andpurified by affinity chromatography (as described in WO01/66754). Thepotencies of these samples were determined by competing a dilutionseries of the purified preparation against human or mouse ST2.Fc forbinding to FLAG® His-tagged human, cynomolgus or mouse IL-33 asdescribed above. Purified scFv preparations that were capable ofinhibiting the IL-33:ST2 interaction to a greater extent than thenegative control were selected for conversion to IgG format (e.g., scFvantibodies IL330002, IL330004, IL330020 and IL330071

FIG. 2A: shows the inhibition of the FRET signal, produced by humanIL-33 binding to human ST2 with increasing concentrations of IL-33 scFvantibodies IL330002, IL330004, IL330020 and IL330071, wherein the x-axisis the concentration of antibody in molar concentration and the y-axisis percent specific binding.

FIG. 2B: shows the inhibition of the FRET signal, produced by cynomolgusmonkey IL-33 binding to human ST2 with increasing concentrations ofIL-33 scFv antibodies IL330002, IL330004, IL330020 and IL330071, whereinthe x-axis is the concentration of antibody in molar concentration andthe y-axis is percent specific binding.

Identification of Partner Antibodies for IL330004

scFv periplasmic extracts of those clones that demonstrated positivebinding to human IL-33 by Phage ELISA were screened by Octet assay(Octet RED 384 system) to identify an antibody that bound IL-33simultaneously with IL330004. Neat periprep samples were captured on aNickel NTA biosensor and sequential binding of IL-33 (200 nM) followedby IL330004 (200 nM) was performed. Biosensors were regenerated tominimise use. Sensors are regenerated in glycine (10 mM, pH 1.7),neutralised in buffer (PBS+1 mg/ml (0.1%) BSA+0.02% Tween20) andreloaded with NiSO4 (10 mM) to replenish the nickel on the biosensorsurface. IL330425 and IL330428 were identified and converted to wholeimmunoglobulin G1 (IgG1) antibody format.

Reformatting of scFv to IgG1

Single chain Fv clones with desirable properties from the IL-33:ST2binding assays, plus a panel of phage-displayed scFv with desirablespecificities by binding experiments were converted to wholeimmunoglobulin G1 (IgG1) antibody format essentially as described byPersic et al. (Gene 187(1):9-18 (1997)) with the followingmodifications. An OriP fragment was included in the expression vectorsto facilitate use with CHO-transient cells and to allow episomalreplication. The variable heavy (VH) domain was cloned into a vector(pEU1.3) containing the human heavy chain constant domains andregulatory elements to express whole IgG1 heavy chain in mammaliancells. Similarly, the variable light (VL) domain was cloned into avector (pEU4.4) for the expression of the human light chain (lambda)constant domains and regulatory elements to express whole IgG lightchain in mammalian cells. To obtain IgGs, the heavy and light chain IgGexpressing vectors were transfected into CHO-transient mammalian cells(Daramola et al. Biotechnol Prog 30(1):132-41 (2014)). IgGs wereexpressed and secreted into the medium. Harvests were filtered prior topurification, then IgG was purified using Protein A chromatography.Culture supernatants were loaded on a column of appropriate size ofCeramic Protein A (BioSepra) and washed with 50 mM Tris-HCl pH 8.0, 250mM NaCl. Bound IgG was eluted from the column using 0.1 M Sodium Citrate(pH 3.0) and neutralized by the addition of Tris-HCl (pH 9.0). Theeluted material was buffer exchanged into PBS using Nap10 columns(Amersham, #17-0854-02) and the concentration of IgG was determinedspectrophotometrically using an extinction coefficient based on theamino acid sequence of the IgG (Mach et al., Anal. Biochem. 200(1):74-80(1992)). The purified IgG were analyzed for aggregation and degradationpurity using SEC-HPLC and by SDS-PAGE. SEQ ID NOs corresponding to thevarious regions of antibodies IL330002, IL330004, IL330020, IL330071,IL330125, and IL330126 are shown in Table 5.

TABLE 5 Anti-IL-33 Antibody Sequences VH VL VH CDRs VL CDRs IgG1Sequence Sequence 1, 2, 3 1, 2, 3 IL330002 SEQ ID SEQ ID SEQ ID SEQ IDNO: 2 NO: 7 NO: 3 NO: 8 SEQ ID SEQ ID NO: 4 NO: 9 SEQ ID SEQ ID NO: 5NO: 10 IL330004 SEQ ID SEQ ID SEQ ID SEQ ID NO: 12 NO: 17 NO: 13 NO: 18SEQ ID SEQ ID NO: 14 NO: 19 SEQ ID SEQ ID NO: 15 NO: 20 IL330020 SEQ IDSEQ ID SEQ ID SEQ ID NO: 22 NO: 27 NO: 23 NO: 28 SEQ ID SEQ ID NO: 24NO: 29 SEQ ID SEQ ID NO: 25 NO: 30 IL330071 SEQ ID SEQ ID SEQ ID SEQ IDNO: 32 NO: 37 NO: 33 NO: 38 SEQ ID SEQ ID NO: 34 NO: 39 SEQ ID SEQ IDNO: 35 NO: 40 IL330125 SEQ ID SEQ ID SEQ ID SEQ ID NO: 42 NO: 47 NO: 43NO: 48 SEQ ID SEQ ID NO: 44 NO: 49 SEQ ID SEQ ID NO: 45 NO: 50 IL330126SEQ ID SEQ ID SEQ ID SEQ ID NO: 52 NO: 57 NO: 53 NO: 58 SEQ ID SEQ IDNO: 54 NO: 59 SEQ ID SEQ ID NO: 55 NO: 60 IL330425 SEQ ID SEQ ID SEQ IDSEQ ID NO: 62 NO: 67 NO: 63 NO: 68 SEQ ID SEQ ID NO: 64 NO: 69 SEQ IDSEQ ID NO: 65 NO: 70 IL330428 SEQ ID SEQ ID SEQ ID SEQ ID NO: 72 NO: 77NO: 73 NO: 78 SEQ ID SEQ ID NO: 74 NO: 79 SEQ ID SEQ ID NO: 75 NO: 80

Inhibition of IL-33 Binding to ST2 by Purified IgG

The ability of anti-IL-33 antibodies to inhibit the binding of FLAG®-Histagged IL-33 to the ST2 receptor was assessed in a biochemical HTRF®(Homogeneous Time-Resolved Fluorescence, Cisbio International)competition assay, the principles of which are described above.

Activity of purified IgG preparations were determined by competing adilution series of the purified IgG against biotinylated human or mouseST2.Fc for binding to FLAG® His-tagged human, cynomolgus or mouse IL-33.

Purified or unpurified anti-IL-33 antibody samples were tested forinhibition of FLAG®-His tagged IL-33 binding ST2-Fc by adding 10microlitres of each dilution of antibody test sample to a 384 well lowvolume assay plate (Costar 3676). Next, a solution containing 4 nMbiotinylated human or mouse ST2-Fc and 20 nM streptavidin XL665detection (Cisbio International, 611SAXLB) was prepared and 5microlitres of the mix added to the assay plate. This was followed bythe addition of 5 microlitres of a solution containing 1.2 nM FLAG®-Histagged human, cynomolgus or mouse IL-33 combined with 1.72 nM anti-FLAG®cryptate detection (Cisbio International, 61FG2KLB). All dilutions wereperformed in assay buffer comprised of Dulbeccos PBS (Invitrogen,14190185) containing 0.8 M potassium fluoride (BDH 103444T) and 0.1% BSA(Sigma A9576). Assay plates were incubated for 2 hour at roomtemperature followed by 16 hour at 4° C. before reading time resolvedfluorescence at 620 nm and 665 nm emission wavelengths using an EnVisionplate reader (Perkin Elmer).

Data were analyzed as described above using Equations 1 to 3.

The negative control (non-specific binding) was defined by replacingtest sample with 100 nM non-biotinylated ST2 prepared in a dilutionbuffer comprised of Dulbecco's PBS (Invitrogen, 14190185) containing0.1% bovine serum albumin (BSA, Sigma A9576).

The representative potencies (IC₅₀) for purified IgG antibodiesIL330002, IL330004, IL330020, IL330071, IL330125, and IL330126 are shownin Table 6.

TABLE 6 IC₅₀ results in the IL-33 FLAG ®-His/ST2-Fc competition assayHuman IL-33 FLAG ® + Cynomolgus IL-33 FLAG ® + IgG Human ST2-Fc HumanST2-Fc IL330002 27 nM  42 nM IL330004 9 nM 170 nM IL330020 40 nM Noinhibition IL330071 59 nM 375 nM IL330125 210 nM No inhibition IL330126226 nM No inhibition

All of the purified IgG preparations (i.e., IL330002, IL330004,IL330020, IL330071, IL330125, and IL330126) were shown to inhibit thehuman IL-33: human ST2 interaction. FIG. 3A: shows the inhibition of theFRET signal, produced by human IL-33 binding to human ST2 withincreasing concentrations of IL-33 IgG1 antibodies IL330002, IL330004,IL330020, IL330071, IL330125 and IL330126, wherein the x-axis is theconcentration of antibody in molar concentration and the y-axis ispercent specific binding.

The IL330002, IL330004, and IL330071 IgG preparations were also shown toinhibit the cynomolgus IL-33: human ST2 interaction. FIG. 3B: shows theinhibition of the FRET signal, produced by cynomolgus monkey IL-33binding to human ST2 with increasing concentrations of IL-33 IgG1antibodies IL330002, IL330004, IL330020 and IL330071, IL330125 andIL330126, wherein the x-axis is the concentration of antibody in molarconcentration and the y-axis is percent specific binding. No inhibitionwas detected in the mouse IL-33 FLAG®-His+mouse ST2-Fc competition assayby any of the above tested antibodies.

Inhibition of NFκB Signaling in Hela-ST2 Reporter Cells by IgG

A reporter assay was used to assess the inhibition of IL-33 induced NFκBsignaling by anti-IL-33 antibodies IL330002, IL330004, IL330020,IL330071, IL330125, and IL330126, using Hela cells co-transfected withST2 and an NFκB responsive luciferase reporter construct. Cells wereexposed to IL-33 in the presence or absence of test antibody, and NFκBsignaling was detected by measuring the activity of the luciferasesubsequently produced. Hela cells containing luciferase reporterconstruct were sourced from Panomics. Human ST2 sequence was cloned intoa lentiviral vector from System Biosciences. Lentiviral particles weregenerated in Ad293 cells (Stratagene) and used to transduce theHela-luciferase reporter cells.

In the reporter assay, stimulation of the ST2 receptor with IL-33resulted in activation of the NFκB signaling pathway and through theNFκB promoter, initiated the expression of the enzyme luciferase.Following lysis of the cells, a luciferase substrate was added, whichunderwent a chemical reaction in the presence of luciferase to produce aluminescent product. The amount of light detected from the cell lysatewas quantified using an Envision plate reader (PerkinElmer) and used asa direct measure of IL-33 mediated NFκB signaling.

Hela transfected cells were maintained in media containing hygromycin Bto maintain stable receptor expression. Cells were exposed to IL-33 inthe presence or absence of test antibody, and NFκB signalling detectedby measuring the activity of the luciferase subsequently produced.

Transfected Hela cells were seeded at 1×10⁴ cells/well (50 microlitresper well) in DMEM culture medium (Invitrogen, 41966) containing 10% v/vFetal Bovine Serum (heat inactivated) and 100 microgram per mLHygromycin B (Invitrogen 10687-010) into 384 well black-walled,Poly-D-Lysine coated plates (Greiner, 781946). Plates were incubated at37 degrees Celsius, 5% CO₂ for 18-24 hours, and then cell medium wasgently aspirated from the wells prior to addition of test samples.

Serial dilutions of samples were prepared by dilution in DMEM culturemedium (Invitrogen 41966) containing 10% v/v FBS (heat inactivated) and100 microgram per mL Hygromycin B (Invitrogen, 10687-010). Fifteenmicrolitres of test sample was added to cells in duplicate. IL-33FLAG®-His was diluted to 0.6 nM in DMEM culture medium (Invitrogen,41966) containing 10% v/v FBS (heat inactivated) and 100 microgram permL Hygromycin B (Invitrogen 10687-010) and 15 microlitres added to thecells and test samples. This concentration represented the EC₅₀ value ofthe reporter cell response to IL-33 FLAG®-His (Geomean 0.32 nM, 95%confidence intervals 0.25-0.40 nM, n=5). Background response was definedby the addition of 30 microlitres DMEM culture medium (Invitrogen,41966) containing 10% v/v FBS (heat inactivated) and 100 microgram permL Hygromycin B (Invitrogen, 10687-010). Plates were incubated at 37degrees Celsius, 5% CO₂ for 4 hours and at room temperature for 1 hour.

To measure production of luciferase in response to NFκB signaling, 30microlitres of Bright Glo® lysis buffer combined with luciferasesubstrate (Promega, E2620) was added to the plate and incubated at roomtemperature for 5 minutes. Luminescence produced as a result ofoxidation of the substrate by luciferase is read using an EnVision platereader (PerkinElmer).

The relative light unit (RLU) values were subsequently used to calculate% specific response as described in equation 5:

${\%{specific}{response}} = {\left( \frac{\left( {{{Sample}{RLU}} - {{Background}{RLU}}} \right)}{\left( {{{Total}{}{RLU}} - {{Background}{RLU}}} \right)} \right) \times 100}$

IC₅₀ values were determined using GraphPad Prism software by curvefitting using a four-parameter logistic equation (Equation 4):

Purified IgG preparations of antibodies IL330002, IL330004, IL330020,IL330071, IL330125, and IL330126 were shown to inhibit the NFκB-drivenluciferase activity with representative potencies (IC50) shown in Table7.

TABLE 7 IC₅₀ results in the human ST2 transfected HeLa NFkB reporterassay IgG Human IL-33 FLAG ®-His IL330002 226 nM IL330004 23 nM IL330020147 nM IL330125 332 nM IL330126 245 nM IL330071 226 nM

FIG. 4A shows the inhibition of NFκB activity in luciferase NFκBreporter assay by IL-33 antibodies IL330002, IL330004 IL330020,IL330071, IL330125, and IL330126 compared to a negative control IgG.

Inhibition of NFκB Signaling in Huvec by IgG

NFκB signaling in Human umbilical vein endothelial cells (Huvecs) inresponse to IL-33 was assessed by nuclear translocation of the p65/RelANFkB subunit detected by immunofluorecence staining. Imaging andquantification of the nuclear staining intensity was performed onArrayScan VTi HCS Reader (Cellomics).

Huvecs were obtained from Cambrex and maintained in complete EBM-2 media(Lonza) according to recommended protocol. Huvecs were harvested fromflasks with accutase (PAA, #L11-007) and seeded at 1×10⁴/100 μl/well inculture media [EBM-2 (Lonza, #CC-3156) with EGM-2 SingleQuot Kit Suppl.& Growth Factors (Lonza, #CC-4176)] into 96-well black walled, clearflat-bottomed Collagen I coated plates (Greiner) and incubated at 37°C., 5% CO₂ for 18-24 hours. After this time, media was aspirated,leaving cell monolayer intact, and replaced with assays test samples asprepared below.

Test samples of purified IgG (in duplicate) were diluted to the desiredconcentration in complete culture media in 96 well U-bottompolypropylene plates (Greiner, 650201). IL-33 (Adipogen) was prepared incomplete culture media mixed with appropriate test antibody to give afinal IL-33 concentration of 1 ng/mL in a total volume of 120 μl/well.All samples were incubated for 30 mins at 37° C., prior to transfer of100 μl of IL-33/antibody mixture to the assay plate. Following 30 minuteincubation at 37° C., media were aspirated, leaving the cell monolayerintact and cells were fixed for 15 minutes with 3.7% formaldehydesolution that had been pre-warmed to 37° C. Fixative was aspirated andcells were washed twice with 100 μL/well of PBS.

Cells were stained for NFκB using a Cellomics NFκB assay kit (ThermoScientific, #8400492) according to manufacturer's instructions. Briefly,cells were permeabilised for 15 minutes at room temperature, blocked for15 minutes and stained for 1 hour with primary antibody solution in avolume of 50 μL. Plates were washed ×2 in blocking buffer and stainedfor 1 hour at room temperature with secondary antibody solution, whichincluded Hoechst nuclear stain as well as secondary antibody. Plateswere washed ×2 in PBS. Cells were stored in a final volume of 150μL/well PBS and covered with a black, light-blocking seal (Perkin Elmer,#6005189) before reading on ArrayScan VTi HCS Reader. The intensity ofnuclear staining was calculated using a suitable algorithm. Data wereanalysed using Graphpad Prism software. IC₅₀ values were determined bycurve fitting using a four-parameter logistic equation (Equation 4).

FIG. 4B shows the inhibition of NFκB activity in Huvec NFκBtranslocation assay by IL-33 antibody IL330004 compared to Anti-NIP IgG1negative control antibody, NIP228. Nuclear translocation of p65/RelANFκB was inhibited by antibody IL330004. When tested as a purified IgG,the IC50 for antibody IL330004 was calculated as being 12 nM.

Binding Affinity Calculation for IL-33 Antibodies Using BIAcore

The binding affinity of purified IgG samples of exemplary bindingmembers to human and cynomolgus IL-33 was determined by surface plasmonresonance using BIAcore 2000 biosensor (BIAcore AB) essentially asdescribed by Karlsson et al., J Immunol Methods 145(1-2):229-40 (1991).In brief, Protein G′ (Sigma Aldrich, P4689) was covalently coupled tothe surface of a CM5 sensor chip using standard amine coupling reagentsaccording to manufacturer's instructions (BIAcore). The protein G′surface was used to capture purified anti-IL-33 antibodies via the Fcdomain to provide a surface density of approximately 290RU per cycle.Human or cynomolgus IL-33 prepared in HBS-EP buffer (BIAcore AB), at arange of concentrations, between 600 nM and 18.75 nM, were passed overthe sensor chip surface. The surface was regenerated using two 10 mMGlycine washes of pH 1.7 and pH 1.5 between each injection of antibody.The resulting sensorgrams were evaluated using BIA evaluation 3.1software and fitted to a 1:1 Langmuir binding model, to provide relativebinding data. The binding results (KD, Ka, and Kd) for antibodiesIL330002 and IL330004 binding to human or cynomolgus IL-33 are shown inTable 8.

TABLE 8 BIAcore binding affinity of exemplary binding members KD Ka KdAntibody Antigen (nM) (1/Ms) (1/s) IL330002 Human IL-33 35 6.16E+042.18E−03 FLAG ®-His IL330002 Cynomolgus IL-33 189 2.34E+04 4.42E−03FLAG ®-His IL330004 Human IL-33 6 1.96E+05 1.10E−03 FLAG ®-His IL330004Cynomolgus IL-33 365 1.25E+04 4.58E−03 FLAG ®-His

Binding of IL-33 Antibodies to Intracellular IL-33

Selection and activity studies described above used recombinant orcommercial sources of mature IL-33 (amino acids 112-270). Studiessuggest full length IL-33 may also be active (Cayrol et al., Proc NatlAcad Sci USA 106(22):9021-6 (2009); Hayakawa et al., Biochem Biophys ResCommun 387(1):218-22 (2009); Talabot-Ayer et al., J Biol Chem.284(29):19420-6 (2009)). The binding of antibodies to full length(“native”) IL-33 was determined by immunofluorescence staining ofprimary bronchial smooth muscle cells (BSMC).

BSMC were obtained from Cambrex and maintained in complete smooth musclegrowth media (SmBM®, Lonza) according to manufacturer's instructions.Cells were harvested from flasks with accutase (PAA #L11-007) and seededat 2×10⁴/100 μl/well in culture media [SMBM (Lonza #CC-3181) with SMGMSingleQuot Kit Suppl. & Growth Factors (Lonza #CC-4149)] into 96-wellblack walled, clear flat-bottomed Collagen I coated plates (Greiner) andincubated at 37° C., 5% CO₂ for 18-24 hours. After this time, media wasaspirated, leaving cell monolayer intact, and cells were fixed for 15minutes with 3.7% formaldehyde solution that had been pre-warmed to 37°C. Fixative was aspirated and cells were washed twice with 100 μL/wellof PBS. Cells were permeabilised for 15 minutes at room temperatureusing permeabilisation buffer (Thermo Scientific, #8400492), washed ×2in PBS and blocked with 100 μL/well of PBS/1% BSA (Sigma, #A9576) for30-60 minutes at room temperature. Blocking buffer was flicked out andreplaced with a titration of anti-IL-33 or suitable isotype controlantibodies, that had been diluted in blocking buffer, for 1 hour at roomtemperature.

Plates were washed ×2 in PBS and stained for 1 hour at room temperaturewith secondary antibody solution, which included Hoechst dye (10 mg/mL;Thermo Scientific) diluted 1:10000 as well as secondary antibody(Anti-Human IgG (H+L), Alexa Fluor® 488 conjugate 2 mg/mL; Invitrogen,#A11013) diluted 1:1000. Plates were washed three times in PBS. Cellswere stored in a final volume of 150 μL/well PBS and covered with ablack, light-blocking seal (Perkin Elmer, #6005189) before imaging onArrayScan VTi HCS Reader.

IL-33 expression by cultured BSMC was confirmed with a commercialpolyclonal antibody (R&D Systems, #AF3625), detected with anti-Goat IgG(H+L), Alexa Fluor® 488 conjugate 2 mg/mL; Invitrogen, #A11055). FIG. 5shows detection of endogenous IL-33 in bronchial smooth muscle cells byimmunofluorescence staining by IL-33 antibody IL330004 (right panel)compared to CAT-002 negative control (left panel). Antibody IL330004showed a clear nuclear staining of BSMC, corresponding with the expectedlocalization of full length IL-33, and that detected with the commercialpAb.

Example 2 Isolation and Identification of Anti-IL-33 scFv AntibodiesIdentification of IL-33 Specific Binders by Phage ELISA

Reagents and selections were as described in Example 1. Single-chain Fvfragments were displayed on phage particles and tested as unpurifiedpreparations in a single point ELISA screen. Phage-displayed scFv wereconsidered to bind the IL-33 antigen if the absorbance 450 nm was >0.5,and <0.1-0.2 for the same sample on controls (insulin and IL-4Rα Flag®His).

FIG. 6 shows data from a single plate screened against human IL-33,cynomolgus IL-33 and insulin. One specific human/cynomolguscross-reactive IL-33 binder is shown in well C4, and wells A12 and B12contain control IL-33 binding clone.

Identification of IL-33 Binders by Axxora IL33305B Competition

The Axxora IL33305B Competition Assay is a homogeneous assay thatutilizes Fluorescence Microvolume Assay Technology (FMAT). The assayassessed the inhibition of Axxora IL33305B mAb (Axxora/Adipogen,#AG-20A-0041-0050) binding to recombinant biotinylated human IL-33 Flag®His in the presence of crude scFv supernatant samples or purified scFvand IgG in a 384-well format.

ScFv were expressed in the bacterial periplasm and screened for theirinhibitory activity in an FMAT epitope competition assay against a knownbiologically active IL33305B mAb. Biotinylated IL-33 was immobilized onstreptavidin coated beads (Spherotec, #SVP-60-5) and the interactionwith Axxora IL33305B Ab was detected using a goat anti-mouseAlexafluor®-647 labeled antibody (Molecular Probes A21236). The FMATsystem is a macroconfocalimager, which measures the red fluorescenceassociated with the beads.

Plates were read on the Applied Biosystems Cellular Detection system8200 reader. The Helium neon excitation laser focuses within 100 μmdepth of the bottom of the well scanning an area 1 mm². The beads settleat the bottom of the well and upon laser excitation at 633 nm thosebeads with fluorophore bound (where the local concentration offluorophore is relatively high compared to unbound fluorophore) emit asignal at 650-685 nm that is measured using PMT1. Unbound fluorophore insolution is outside the excitation depth or at a relatively low localconcentration and thus does not emit a significant signal. ScFv or IgGsamples that effectively block IL33305B binding to IL-33 will thereforecause a reduction in the amount of bead:IL-33:IL33305B:anti-mouseAlexafluor®-647 labeled antibody complexes at the bottom of the wellwhich results in a reduction in measured fluorescence.

For the assay setup, the following were prepared:

-   -   (1) IL33305B and anti-mouse AF647 mix, IL33305B was diluted to        2.25 nM in assay buffer [PBS (Gibco, 14190-094) containing 0.1%        BSA (Sigma, #A9576) and 0.1% Tween-20 (Sigma, P2287)] and mixed        with anti-mouse AF647 diluted to 2 μg/ml (final 400 ng/ml) in        assay buffer.    -   (2) IL-33 and bead mix, 2.5 nM biotinylated human IL-33 FLAG®        His was added to 0.0095% w/v streptavidin beads in assay buffer        and incubated with rotation at room temperature for 1        hour—before use these particles were spun down at 2000 rpm for        15 minutes and resuspended in original volume assay buffer.    -   (3) Sample Preparation, crude scFv supernatant samples were        generated in 96 deep well plates. 5 μl culture from each well of        a 96-well master plate was transferred into a Greiner deep well        culture plate containing 900 μl of 2TY+100 μg/ml ampicillin+0.1%        glucose media and incubated for 5 hours at 37° C., 280 rpm. 10        mM IPTG in TY was then added at 100 ul/well and the plate        incubated overnight at 30° C., 280 rpm. The next morning, the        plate was spun down at 3200 rpm for 15 minutes. For        high-throughput screening, scFv supernatants from the deep well        plate were transferred directly to the assay plate to achieve a        final concentration of 20%.

For IC50 determinations, typically purified scFv or IgGs were diluted3-fold in assay buffer, in duplicate, to give 11 concentration points.96 well Greiner polypropylene (Greiner, 650201) plates are used fordilution preparation.

Into columns 1-22 of a 384-well clear bottomed non-binding surface blackplate (Costar, #3655), the following were added: 10 μl sample, 20 μlIL33305B/anti-mouse AF647 mix, and 20 μl IL-33/bead mix. In all cases,total well volume was 40 μl. Controls typically used in theseexperiments included: IL-33/bead mix plus anti-mouse AF647 was added(non-specific binding); IL330305B/anti-mouse AF647 mix plus IL-33/beadmix (total binding). The plates were sealed and incubated for four hoursat room temperature in the dark and then read on the Applied BiosystemsCellular Detection system 8200 reader. Data was analyzed with theVelocity algorithm, with gating set as color ratio <0.4, size <15 andminute count 20. Hits from the crude scFv supernatant samples weredefined as showing 50% or greater inhibition of signal compared to thetotal binding control wells. Dose response curves were plotted forpurified scFv and IgG titrations using Prism (Graphpad) curve-fittingsoftware.

Reformatting of scFv to IgG1

scFv that displayed a desirable species cross-reactivity and specificityprofile as determined by phage-displayed scFv binding experiments orshowed an inhibitory effect in the epitope competition assay againstAxxora 1133305B (as described above), were subjected to DNA sequencing(Osbourn et al., Immunotechnology 2(3):181-96 (1996); Vaughan et al.,Nat. Biotechnol. 14(3):309-14 (1996)). First, scFv with desirableproperties were converted to whole immunoglobulin G1 (IgG1), or aneffector-null isotype IgG1 TM (IgG1 Fc sequence incorporating mutationsL234F, L235E and P331S), antibody format as described in Example 1. SEQID NOs corresponding to the various regions of antibodies IL330065,IL330099, IL330101, IL330107, IL33149, and IL330180 are shown in Table9.

TABLE 9 Anti-IL-33 Antibody Sequences VH VL VH CDRs VL CDRs IgG1Sequence Sequence 1, 2, 3 1, 2, 3 IL330065 SEQ ID SEQ ID SEQ ID SEQ IDNO: 82 NO: 87 NO: 83 NO: 88 SEQ ID SEQ ID NO: 84 NO: 89 SEQ ID SEQ IDNO: 85 NO: 90 IL330099 SEQ ID SEQ ID SEQ ID SEQ ID NO: 92 NO: 97 NO: 93NO: 98 SEQ ID SEQ ID NO: 94 NO: 99 SEQ ID SEQ ID NO: 95 NO: 100 IL330101SEQ ID SEQ ID SEQ ID SEQ ID NO: 102 NO: 107 NO: 103 NO: 108 SEQ ID SEQID NO: 104 NO: 109 SEQ ID SEQ ID NO: 105 NO: 110 IL330107 SEQ ID SEQ IDSEQ ID SEQ ID NO: 122 NO: 127 NO: 123 NO: 128 SEQ ID SEQ ID NO: 124 NO:129 SEQ ID SEQ ID NO: 125 NO: 130 IL330149 SEQ ID SEQ ID SEQ ID SEQ IDNO: 132 NO: 137 NO: 133 NO: 138 SEQ ID SEQ ID NO: 134 NO: 139 SEQ ID SEQID NO: 135 NO: 140 IL330180 SEQ ID SEQ ID SEQ ID SEQ ID NO: 142 NO: 147NO: 143 NO: 148 SEQ ID SEQ ID NO: 144 NO: 149 SEQ ID SEQ ID NO: 145 NO:150

Binding Assay for IgGs

Species cross-reactivity of anti-IL-33 antibodies was determined using aplate-based ELISA. Streptavidin plates (Thermo Scientific, AB-1226) werecoated with biotinylated antigen at 0.5 μg/ml in PBS. Binding ofpurified IgG preparations was detected with anti-human IgG HRP (Sigma,A0170). EC50 data for binding curves are shown in Table 10.

TABLE 10 Binding of IL-33 antibodies to Flag ®His- tagged human,cynomolgus or mouse IL-33 EC50 (nM) Human IL-33 Cynomolgus IL-33 MouseIL-33 Antibody Flag ®His Flag ®His Flag ®His IL330065 0.65 0.66 Nobinding IL330099 0.40 0.35 0.38 IL330101 1.19 1.20 0.85 IL330107 0.861.09 0.83 IL330149 0.23 0.35 0.17 IL330180 Not determined* Notdetermined* Not determined* IL330180 was determined to bind to humanIL-33, but not Cynomolgus or mouse IL-33 in phage-displayed scFv format.

Inhibition of IL-33 Functional Responses by Anti-IL-33 AntibodiesInhibition of TF-1 Cell Proliferation by IgG

A cell viability assay was used to assess the inhibition of IL-33induced proliferation/survival from TF-1 cells by anti-IL-33 antibodies.The CellTiter-Glo® Luminescent Cell Viability Assay (Promega) is ahomogeneous method to determine the number of viable cells in culturebased on quantitation of the ATP present, which signals the presence ofmetabolically active cells. Cells were exposed to IL-33 in the presenceor absence of test antibody. Cell viability was measured byCellTiter-Glo following 72 hour stimulation with IL-33.

In particular, the proliferation assay was used to assess the inhibitionof IL-33 induced proliferation from TF-1 cells by anti-IL-33 antibodies.TF-1 cells were a gift from R&D Systems and maintained according tomanufacturer's instructions. The assay media comprised RPMI-1640 withGLUTAMAX I (Invitrogen, 61870) containing 5% fetal bovine serum (heatinactivated, gamma-irradiated), 1% sodium pyruvate (Sigma, S8636), 1-2%Penicillin/streptomycin (Invitrogen, 15140-122). Prior to each assay,TF-1 cells were pelleted by centrifugation at 300×g for 5 minutes, themedia were removed by aspiration, and the cells were then re-suspendedin assay media. This process was repeated twice with cells re-suspendedat a final concentration of 2×10⁵ cells/ml in assay media. Testsolutions of IgG (in duplicate) were titrated to the desiredconcentration range in assay media in 96 well U-bottom polypropyleneplates (Greiner, 650201) and 50 μL transferred to 96-well flat-bottomedtissue culture-treated plates (Costar, #3598). Recombinant human IL-33(Alexis, ALX-522-098-3010) was added to the appropriate test antibodytitrations to give a total volume of 100 μl/well. 100 μl of cellsuspension was then added to 100 μl of IL-33 or IL-33 and antibodymixture to give a total assay volume of 200 μl/well and total cellnumber of 20,000 per well. A final assay concentration of 100 ng/mLIL-33 was used in the assay, which was selected as the dose that gaveapproximately 80% of maximal proliferative response. Plates wereincubated for 72 hours at 37° C. and 5% CO₂. 100 μL of supernatant wascarefully removed from the assay plates. 100 μL of CellTiter-Glo(Promega, G7571), reconstituted according to manufacturers instructions,was added per well. Plates were shaken on a plate shaker at 500 rpm for5 minutes and luminescence read on EnVision plate reader (PerkinElmer).Data were analyzed using Graphpad Prism software. IC50 values weredetermined by curve fitting using a three or four-parameter logisticequation.

For those antibodies that achieved full inhibition curves, IC50 valueswere calculated and are summarized in Table 11 below. Purified IgGpreparations were capable of inhibiting TF-1 proliferation in responseto IL-33. FIG. 7A shows percent inhibition for IL330065 and IL330101(compared to control mAb and hST2/Fc) for the TF-1 proliferation assay,wherein the x-axis is the concentration of antibody in molarconcentration and the y-axis is a percentage of the maximum response.

Inhibition of Huvec IL-6 Release by IL-33 Antibodies

A cytokine release assay was used to assess the inhibition of IL-33induced IL-6 production from human umbilical vein endothelial cells(Huvec) by anti-IL-33 antibodies. Cells were exposed to IL-33 in thepresence or absence of test antibody.

Huvecs were obtained from Cambrex and maintained in complete EBM-2 media(Lonza) according to manufacturer's protocol. Cells were harvested fromflasks with accutase (PAA, #L11-007) and seeded at 1×10⁴/100 μl/well inculture media (EBM-2 (Lonza, #CC-3156) with EGM-2 SingleQuot Kit Suppl.& Growth Factors (Lonza, #CC-4176)) into 96-well flat-bottomedtissue-culture treated plates (Costar, #3598) and incubated at 37° C.,5% CO₂ for 18-24 hours. After this time, media was aspirated, leavingcell monolayer intact, and replaced with assay test samples as discussedbelow.

Test solutions of purified IgG (in duplicate) were diluted to thedesired concentration in complete culture media in 96 well U-bottompolypropylene plates (Greiner, 650201). IL-33 (Adipogen) was prepared incomplete culture media mixed with appropriate test antibody to give afinal IL-33 concentration of 30 ng/mL. All samples were incubated for 30minutes at room temperature, prior to transfer of 120 μl ofIL-33/antibody mixture to the assay plate. Following 18-24 hourincubation, IL-6 was measured in cell supernatants by ELISA (R&DSystems, DY206) adapted for europium readout. Black Fluro-Nunc Maxisorpplates (VWR, #437111) were coated with 50 μL capture antibody, washedthree times with PBS-Tween (0.01%) using an automated plate washer(Biotek) and blocked with 250 μL/well of PBS/1% BSA (Sigma, #A9576) for1-2 hours at room temperature. Plates were washed as above and incubatedwith 50 uL mast cell assay supernatants for 1-2 hours at roomtemperature. Following 3× wash with PBS-Tween, plates were incubatedwith detection antibody (50 uL/well) according to manufacturer'sinstructions. ELISA plates were washed three times in PBS-Tween, andStreptavidin-Europium (PerkinElmer, 1244-360) was diluted 1:1000 inDELFIA® assay buffer (PerkinElmer, 4002-0010) and added at 50 μl/wellfor 45-60 minutes at room temperature. Plates were then washed 7 timesin DELFIA wash buffer before the addition of 50 μl/well of enhancementsolution (PerkinElmer, 4001-0010) and analyzed using time resolvedfluorometry (Excitation 340 nM, Emission 615 nM). Data were analyzedusing Graphpad Prism software. IC50 values were determined by curvefitting using a three or four-parameter logistic equation. For thoseantibodies that achieved full inhibition curves, IC50 values werecalculated and are summarized in Table 11 below. Purified IgGpreparations (IgG1 or IgG1-TM) of antibodies IL330065, IL330099,IL330101, IL330107, IL330149, and IL330180 inhibited IL-6 production incomparison with control antibodies. Potency of exemplary binding memberswas essentially unaffected by the presence of IgG1-TM Fc sequencemutations (L234F, L235E and P331S), and the data as shown combinesinformation for both formats. FIG. 7B shows percent maximal IL-6 releasefor IL330065 and IL330101 (compared to human ST2-Fc, anti-IL33 pAbAF3625 (R & D Systems), and control mAb), wherein the x-axis is theconcentration of antibody in molar concentration and the y-axis is apercentage of the maximum response.

Inhibition of Human Mast Cell Cytokine Release

A cytokine release assay was used to assess the inhibition of IL-33induced IL-6 production by anti-IL-33 antibodies from human mast cells.In addition to IL-6, other cytokines (IL-5, IL-6, IL-8, IL-10, IL-13,GM-CSF and TNFα) in cell supernatants were measured using alternativeduoset ELISAs or Mesoscale Discovery multiplex analysis.

Human mast cells were produced by in vitro differentiation of cord bloodCD133+ progenitor cells (Lonza, #2C-108) essentially as described inAndersen et al. (J Immunol Methods 336:166-174 (2008)). Progenitor cellswere thawed according to manufacturer's instructions and cultured invitro in Serum Free Expansion Media (StemSpan, #09650) supplemented with1% Penicillin/streptomycin (Invitrogen, 15140-122) and growth factors:100 ng/mL Stem Cell Factor (Peprotech, #AF-300-07) and 50 ng/mL IL-6(Peprotech, #AF-200-6) for 8 weeks. In addition, 1 ng/mL IL-3 (R&DSystems, #203-IL) was included in the culture media during the firstthree weeks. Cells were maintained throughout at <5×10⁵/mL.

Mast cells were cultured overnight in assay media (StemSpan, #09650; 1%Penicillin/streptomycin (Invitrogen, 15140-122) and 100 ng/mL Stem CellFactor (Peprotech, #AF-300-07)), prior to exposure to IL-33 in thepresence or absence of test antibody.

For cytokine release assays, cells were removed, pelleted (150 g for 10minutes) and resuspended in assay media (StemSpan, #09650, 1%Penicillin/streptomycin (Invitrogen, 15140-122) and 100 ng/mL Stem CellFactor (Peprotech, #AF-300-07)). Cells were returned to a flask andcultured for 18-24 hours prior to assay setup. For sample assessment,test solutions of IgG (in duplicate) were titrated to the desiredconcentration range in assay media in 96 well U-bottom polypropyleneplates (Greiner, 650201) and 50 μL of test solutions transferred to96-well flat-bottomed tissue-culture treated plates (Costar, #3598). 50μL of recombinant human IL-33 (Adipogen, #522-098-3010), diluted inassay media to 90 ng/mL was added to the appropriate test antibodytitrations to give a total volume of 100 μl/well. 50 μl of cellsuspension (1.5×10⁵) was then added to 100 μl of IL-33 or IL-33 andantibody mixture to give a total assay volume of 150 μl/well and totalcell number of 5×10⁴ per well. A final assay concentration of 30 ng/mLIL-33 was used in the assay, selected as the dose that gaveapproximately 50-80% of maximal cytokine response. Plates were incubatedfor 18-24 hours at 37° C. and 5% CO₂.

IL-6 was measured in cell supernatants by ELISA (R&D Systems, DY206)adapted for europium readout. Black Fluro-Nunc Maxisorp plates (VWR,#437111) were coated with 50 μL capture antibody, washed three timeswith PBS-Tween (0.01%) using an automated plate washer (Biotek) andblocked with 250 μL/well of PBS/1% BSA (Sigma, #A9576) for 1-2 hours atroom temperature. Plates were washed as above and incubated with 50 μLmast cell assay supernatants for 1-2 hours at room temperature.Following 3λ wash with PBS-Tween, plates were incubated with detectionantibody (50 μL/well) according to manufacturer's instructions. ELISAplates were washed three times in PBS-Tween, and Streptavidin-Europium(PerkinElmer, 1244-360) was diluted 1:1000 in DELFIA assay buffer(PerkinElmer, 4002-0010) and added at 50 μl/well for 45-60 minutes atroom temperature. Plates were then washed 7 times in DELFIA wash bufferbefore the addition of 50 μl/well of enhancement solution (PerkinElmer,4001-0010) and analyzed using time resolved fluorometry (Excitation 340nM, Emission 615 nM). Data were analyzed using Graphpad Prism software.IC50 values were determined by curve fitting using a three orfour-parameter logistic equation.

FIG. 8A shows the reduction of IL-6 production by increasingconcentrations of antibodies IL330065, IL330099, IL330101, IL330107,IL33149, and IL330180, wherein the x-axis is the concentration ofantibody in molar concentration and the y-axis is % maximum response.Purified IgG preparations of test antibodies were capable of inhibitingthe IL-6 activity in comparison with control antibodies. Potency ofexemplary binding members was essentially unaffected by the presence ofIgG1-TM Fc sequence mutations (L234F, L235E and P331S) and the datacombines information for both formats. IC50 results for TF-1proliferation assay, HUVEC IL-6 production, and mast cell IL-6production are shown in Table 11.

TABLE 11 Example potencies of clones identified from naïve human scFvphage display libraries IgG1 Geomean (95% CI) IC50 (nM) TF-1 Huvec IL-6Mast cell IL-6 Antibody proliferation production production IL330065 81(19-345) 87 (60-129) 12 (4-40) IL330099 Incomplete curve Incompletecurve 1221 (n = 1) IL330101 149 (n = 1) 497 (167-1474) 49 (31-75)IL330107 94 (n = 1) Incomplete curve 283 (154-522) IL330149 Incompletecurve Incomplete curve 298 (n = 2) IL330180 Not Determined NotDetermined 22 (n = 1)

Additional cytokines (IL-5, IL-6, IL-8, IL-10, IL-13, and GM-CSF) incell supernatants were detected using Meso-Scale DiagnosticsDemonstration 10-plex human cytokine assay (#K15002B-1) according tomanufacturer's instructions. Cytokines were measured in cellsupernatants by ELISA adapted for europium readout using a similarprotocol to the IL-6 ELISA described above.

Mast cells were shown to produce a range of cytokines after stimulationwith IL-33 (Meso-Scale Diagnostics Demonstration 10-plex human cytokineassay #K15002B-1; R&D Systems, #DY213). FIGS. 8B-F show the inhibitionof IL-33-driven production of GM-CSF, IL10, IL-8, IL-13 and IL-5,respectively. These results show that antibodies IL330065, IL330101,IL330107, and IL330149 were able to inhibit IL-33-driven production ofall cytokines measured.

Binding and Neutralization of Native Full Length IL-33

Selection and activity studies described above used recombinant in houseor commercial sources of mature IL-33 (amino acids 112-270). Full lengthIL-33 may also be active (Cayrol et al., Proc Natl Acad Sci USA106(22):9021-6 (2009); Hayakawa et al., Biochem Biophys Res Commun387(1):218-22 (2009); Talabot-Ayer et al., J Biol Chem. 284(29):19420-6(2009)). To assess binding of antibodies to full length IL-33, fulllength IL-33 was cloned and expressed in HEK293-EBNA cells. As describedbelow, selected antibodies were shown to bind to full length IL-33 asdetermined by Western blot.

Cloning and Expression of Full-Length Human IL-33

The cDNA molecule encoding full-length (FL) IL-33 from human (Swiss Protaccession number 095760 amino acids 1-270) was synthesized by primerextension PCR cloning and cloned into pDONR221 (Invitrogen, 12536-017)and was transferred to the mammalian expression vector pDEST12.2(Invitrogen) using LR Gateway Clonase II enzyme according to themanufacturer's instructions (Invitrogen, 12538-120). The pDEST12.2vector had been modified to contain the oriP origin of replication fromthe pCEP4 vector (Invitrogen) allowing episomal plasmid replication upontransfection into cell lines expressing the EBNA-1 gene product (such asHEK293-EBNA cells). HEK293-EBNA cells were transfected withLipofectamine 2000 (Invitrogen, 11668-019). Cells expressing FL HuIL-33(and mock-transfected controls) were lysed using sonication in thepresence of protease inhibitors (Roche, 05892791001).

Western Blot Analysis of Cell Lysates Expressing Full-Length Human IL-33

Proteins from cell lysates were denatured and reduced with SDS samplebuffer and DTT prior to separation by SDS-PAGE electophoresis andtransfer to Nitrocellulose membranes. Membranes were blocked with 5%non-fat dried milk in PBS-T for 1 h, incubated with primary antibody(0.5 pg per ml) for 1 h, washed three times in PBS-T, then incubated for1 h with HRP-conjugated secondary antibody (1 in 10,000 dilution of goatanti-human IgG (Sigma, A0170)) and washed three times in PBS-T. HRP wasdetected with Amersham ECL plus detection reagent (GE healthcare,RPN2132). Sizes were estimated by comparing migration to that of MagicMark XP (Invitrogen, LC5602). FIG. 9 shows binding of IL-33 antibodies(IL330065, IL330101, IL330107, and IL330149) to full length human IL-33by Western blot.

Neutralization of Mast Cell Cytokine Responses to Full Length IL-33 CellLysate

HEK293-EBNA cells expressing full length (FL) HuIL-33 (andmock-transfected controls) were harvested 24 hours followingtransfection with accutase (PAA, #L11-007). Cells were diluted to5×10⁷/mL with PBS and homogenized for 30 seconds using a tissuehomogenizer. Cell debris was removed by centrifugation. Mast cells werestimulated with cell lysates at varying concentrations. Stimulation ofcytokine production was only observed with full length IL-33-transfectedcell lysate and not with mock transfected cell lysate. A concentrationof lysate that stimulated a sub-maximal cytokine release (approx EC50)was selected for antibody neutralization studies.

For cytokine release assays, mast cells were cultured overnight in assaymedia (StemSpan, #09650; 1% Penicillin/streptomycin (Invitrogen,15140-122) and 100 ng/mL Stem Cell Factor (Peprotech, #AF-300-07)),prior to exposure to FL HuIL-33 in the presence or absence of testantibody. IL-6 and IL-13 production was detected by ELISA of assaysupernatants after 18-24 hours. A detailed description of the protocolwas described above (Example 2-0007).

FIG. 10 shows the effect of anti-IL-33 antibodies IL330065 and IL330101on mast cell IL-6 and IL-13 production stimulated by cell lysates offull length IL-33-transfected cells. Purified IgG preparations werecapable of inhibiting IL-6 (FIG. 10A) and IL-13 (FIG. 10B) productioninduced by full length IL-33 cell lysates.

Non-Competitive Mode of Action of IL-33 Antibodies Inhibition of IL-33Binding to ST2 by Purified IgG

The ability of anti-IL-33 antibodies to inhibit the binding of Flag®-Histagged IL-33 to the ST2 receptor was assessed in a biochemical HTRF®(Homogeneous Time-Resolved Fluorescence, Cisbio International)competition assay the full methods of which are described in Example 1.

FIG. 11A shows specific binding results for HTRF® receptor-ligandcompetition assay with increasing concentrations of antibodies IL330065,IL330099, IL330101, IL330107, IL33149, and IL330180. These results showthat antibodies IL330065, IL330099, IL330101, IL330107, IL33149, andIL330180 are not competitive inhibitors of the IL-33:ST2 interaction.

Inhibition of NFkB Signalling in Huvec by IgG

NFkB signaling in Huvecs in response to IL-33 was assessed by nucleartranslocation of the p65/RelA NFkB subunit, detected byimmunofluorecence staining as described in Example 1.

FIG. 11B shows Huvec NFkB translocation with increasing concentrationsof antibodies IL330065, IL330099, IL330101, IL330107, and IL330149.These results show that IL330065, IL330099, IL330101, IL330107, andIL330149 did not inhibit nuclear translocation of p65/RelA NFkB inIL-33-stimulated Huvecs 30 minutes following stimulation. The resultsare consistent with failure of antibodies IL330065, IL330099, IL330101,IL330107, IL33149, and IL330180 to inhibit IL-33 binding to ST2.

Epitope Binning of IL-33 Antibodies in HTRF Epitope Competition Assays

The ability of antibodies to compete with mAb IL330101 or mAb IL330180for binding to biotinylated human IL-33 was assessed in a biochemicalHTRF® (Homogeneous Time-Resolved Fluorescence, Cisbio International)epitope competition assay.

The HTRF® epitope competition assays, described below, were used tomeasure the binding of a lead antibody in IgG format to biotinylatedIL-33. Test scFv samples which recognize a similar epitope to the leadantibody, will compete with the lead antibody for binding to IL-33,leading to a reduction in assay signal.

Purified anti-IL-33 scFv antibody samples were tested for inhibition ofbiotinylated human IL-33 binding the lead antibody by adding 5microliters of each dilution of antibody test sample to a 384 well lowvolume assay plate (Costar, 3673). Next, a solution containing 8 nMIL330180 IgG1 or 12 nM IL330101 IgG1 and 40 nM anti human Fc detection(Cisbio International, 61HFXLB) was prepared and 2.5 microliters addedto the assay plate. This was followed by the addition of 2.5 microlitersof a solution containing 4 nM (for IL330180 epitope competition assay)or 18 nM (for IL330101 epitope competition assay) biotinylated humanIL-33 (Axxora, AG-40B-0038; biotinylated) and 4.65 nM streptavidincryptate detection (Cisbio International, 610SAKLB). All dilutions wereperformed in assay buffer comprised of Dulbeccos PBS (Invitrogen,14190185) containing 0.8 M potassium fluoride (BDH, 103444T) and 0.1%bovine serum albumin (BSA, Sigma A9576). Assay plates were incubated for2 hour at room temperature followed by 16 hour at 4° C. before readingtime resolved fluorescence at 620 nm and 665 nm emission wavelengthsusing an EnVision plate reader (Perkin Elmer). Data were analyzed usingEquations 1 to 3 as described previously. The negative control(non-specific binding) is defined by replacing biotinylatedIL-33/streptavidin cryptate combination with streptavidin cryptatedetection only.

Results for IL330101 and IL330180 epitope competition assay are shown inFIGS. 8A and 8B, respectively. FIG. 12A shows the competitive binding ofIL330101 scFv, IL330107 scFv, IL330149 scFv, IL330065 scFv, IrrelevantscFv, and IL330180 scFv with mAb IL330101 for binding to biotinylatedhuman IL-33. These results show that IL330101 scFv, IL330107 scFv,IL330149 scFv competitively inhibited IL330101 binding to biotinylatedhuman IL-33.

FIG. 12B shows the competitive binding of IL330180, IL330101, IL330149,IL330065, and Irrelevant scFv with mAb IL330180 for binding tobiotinylated human IL-33 assessed in a biochemical HTRF®. These resultsshow that IL330101, IL330149, and IL330065 do not competitively inhibitIL330180 binding to biotinylated human IL-33.

Epitope binning using this method shows three panels of antibodiescomprising IL330101, IL330107 and IL330149 in panel 1, IL330065 in panel2 and IL330180 in panel 3, as detailed in Table 12.

TABLE 12 Epitope Binning Panels Inhibition in IL330101 Inhibition inIL330180 Epitope Competition Assay Epitope Competition Assay IL330101 ✓X IL330107 ✓ X IL330149 ✓ X IL330065 X X IL330180 X ✓

Example 3 Optimization of anti-IL-33 Ab IL330101 Affinity Maturation

IL330101 was optimised using a targeted mutagenesis approach andaffinity-based phage display selections. Large scFv-phage librariesderived from the lead clone were created by oligonucleotide-directedmutagenesis of the variable heavy (VH) complementarity determiningregions 2 and 3 (CDR2 and CDR3) and light (VL) chain CDR3 using standardmolecular biology techniques as described (Clackson, T. and Lowman, H.B. Phage Display—A Practical Approach, 2004. Oxford University Press).The libraries were subjected to affinity-based phage display selectionsin order to select variants with higher affinity for human and mouseIL-33. The selections were performed essentially as described previously(Thompson, J et al. J Mol Biol, 1996. 256: p. 77-88) using reagents asdescribed in Examples 1 and 2. In brief, the scFv-phage particles wereincubated with recombinant biotinylated human IL-33 in solution(Adipogen; biotinylated as described in Protein Modifications withinExample 1). ScFv-phage bound to antigen were then captured onstreptavidin-coated paramagnetic beads (Dynabeads® M-280) following themanufacturer's recommendations. The selected scFv-phage particles werethen rescued as described previously (Osbourn, J. K., et al.Immunotechnology, 1996. 2(3): p. 181-96), and the selection process wasrepeated in the presence of alternating and decreasing concentrations ofhuman or mouse biotinylated IL-33—typically from 500 nM to 500 pM overfour rounds of selection.

Inhibition of IL-33 Binding to mAb by Unpurified scFv

A representative number of individual clones from the selection outputswere grown up in 96-well plates. ScFv were expressed in the bacterialperiplasm (Kipriyanov, et al. J Immunol Methods 200(1-2): 69-77 (1997))and screened for their inhibitory activity in a homogeneous FRET(fluorescence resonance energy transfer) HTRF® (HomogeneousTime-Resolved Fluorescence, Cisbio International) basedIL-33:mAb-binding assay. In this assay, samples competed with IL330101IgG for binding to biotinylated human IL-33 or mouse IL-33 FLAG® His.Such epitope competition assays are based on the principle that a testantibody sample, which recognizes a similar epitope to the anti-IL-33IgG, will compete with the IgG for binding to biotinylated IL-33resulting in a reduction in assay signal.

Unpurified anti-IL-33 scFv samples were tested for inhibition ofbiotinylated human or mouse IL-33 FLAG® His binding to IL330101 byadding 5 microlitres of sample to a 384 well low volume assay plate(Costar, 3673). Next, a solution containing 12 nM IL330101 combined with40 nM anti human Fc XL665 detection (Cisbio International, 61HFCXLB) wasprepared for the human IL-33 assay and 2 nM IL330101 combined with 40 nManti human Fc XL665 detection (Cisbio International, 61HFCXLB) wasprepared for the mouse assay. 2.5 microlitres was added to the assayplates. This was followed by the addition of 2.5 microlitres of asolution containing 18 nM biotinylated human IL-33 (Adipogen,AG-40B-0038) combined with 4.6 nM streptavidin cryptate detection(Cisbio International, 610SAKLB) for the human assay or a solutioncontaining 2 nM biotinylated mouse IL-33 FLAG® His combined with 4.6 nMstreptavidin cryptate detection (Cisbio International, 610SAKLB) for thecynomolgus assay. All dilutions were performed in assay buffercontaining 0.8 M potassium fluoride (VWR, 26820.236) and 0.1% bovineserum albumin (BSA, PAA, K05-013) in Dulbeccos PBS (Invitrogen,14190185). Assay plates were incubated for 4 hour at room temperaturefollowed by 16 hour at 4 degrees Celsius and time resolved fluorescencewas read at 620 nm and 665 nm emission wavelengths using an EnVisionplate reader (Perkin Elmer). Data were analysed by calculating the665/620 nm ratio followed by the % Delta F values for each sample. The665/620 nm ratio was used to correct for sample interference usingEquation 1. The % Delta F for each sample was then calculated usingEquation 2. The negative control (non-specific binding) was defined byreplacing biotinylated IL-33 combined with streptavidin cryptatedetection with streptavidin cryptate detection only. The % Delta Fvalues were subsequently used to calculate % specific binding asdescribed in Equation 3.

As the epitope competition assay reached its limit of sensitivity, anassay using an intermediate optimised mAb IL330259 was used for testingunpurified scFv samples. Unpurified anti-IL-33 antibody samples weretested for inhibition of biotinylated human IL-33 or biotinylated mouseIL-33 FLAG® His binding DyLight labelled IL330259 by adding 5microlitres of each sample to a 384 well low volume assay plate (Costar,3673). Next, a solution containing 20 nM DyLight labelled IL330259 wasprepared for the human IL-33 assay and 4 nM DyLight labelled IL330259was prepared for the mouse assay and 2.5 microlitres added to the assayplates (IgG labelled using kit (Thermo Scientific, 53051) as permanufacturer's instructions). This was followed by the addition of 2.5microlitres of a solution containing 20 nM biotinylated human IL-33(Adipogen, AG-40B-0038) or 1.6 nM biotinylated mouse IL-33 FLAG® Hiscombined with 6 nM streptavidin cryptate detection (CisbioInternational, 610SAKLB). All dilutions were performed in assay buffercontaining 0.8 M potassium fluoride (VWR, 26820.236) and 0.1% bovineserum albumin (BSA, PAA, K05-013) in Dulbeccos PBS (Invitrogen,14190185). Assay plates were incubated for 4 hour at room temperaturefollowed by 16 hour at 4 degrees Celsius and time resolved fluorescencewas read at 620 nm and 665 nm emission wavelengths using an EnVisionplate reader (Perkin Elmer). Data were analysed by calculating the665/620 nm ratio followed by the % Delta F values for each sample. The665/620 nm ratio was used to correct for sample interference usingEquation 1. The % Delta F for each sample was then calculated usingEquation 2. The negative control (non-specific binding) was defined byreplacing biotinylated IL-33 combined with streptavidin cryptatedetection with streptavidin cryptate detection only. The % Delta Fvalues were subsequently used to calculate % specific binding asdescribed in Equation 3.

Inhibition of IL-33 Binding to mAb by Purified scFv

Single chain Fv clones which showed a greater inhibitory effect onIL-33:mAb interaction as unpurified periplasmic extracts compared toIL330101 were subjected to DNA sequencing (Osbourn, et al.Immunotechnology 2(3):181-96 (1996); Vaughan, et al. Nat Biotechnol14(3):309-14 (1996)). Unique scFv were expressed again in bacteria andpurified by affinity chromatography (as described in WO01/66754). Thepotencies of these samples were determined by competing a dilutionseries of the purified preparation against IL330101 IgG for binding tobiotinylated human IL-33, biotinylated mouse IL-33 FLAG® His orbiotinylated cynomolgus IL-33 FLAG® His as described above but with theaddition of the biotinylated cynomolgus IL-33 FLAG® His assay(biotinylated cynomolgus IL-33 FLAG® His was added at 12 nMconcentration).

FIG. 13 : shows inhibition of the FRET signal, produced by biotinylatedhuman IL-33 binding to IL330101 with increasing concentrations of IL-33scFv antibodies IL330101, IL330259, wherein the x-axis is theconcentration of antibody in molar concentration and the y-axis ispercent specific binding.

Purified scFv preparations that were capable of inhibiting the IL-33:mAbinteraction to a greater extent than IL330101 were selected forconversion to IgG format. The method of IgG expression and purificationis described in Example 1.

As the epitope competition assay reached its limit of sensitivity, anassay using an intermediate optimised mAb (IL330259) was used fortesting purified scFv samples. Purified anti-IL-33 antibody samples weretested for inhibition of biotinylated human IL-33, biotinylated mouseIL-33 FLAG® His or biotinylated cynomolgus FLAG® His IL-33 bindingIL330259 as described above with the addition of the biotinylatedcynomolgus IL-33 FLAG® His assay (biotinylated cynomolgus IL-33 FLAG®His was added at 12 nM concentration).

Based on sequence and epitope competition data, selected VH and VLoutputs were recombined by standard molecular biology techniques to formlibraries in which clones contained randomly paired VH and VL sequences(for example, VH CDR2/VL CDR3 and VH CDR3/VL CDR3 libraries).Alternatively, VH CDR3 and VL CDR3 sequences were randomly paired andrecombined with specific VH CDR2 sequences selected from a pool ofimproved variants, to generate libraries in which all three CDRs werenon-parental. Typically five rounds of affinity selection usingdecreasing and alternating concentrations of human and mousebiotinylated IL-33, from 10 nM to 10 pM, were performed on allrecombination libraries to identify scFv sequences with improvedkinetics. Alternatively, recombination libraries were selected using afixed concentration of biotinylated IL-33 (for example, 1 nM, 100 pM or300 pM) in the presence of 1000× unbiotinylated IL-33 for increasingamounts of time (for example 30 minutes, 1 hour, 2 hours or 4 hours)over four rounds of selection—a process known in the art as ‘off rate’or ‘competition’ selection—to identify scFv's with improved kinetics.

Samples were again screened in an HTRF® epitope competition assay forthe ability to inhibit the binding of labelled-huIL-33 to IL330101parent antibody or VH CDR2 optimized antibody IL330259 as describedpreviously. ScFv's which showed a significantly improved inhibitoryeffect when compared to IL330101, were subjected to DNA sequencing, andunique variants were produced as purified scFv for furthercharacterisation. Inhibitory scFv's were converted to wholeimmunoglobulin G1 (IgG1) antibody format as described in Example 1.

Alternatively, individual unique VH CDR2, VH CDR3 and VL CDR3 sequenceswere specifically and rationally recombined and produced as IgGdirectly. In this example, IgGs were tested for improved kineticswithout any additional affinity selection.

Antibodies with improved kinetics were identified from all strategiesand are exemplified by IL330259, IL330377, IL330388, IL330396, IL330398and H338L293.

The amino acid sequences of the V H and V L domains of IL330101 parentand the optimised anti-IL-33 antibodies were aligned to the known humangermline sequences in the IMGT database (Lefranc, M. P. et al. Nuci.Acids Res. 2009. 37(Database issue): D1006-D1012), and the closestgermline was identified by sequence similarity. For the V H domain ofthe IL330101 antibody lineage this was IGHV3-21/IGHJ2. For the V Ldomain it was IGLV3-25/IGLJ3. Without considering the Vernier residues(Foote, J., et al. J Mol Biol, 1992. 224: p. 487), which were leftunchanged, there were no changes required in the frameworks of the V Hdomains and 4 changes in the V L frameworks (V3E, TSM, A45V and V104L;Kabat numbering). These positions were changed as indicated usingstandard site directed mutagenesis techniques with appropriate mutagenicprimers. Antibodies that were germlined in this way appear in thesequence listings with the ‘fg1’ suffix. SEQ ID NOs corresponding to thevarious regions of antibodies IL330259, H338L293, IL330377, IL330388,IL330396, and IL330398 are shown in Table 13.

TABLE 13 Anti-IL-33 Antibody Sequences VH SEQ VL SEQ VH CDRs VL CDRsIgG1 ID NO: ID NO: 1, 2, 3 1, 2, 3 IL330101_fgl 112 117 SEQ ID SEQ IDNO: 113 NO: 118 SEQ ID SEQ ID NO: 114 NO: 119 SEQ ID SEQ ID NO: 115 NO:120 IL330259 152 157 SEQ ID SEQ ID NO: 153 NO: 158 SEQ ID SEQ ID NO: 154NO: 159 SEQ ID SEQ ID NO: 155 NO: 160 IL330259_fgl 162 167 SEQ ID SEQ IDNO: 163 NO: 168 SEQ ID SEQ ID NO: 164 NO: 169 SEQ ID SEQ ID NO: 165 NO:170 H338L293 172 177 SEQ ID SEQ ID NO: 173 NO: 178 SEQ ID SEQ ID NO: 174NO: 179 SEQ ID SEQ ID NO: 175 NO: 180 H338L293_fgl 182 187 SEQ ID SEQ IDNO: 183 NO: 188 SEQ ID SEQ ID NO: 184 NO: 189 SEQ ID SEQ ID NO: 185 NO:190 IL330377 192 197 SEQ ID SEQ ID NO: 193 NO: 198 SEQ ID SEQ ID NO: 194NO: 199 SEQ ID SEQ ID NO: 195 NO: 200 IL330377_fgl 202 207 SEQ ID SEQ IDNO: 203 NO: 208 SEQ ID SEQ ID NO: 204 NO: 209 SEQ ID SEQ ID NO: 205 NO:210 IL330388 212 217 SEQ ID SEQ ID NO: 213 NO: 218 SEQ ID SEQ ID NO: 214NO: 219 SEQ ID SEQ ID NO: 215 NO: 220 IL330388_fgl 222 227 SEQ ID SEQ IDNO: 223 NO: 228 SEQ ID SEQ ID NO: 224 NO: 229 SEQ ID SEQ ID NO: 225 NO:230 IL330396 232 237 SEQ ID SEQ ID NO: 233 NO: 238 SEQ ID SEQ ID NO: 234NO: 239 SEQ ID SEQ ID NO: 235 NO: 240 IL330396_fgl 242 247 SEQ ID SEQ IDNO: 243 NO: 248 SEQ ID SEQ ID NO: 244 NO: 249 SEQ ID SEQ ID NO: 245 NO:250 IL330398 252 257 SEQ ID SEQ ID NO: 253 NO: 258 SEQ ID SEQ ID NO: 254NO: 259 SEQ ID SEQ ID NO: 255 NO: 260 IL330398_fgl 262 267 SEQ ID SEQ IDNO: 263 NO: 268 SEQ ID SEQ ID NO: 264 NO: 269 SEQ ID SEQ ID NO: 265 NO:270

Inhibition of IL-33 Binding to mAb by Purified IgG

The ability of anti-IL-33 antibodies to inhibit the binding ofbiotinylated human IL-33, biotinylated mouse IL-33 FLAG® His orcynomolgus IL-33 FLAG ° His to the DyLight labelled IL330101 IgG wasassessed in a biochemical HTRF® (Homogeneous Time-Resolved Fluorescence,Cisbio International) competition assay.

Purified anti-IL-33 antibody samples were tested for inhibition ofbiotinylated human IL-33, biotinylated mouse IL-33 FLAG® His orbiotinylated cynomolgus FLAG® His IL-33 binding DyLight labelledIL330101 by adding 5 microlitres of each concentration of sample to a384 well low volume assay plate (Costar, 3673). Next, a solutioncontaining 40 nM DyLight labelled IL330101 was prepared and 2.5microlitres added to the assay plates (labelled using kit (ThermoScientific, 53051) as per manufacturer's instructions). This wasfollowed by the addition of 2.5 microlitres of a solution containing 40nM biotinylated human IL-33 (Adipogen, AG-40B-0038), 2.5 nM biotinylatedmouse IL-33 FLAG® His or 12 nM biotinylated cynomolgus IL-33 FLAG® Hiscombined with 4.6 nM streptavidin cryptate detection (CisbioInternational, 610SAKLB). All dilutions were performed in assay buffercontaining 0.8 M potassium fluoride (VWR, 26820.236) and 0.1% bovineserum albumin (BSA, PAA, K05-013) in Dulbeccos PBS (Invitrogen,14190185). Assay plates were incubated for 4 hour at room temperaturefollowed by 16 hour at 4 degrees Celsius and time resolved fluorescencewas read at 620 nm and 665 nm emission wavelengths using an EnVisionplate reader (Perkin Elmer). Data were analysed by calculating the665/620 nm ratio followed by the % Delta F values for each sample. The665/620 nm ratio was used to correct for sample interference usingEquation 1. The % Delta F for each sample was then calculated usingEquation 2. The negative control (non-specific binding) was defined byreplacing biotinylated IL-33 combined with streptavidin cryptatedetection with streptavidin cryptate detection only. The % Delta Fvalues were subsequently used to calculate % specific binding asdescribed in Equation 3.

FIG. 14A: shows inhibition of the FRET signal, produced by biotinylatedhuman IL-33 binding to IL330101 with increasing concentrations of IL-33IgG1 antibodies IL330101, IL330259, wherein the x-axis is theconcentration of antibody in molar concentration and the y-axis ispercent specific binding.

As the epitope competition assay reached its limit of sensitivity anassay using an intermediate optimised mAb IL330259 was used for testingpurified IgG samples. This is as described for testing purified scFv.

As the IL330259 epitope competition assay reached its limit ofsensitivity, a third assay using an optimised mAb (H338L293) was usedfor testing purified IgG samples. Purified anti-IL-33 antibody sampleswere tested for inhibition of biotinylated human IL-33, biotinylatedcynomolgus IL-33 FLAG® His or biotinylated mouse IL-33 FLAG® His bindingDyLight labelled H338L293 by adding 5 microlitres of each sample to a384 well low volume assay plate (Costar, 3673). Next, a solutioncontaining 20 nM DyLight labelled H338L293 was prepared and 2.5microlitres added to the assay plates (labelled using kit (ThermoScientific, 53051) as per manufacturer's instructions). This wasfollowed by the addition of 2.5 microlitres of a solution containing 4nM biotinylated human IL-33 (Adipogen, AG-40B-0038), 0.8 nM biotinylatedmouse IL-33 FLAG® His or 1.6 nM biotinylated cynomolgus IL-33 FLAG® Hiscombined with 4.6 nM streptavidin cryptate detection (CisbioInternational, 610SAKLB). All dilutions were performed in assay buffercontaining 0.8 M potassium fluoride (VWR, 26820.236) and 0.1% bovineserum albumin (BSA, PAA, K05-013) in Dulbeccos PBS (Invitrogen,14190185). Assay plates were incubated for 4 hour at room temperaturefollowed by 16 hour at 4° C. and time resolved fluorescence was read at620 nm and 665 nm emission wavelengths using an EnVision plate reader(Perkin Elmer). Data were analysed by calculating the 665/620 nm ratiofollowed by the % Delta F values for each sample. The 665/620 nm ratiowas used to correct for sample interference using Equation 1. The %Delta F for each sample was then calculated using Equation 2. Thenegative control (non-specific binding) was defined by replacingbiotinylated IL-33 combined with streptavidin cryptate detection withstreptavidin cryptate detection only. The % Delta F values weresubsequently used to calculate % specific binding as described inEquation 3.

FIG. 14B: shows inhibition of the FRET signal, produced by biotinylatedhuman IL-33 binding to H338L293 with increasing concentrations of IgG1antibodies H338L293, IL330396 and IL330388 wherein the x-axis is theconcentration of antibody in molar concentration and the y-axis ispercent specific binding.

Inhibition of Huvec IL-6 Production by IL-33 Antibodies

Antibodies were assessed for ability to inhibit IL-33-stimulated IL-6production from Huvecs as described in Example 2

FIG. 15A shows the reduction of IL-6 production by increasingconcentrations of antibodies (IL330101, IL330377, H338L293, IL330388,IL330396, IL330398) wherein the x-axis is the concentration of antibodyin molar concentration and the y-axis is % maximum response. PurifiedIgG preparations of antibodies inhibited the IL-6 activity by a maximumof ˜70%, compared to a commercial polyclonal antibody which inhibited100%.

Inhibition of Mast Cell IL-6 Production by IL-33 Antibodies

Antibodies were assessed for ability to inhibit IL-33-stimulated IL-6production from human cord blood derived mast cells as described inExample 2

FIG. 15B shows the reduction of IL-6 production by increasingconcentrations of antibodies (IL330101, H338L293, IL330388, IL330396)wherein the x-axis is the concentration of antibody in molarconcentration and the y-axis is % maximum response. Purified IgGpreparations of antibodies inhibited the IL-6 activity by 100%, comparedto the negative control antibody.

IC50 results for HUVEC IL-6 production and mast cell IL-6 production areshown in Table 14.

TABLE 14 Example potencies of optimised antibodies IgG1 Geomean (95% CI)IC50 (nM) Clone Huvec IL-6 production Mast cell IL-6 production IL330101193 93 IL330377_FGL 6.6 1.3 H338L293 1.9 1.7 IL330388_FGL 2.1 1.2IL330396_FGL 2.8 1.5 IL330398_FGL 1.5 0.9

Antibody Pharmacology

IL-6 production from cord blood-derived mast cells was induced byincreasing concentrations of IL-33 (Adipogen) using the method describedin Example 2. This dose-response was carried out in the presence ofincreasing concentrations of H338L293 or IL330388 to produce a rightwardshift of the IL-33 dose-response curve. EC₅₀ values for IL-33 in theabsence and presence of antibody were calculated using GraphPad PRISMsoftware (La Jolla, CA, USA), and the dose ratio (DR) was calculated.Data were plotted as log [Antibody] M (x-axis) versus log [DR−1](y-axis). This clearly shows a non-competitive profile (curved plot),characteristic of an allosteric modulator. To investigate this, datafrom each experiment were normalised and combined into a single dataset. An allosteric model was fitted using Prism Graphpad Software andthe K_(b) and value of alpha determined. Values of alpha were similarfor both leads examined, indicating a value for alpha of ˜0.02 (i.e. themaximum reduction in IL-33 affinity/potency when antibody is bound is˜50-fold). Functional affinity (K_(b)) can be estimated for H338L293(˜4.2 nM) and IL330388˜1.7 nM).

FIG. 16 shows a Schild analysis of IL330388 and H338L293 in a mast cellIL-6 production assay. Both antibodies display the profile of anallosteric modulator.

Binding Affinity Calculation for IL-33 Antibodies Using BIAcore

The binding affinity of purified IgG samples of exemplary bindingmembers to human, cynomolgus or mouse IL-33 was determined by solutionaffinity using a BIAcore 2000 (GE healthcare). A biotinylated-IL33surface was immobilised on a streptavin coated sensor chip (GEhealthcare cat. No. BR-1000-32). Anti-IL33 antibodies were incubatedwith various concentrations of unlabelled IL33 and equilibrated at 25°C. for 48 hours. The amount of free antibody was determined by flowingthe samples over the IL33 chip and measuring the response compared to astandard curve of antibody. Affinities were determined using thesolution affinity fit in BIAevaluation software. The affinities forantibodies IL330101, H338L293, IL330388, IL330396 binding to human,cynomolgus or mouse IL-33 are shown in Table 15.

TABLE 15 BIAcore solution affinity of exemplary binding members AntibodyAntigen KD (nM) IL3300101 Human IL-33 FLAG ®-His 3.20E−06 H338L293 HumanIL-33 FLAG ®-His 5.90E−10 H338L293 Cynomolgus IL-33 FLAG ®-His 5.45E−10H338L293 Mouse IL-33 FLAG ®-His 4.52E−10 IL3300388 Human IL-33FLAG ®-His 3.00E−10 IL3300388 Cynomolgus IL-33 FLAG ®-His 2.92E−10IL3300388 Mouse IL-33 FLAG ®-His 8.82E−11 IL3300396 Human IL-33FLAG ®-His 5.93E−10

Example 4 Redox Regulation of IL-33 Reagents

cDNA encoding the mature component of Human IL-33 (amino acids 112-270);accession number (Swiss-Prot) O95760 was synthesized by primer extensionPCR and cloned into pJexpress404 (DNA 2.0). The coding sequence wasmodified to contain a 10× his, Avitag, and Factor-Xa protease cleavagesite (MHHHHHHHHHHAAGLNDIFEAQKIEWHEAAIEGR) at the N-terminus of theprotein. N-terminal tagged His10/Avitag IL33-01 (WT, SEQ ID 632) wasgenerated by transforming E. coli BL21(DE3) cells. Transformed cellswere cultured in autoinduction media (Overnight Express™ AutoinductionSystem 1, Merck Millipore, 71300-4) at 37° C. for 18 hours before cellswere harvested by centrifugation and stored at −20° C. Cells wereresuspended in BugBuster (Merck Millipore, 70921-5), containing completeprotease inhibitor cocktail tablets (Roche, 11697498001), 2.5u/mlBenzonase nuclease (merck Millipore, 70746-3) and 1 mg/ml recombinantlysozyme. Cell lysate was clarified by centrifugation at 75,000×g for 2hours at 4° C. IL-33 proteins were purified from the supernatant byNickel affinity chromatography in 50 mM Sodium phosphate, pH 8.0, 300 mMNaCl, 20 mM Imidazole, eluting in 50 mM Sodium phosphate, pH 8.0, 300 mMNaCl, 250 mM Imidazole. IL-33 was further purified by size exclusionchromatography using a Superdex 75 10/300 GL column in PhosphateBuffered Saline pH 7.4. Peak fractions were analysed by SDS PAGE.Fractions containing pure IL-33 were pooled and the concentrationmeasured by Nanodrop A280 measurement. Final samples were analysed bySDS PAGE.

To generate detagged IL-33 (BK349), N-terminal tagged His10/AvitagIL33-01 was incubated with 10 untis of Factor Xa (GE healthcare27-0849-01) per mg of protein in 2×DPBS buffer at RT for 1 hour.Untagged IL33 was purified using SEC chromatography in 2×DPBS on a S75column (GE healthcare 28-9893-33) with a flow rate of 1 ml/min.

Other reagents outlined in Table 16 were generated as described inExample 1.

TABLE 16 IL-33 reagents Catalogue Number/ Reagent Supplier DesignationSEQ ID Human IL-33 Flag ®His In house SEQ ID NO. 627 Mouse IL-33Flag ®His In house SEQ ID NO. 628 Human His10/Avitag In house SEQ IDIL33-01 NO. 632 Human IL33-01 detagged In house BK349 Human IL-33Axxora/Alexis ALX-522-098 Mouse IL-33 Peprotech 210-33 Mouse IL-33 R&Dsystems 3626/ML

Protein Modifications

IgGs and modified receptor proteins used herein were biotinylated viafree amines using EZ link Sulfo-NHS-LC-Biotin (Thermo/Pierce, 21335) asdescribed in Example 1. IL-33 proteins used herein were biotinylated viafree cysteines using EZ link Biotin-BMCC (Perbio/Pierce, product no.21900).

IL-33 Loses Activity Rapidly In Vitro

IL-33 activity was measured in HUVEC signaling assays (30 minutes) andIL-6 production assay (18-24 hours), the methods of which are describedin Examples 1 and 2 respectively.

FIG. 17 shows the activity of human IL-33, cysteine-biotinylated IL-33or cell culture media-pretreated IL-33, measured in HUVEC signalingassays (30 minutes) and IL-6 production assay (18-24 hours). FIG. 17Ashows the comparison of human IL-33 activity (Adipogen) as measured bythe NFkB or IL-6 assays wherein the x-axis is the concentration of humanIL-33 in molar concentration and the y-axis is percent maximal response.IL-33 was significantly less potent in overnight compared with short (30minute) assays. Human IL-33 Flag® His biotinylated via cysteine residuesdid not lose activity between short (30 minute) and longer (overnight)assays (FIG. 17B). To investigate this phenomenon, IL-33 (BK349) waspretreated for 18 hours in cell culture media (EBM-2 (Lonza, #CC-3156)with EGM-2 SingleQuot Kit Suppl. & Growth Factors (Lonza, #CC-4176)) andthen compared with untreated IL-33 for ability to induce NFkB signaling.IL-33 that has been pre-treated with culture media displayed asignificant loss of activity (FIG. 17C).

SDS-PAGE Analysis of IL-33

To investigate potential changes to the IL-33 protein, PBS/0.1% bovineserum albumin (BSA) or Iscoves Modified Dulbeccos Medium (IMDM)-treatedhuman IL-33 (BK349 or human IL-33 Flag® His) and mouse IL-33 Flag® Hiswere analysed by SDS PAGE electrophoresis under reducing or non-reducingconditions. Samples were made up in 1× NuPAGE gel loading buffer(Invitrogen) and denatured at 90° C. for 3 min. Reduced samplescontained 2% beta-mercaptoethanol. Samples were run on NuPAGE Novex 12%Bis-Tris mini gels (Invitrogen) with MOPS running buffer (Invitrogen)according to manufacturer's instructions. Reduced and non-reducedsamples were run on separate gels. 500 ng of IL-33 was loaded per lane.Gels were washed 3×5 min on shaking platform in ddH20 and then stainedfor 1 hour using EzBlue (Coomassie brilliant blue G-250 based gelstaining reagent, Sigma G1041). Gels were destained in dH2O and scannedusing an Epsom Scanner.

FIG. 18 shows SDS-PAGE of human or mouse IL-33 under reducing ornon-reducing conditions, before or after treatment with Iscoves ModifiedDulbeccos Medium (IMDM). Differences in apparent molecular weight ofIL-33 after treatment with IMDM were observed only under non-reducingconditions implying the presence of redox-related modifications for bothhuman and mouse IL-33. FIG. 18A shows difference in apparent molecularweight of the human IL-33 (BK349) after treatment with IMDM that wasobserved only under non-reducing conditions. FIG. 18B shows human IL-33Flag® His, non-biotinylated versus biotinylated under non-reducingconditions. Difference in apparent molecular weight was observed forIL-33 Flag® His, but not cysteine biotnylated IL-33 Flag® His after IMDMtreatment. FIG. 18C shows difference in apparent molecular weight of themouse IL-33 Flag® His after treatment with IMDM that was observed onlyunder non-reducing conditions.

Mass Spectrometry Analysis and Disulphide Mapping

The media-treated form of human IL-33 was purified for further analysis.Human IL-33 (BK349) was was incubated with 60% IMDM media or in PBS at afinal protein concentration of 300 ug/ml for 18 hours at 37° C. After 18hours, media-treated IL33 was purified from media components using SizeExclusion Chromatography (SEC) on an S75 16:600 Superdex column (GEhealthcare 28-9893-33) in 2×DPBS using an AKTAxpress FPLC system (GEhealthcare). Peak fractions were analysed by SDS PAGE, and thenon-aggregated, pure fractions were pooled and analysed by LC-MS.

FIG. 19 shows the purification of IMDM-treated human IL-33 by SEC. Themonomer fraction was collected for further analysis.

LC-MS

Reverse phase (RP) LC-MS analysis was performed using an Acquity UPLCcoupled to a Synapt G1 quadrupole time of flight (QToF) massspectrometer (Waters, Milford, US). 1 μg of purified protein diluted in10 mM Tris HCl pH 8 at 1 mg/ml was injected onto a 50 mm×2.1 mm, 1.7 μmparticle size BEH300 C4 analytical column held at 65° C. (Waters,Milford, US). Protein was eluted at a constant flow rate of 0.15 mL/minusing a 5 minute binary gradient; solvent B was initially increased from5 to 95% over 1 minute, reduced to 20% over 2 minutes and returned to 5%over a further 2 minutes. The column was cleaned prior to the subsequentinjection by oscillating between high (95%) and low (5%) solvent B for 5minutes. Solvent A (water) and B (acetonitrile) were supplemented with0.01% (v/v) trifluoroacetic acid and 0.1% (v/v) formic acid. Spectrawere acquired between 500-4500 m/z. Key instrument parameters included+ve ionisation mode, source voltage: 3.4 kV, sample cone voltage: 50 V,source temperature: 140° C., desolvation temperature: 400° C.BioPharmaLynx (Waters, Milford, US) was used to deconvolute the chargeenvelopes.

FIG. 20 shows the intact mass of PBS versus IMDM treated IL-33determined by LC-MS. IMDM-treated IL-33 displayed a 4 Da loss comparedwith PBS-treated IL-33 compatible with the formation of two disulphidebonds.

Disulphide Bond Mapping

For each sample, 50 μg of protein was prepared at 3 mg/ml in 100 mMsodium phosphate, 1 mM N-ethylmaleimide, pH 7.0 buffer and incubated for20 minutes at room temperature. Dried samples were resuspended in 7 MGuanidine HCl, 100 mM NaCl, 10 mM sodium phosphate and incubated at 37°C. for 30 minutes. Denatured protein was diluted to 0.3 mg/ml anddigested with Glu-C at an E:S ratio of 1:50 in 2 M Guanadine, 100 mMsodium phosphate, 0.1 mM EDTA, pH7.0 at 37° C. After 2 hours a second,equal aliquot of Lys-C was added. After a further 2 hours the digest wassplit; for the reduced analysis the digest was incubated with 50 mMDithiothreitol for 15 min at room temperature. Reduced and non-reducedsamples were analysed by RP LC-MS using an Acquity UPLC coupled to aSynapt G2 QToF mass spectrometer (Waters, Milford, US). For each sample,5 ug of Lys-C digest was injected onto a 150 mm×2.1 mm, 1.7 μm particlesize BEH300 C18 analytical column held at 55° C. (Waters, Milford, US).Peptides were eluted at a constant flow rate of 0.2 mL/min using a 75minute binary gradient; solvent B was increased from 0% to 35%. Thecolumn was cleaned prior to the subsequent injection by oscillatingbetween high (95%) and low (5%) solvent B for 5 minutes. Solvent A(water) and B (acetonitrile) were supplemented with 0.02% (v/v)trifluoroacetic acid. Spectra were acquired between 50-2000 m/z using adata independent mode of acquisition. Low and high energy spectra wereprocessed using BioPharmaLynx (Waters, Milford, US).

FIG. 21 shows the disulphide mapping of IMDM-treated human IL-33. FIG.21A shows combined, deconvoluted mass spectra from non-reduced andreduced Lys-C peptide mapping analysis of DSB IL-33. FIG. 21B showsisolated spectra for cysteine containing peptides. Peptides unique toreduced and non-reduced samples are highlighted in green and blue,respectively. Data were consistent with the formation of two disulphidebridges. One species identified had bridges between cysteines C208-C249and C227-C232, respectively. However, the predominant peak was notresolved and other species may exist. FIG. 21C shows sequences ofdisulphide bonded peptides identified by non-reduced and reduced Lys-Cpeptide mapping analysis of disulphide bonded IL-33. Disulphide linkagesare represented by two hyphens (--). Lys-C miscleavages are representedby square brackets.

NMR Analysis of the Disulphide Bonded IL-33

Based on the reported structure of IL-33 (Lingel, A. et al. Structure17, 1398-1410 (2009); Liu, X. et al. Proc. Natl. Acad. Sci. U.S.A. 110,14918-14923 (2013)), cysteine residues are not in sufficiently closeproximity for disulphide bonding to occur without significantconformational change. To investigate this NMR heteronuclear multiplequantum coherence (HMQC) analysis was performed.

Production of ¹⁵N-IL-33 Proteins

DNA encoding wild type IL-33 with an N-terminal 6His tag and TEVprotease cleavage site (SEQ ID. 633) was used to transform E. coli BL21Gold cells. Transformed cells were cultured at 37° C. in M9 minimalmedia supplemented with 5 g/L of ¹⁵N-IsoGro™ powder until they reachedan OD600 nm of 0.6 to 0.8, when protein expression was induced byaddition of 100 mM IPTG. Cultures were continued at 18° C. for a further20 hours before cells were harvested by centrifugation and stored at−80° C. Cells were resuspended in 50 mM Sodium phosphate, pH 8.0, 300 mMNaCl, 20 mM Imidazole, 5 mM BetaMercaptoethanol containing Completeprotease inhibitor tablets (Roche, 11697498001), 2.5 U/ml Benzonasenuclease (merck Millipore, 70746-3) and 1 mg/ml recombinant lysozyme.Resuspended cells were lysed using a Constant Systems cell disruptor at25 kpsi and clarified by centrifugation at 75,000×g for 2 hours at 4° C.IL-33 was purified from the supernatant by Nickel affinitychromatography in 50 mM Sodium phosphate, pH 8.0, 300 mM NaCl, 20 mMImidazole, 5 mM BetaMercaptoethanol, eluting in 50 mM Sodium phosphate,pH 8.0, 300 mM NaCl, 250 mM Imidazole, 5 mM BetaMercaptoethanol. Elutedprotein was incubated with TEV protease and dialysed into 50 mM Sodiumphosphate, pH 8.0, 300 mM NaCl, 20 mM Imidazole, 5 mMBetaMercaptoethanol at 4° C. De-tagged protein was separated fromuncleaved IL-33 by Nickel affinity chromatography in 50 mM Sodiumphosphate, pH 8.0, 300 mM NaCl, 20 mM Imidazole, 5 mMBetaMercaptoethanol. IL-33 was further purified by size exclusionchromatography using a HiLoad 16/60 Superdex 75 column (GE healthcare)in 20 mM Sodium phosphate pH 6.5, 100 mM NaCl, 5 mM BetaMercaptoethanol,using an AKTAxpress FPLC system (GE healthcare). Peak fractions wereanalysed by SDS PAGE.

Fractions containing pure IL-33 were pooled and the concentrationmeasured by Nanodrop A280 measurement. Protein was concentrated using anAmicon 10,000 molecular weight cut-off spin concentrator to a finalconcentration of 9.5 mg/ml for NMR analysis.

Purified ¹⁵N labelled protein in PBS pH7.4 was incubated with 60% IMDMmedia at a final protein concentration of 0.28 mg/ml for 18 hours at 37°C. After 18 hours, the protein was concentrated using an Amicon 10,000molecular weight cut-off spin concentrator to a concentration of 0.8mg/ml. The protein was then purified by size exclusion chromatographyusing a HiLoad 16/60 Superdex 75 in PBS pH 7.4. Peak fractions wereanalysed by SDS PAGE, and the non-aggregated, pure fractions werepooled. Finally protein was concentrated using an Amicon 10,000molecular weight cut-off spin concentrator to a concentration of 1.8mg/ml (100 μM) for NMR analysis.

NMR Analysis

NMR spectra were recorded at 298 K on a Bruker Avance 600 MHzspectrometer running Topspin 2.3 equipped with a 5 mm TCI Cryoprobe withZ-axis gradients. The ¹⁵N-labelled IL33 WT sample was prepared asdescribed with the addition of 5% deuterium oxide to allow samplelocking. The exemplified ¹H-¹⁵N correlation spectra were acquiredemploying the sofast HMQC pulse sequence (Schanda, P; Brutscher, B; Veryfast two-dimensional NMR spectroscopy for real-time investigation ofdynamic events in proteins on the time scale of seconds, J. Am. Chem.Soc. (2005) 127, 8014-5) with (F2×F1) 1024×64 complex points (instates-TPPI mode), 9615×1460 Hz sweep width, 53.4 ms×43.8 ms acquisitiontimes.

FIG. 22A shows SDS PAGE analysis of IMDM treated WT IL33. SDS PAGEshowing reduced and non-reduced IMDM treated WT IL33 before and afterconcentration for NMR.

FIG. 22B shows NMR analysis of WT IL33. Overlay of the ¹H-¹⁵N HMQCspectra for 0.1 mM ¹⁵N-labeled IL33 WT before and after IMDM mediatreatment plotted in black and red, respectively. Comparison of the twospectra indicate an entirely different, and less ordered, structureafter IMDM treatment.

Circular Dichroism (CD) Spectroscopy.

To confirm conformational change and investigate further, CircularDichroism (CD) Spectroscopy analysis was performed.

Far-UV and near-UV CD analysis were performed on a Jasco-815 instrument(Easton, Maryland). For Far-UV CD the spectra were recorded overwavelength range 180-260 nm in a 1 mm pathlength cuvette at sampleconcentration of 0.14 mg/mL and 0.12 mg/mL for respectively redIL-33 andDSB IL-33 at 20° C. in buffer solution 10 mM Phosphate pH=6.9. Fornear-UV CD the spectra were recorded over wavelength range 260-350 nm ina 10 mm pathlength cuvette at sample concentration of 1.38 mg/mL and0.89 mg/mL for respectively redIL-33 and DSB IL-33 at 20° C. in buffersolution DPBS. CD spectra of the buffer solution were recorded andsubtracted from all sample spectra to correct for instrument, cuvetteand baseline effects. CD Pro software was employed for the deconvolutionof spectra into secondary structure elements.

FIG. 22C: Near-UV circular dichroism (CD) Spectroscopy. Spectra wererecorded over wavelength range 260-350 nm. The final spectra were theaverage of 4 scans. Aromatic amino-acids and disulphide absorption bandsare adapted from Kelly (Kelly S. M. et al. How to study proteins byCircular Dichroism. Biochimica et Biophysica Acta, 1751, 119-139 (2005))The difference observed in ellipticity around Trp absorption isconsistent with change in environment of the sole Tryptophan (W193)demonstrating changes to tertiary structure in this region betweenreduced and DSB IL-33. The difference in intensity around 260 nm isconsistent with the introduction of additional chromophores fromdisulphide bond formation.

FIG. 22D: Key features of IL-33. Trp193, cysteines, and ST2 binding site(Liu, X et al. Structural insights into the interaction of IL-33 withits receptors. Proc. Natl. Acad. Sci. U.S.A. 110, 14918-14923 (2013))are indicated within the solved IL-33 structure (Lingel 2009)

FIG. 22E: Far-UV circular dichroism (CD) Spectroscopy. Spectra wererecorded over wavelength range 190-260 nm. The final spectra were theaverage of 8 scans. Far-UV spectra are consistent with predominantlyβ-sheet secondary structures as seen previously with this family ofproteins (Chang B. S. et al, Formation of an active dimer during storageof interleukin-1 receptor antagonist in aqueous solution. BiophysicalJournal. 71, 3399-3406 (1996); Craig S. et al. Conformation, Stabilityand folding of Interleukin1β. Biochemistry. 26, 3570-3576 (1987); HaileyK. L. et al. Pro-interleukin (IL)-1β shares a core region of stabilityas compared with mature IL-1β while maintaining a distinctly differentconfigurational landscape. J. Biol. Chem. 284. 26137-26148 (2009);Hazudat D. et al. Purification and characterisation of Human RecombinantPrecursor Interleukin 1β. J. Biol. Chem. 264, 1689-1693 (1989); MeyersC. A. et al, Purification and characterization of Human recombinantinterleukin-1β. J. Biol. Chem. 262, 11176-11181 (1987)). Spectra aresignificantly different demonstrating a change in secondary structure inDSB IL-33, relative to reduced IL-33.

CD spectra indicated a significant conformatonal change between theIL-33 forms. redIL-33 spectra were consistent with published data.DSB-IL-33 spectra were consistent with a structured protein that wasdifferent to the reduced form. To map the areas that may be most alteredbetween reduced and DSB-IL-33, we performed hydrogen/deuterium-exchangemass spectrometry.

Hydrogen/Deuterium-Exchange Mass Spectrometry (HDX-MS).

Proteins were diluted to 3.5 uM in phosphate buffered saline, pH 7.4.This stock was used to initiate labeling experiments by diluting 10-foldwith deuterated (10 mM sodium phosphate, pD 6.6) aqueous solvent.Initial mapping experiments were done to assign species from the massspectra to peptic peptide sequences from IL33. This was done largely asdescribed²¹. Briefly, protonated diluted protein was mixed 1:1 with aquench solution (100 mM potassium phosphate, pH 2.55, 0.1 M TCEP, 1°C.), such that the final mixture pH was 2.55. The quenched protein wasinjected into a Waters HDX Manager with an immobilized pepsin column(2.0×30 mm; Poroszyme, Life Technologies), C18 trapping column (VanGuardACQUITY BEH 2.1×5 mm; Waters) and analytical C18 column (1.0×100 mmACQUITY BEH; Waters). Mobile phases were 0.1% formic acid in H₂O (A) and0.1% formic acid in ACN (B), such that their pH was 2.55. Protein wasapplied to the pepsin and trapping columns in 100 μL/min buffer A andeluted from the analytical column in a linear gradient of 3-40% B at 40μL/min. Peptide sequences were assigned from MSE fragment data withProtein Lynx Global Server (Waters) 3.0.2 and DynamX 3.0 (Waters).Labeling data was acquired as for sequencing, except the massspectrometer was set to MS scans only. Peptide-level data were analyzedin DynamX and MatLab (Mathworks).

FIG. 23 shows hydrogen-exchange mass spectrometry (HX-MS) analysis ofreduced and DSB IL-33. FIG. 23A Comparison of fractional hydrogenexchange (for deuterium) in reduced IL-33 (left panel) and DSB IL-33(right panel). Data are mapped onto the published IL-33structure^((lingel 2009)) in both cases for comparison purposes. Gaps insequence coverage where no data HX-MS data could be obtained arehighlighted in slate blue. Side chains of cysteine residues aredisplayed as sticks. FIG. 23B shows a structural model of differentialHX-MS data overlaid with the ST2 binding site (red andmagenta).^((Liu 2013)) Dark blue indicates regions of increased hydrogenexchange in DSB IL-33 relative to reduced IL-33. The ST2 binding site 1is in the area of greatest difference in H/D exchange and has likelybeen altered in structure.

Binding of Reduced Vs DSB IL-33 to ST2 (BIAcore)

The disulphide bonded IL-33 is likely a very different structure to thereduced, ST2-binding IL-33 form (FIG. 22 , 23), and conversion to thedisulphide bonded form was associated with loss of functional activity(FIG. 17C). To investigate this, the disulphide bonded form of IL-33 wastested for ability to bind ST2 by BIAcore analysis. Direct binding ofIL-33 to the extracellular domain of ST2 was determined by SurfacePlasmon Resonance using a BIAcore 2000 (GE healthcare). ST2 wasimmobilised via the Fc-tag using an anti-human Fc capture (GE healthcareBR-1003-39) on a CM5 sensor chip (GE healthcare BR-1003-99) to give astable surface of approximately 150 RU. IL-33 was flowed over thesurface at 30 ul/min for three minutes to determine association rates.Dissociation was measured by flowing buffer at 30 ul/min for 15 minutes.Sensorgrams were interpreted using BIAevaluation software and kineticswere determined using double reference subtracted sensorgrams using a1:1 (Langmuir) binding model.

FIG. 24A shows redIL-33 binding to ST2. Sensorgrams from 7.8 nM to 0.24nM are shown, giving a KD of 0.2 nM.

FIG. 24B shows disulphide bonded IL-33 (IL33-DSB) binding to ST2.Sensorgrams from 500 nM to 0.24 nM are shown with no obvious bindingobserved.

Loss of ST2 binding and activity led us to hypothesise that oxidationcould be a mechanism to terminate IL-33 activity and limit duration ofST2-dependent immunological responses in vivo.

Detection of IL-33 Forms

To ascertain that the disulphide-bonded form of IL-33 indeed exists invivo, we used three different commercial IL-33 detection assays (2 humanIL-33 and one mouse IL-33). Human and mouse IL-33 Duoset ELISAs (RnDSystems) were converted to MSD format (Meso Scale Discovery, Rockville,MD). Coating concentrations of capture antibodies were as follows:anti-mouse IL-33 pAb 37.5 ug/ml; anti-human IL-33 pAb 18 ug/mL. Captureantibody was diluted in PBS with 0.03% Triton X-100 and 5 μl was spotcoated onto standard bind plates (Meso Scale Discovery, Rockville, MD)into the centre of each well and left to dry overnight at roomtemperature. Plates were washed ×3 in PBS-Tween and blocked with 25 μlAssay Diluent by sealing plates and incubating for 30 minutes at roomtemperature with shaking (450 rpm). 25 μl of samples or calibratordiluted in Assay Diluent were transferred to the blocked assay plates,which were incubated for 2 hours at room temperature with shaking (450rpm). Plates were washed ×3 in PBS-Tween and 25 μl of detection reagent(detection antibody plus streptavidin SulfoTag both diluted to 1 μg/mlin antibody diluent). Plates were sealed and incubated for 1 hour at RTwith shaking. Plates were washed ×3 in PBS-Tween. 150 μl of Read BufferT diluted to 2× in distilled water was added. Plates were read within 15minutes (Meso Scale Discovery, Rockville, MD).

The Millipore human IL-33 assay (Cat #HTH17MAG-14K lot 2159117) wasperformed according to manufacturer's instructions. Briefly, IL-33standards and samples were diluted in assay buffer and incubated withbeads for 1 hour at room temperature with shaking (500 rpm), protectedfrom light. Well contents were removed and washed ×2 with 200 uL of washbuffer. 25 uL of detection antibody was added per well and platesincubated for 1 hour at room temperature. 25 uL streptavidin-PE wasadded (without washing) and plates incubated for a further 30 minutes,shaking (850 rpm) and protected from light. Well contents were removedand washed ×2 with 200 uL of wash buffer. Samples were resuspended in125 uL assay buffer, covered and shaken at 850 rpm for 30 seconds.Samples were analysed on Bio-Plex 200 (BioRad). Plate was read at lowRP1, counting 50 beads per region (region 44) with doublet detectiongates set to 5000 (low) and 25000 (high).

FIG. 25 shows analysis of three commercial IL-33 ELISA assays fordetection of reduced and disulphide bonded IL-33 forms. The effect ofST2 on interference with the assay signal for both reduced anddisulphide bonded forms is also shown. FIGS. 25A and B shows that thetwo commercial human IL-33 assays predominantly detect thedisulphide-bonded form of IL-33 (IL33-DSB), suggesting that this is themain species that others have measured to date in human ex vivo samples.The ‘reduced’ but not oxidized/disulphide bonded IL-33 assay signal canbe eliminated by addition of sST2. FIG. 25C shows the mouse IL-33 assaywhich detects both reduced and oxidized forms of mouse IL-33. The‘reduced’ but not oxidized IL-33 assay signal can be eliminated byaddition of sST2.

As we were unable to identify a commercial assay specific for thereduced, ST2-active form of human IL-33, we developed our own novelassays. IL330425 mAb (SEQ ID NOs. 62 and 67) or IL330004 mAb (SEQ IDNOs. 12 and 17) were used as capture antibodies. Captured IL-33 wasdetected with biotinylated sST2.Fc (R&D systems) or biotinylatedIL330425 (SEQ ID NOs. 62 and 67) respectively. Capture antibody wasdiluted to 150 ug/mL in PBS with 0.03% Triton X-100 and 5 μl was spotcoated onto standard bind plates (Meso Scale Discovery, Rockville, MD)into the centre of each well and left to dry overnight at roomtemperature. Plates were washed ×3 in PBS-Tween and blocked with 25 μlAssay Diluent by sealing plates and incubating for 30 minutes at roomtemperature with shaking (450 rpm). 25 μl of samples or calibratordiluted in Assay Diluent were transferred to the blocked assay plates,which were incubated for 2 hours at room temperature with shaking (450rpm). Plates were washed 3× in PBS-Tween and 25 μl of detection reagent(detection antibody plus streptavidin SulfoTag both diluted to 1 μg/mlin antibody diluent). Plates were sealed and incubated for 1 hour at RTwith shaking. Plates were washed ×3 in PBS-Tween. 150 μl of Read BufferT diluted to 2× in distilled water was added. Plates were read within 15minutes (Meso Scale Discovery, Rockville, MD).

FIG. 26A, B shows ELISA assays that are specific for detection ofreduced IL-33. No detection of the disulphide bonded form is observed.

Timecourse of Conversion to Disulphide Bonded Form of IL-33

Assays detecting different IL-33 forms as described above were used tomonitor a time course of conversion from redIL-33 to its disulphidebonded form. 10 ug/mL of detagged redIL-33 was incubated in 100% humanserum, PBS/1% BSA or IMDM/1% BSA at 37° C. At timepoints t=0, 15minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24hours a 10 ul aliquot was removed and added to 90 ul PBS/1% BSA (1 in 10dilution to 1 ug/ml), this was divided into 3×30 ul aliquots and snapfrozen on dry ice before storage at −80° C. A t=0 sample was alsoprepared fresh immediately prior to the ELISA analysis as a control forthe freeze/thaw cycle. Samples were analysed using the human MSD (R&DSystems) and the IL33004/IL330425-biotin assays described above tomeasure disulphide bonded and reduced IL-33 respectively. Together,these assays allowed monitoring of the conversion from the reduced tothe disulphide-bonded form of IL-33.

To confirm the result from the ELISAs, IL-33 in the timecourse sampleswas analysed by Western blot. Samples were subjected to SDS-PAGE underreducing or non-reducing conditions. Samples were made up in 1× NuPAGEgel loading buffer (Invitrogen) and denatured at 90° C. for 3 minutes.Reduced samples contained 2% beta-mercaptoethanol. Samples were run onNuPAGE Novex 12% Bis-Tris mini gels (Invitrogen) with MOPS runningbuffer (Invitrogen) according to manufacturer's instructions. Reducedand non-reduced samples were run on separate gels. 100 pg of IL-33 wasloaded per lane. Proteins were transfered to Nitrocellulose membranes(Invitrogen cat. no. IB3010-02) and detected by Western blotting withanti-IL-33 pAb (R&D systems).

FIG. 27 shows a time course of human IL-33 incubated in IMDM or humanserum. FIG. 27A: IL-33 ELISAs (IL33004/IL330425-biotin and human R&Dsystems MSD assays) were used to detect reduced and disulphide bondedIL-33 respectively. FIG. 27B: Western blot analysis was used to detectreduced and disulphide bonded IL-33 forms. The conversion to thedisulphide bonded form of IL-33 occurred rapidly with a 50% conversionin 1-2 hours. The disappearance of reduced IL-33 correlated well withthe appearance of oxidised IL-33 in both ELISA and Western blotanalysis.

Generation of a Humanized IL-33 Transgenic Mouse

To study the behaviour and lifecycle of endogenous IL-33, we used atransgenic mouse with the gene for mouse IL-33 replaced with the humanIL-33 gene. A humanized IL-33 transgenic mouse were generated asdescribed below. Briefly, mouse genomic fragments (obtained from theC57BL/6J RPCIB-731 BAC library), a human genomic fragment (obtained fromthe human RPCIB-753 BAC library) and selected features (such asrecombination sites and selection markers) were combined to make thetargeting vector (data not shown).

The targeting vector was linearized with B stBI and electroporated intoTaconicArtemis Balb/cJ ES cell line (Balb/c.2) and ES cell clones wereselected with Puromycin (positive selection) and Gancyclovir (negativeselection). The resultant puromycin-resistant ES cell clones were thenscreened by a combination of PCR and Southern analyses to identifycorrectly targeted ES clones. These were expanded and frozen in liquidnitrogen.

After administration of hormones, superovulated C57BL/6 females weremated with C57BL/6 males. Blastocysts were isolated from the uterus atdpc 3.5. For microinjection, blastocysts were placed in a drop of DMEMwith 15% FCS under mineral oil. A flat tip, piezo actuatedmicroinjection-pipette with an internal diameter of 12-15 micrometer wasused to inject 10-15 targeted BALB/c ES cells into each blastocyst.After recovery, 8 injected blastocysts were transferred to each uterinehorn of 2.5 days post coitum, pseudopregnant NMRI females. Chimerism wasmeasured in chimeras (G0) by coat colour contribution of ES cells to theC57BL/6 host (white/black). Highly chimeric mice were bred to strainBALB/cJBomTac females mutant for the presence of a Flp recombinase gene(Flp-Deleter strain). Germline transmission by coat colour wasidentified by the presence of white, strain BALB/c, offspring (G1).Actual germline transmission was confirmed by PCR genotyping usingprimers specific for the targeted allele (data not shown).

Existence of Redox Forms of IL-33 In Vivo.

Models of Alternaria alternata induced airway inflammation in mice havebeen previously described (Kouzaki et al. J. Immunol. 2011, 186:4375-4387; Bartemes et al J Immunol, 2012, 188: 1503-1513). Male orfemale wildtype or humanized IL-33 mice (6-10 weeks) were anaesthetizedbriefly with isofluorane and administered either 25 μg of Alternariaalternata (ALT) extract (Greer, Lenoir, NC) or vehicle intranasally in atotal volume of 50 μl. At multiple timepoints after ALT challenge, micewere terminally anaesthetised with pentobarbital sodium prior tobronchoalveolar lavage (BAL). Bronchoalveolar lavage fluid (BALF) wascollected by lavage (0.3 ml, 0.3 ml & 0.4 ml) via tracheal cannula. BALFwas centrifuged and supernatant was analysed for presence of redox formsof IL-33 using assays described above. All work was carried out to UKHome Office ethical and husbandry standards under the authority of anappropriate project licence.

FIG. 28 shows analysis of BALF from humanized IL-33 mice collected atvarying timepoints following ALT intranasal challenge, using acombination of multiple ELISA assays. (A) Millipore, (B) R&D systems and(C) IL330425/sST2-biotin assays were used to measure IL-33 in thepresence or absence of sST2 (left hand graphs). Signals in the presenceof sST2 (signal from the reduced IL-33 fraction eliminated) werecompared with a disulphide bonded IL-33 standard to quantify the levelsof disulphide bonded IL-33. The reduced IL-33 signal was calculated asthe difference in signal between IL-33 measurements in the presence andabsence of ST2, quantified against a reduced IL-33 standard. Estimationsfor reduced IL-33 are shown on the right hand graphs. All assays showthat the released IL-33 was predominantly in its reduced form with amaximum between 5 and 30 min, followed by a rapid decline becomingundetectable by 120 minutes. Conversely, IL-33-DSB gradually increasedfrom time 0, peaking at 30-120 minutes and disappearing by 24 hours.These data are consistent with a model where IL-33 is released inreduced form and then rapidly oxidised in vivo to IL33-DSB.

FIG. 29 shows analysis of BALF from wild type BALB/c mice collected atvarying timepoints following ALT intranasal challenge. FIG. 29A MouseIL-33 ELISA (R&D systems) was used to measure IL-33 in the presence orabsence of sST2 (media-treated mouse IL-33 used as standard curve). FIG.29B Signals in the presence of sST2 (signal from the reduced IL-33fraction eliminated) were compared with a media-treated mouse IL-33standard to quantify the levels of oxidised IL-33. The reduced IL-33signal was calculated as the difference in signal between IL-33measurements in the presence and absence of ST2, quantified against areduced mouse IL-33 standard. Data show that the released IL-33 waspredominantly in its reduced form peaking at 15 minutes, followed by arapid decline becoming undetectable by 120 minutes. Conversely,IL-33-DSB gradually increased from time 0, peaking at 45-60 minutes anddisappearing by 24 hours. These data are consistent with a model whereIL-33 is released in reduced form and then rapidly oxidised in vivo toIL33-DSB.

Example 5 Characterisation of Anti-IL-33 Antibodies H338L293 Causes aConformational Change

Monoclonal antibody H338L293 (SEQ ID NOs 182 and 187), the generation ofwhich is described in examples 2 and 3, is an allosteric modulator ofIL-33. IL-33 can significantly change conformation into a disulfidebonded form (as described in Example 4). The following experimentsdemonstrate that H338L293 mAb appears to destabilize the IL-33 molecule,promoting its unfolding and accelerating conversion to the disulfidebonded form. Reagents and protein modifications used herein were asdescribed in previous examples.

Sypro Orange Assay

Sypro orange binds nonspecifically to hydrophobic surfaces, and waterstrongly quenches the fluorescence of Sypro Orange. When a proteinunfolds, the exposed hydrophobic surfaces bind the dye, resulting in anincrease in fluorescence. 5 uM of antibody was incubated with 20 uMredIL-33 at 25° C. in the presence of 8×SYPRO orange dye diluted from a5000× stock (Life technologies S-6650) in 1×DPBS. Fluorescence(excitation 490 nm and emission 575 nm) was measured every minute usinga Chromo4 Real Time detector (Bio-rad). We observed that incubatingredIL-33 with H338L293 antibody, and not redIL-33 or antibody alone,there was an increase in the fluorescence signal indicative of proteinunfolding.

FIG. 30A shows relative fluorescence units at 100 minutes followingincubation of 5 uM antibody with 20 uM redIL33 at 25° C. in the presenceof 8×SYPRO orange dye. In the presence of redIL-33 H338L293, but notIL330004 or the control mAb, increased the fluorescent signal indicativeof protein unfolding.

FIG. 30B shows relative fluorescence units over time followingincubation of varying concentrations of H338L293 with 20 uM redIL33 at25° C. in the presence of 8×SYPRO orange dye. Fluorescent signalincreased with increasing antibody concentration.

SDS-PAGE Electrophoresis

To determine if H338L293 could influence disulfide bonding of IL-33,IL-33 was monitored in the presence of H338L293 by comparing reduced andnon-reduced SDS-PAGE analysis. 100 ug/ml recombinant human IL-33¹¹²⁻²⁷⁰(BK349) was incubated in PBS/0.1% BSA containing either 1.5 mg/mlH338L293 mAb, NIP228 mAb or without addition of a mAb. Samples wereincubated for 20 h at 37 C in a standard tissue culture incubator.Samples containing 1 ug of IL-33 were analysed by SDS-PAGE on Novex 12%Bis-Tris mini NuPAGE gels (Invitrogen) under reducing and non-reducingconditions. Following SDS-PAGE gels were washed 3×5 min in ddH20,incubated in EzBlue (Sigma G1041, a coomassie brilliant blue G-250 basedprotein stain) for 1 h, and destained in ddH20 until background of gelwas clear. All gel staining steps performed at room temperature on arocking platform. Gels were visualised using Epsom digital scanner.

FIG. 30C shows SDS-PAGE analysis of IL-33. Preincubation of IL-33 withH338L293, but not control mAb or no mAb, increased the presence of thefaster migrating, disulfide bonded form of IL-33 under non-reducingconditions.

Inhibition of NFkB Signalling in Huvec by IgG

NFkB signaling in human umbilical vein endothelial cells in response toIL-33 was assessed by nuclear translocation of the p65/RelA NFkBsubunit, detected by immunofluorecence staining as described inExample 1. Cells were stimulated with varying IL-33 concentrations inthe presence of multiple concentrations of test antibody H338L293 foreither 30 minutes or 6 hours.

FIG. 31 shows the effect of H338L293 on IL-33 stimulated NFkBtranslocation on HUVECs. These results show that, as seen previously,H338L293 did not inhibit nuclear translocation of p65/RelA NFkB inIL-33-stimulated Huvecs 30 minutes following stimulation. However, after6 hours, inhibition is seen. The results are consistent with failure ofH338L293 to inhibit IL-33 binding to ST2 directly but ability to convertIL-33 to a non-ST2 binding form within hours.

Inhibition of IL-33 Binding to ST2 by Purified IgG

The ability of H338L293 to inhibit the binding of FLAG® His tagged IL-33to the ST2 receptor was assessed in a biochemical HTRF® (HomogeneousTime-Resolved Fluorescence, Cisbio International) competition assay asdescribed in Example 1. Two conditions were tested. Firstly the antibodyand IL-33 were added simultaneously to the assay exactly as inExample 1. As previously, purified IgG preparations were not able toinhibit the IL-33:ST2 interaction at concentrations tested. Secondly,H338L293 was preincubated with the IL-33FLAG® His for 18 hours prior toaddition to the assay. In this case concentration-dependent inhibitionof IL-33:ST2 binding was observed. Taken together these data areconsistent with H338L293 converting IL-33 to a non-ST2 binding form overtime.

FIG. 32 shows the inhibition of the FRET signal, produced by human IL-33binding to human ST2 with increasing concentrations of H338L293, whereinthe x-axis is the concentration of antibody in molar concentration andthe y-axis is percent specific binding. These results show that H338L293inhibits IL-33 binding to ST2 only after prolonged pre-incubation withthe ligand.

Epitope Mapping

Epitope mapping of H338L293 IgG was attempted in order to clarify themode of IL-33 binding to this IgG. Size Exclusion Chromatography (SEC)experiments were performed in order to observe the formation ofIL-33:IgG complexes. A BioSep-SES-S 2000 column (300×7.4 mm, s/n550331-4) was equilibrated with Dulbecco's PBS at 0.5 mL min′ on anAgilent HP1100 HPLC. Peaks were detected using the 280 nm signal from aDiode Array Detector (DAD). These studies confirmed thatantibody-antigen complex formation was fairly slow taking at leastseveral hours. Once sufficient time for full complex formation had beenallowed, trypsin was added to pre-formed IL-33:IgG complexes, followedby SEC analysis. 36 min trypsin digest led to an increase in theretention time of the main peak to 14.1 minutes (intermediate betweenthe untreated complex peak elution time (13.6 min) and the intactH338L292 IgG elution (14.4 min)). Mass spectrometry methods were thenused to identify the minimal H338L293 IgG epitope. The ShimadzuMALDI-TOF MS observed masses from captured 14.1 min peak were 3,209 and4,485.3 Da. ABI4800 MALDI-TOF MS observed masses were 3,208.9 Da peak athigh intensity with a secondary 4,486.4 Da peak also present. Theobserved precursor ion mass of 3206-3208 Da and ABI4800 MS/MSfragmentation analysis of the 3,206 Da precursor ions matched thepredicted tryptic IL-33 fragment MLMVTLSPTKDFWLHANNKEHSVELHK. This lieswithin the overall primary sequence of r Human IL-33-Flag His10 (SEQ IDNO. 627) as shown below:—

MSITGISPITEYLASLSTYNDQSITFALEDESYEIYVEDLKKDEKKDKVLLSYYESQHPSNESGDGVDGKMLMVTLSPTKDFWLHANNKEHSVELHKCEKPLPDQAFFVLHNMHSNCVSFECKTDPGVFIGVKDNHLALIKVDSSENLCTENILFKLSETNPAFLYKVVGAADYKDDDDKAAHHHHHHHHHH

The identified peptide together with a truncate (LSPTKDFWLHANNKEHSVELHKAand scrambled variants of both, were then chemically synthesised andused in confirmatory T100 Biacore (GE Healthcare) binding studies.Protein G′ (Sigma Aldrich, P4689) was covalently coupled to the surfaceof a CM5 sensor chip (GE Healthcare) using standard amine couplingreagents according to manufacturer's instructions. The protein G′surface was used to capture H338L293 or ST2-Fc via the Fc domain toprovide a surface density of approximately 290RU per cycle. IL33peptides prepared in HBS-EP+ buffer, at a range of concentrations werepassed over the sensor chip surface. The surface was regenerated usingtwo 10 mM Glycine washes of pH 1.7 and pH 1.5 between each injection ofantibody. The resulting sensorgrams were evaluated using Biacore T100evaluation software 2.0.3 (GE Healthcare) and fitted to a 1:1 Langmuirbinding model, to provide relative binding data.

The full length synthetic epitope peptide bound strongly to H338L293 IgGbut not the IL-33 receptor (ST2-Fc). Both the full length and thetruncated synthetic peptide bound strongly to H338L293 but the scrambledfull length and truncated versions did not. This is strong evidence thatIL-33 fragment identified by peptide excision is not an artefact andrepresents the core of the H338L293 epitope. 0.625-20 nM of thetruncated peptide was flowed over H338L293 IgG to estimate affinity.Good quality 1:1 fits were obtained giving a K_(D) value of 2.36 nM.

FIG. 33 shows epitope mapping of H338L293. The top panel shows SECanalysis of IL33:IgG complexes with H338L293 pre and post digestion withtrypsin. The lower panel shows the truncate peptide that was determinedto bind strongly to H338L293 coloured black within the IL-33 structuredescribed by Lingel et al 2009.

Example 6 Cys→Ser IL-33 Mutants

To understand the role of the four free cysteines of human IL-33 in itsconversion to the disulphide bonded form, we generated a full panel ofall possible Cys-to-Ser mutants. Most of these mutant IL-33 moleculesshowed similar initial activity through ST2 compared with wild typeIL-33. Following incubation in media mutants did not display faster gelmigration, consistent with lack of ability to form 2 disulfide bonds.However, loss of potency after media treatment varied between mutants.

Generation of IL-33 Cysteine to Serine Mutant Panel

cDNA molecules encoding the mature component of Human IL-33 (112-270);accession number (Swiss-Prot) O95760, and a series of variants with 1,2, 3 or 4 cysteine residues mutated to serine in all combinations (15 intotal) were synthesized by primer extension PCR and cloned intopJexpress404 (DNA 2.0). The wild-type (WT) and mutant IL-33 codingsequences were modified to contain a 10× his, Avitag, and Factor-Xaprotease cleavage site (MHHHHHHHHHHAAGLNDIFEAQKIEWHEAAIEGR) at theN-terminus of the proteins.

DNA encoding the IL-33 mutants was used to transform E. coli BL21 Goldcells. Transformed cells were cultured at 37° C. until they reached anOD600 nm of 0.3 to 0.5. Cultures were then grown at 18° C. until theyreached an OD600 nm of 0.6 to 0.8, when protein expression was inducedby addition of 100 mM IPTG. Cultures were continued at 18° C. for afurther 20 hours before cells were harvested by centrifugation andstored at −80° C.

Cells were resuspended in 50 mM Sodium phosphate, pH 8.0, 300 mM NaCl,20 mM Imidazole, 5 mM BetaMercaptoethanol containing complete proteaseinhibitor tablets (Roche, 11697498001), 2.5 u/ml Benzonase nuclease(merck Millipore, 70746-3) and 1 mg/ml recombinant lysozyme. Resuspendedcells were lysed using a Constant Systems cell disruptor at 25 kpsi andclarified by centrifugation at 75,000×g for 2 hours at 4° C. IL33 waspurified from the supernatant by Nickel affinity chromatography in 50 mMSodium phosphate, pH 8.0, 300 mM NaCl, 20 mM Imidazole, 5 mMBetaMercaptoethanol, eluting in 50 mM Sodium phosphate, pH 8.0, 300 mMNaCl, 250 mM Imidazole, 5 mM BetaMercaptoethanol. IL33 was furtherpurified by size exclusion chromatography using a Superdex 75 10/300 GLcolumn (GE Healthcare) in Phosphate Buffered Saline pH 7.4. Peakfractions were analysed by SDS PAGE. Fractions containing pure IL33 werepooled and the concentration measured by Nanodrop A280 measurement.Final samples were analysed by SDS PAGE and intact mass spectrometry.Protein was snap frozen in liquid nitrogen.

TABLE 17 IL-33 mutant sequences Position Position Position PositionMutant 208 227 232 259 AA.112-270 IL33-01 C C C C SEQ ID NO: 632 IL33-02S C C C SEQ ID NO: 634 IL33-03 C S C C SEQ ID NO: 635 IL33-04 C C S CSEQ ID NO: 636 IL33-05 C C C S SEQ ID NO: 637 IL33-06 S S C C SEQ ID NO:638 IL33-07 C C S S SEQ ID NO: 639 IL33-08 S C S C SEQ ID NO: 640IL33-09 C S C S SEQ ID NO: 641 IL33-10 C S S C SEQ ID NO: 642 IL33-11 SC C S SEQ ID NO: 643 IL33-12 S S S C SEQ ID NO: 644 IL33-13 S S C S SEQID NO: 645 IL33-14 S C S S SEQ ID NO: 646 IL33-15 C S S S SEQ ID NO: 647IL33-16 S S S S SEQ ID NO: 648

Activity of IL-33 Cys→Ser Mutants

To check protein integrity, activity of untreated wild type IL-33(IL33-01) and the IL-33 mutants were measured in a ST2-dependentsignaling assay. NFκB signaling in Human umbilical vein endothelialcells (Huvecs) in response to IL-33 was assessed by nucleartranslocation of the p65/RelA NFkB subunit detected by immunofluorecencestaining as described in Example 1. To investigate loss of activityafter cell culture media treatment, IL-33 proteins 01-16 were incubatedovernight in Iscoves Modified Dulbeccos Medium (IMDM) and assessed incomparison with the untreated proteins.

TABLE 18 Activity of IL-33 mutants in HUVEC NFkB translocation assayLoss of  activity IC50 (nM) after IMDM Name Sequence Untreated treatmentSEQUENCE IL33-01 CCCC 0.13 +++ SEQ ID NO: 632 (WT) IL33-02 SCCC 0.19 ++SEQ ID NO: 634 IL33-03 CSCC 0.16 ++ SEQ ID NO: 635 IL33-04 CCSC 0.17 +SEQ ID NO: 636 IL33-05 CCCS 0.10 ++ SEQ ID NO: 637 IL33-06 SSCC 0.28 +SEQ ID NO: 638 IL33-07 CCSS 0.22 + SEQ ID NO: 639 IL33-08 SCSC 0.21 −SEQ ID NO: 640 IL33-09 CSCS 0.20 ++ SEQ ID NO: 641 IL33-10 CSSC 0.61 +SEQ ID NO: 642 IL33-11 SCCS 0.49 + SEQ ID NO: 643 IL33-12 SSSC 0.39 −SEQ ID NO: 644 IL33-13 SSCS 0.08 + SEQ ID NO: 645 IL33-14 SCSS 0.14 −SEQ ID NO: 646 IL33-15 CSSS 0.12 − SEQ ID NO: 647 IL33-16 SSSS 0.17 −SEQ ID NO: 648

FIG. 34 shows activity of the IL-33 mutants before and after treatmentfor 18 hours with IMDM. Wild type IL-33 (IL33-01) that has beenpre-treated with culture media completely lost detectable activity. Allmutants displayed less potency loss than WT. Some mutants werecompletely protected from potency loss.

Human Mast Cell Cytokine Release

To see if mutants were more potent at stimulating downstream responsesat longer timepoints in vitro, an overnight mast cell IL-6 productionassay was used to measure activity of human IL-33 wild type and selectedmutants. Assay methods are described in Example 2. Data are exemplifiedby IL33-11.

FIG. 35A shows that IL33-11 has greater potency than IL-33 WT atstimulating human mast cell IL-6 production. IL33-01 (WT) and IL33-11without prior treatment were used to stimulate IL-6 production fromhuman cord blood derived mast cells at varying concentrations, whereinthe x-axis is the concentration of IL-33 in molar concentration and they-axis is the level of IL-6 detected in the supernatants after 18 hours.

In Vivo Potency of Mutant IL-33

Female BALB/c mice (6-8 weeks) were anaesthetized briefly withisofluorane and administered either 0.1-10 ug of wild type human IL-33(IL33-01, SEQ ID NO: 632), IL33-11 (SEQ ID NO: 643) or vehicleintranasally in a total volume of 50 μl. 24 hours after challenge, micewere terminally anaesthetised with pentobarbital sodium prior tobronchoalveolar lavage (BAL). B ALF was collected and analysed asdescribed in Example 4.

FIG. 35B shows that intranasal administration of IL33-11 double mutantrequired only a tenth as much protein for an equivalent ST2-dependentIL-5 response compared to native IL-33. This is consistent withprolonged activity of the mutant in contrast to the more rapidinactivation of the wild type IL-33 in the mouse lung environment.

NMR Analysis of IL33-11

To investigate conformational differences between IL33-11 and wild typehuman IL-33 protein (IL33-01), NMR analysis was performed.

Production of ¹⁵N-IL-33 Proteins

DNA encoding wild type IL-33 with an N-terminal 6His tag and TEVprotease cleavage site (SEQ ID. 633) was used to transform E. coli BL21Gold cells. Transformed cells were cultured at 37° C. in M9 minimalmedia supplemented with 5 g/L of ¹⁵N-IsoGro™ powder until they reachedan OD600 nm of 0.6 to 0.8, when protein expression was induced byaddition of 100 mM IPTG. Cultures were continued at 18° C. for a further20 hours before cells were harvested by centrifugation and stored at−80° C. Cells were resuspended in 50 mM Sodium phosphate, pH 8.0, 300 mMNaCl, 20 mM Imidazole, 5 mM BetaMercaptoethanol containing Completeprotease inhibitor tablets (Roche, 11697498001), 2.5 U/ml Benzonasenuclease (merck Millipore, 70746-3) and 1 mg/ml recombinant lysozyme.Resuspended cells were lysed using a Constant Systems cell disruptor at25 kpsi and clarified by centrifugation at 75,000×g for 2 hours at 4° C.IL-33 was purified from the supernatant by Nickel affinitychromatography in 50 mM Sodium phosphate, pH 8.0, 300 mM NaCl, 20 mMImidazole, 5 mM BetaMercaptoethanol, eluting in 50 mM Sodium phosphate,pH 8.0, 300 mM NaCl, 250 mM Imidazole, 5 mM BetaMercaptoethanol. Elutedprotein was incubated with TEV protease and dialysed into 50 mM Sodiumphosphate, pH 8.0, 300 mM NaCl, 20 mM Imidazole, 5 mMBetaMercaptoethanol at 4° C. De-tagged protein was separated fromuncleaved IL-33 by Nickel affinity chromatography in 50 mM Sodiumphosphate, pH 8.0, 300 mM NaCl, 20 mM Imidazole, 5 mMBetaMercaptoethanol. IL-33 was further purified by size exclusionchromatography using a HiLoad 16/60 Superdex 75 column (GE healthcare)in 20 mM Sodium phosphate pH 6.5, 100 mM NaCl, 5 mM BetaMercaptoethanol,using an AKTAxpress FPLC system (GE healthcare). Peak fractions wereanalysed by SDS PAGE. Fractions containing pure IL-33 were pooled andthe concentration measured by Nanodrop A280 measurement. Protein wasconcentrated using an Amicon 10,000 molecular weight cut-off spinconcentrator to a final concentration of 1.8 mg/ml (100 μM) for NMRanalysis.

NMR Analysis

NMR spectra were recorded at 298 K on a Bruker Avance 600 MHzspectrometer running Topspin 2.3 equipped with a 5 mm TCI Cryoprobe withZ-axis gradients. The ¹⁵N-labelled IL33 WT sample was prepared asdescribed with the addition of 5% deuterium oxide to allow samplelocking. The exemplified ¹H-¹⁵N correlation spectra were acquiredemploying the sofast HMQC pulse sequence (Schanda, P; Brutscher, B; Veryfast two-dimensional NMR spectroscopy for real-time investigation ofdynamic events in proteins on the time scale of seconds, J. Am. Chem.Soc. (2005) 127, 8014-5) with (F2×F1) 1024×64 complex points (instates-TPPI mode), 9615×1460 Hz sweep width, 53.4 ms×43.8 ms acquisitiontimes.

FIG. 36 shows overlay of the ¹H-¹⁵N HMQC spectra for 0.1 mM ¹⁵N-labeledIL33-01 and IL33-11 plotted in black and red, respectively. Assignmentfor relevant residues are indicated. Data show peak shifts around C208and C259 as expected. However, there are more more peak shifts thanexpected from T185 to A196 which might indicate a conformation change.

Example 7 Isolation and Identification of Anti-IL-33 Antibodies UsingIL33-11

Cys→Ser mutant IL-33 proteins stabilise IL-33 in its reduced form andhave different conformations to wild type (as described in Example 6).Mutant proteins may provide availability of different antibody epitopesor greater longevity/stability of epitopes and may therefore be usefulfor isolating neutralizing IL-33 antibodies, in particular to thereduced form of IL-33. This example uses oxidation-resistant mutantIL33-11 protein to isolate IL-33 antibodies by phage display.

Recombinant Proteins

N-Terminal Tagged His10/Avitag IL33-01 (WT, SEQ ID NO. 632), N-TerminalTagged

His10/Avitag IL33-11 (C208S, C259S, SEQ ID 643) and N-terminal taggedHis10/Avitag cyno IL-33 (SEQ ID 649), were generated by transforming E.coli BL21(DE3) cells. Transformed cells were cultured in autoinductionmedia (Overnight Express™ Autoinduction System 1, Merck Millipore,71300-4) at 37° C. for 18 hours before cells were harvested bycentrifugation and stored at −20° C. Cells were resuspended in BugBuster(Merck Millipore, 70921-5), containing complete protease inhibitorcocktail tablets (Roche, 11697498001), 2.5u/ml Benzonase nuclease (merckMillipore, 70746-3) and lmg/ml recombinant lysozyme. Cell lysate wasclarified by centrifugation at 75,000×g for 2 hours at 4° C. IL-33proteins were purified from the supernatant by Nickel affinitychromatography in 50 mM Sodium phosphate, pH 8.0, 300 mM NaCl, 20 mMImidazole, eluting in Sodium phosphate, pH 8.0, 300 mM NaCl, 250 mMImidazole. IL-33 was further purified by size exclusion chromatographyusing a Superdex 75 10/300 GL column in Phosphate Buffered Saline pH7.4. Peak fractions were analysed by SDS PAGE. Fractions containing pureIL-33 were pooled and the concentration measured by Nanodrop A280measurement. Final samples were analysed by SDS PAGE.

The human ST2 vector described in Example 1 was modified to containhuman ST2 ECD with a C-terminal Flag-His tag (SEQ ID NO 650).

TABLE 19 Reagents Catalogue Number/ Reagent Supplier Designation SEQHis10/Avi Human IL33-01 In house PS-937 SEQ ID NO. 632 His10/Avi HumanIL33-11 In house PS-938 SEQ ID NO. 643 His10/Avi Cyno IL-33 In House CCH3^(rd) Apr. SEQ ID 2014 NO. 649 IL-4Rα Flag ®His In house 020629080Bovine insulin - biotin Sigma I2258 Human ST2 Flag His In house BK282SEQ ID NO. 650 Human ST2.Fc R&D Systems

Protein Modifications

Proteins containing the Avitag sequence motif (GLNDIFEAQKIEWHE) werebiotinylated using the biotin ligase (BirA) enzyme (Avidty, Bulk BirA)following the manufacturer's protocol. All IgGs and modified proteinswithout Avitag used herein were biotinylated via free amines using EZlink Sulfo-NHS-LC-Biotin (Thermo/Pierce, 21335) as described in Example1.

Selections

Selections were performed essentially as described in Example 1 butusing the IL33-11 C208S, C259S mutant protein. In brief, the scFv-phageparticles were incubated with biotinylated recombinant IL-33-11 insolution (biotinylated via Avi tag). Particles were incubated with 100nM biotinylated recombinant IL33-11 for 2 hours. ScFv bound to antigenwere then captured on streptavidin-coated paramagnetic beads(Dynabeads®, M-280) following manufacturer's recommendations. Unboundphage was washed away in a series of wash cycles using PBS-Tween. Thephage particles retained on the antigen were eluted, infected intobacteria and rescued for the next round of selection. Two more rounds ofselections were carried out in the presence of decreasing concentrationsof biotinylated IL33-11 (50 nM and 25 nM).

Inhibition of IL-33 Binding to ST2 by Unpurified scFv

A representative number of individual clones from the selection outputsafter two or three rounds of selection described above were grown up in96-well plates. ScFv were expressed in the bacterial periplasm(Kipriyanov, et al. J Immunol Methods 200(1-2): 69-77 (1997)) andscreened for their inhibitory activity in a homogeneous FRET(fluorescence resonance energy transfer) HTRF® (HomogeneousTime-Resolved Fluorescence, Cisbio International) basedIL-33:ST2-binding assay. Essentially methods were similar to thosedescribed in Example 1. In this assay, samples competed with FLAG®His-tagged human ST2 for binding to biotinylated human IL33-01 (IL33-01,SEQ ID No. 632) (wild type) or biotinylated human IL33-11 (IL33-11, SEQID No. 643).

Unpurified anti-IL-33 antibody samples were tested for inhibition ofbiotinylated IL-33 binding FLAG® His-tagged ST2 by adding 5 microlitresof each dilution of antibody test sample to a 384 well low volume assayplate (Costar, 3673). Next, a solution containing 4 nM human FLAG®His-tagged ST2 and 5 nM anti-FLAG® XL665 detection (CisbioInternational, 61FG2XLB) was prepared and 2.5 microlitres of the mixadded to the assay plate. This was followed by the addition of 2.5microlitres of a solution containing 2.4 nM biotinylated human IL33-01or IL33-11 combined with 1.5 nM streptavidin cryptate detection (CisbioInternational, 610SAKLB). All dilutions were performed in assay buffercontaining 0.8 M potassium fluoride (VWR, 26820.236) and 0.1% bovineserum albumin (BSA, PAA, K05-013) in Dulbeccos PBS (Invitrogen,14190185). Assay plates were incubated for 1 hour at room temperatureand time resolved fluorescence was read at 620 nm and 665 nm emissionwavelengths using an EnVision plate reader (Perkin Elmer). Plates wereincubated for a further 16 hour (overnight) at 4 degrees Celsiusand timeresolved fluorescence read again. The negative control (non-specificbinding) was defined by replacing biotinylated human IL33-01 or IL33-11combined with streptavidin cryptate detection with streptavidin cryptatedetection only. Data were analysed as described in Example 1.

Inhibition of IL-33 Binding to ST2 by Purified scFv

Single chain Fv clones which showed an inhibitory effect on IL-33:ST2interaction as unpurified periplasmic extracts at both time points weresubjected to DNA sequencing (Osbourn, et al. Immunotechnology2(3):181-96 (1996); Vaughan, et al. Nat Biotechnol 14(3):309-14 (1996)).Unique scFv were expressed again in bacteria and purified by affinitychromatography (as described in WO01/66754). The potencies of thesesamples were determined by competing a dilution series of the purifiedpreparation against FLAG® His-tagged human ST2 for binding tobiotinylated IL33-01 or biotinylated IL33-11 as described above. Assayplates were incubated for 1 hour at room temperature (1 hourincubation), or assay plates were incubated for 1 hour at roomtemperature followed by 16 hour at 4 degrees Celsius (overnightincubation). Purified scFv preparations that were capable of inhibitingthe IL-33:ST2 interaction at both timepoints were selected forconversion to IgG format.

FIG. 37A: shows the inhibition of the FRET signal after 1 hourincubation, produced by human IL-33-01 binding to human ST2 withincreasing concentrations of IL-33 scFv antibody 33v20064, wherein thex-axis is the concentration of antibody in molar concentration and they-axis is percent specific binding.

FIG. 37B: shows the inhibition of the FRET signal after 1 hourincubation, produced by IL33-11 binding to human ST2 with increasingconcentrations of IL-33 scFv antibody 33v20064, wherein the x-axis isthe concentration of antibody in molar concentration and the y-axis ispercent specific binding.

FIG. 37C: shows the inhibition of the FRET signal after overnightincubation, produced by human IL-33-01 binding to human ST2 withincreasing concentrations of IL-33 scFv antibody 33v20064, wherein thex-axis is the concentration of antibody in molar concentration and they-axis is percent specific binding.

FIG. 37D: shows the inhibition of the FRET signal after overnightincubation, produced by IL33-11 binding to human ST2 with increasingconcentrations of IL-33 scFv antibody 33v20064, wherein the x-axis isthe concentration of antibody in molar concentration and the y-axis ispercent specific binding.

Reformatting of scFv to IgG1

Purified scFv preparations that were capable of inhibiting the IL-33:ST2interaction were converted to whole immunoglobulin G1 (IgG1) antibodyformat as described in Example 1. Antibodies that inhibited to a similaror greater extent then IL330004 (Example 1, SEQ ID Nos. 12 and 17) weretaken forward for further analysis. Such antibodies are exemplified by33v20064. SEQ ID NOs. corresponding to the various regions of antibody33v20064 are shown in Table 20.

TABLE 20 Anti-IL-33 Antibody Sequences VH VL VH CDRs VL CDRs IgG1Sequence Sequence 1, 2, 3 1, 2, 3 33v20064 SEQ ID SEQ ID SEQ ID SEQ IDNO: 272 NO: 277 NO: 273 NO: 278 SEQ ID SEQ ID NO: 274 NO: 279 SEQ ID SEQID NO: 275 NO: 280

Inhibition of IL-33 Binding to ST2 by Purified IgG

The ability of anti-IL-33 antibodies to inhibit the binding ofbiotinylated IL-33-01 to the FLAG®-His tagged ST2 receptor was assessedin a biochemical HTRF® (Homogeneous Time-Resolved Fluorescence, CisbioInternational) competition assay, the principles of which are describedabove. Activity of purified IgG preparations were determined bycompeting a dilution series of the purified IgG against human FLAG®-Histagged ST2 for binding to human biotinylated human IL-33-01 (SEQ ID No.632).

FIG. 38A: shows the inhibition of the FRET signal after 1 hourincubation, produced by human IL-33 binding to human ST2 with increasingconcentrations of 33v20064 IgG1 antibody, wherein the x-axis is theconcentration of antibody in molar concentration and the y-axis ispercent specific binding.

FIG. 38B: shows the inhibition of the FRET signal after overnightincubation, produced by human IL-33 binding to human ST2 with increasingconcentrations of 33v20064 IgG1 antibody, wherein the x-axis is theconcentration of antibody in molar concentration and the y-axis ispercent specific binding.

Inhibition of IL-6 Production in Huvec by IgG

33v20064 was assessed for inhibition of IL-33 stimulated IL-6 productionin HUVECs, the methods of which are described in Example 2. His-Avihuman IL-33 wild type (IL33-01, SEQ ID No. 632) (30 ng/mL) or His-Avimutant IL-33 (IL33-11, SEQ ID No. 643) (30 ng/mL) were used to stimulateHUVECs in the presence of varying concentrations of test antibodies.

FIG. 39A: shows the inhibition of IL-6 production from IL33-01 (WT)stimulated HUVECs by antibody 33v20064 compared with IL330004 andanti-NIP IgG1 negative control antibody, NIP228, wherein the x-axis isthe concentration of antibody in molar concentration and the y-axis ispercent maximal response. 33v20064 showed partial inhibition of theresponse to WT IL-33 at high antibody concentrations, whereas IL330004showed no effect.

FIG. 39B: shows the inhibition of IL-6 production from IL33-11stimulated HUVECs by antibody 33v20064 compared with IL330004 andanti-NIP IgG1 negative control antibody, NIP228, wherein the x-axis isthe concentration of antibody in molar concentration and the y-axis ispercent maximal response. 33v20064 showed a more complete inhibition ofIL-6 production stimulated by IL33-11 mutant compared with IL330004.

Cross-Reactivity of Anti-IL-33 Antibodies

Cross-reactivity of anti IL-33 antibody 33v20064 was determined using ahomogeneous FRET (fluorescence resonance energy transfer) HTRF®(Homogeneous Time-Resolved Fluorescence, Cisbio International) basedIL-33:mAb-binding assay. In this assay, samples competed withbiotinylated human IL-33-01 (SEQ ID No. 632) for binding to DyLightlabelled 33v20064 IgG.

TABLE 21 FRET Assay Reagents Catalogue Number/ Reagent SupplierDesignation SEQUENCE Human IL-33 Flag ®His In house PS-582 SEQ ID No.627 Mouse IL-33 Flag ®His In house BK-265 SEQ ID No. 628 CynomolgusIL-33 In house PS-368 SEQ ID Flag ®His No. 629 B7H3 Avi-His In houseDBPur125 Human IL-1 alpha R&D Systems 201-LB/CF Human IL-1 beta R&DSystems 200-LA/CF

Human, cyno and mouse IL-33 FLAG® His (described in Example 1) weretested for inhibition of human IL-33 binding to DyLight labelled33v20064 by adding 5 microlitres of each dilution of IL-33 sample to a384 well low volume assay plate (Costar, 3673). Next, a solutioncontaining 20 nM DyLight labelled 33v20064 was prepared and 2.5microlitres added to the assay plate (labelled using kit (InnovaBiosciences, 326-0010) as per manufacturer's instructions). This wasfollowed by the addition of 2.5 microlitres of a solution containing 1.2nM biotinylated human IL-33-01 combined with 1.5 nM streptavidincryptate detection (Cisbio International, 610SAKLB). All dilutions wereperformed in assay buffer containing 0.8 M potassium fluoride (VWR,26820.236) and 0.1% bovine serum albumin (BSA, PAA, K05-013) inDulbeccos PBS (Invitrogen, 14190185). Assay plates were incubated for 1hour at room temperature and time resolved fluorescence was read at 620nm and 665 nm emission wavelengths using an EnVision plate reader(Perkin Elmer). Data were analysed by calculating the 665/620 nm ratiofollowed by the % Delta F values for each sample. The 665/620 nm ratiowas used to correct for sample interference using Equation 1. The %Delta F for each sample was then calculated using Equation 2. Thenegative control (non-specific binding) was defined by replacingbiotinylated human IL-33 combined with streptavidin cryptate detectionwith streptavidin cryptate detection only. The % Delta F values weresubsequently used to calculate % specific binding as described inEquation 3. IC₅₀ values were determined using GraphPad Prism software bycurve fitting using a four-parameter logistic equation (Equation 4).These results demonstrated that 33v20064 cross reacts with cynomolgusIL-33. 33v20064 but did not show competition with mouse IL-33.

FIG. 40A: shows the inhibition of the FRET signal, produced bybiotinylated human IL-33-01 binding to DyLight labelled 33v20064, withincreasing concentrations of test proteins, wherein the x-axis is theconcentration of test sample in molar concentration and the y-axis ispercent specific binding. Inhibition of the FRET signal was observedwith human and cynomolgus, but not mouse, IL-33.

Selectivity of Anti-IL-33 Antibodies

Selectivity of anti IL-33 antibody 33v20064 was determined using ahomogeneous FRET (fluorescence resonance energy transfer) HTRF®(Homogeneous Time-Resolved Fluorescence, Cisbio International) basedIL-33:mAb-binding assay. In this assay, samples competed withbiotinylated His-Avi human IL-33 (IL33-01, SEQ ID No. 632) for bindingto wild type DyLight labelled 33v20064 IgG. Human IL-1 alpha and humanIL-1 beta were tested for inhibition of biotinylated IL-33-01 bindingDyLight labelled 33v20064 as described above. These results demonstratedthat 33v20064 did not show competition with human IL-1 alpha or IL-1beta.

FIG. 40B: shows the inhibition of the FRET signal, produced bybiotinylated human IL-33-01 binding to DyLight labelled 33v20064, withincreasing concentrations of test proteins, wherein the x-axis is theconcentration of test sample in molar concentration and the y-axis ispercent specific binding. Inhibition of the FRET signal was not observedwith with human IL-1 alpha or IL-1 beta.

Example 8 Optimization of anti-IL-33 Ab 33v20064

Germlining Framework Regions of 33v20064

The amino acid sequences of the V_(H) and V_(L) domains of the parentantibody 33v20064 were aligned to the known human germline sequences inthe IMGT database (Lefranc, M. P. et al. Nucl. Acids Res. 2009.37(Database issue): D1006-D1012), and the closest germline wasidentified by sequence similarity. For the V_(H) domains of the 33v20064antibody lineage this was IGHV3-23*01. For the V_(L) domains it wasIGLV3-1. Germlining was carried out on 33v20064 prior to the affinitymaturation process. Without considering the Vernier residues (Foote1992), which were left unchanged, there were 6 residues in theframeworks of the V_(L) domains of 33v20064 which differed fromgermline, 5 of which were reverted to the closest germline sequenceusing the Kunkel mutagenesis method (Clackson, T. and Lowman, H. B.Phage Display—A Practical Approach, 2004. Oxford University Press) withthe appropriate mutagenic primers. The product of this germlining was33_640001. Sequence ID Numbers are described in Table 22.

TABLE 22 Antibody 33v20064 Germline Sequences VH VL VH CDRs VL CDRs IgG1Sequence Sequence 1, 2, 3 1, 2, 3 33_640001 SEQ ID SEQ ID SEQ ID SEQ IDNO: 282 NO: 287 NO: 283 NO: 288 SEQ ID SEQ ID NO: 284 NO: 289 SEQ ID SEQID NO: 285 NO: 290Inhibition of IL-33 Binding to ST2 by Purified scFv

Activity of 33_640001 was compared with its non-germlined parent,33v20064. The ability of scFv antibodies to inhibit the binding ofbiotinylated His Avi human IL-33 (IL33-01, SEQ ID No. 632) to theFLAG®-His tagged ST2 receptor was assessed in a biochemical HTRF®(Homogeneous Time-Resolved Fluorescence, Cisbio International)competition assay as described in Example 7.

FIG. 41A: shows the inhibition of the FRET signal after 1 hourincubation, produced by human IL-33 binding to human ST2 with increasingconcentrations of scFv antibodies, wherein the x-axis is theconcentration of antibody in molar concentration and the y-axis ispercent specific binding. 33_640001 had equivalent activity to itsnon-germlined parent.

FIG. 41B: shows the inhibition of the FRET signal after overnightincubation, produced by human IL-33 binding to human ST2 with increasingconcentrations of scFv antibodies, wherein the x-axis is theconcentration of antibody in molar concentration and the y-axis ispercent specific binding. 33_640001 had equivalent activity to itsnon-germlined parent.

Affinity Maturation

33v20064 was optimised using a targeted mutagenesis approach andaffinity-based phage display selections. Large scFv-phage librariesderived from the germlined parent (33_640001) were created byoligonucleotide-directed mutagenesis of the variable heavy (V_(H))complementarity determining region 3 (CDR3) and light (V_(L)) chain CDR3using standard molecular biology techniques as described (Clackson2004). For the V_(H) CDR3, the two Vernier positions preceding theKabat-defined CDRs (i.e. V_(H) positions 93 and 94) were also includedfor potential optimisation in the targeted mutagenesis approach. Thelibraries were subjected to affinity-based phage display selections inorder to select variants with higher affinity for human IL-33. Theseselections were carried out by either alternating the biotinylatedHis-Avi human IL-33 wild type (IL33-01, SEQ ID NO. 632) and biotinylatedHis Avi mutant IL-33 (IL33-11, SEQ ID NO. 643) antigens in sequentialrounds, or with the biotinylated IL33-11 antigen only in all rounds. Theselections were performed essentially as described previously (Thompson1996). In brief, the scFv-phage particles were incubated with therecombinant biotinylated antigen in solution. ScFv-phage bound toantigen were then captured on streptavidin-coated paramagnetic beads(Dynabeads® M-280) following the manufacturer's recommendations. Theselected scFv-phage particles were then rescued as described previously(Osbourn, J. K., et al. Immunotechnology, 1996. 2(3): p. 181-96), andthe selection process was repeated in the presence of decreasingconcentrations of biotinylated antigen—typically from 50 nM to 10 pMover five rounds of selection.

33v20064 was also optimised using ribosome display technologyessentially as described by Hanes et al. (Hanes, J., et al. Methods inEnzymology, 2000. 328: p. 404-30). The parent scFv clone 33v20064 wasused as a template for library construction and conversion to a ribosomedisplay format for subsequent selections. On the DNA level, a T7promoter was added at the 5′-end for efficient transcription to mRNA. Onthe mRNA level, the construct contained a prokaryotic ribosome-bindingsite (Shine-Dalgarno sequence). At the 3′-end of the single chain, thestop codon was removed and a portion of M13 bacteriophage gIII (geneIII) was added to act as a spacer between the nascent scFv polypeptideand the ribosome (Hanes 2000).

A ribosome display library derived from the parent (33v20064) scFvconstruct was created by random mutagenesis using the Diversify™ PCR(polymerase chain reaction) Random Mutagenesis Kit (BD Biosciences)following the manufacturer's recommendations. The conditions for thiserror-prone PCR (EP) were chosen to introduce on average 8.1 nucleotidechanges per 1000 basepairs (according to the manufacturer). Theresulting EP library was then used in affinity-based ribosome displayselections (Hanes 2000). The scFvs were expressed in vitro using theRiboMAX™ Large Scale RNA Production System (T7) (Promega) following themanufacturer's protocol and an E. coli-based prokaryotic cell-freetranslation system. The produced scFv antibody-ribosome-mRNA (ARM)complexes were incubated in solution with biotinylated human IL-33antigen, with either alternating the biotinylated IL33-01 andbiotinylated IL33-11 antigens in sequential rounds, or with thebiotinylated IL-33-11 antigen only in all rounds. The specifically boundtertiary complexes (IL-33:ARM) were captured on streptavidin-coatedparamagnetic beads (Dynabeads® M-280) following the manufacturer'srecommendations (Dynal) whilst unbound ARMs were washed away. The mRNAencoding the bound scFvs were then recovered by reversetranscription-PCR (RT-PCR). The selection process was repeated on theobtained population for further rounds of selections with decreasingconcentrations of biotinylated human IL-33 (100 nM to 100 pM over 5rounds), in order to enrich and thereby select clones with higheraffinity for IL-33. The outputs from selection rounds 3, 4 and 5 weresub-cloned into pCantab6 (McCafferty, J., et al. Appl BiochemBiotechnol, 1994. 47(2-3): p. 157.), and improved clones were identifiedas described below.

Inhibition of IL-33 Binding to mAb by Unpurified scFv

A representative number of individual clones from the selection outputswere grown up in 96-well plates. ScFv were expressed in the bacterialperiplasm (Kipriyanov, et al. J Immunol Methods 200(1-2): 69-77 (1997))and screened for their inhibitory activity in a homogeneous FRET(fluorescence resonance energy transfer) HTRF® (HomogeneousTime-Resolved Fluorescence, Cisbio International) basedIL-33:mAb-binding assay. In this assay, samples competed with DyLightlabelled 33v20064 IgG for binding to biotinylated His Avi IL-33-01 (SEQID NO. 632) or biotinylated His Avi cynomolgus IL-33 (SEQ ID NO. 649).Such epitope competition assays are based on the principle that a testantibody sample, which recognizes a similar epitope to the labelled antiIL-33 IgG, will compete with the labelled IgG for binding tobiotinylated IL-33 resulting in a reduction in assay signal.

Unpurified anti-IL-33 antibody samples were tested for inhibition ofbiotinylated His Avi IL33-01 (human) or biotinylated His Avi cynomolgusIL-33 binding DyLight labelled 33v20064 by adding 5 microlitres ofsample to a 384 well low volume assay plate (Costar, 3673). Next, asolution containing 2.4 nM DyLight labelled 33v20064 was prepared forthe human IL-33 assay and 6 nM DyLight labelled 33v20064 was preparedfor the cynomolgus assay and 2.5 microlitres added to the assay plates(labelled using kit (Innova Biosciences, 326-0010) as per manufacturer'sinstructions). This was followed by the addition of 2.5 microlitres of asolution containing 0.8 nM biotinylated human IL-33-01 combined with0.75 nM streptavidin cryptate detection (Cisbio International, 610SAKLB)for the human assay or a solution containing 4 nM biotinylatedcynomolgus IL-33 combined with 1.5 nM streptavidin cryptate detection(Cisbio International, 610SAKLB) for the cynomolgus assay. All dilutionswere performed in assay buffer containing 0.8 M potassium fluoride (VWR,26820.236) and 0.1% bovine serum albumin (BSA, PAA, K05-013) inDulbeccos PBS (Invitrogen, 14190185). Assay plates were incubated for 1hour at room temperature and time resolved fluorescence was read at 620nm and 665 nm emission wavelengths using an EnVision plate reader(Perkin Elmer). Data were analysed by calculating the 665/620 nm ratiofollowed by the % Delta F values for each sample. The 665/620 nm ratiowas used to correct for sample interference using Equation 1. The %Delta F for each sample was then calculated using Equation 2. Thenegative control (non-specific binding) was defined by replacingbiotinylated IL-33 combined with streptavidin cryptate detection withstreptavidin cryptate detection only. The % Delta F values weresubsequently used to calculate % specific binding as described inEquation 3.

As the epitope competition assay reached its limit of sensitivity anassay using an intermediate optimised mAb 33_640027 was used for testingunpurified scFv samples. The assay was essentially as described for the33v20064 competition assay with the following modifications: 20 nMDyLight labelled 33_640027 was prepared and 2.5 microlitres added to theassay plates. This was followed by the addition of 2.5 microlitres of asolution containing 0.32 nM biotinylated human IL-33-01 combined with0.75 nM streptavidin cryptate detection (Cisbio International, 610SAKLB)for the human assay or a solution containing 0.8 nM biotinylatedcynomolgus IL-33 combined with 1.5 nM streptavidin cryptate detection(Cisbio International, 610SAKLB) for the cynomolgus assay.

Inhibition of IL-33 Binding to mAb by Purified scFv

Single chain Fv clones which showed an inhibitory effect on IL-33:mAbinteraction as unpurified periplasmic extracts were subjected to DNAsequencing (Osbourn, et al. Immunotechnology 2(3):181-96 (1996);Vaughan, et al. Nat Biotechnol 14(3):309-14 (1996).). Unique scFv wereexpressed again in bacteria and purified by affinity chromatography (asdescribed in WO01/66754). Purified anti-IL-33 antibody samples weretested for potency of inhibition by competing a dilution series of thepurified preparation against DyLight labelled 33v20064 IgG or DyLightlabelled 33_640027 IgG for binding to biotinylated His Avi IL33-01,biotinylated His Avi IL33-11 or biotinylated His Avi cynomolgus IL-33.Methods are as described in the previous section.

TABLE 23 Activity of scFv antibodies in epitope competition assaysPotency IC50 (nM) Assay 33v20064 33_640027 33_640047 33_640050 33v20064IL33-01 12 0.4 0.4 0.2 IL33-11 26 0.6 0.5 0.4 Cyno IL-33 103 8.2 2.7 1.433_640027 IL33-01 1498 3.8 2.3 2.5 IL33-11 1467 2.9 Not determined 2.4Cyno IL-33 3433 38 8.8 4.1Reformatting of scFv to IgG1

Single chain Fv clones with desirable properties from the IL-33:mAbbinding assays were converted to whole immunoglobulin G1 (IgG1) antibodyformat as described in Example 1. These include antibodies 33_640027(derived from the EP library selections), and 33_640047, 33_640050(derived from the V_(H) CDR3 block mutagenesis library selections) SEQID NOs corresponding to the various regions of these antibodies areshown in Table 24

TABLE 24 Sequences of IL33 antibodies VH VL VH CDRs VL CDRs IgG1Sequence Sequence 1, 2, 3 1, 2, 3 33_640027 SEQ ID SEQ ID SEQ ID SEQ IDNO: 292 NO: 297 NO: 293 NO: 298 SEQ ID SEQ ID NO: 294 NO: 299 SEQ ID SEQID NO: 295 NO: 300 33_640047 SEQ ID SEQ ID SEQ ID SEQ ID NO: 312 NO: 317NO: 313 NO: 318 SEQ ID SEQ ID NO: 314 NO: 319 SEQ ID SEQ ID NO: 315 NO:320 33_640050 SEQ ID SEQ ID SEQ ID SEQ ID NO: 302 NO: 307 NO: 303 NO:308 SEQ ID SEQ ID NO: 304 NO: 309 SEQ ID SEQ ID NO: 305 NO: 310

Inhibition of IL-33 Binding to mAb by Purified IgG

The ability of anti-IL-33 antibodies to inhibit the binding ofbiotinylated His Avi IL33-01, biotinylated His Avi IL33-11 orbiotinylated His Avi cynomolgus IL-33 to the DyLight labelled 33v20064IgG or DyLight labelled 33_640027 IgG was assessed in a biochemicalHTRF® (Homogeneous Time-Resolved Fluorescence, Cisbio International)competition assay as described. IgGs with desirable properties from theIL-33:mAb binding assays were selected for further analysis.

Inhibition of IL-8 Production in Huvec by IgG

A cytokine release assay was used to assess the inhibition of IL-33induced IL-8 production from human umbilical vein endothelial cells(Huvec) by anti-IL-33 antibodies. Cells were exposed to IL-33 in thepresence or absence of test antibody or ST2.Fc (R&D systems) essentiallyas described in Example 2 with minor modifications. Test solutions ofpurified IgG (in duplicate) were diluted to the desired concentration incomplete culture media. N-terminal His Avi IL-33 (IL33-01, SEQ ID NO632) was prepared in complete culture media mixed with appropriate testantibody to give a final IL-33 concentration of 2 ng/mL. All sampleswere incubated for 30 minutes at room temperature, prior to transfer ofIL-33/antibody mixture to the assay plate. Following 18-24 hourincubation, IL-8 was measured in cell supernatants by ELISA (R&DSystems, DY208) adapted for europium readout as described in Example 2.Data were analyzed using Graphpad Prism software. IC₅₀ values weredetermined by curve fitting using a four-parameter logistic equation.IC₅₀ values were calculated and are summarized in Table 25 below.

FIG. 42A shows HUVECs stimulated with IL33-01 in the presence of33v20064, 33_640050, human ST2-Fc or control mAb, wherein the x-axis isthe concentration of antibody in molar concentration and the y-axis is apercentage of the maximum response (IL-8 production).

Neutralization of Mammalian Full Length IL-33

Full length IL-33 is also active (Cayrol et al., Proc Natl Acad Sci USA106(22):9021-6 (2009); Hayakawa et al., Biochem Biophys Res Commun387(1):218-22 (2009); Talabot-Ayer et al., J Biol Chem. 284(29):19420-6(2009)).

To evaluate the ability of antibodies to neutralize full length IL-33,HEK293-EBNA cells expressing full length (FL) HuIL-33 (andmock-transfected controls) were harvested 24 hours followingtransfection with accutase (PAA, #L11-007). Cells were diluted to1×10⁸/mL with PBS and homogenized for 30 seconds using a tissuehomogenizer. Cell debris was removed by centrifugation. HUVECs werestimulated with cell lysates at varying concentrations. Stimulation ofcytokine production was only observed with full length IL-33-transfectedcell lysate and not with mock transfected cell lysate. A 1:1000concentration of lysate that stimulated a sub-maximal cytokine release(approx EC₅₀) was selected for antibody neutralization studies.Experiments were performed as described above. IC₅₀ values werecalculated and are summarized in Table 25 below.

FIG. 42B shows HUVECs stimulated with full length IL-33 cell lysate inthe presence of 33v20064, 33_640050, human ST2-Fc or control mAb,wherein the x-axis is the concentration of antibody in molarconcentration and the y-axis is a percentage of the maximum response(IL-8 production).

TABLE 25 IC50 values in the Huvec IL-8 assay Geomean IC50 (95% CI) (nM)vs. full length IL-33 Antibody vs. His Avi IL-33 cell lysate 33v20064Partial inhibition 185 33_640050 0.7 (0.3-1.5) 0.32 ST2.Fc 0.3 (0.1-0.9)0.67

Prevention of Disulphide Bonded Form of IL-33 by IgG

IL-33-01 (0.14 nM or 3 ng/mL) was incubated in IMDM or PBS, bothcontaining 1% BSA in the presence of absence of antibodies (25 ug/mL) orhuman ST2-Fc (105 ug/mL) for 0-24 hours at 37° C., 5% CO₂. At varioustime points aliquots were removed and added to a pre-chilled platecontaining PBS or sST2 (final concentration 10.5 ug/mL). sST2 was spikedinto control mAb and untreated samples at harvesting to stop the IL-33oxidation reaction continuing. Samples were aliquoted into pre-frozen 96well plates and stored at −80° C. The human IL-33 ELISA was performedaccording to manufacturer's instructions (R&D Systems, Cat #DY3625, Lot#1362797) with the substitution of DELFIA detection system (PerkinElmer) in place of streptavidin-HRP and onwards. Briefly, black 96 wellMaxisorp plates were coated with 50 uL per well of capture antibodyovernight at room temperature. Plates were washed 3× with 300 uL 0.05%Tween-20 in PBS and blocked with 150 uL 1% BSA in PBS for 1 hour at roomtemperature. Plates were washed 3× and 50 uL per well of samples orstandards were added to the plate for 2 hours at room temperature withshaking (400 rpm). Plates were washed 3× and 50 uL per well of detectionantibody was added to the plate for 2 hours at room temperature withshaking (400 rpm). Plates were washed as previously stated and 50 uL perwell of streptavidin-europium diluted 1 in 1000 in DELFIA Assay Bufferwas added to the plate for 40 minutes at room temperature, protectedfrom light, with shaking (400 rpm). Plates were washed 7× with 300 uLper well of DELFIA Wash Buffer. 50 uL per well of DELFIA EnhancementSolution (pre-warmed to room temperature) was added to the plate. After10 minutes incubation at room temperature protected from the light,fluorescence was measured using an EnVision plate reader (PerkinElmer).Standards and data interpolation were performed in Microsoft Excel withsubsequent analysis performed in GraphPad Prism software.

As discussed in Example 4, FIG. 24A, this ELISA detects predominantlydisulphide bonded IL-33 (IL33-DSB) within the range of IL-33concentrations measured in this experiment. The ELISA is used here tomonitor the conversion of IL-33 to its disulphide bonded form in thepresence of test antibodies.

FIG. 43 shows conversion of IL33-01 to its disulphide bonded form(IL33-DSB) during incubation in IMDM (FIG. 43A) or PBS (FIG. 43B) in thepresence or absence of test antibodies, wherein the x-axis is time inhours and the y-axis is the concentration of IL-33-DSB. IL330004 and33v20064 slow the rate of IL-33 conversion to IL33-DSB. 33_640050 andST2.Fc prevent conversion to IL-33-DSB over the time course tested.

Recombination of Beneficial Mutations and Further Optimization

With the aim of generating further affinity improvements, beneficialmutations identified from previous selection and screening cascades wererecombined in a number of different ways, either by a simple additiveapproach or via a recombination library approach with furtherselections.

Sequence analyses suggested that there were two single-point mutational‘hotspots’ which were prevalent in many of the lead antibody sequences;I98M in V_(H) CDR3 and Q50R in V_(L) CDR2 (Kabat numbering). These twomutations were grafted onto the 33_640001 construct to generate a newantibody, 33_640036, using standard molecular biology techniques. In afurther recombination, the V_(H) of 33_640047 was paired with the V_(L)of 33_640036 to generate antibody 33_640117. These are examples ofsequence recombination using an additive approach. SEQ ID NOs are shownin Table 26.

TABLE 26 Sequences of IL33 antibodies VH VL VH CDRs VL CDRs IgG1Sequence Sequence 1, 2, 3 1, 2, 3 33_640036 SEQ ID SEQ ID SEQ ID SEQ IDNO: 352 NO: 357 NO: 353 NO: 358 SEQ ID SEQ ID NO: 354 NO: 359 SEQ ID SEQID NO: 355 NO: 360 33_640117 SEQ ID SEQ ID SEQ ID SEQ ID NO: 362 NO: 367NO: 363 NO: 368 SEQ ID SEQ ID NO: 364 NO: 369 SEQ ID SEQ ID NO: 365 NO:370

In addition, selection outputs from block mutagenesis libraries coveringthe V_(H) CDR3 and V_(L) CDR3 regions had shown affinity improvementsand good sequence diversity and were thus recombined using a populationcloning approach. Round 3 selection outputs were recombined to formlibraries in which clones contained randomly paired, individuallyrandomised V_(H) CDR3 and VL CDR3 sequences. These recombined V_(H)CDR3/V_(L) CDR3 libraries were then used in ribosome display selectionswith either alternating the biotinylated His Avi human IL-33 wild type(IL33-01, SEQ ID NO. 632) and biotinylated His Avi mutant IL-33(IL33-11, SEQ ID NO. 643) antigens in sequential rounds, or with thebiotinylated His Avi IL33-11 antigen only in all rounds. The selectionswere performed essentially as described for the individual CDR3libraries, in the presence of decreasing concentrations of biotinylatedantigen—from 50 nM to 30 pM over five rounds of selection.

Crude scFv-containing periplasmic extracts were prepared of arepresentative number of individual scFv's from the selection outputs ofthe recombined V_(H) CDR3/V_(L) CDR3 libraries. The ability ofanti-IL-33 antibodies to inhibit the binding of biotinylated His AviIL33-01 or biotinylated His Avi cynomolgus IL-33 to the DyLight labelled33v20064 IgG or DyLight labelled 33_640027 IgG was assessed in abiochemical HTRF® (Homogeneous Time-Resolved Fluorescence, CisbioInternational) competition assay as described. ScFv variants whichshowed a significantly improved inhibitory effect when compared toparent scFv and leads generated pre-recombination, were subjected to DNAsequencing, and unique recombined variants were produced as purifiedscFv and tested as described in the previous section.

Optimised antibodies obtained from these recombined libraries areexemplified by 33_640076, 33_640081, 33_640082, 33_640084, 33_640086 and33_640087. The SEQ ID NOs. of these antibodies are shown in Table 27.

TABLE 27 Sequences of IL33 antibodies VH VL VH CDRs VL CDRs IgG1Sequence Sequence 1, 2, 3 1, 2, 3 33_640076 SEQ ID SEQ ID SEQ ID SEQ IDNO: 372 NO: 377 NO: 373 NO: 378 SEQ ID SEQ ID NO: 374 NO: 379 SEQ ID SEQID NO: 375 NO: 380 33_640081 SEQ ID SEQ ID SEQ ID SEQ ID NO: 382 NO: 387NO: 383 NO: 388 SEQ ID SEQ ID NO: 384 NO: 389 SEQ ID SEQ ID NO: 385 NO:390 33_640082 SEQ ID SEQ ID SEQ ID SEQ ID NO: 392 NO: 397 NO: 393 NO:398 SEQ ID SEQ ID NO: 394 NO: 399 SEQ ID SEQ ID NO: 395 NO: 40033_640084 SEQ ID SEQ ID SEQ ID SEQ ID NO: 402 NO: 407 NO: 403 NO: 408SEQ ID SEQ ID NO: 404 NO: 409 SEQ ID SEQ ID NO: 405 NO: 410 33_640086SEQ ID SEQ ID SEQ ID SEQ ID NO: 412 NO: 417 NO: 413 NO: 418 SEQ ID SEQID NO: 414 NO: 419 SEQ ID SEQ ID NO: 415 NO: 420 33_640087 SEQ ID SEQ IDSEQ ID SEQ ID NO: 422 NO: 427 NO: 423 NO: 428 SEQ ID SEQ ID NO: 424 NO:429 SEQ ID SEQ ID NO: 425 NO: 430

Additional spontaneous mutations were introduced into the variableregions of these antibodies in scFv format during the ribosome displayselection procedures as a result of repeated rounds of PCRamplifications. These events add to the sequence diversity of theoutputs but are often undesirable when they occur in the frameworkregions. Hence the spontaneous mutations which occurred in the frameworkregions of 33_640076, 33_640081, 33_640082, 33_640084, 33_640086 and33_640087 were reverted back to germline on the IgG constructs asdescribed in Example 3 using standard molecular biology techniques. Suchspontaneous mutations which occurred in any of the CDRs or in theVernier residues adjacent to the CDRs (e.g. V_(H) positions 27, 28, 29,30, 93 and 94 by Kabat numbering) were left unchanged. As an additionalstrategy to increase affinity, a previously identified ‘hotspot’ (theQ50R mutation in V_(L) CDR2) was also grafted onto the constructs at thesame time. The antibodies resulting from these germlining and hotspotgrafting modifications were named 33_640076-1, 33_640081-A, 33_640082-2,33_640084-2, 33_640086-2 and 33_640087-2, corresponding to theirparental antibodies of 33_640076, 33_640081, 33_640082, 33_640084,33_640086 and 33_640087 respectively. The SEQ ID NO. of these antibodiesare shown in Table 28.

TABLE 28 Sequences of IL33 antibodies VH VL VH CDRs VL CDRs IgG1Sequence Sequence 1, 2, 3 1, 2, 3 33_640076-1 SEQ ID SEQ ID SEQ ID SEQID NO: 432 NO: 437 NO: 433 NO: 438 SEQ ID SEQ ID NO: 434 NO: 439 SEQ IDSEQ ID NO: 435 NO: 440 33_640081-A SEQ ID SEQ ID SEQ ID SEQ ID NO: 442NO: 447 NO: 443 NO: 448 SEQ ID SEQ ID NO: 444 NO: 449 SEQ ID SEQ ID NO:445 NO: 450 33_640082-2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 452 NO: 457 NO:453 NO: 458 SEQ ID SEQ ID NO: 454 NO: 459 SEQ ID SEQ ID NO: 455 NO: 46033_640084-2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 462 NO: 467 NO: 463 NO: 468SEQ ID SEQ ID NO: 464 NO: 469 SEQ ID SEQ ID NO: 465 NO: 470 33_640086-2SEQ ID SEQ ID SEQ ID SEQ ID NO: 472 NO: 477 NO: 473 NO: 478 SEQ ID SEQID NO: 474 NO: 479 SEQ ID SEQ ID NO: 475 NO: 480 33_640087-2 SEQ ID SEQID SEQ ID SEQ ID NO: 482 NO: 487 NO: 483 NO: 488 SEQ ID SEQ ID NO: 484NO: 489 SEQ ID SEQ ID NO: 485 NO: 490

Optimisation of Additional CDRs

As a further strategy to increase affinity, additional CDRs wereoptimised. Large scFv-phage libraries derived from the germlined parent(33_640001) were created by oligonucleotide-directed mutagenesis of thevariable heavy (V_(H)) CDR1 and CDR2 and light (V_(L)) chain CDR1 andCDR2 using standard molecular biology techniques as described (Clackson2004). Selections and screening were performed as described for V_(H)V_(L) CDR3 libraries. The most improved antibody variants were obtainedfrom the V_(H) CDR2 library. These are exemplified by 33_640166,33_640169, 33_640170. The SEQ ID NOs. of these antibodies are shown inTable 29.

TABLE 29 Sequences of IL33 antibodies VH VL VH CDRs VL CDRs IgG1Sequence Sequence 1, 2, 3 1, 2, 3 33_640166 SEQ ID SEQ ID SEQ ID SEQ IDNO: 322 NO: 327 NO: 323 NO: 328 SEQ ID SEQ ID NO: 324 NO: 329 SEQ ID SEQID NO: 325 NO: 330 33_640169 SEQ ID SEQ ID SEQ ID SEQ ID NO: 332 NO: 337NO: 333 NO: 338 SEQ ID SEQ ID NO: 334 NO: 339 SEQ ID SEQ ID NO: 335 NO:340 33_640170 SEQ ID SEQ ID SEQ ID SEQ ID NO: 342 NO: 347 NO: 343 NO:348 SEQ ID SEQ ID NO: 344 NO: 349 SEQ ID SEQ ID NO: 345 NO: 350

As an additive strategy to achieve further improvements in affinity, theV_(H) CDR2 sequences of 33_640166, 33_640169 and 33_640170 were graftedonto the IgG constructs of 33_640076-1, 33_640082-2, 33_640086-2 and33_640087-2, using standard molecular biology methods. Antibodiesresulting from these recombinations were exemplified by 33_640076-4,33_640082-4, 33_640082-6, 33_640082-7, 33_640086-6 and 33_640087-7. Thesequence origins and SEQ ID NO are shown in Table 30.

TABLE 30 Sequence origin and SEQ ID numbers of IL33 antibodies VH VL VHCDRs VL CDRs IgG1 Origin Sequence Sequence 1, 2, 3 1, 2, 3 33_640076-4Grafting of the SEQ ID SEQ ID SEQ ID SEQ ID V_(H) CDR2 NO: 492 NO: 497NO: 493 NO: 498 sequence of SEQ ID SEQ ID 33_640170 onto NO: 494 NO: 49933_640076-1 SEQ ID SEQ ID NO: 495 NO: 500 33_640082-4 Grafting of theSEQ ID SEQ ID SEQ ID SEQ ID V_(H) CDR2 NO: 502 NO: 507 NO: 503 NO: 508sequence of SEQ ID SEQ ID 33_640166 onto NO: 504 NO: 509 33_640082-2 SEQID SEQ ID NO: 505 NO: 510 33_640082-6 Grafting of the SEQ ID SEQ ID SEQID SEQ ID V_(H) CDR2 NO: 512 NO: 517 NO: 513 NO: 518 sequence of SEQ IDSEQ ID 33_640169 onto NO: 514 NO: 519 33_640082-2 SEQ ID SEQ ID NO: 515NO: 520 33_640082-7 Grafting of the SEQ ID SEQ ID SEQ ID SEQ ID V_(H)CDR2 NO: 522 NO: 527 NO: 523 NO: 528 sequence of SEQ ID SEQ ID 33_640170onto NO: 524 NO: 529 33_640082-2 SEQ ID SEQ ID NO: 525 NO: 53033_640086-6 Grafting of the SEQ ID SEQ ID SEQ ID SEQ ID V_(H) CDR2 NO:532 NO: 537 NO: 533 NO: 538 sequence of SEQ ID SEQ ID 33_640169 onto NO:534 NO: 539 33_640086-2 SEQ ID SEQ ID NO: 535 NO: 540 33_640087-7Grafting of the SEQ ID SEQ ID SEQ ID SEQ ID V_(H) CDR2 NO: 542 NO: 547NO: 543 NO: 548 sequence of SEQ ID SEQ ID 33_640170 onto NO: 544 NO: 54933_640087-2 SEQ ID SEQ ID NO: 545 NO: 550

The recombination of beneficial V_(H) CDR3/V_(L) CDR3 and V_(H) CDR2sequences was also carried out using a population cloning and selectionapproach. The round 3 selection outputs from the block mutagenesislibraries covering the V_(H) CDR2 region was recombined with the round 3selection outputs of the recombined V_(H) CDR3/V_(L) CDR3 library in apopulation cloning approach using standard molecular biology techniques.Selection outputs comprising of large numbers of scFv variants wererecombined to form libraries in which clones contained randomly pairedsequences derived from the V_(H) CDR3/V_(L) CDR3 and V_(H) CDR2selections. Selections were performed as described for V_(H) V_(L) CDR3libraries in the presence of decreasing concentrations of biotinylatedantigen—typically from 3 nM to 3 pM over five rounds of selection. CrudescFv-containing periplasmic extracts from a representative number ofindividual scFv's from the selection outputs were screened inbiochemical HTRF® assays as described for V_(H) V_(L) CDR3 libraries.ScFv variants which showed a significantly improved inhibitory effectwhen compared to parent scFv and leads generated pre-recombination, weresubjected to DNA sequencing.

As the epitope competition assay utilising 33_640027 reached its limitof sensitivity, an assay using 33_640117 was used for testing purifiedscFv samples. The assay was essentially as described for the 33v20064competition assay with the following modifications: 2.5 nM DyLightlabelled 33_640117 was prepared and 2.5 microlitres added to the assayplates. This was followed by the addition of 2.5 microlitres of asolution containing 0.12 nM biotinylated human IL-33-01 combined with0.75 nM streptavidin cryptate detection (Cisbio International, 610SAKLB)for the human assay or a solution containing 0.24 nM biotinylatedcynomolgus IL-33 combined with 1.5 nM streptavidin cryptate detection(Cisbio International, 610SAKLB) for the cynomolgus assay. Fluorescencewas read after one hour and overnight incubation. The most potentsamples at both time points were taken forward for reformatting to IgG.

Unique recombined variants were evaluated as purified scFv and the mostactive scFv's were then selected and converted to IgG1 format asdescribed in Example 1. Antibodies obtained from these recombinedlibraries are exemplified by 33_640201 and 33_640237. The spontaneousmutations which were introduced into the framework regions of 33_640201and 33_640237 during ribosome display selections were reverted back togermline sequences as described previously in this section, and theirgermlined counterparts were named 33_640201-2 and 33_640237-2respectively. The SEQ IDs of these antibodies are shown in Table 31.

TABLE 31 Sequences of IL33 antibodies VH VL VH CDRs VL CDRs IgG1Sequence Sequence 1, 2, 3 1, 2, 3 33_640201 SEQ ID SEQ ID SEQ ID SEQ IDNO: 552 NO: 557 NO: 553 NO: 558 SEQ ID SEQ ID NO: 554 NO: 559 SEQ ID SEQID NO: 555 NO: 560 33_640237 SEQ ID SEQ ID SEQ ID SEQ ID NO: 562 NO: 567NO: 563 NO: 568 SEQ ID SEQ ID NO: 564 NO: 569 SEQ ID SEQ ID NO: 565 NO:570 33_640201-2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 572 NO: 577 NO: 573 NO:578 SEQ ID SEQ ID NO: 574 NO: 579 SEQ ID SEQ ID NO: 575 NO: 58033_640237-2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 582 NO: 587 NO: 583 NO: 588SEQ ID SEQ ID NO: 584 NO: 589 SEQ ID SEQ ID NO: 585 NO: 590

Data for antibodies optimised for V_(H) CDR3/V_(L) CDR3 and V_(H) CDR2by rational recombination or population approaches are exemplified by33_640082-6, 33_640087-7, 33_640201 and 33_640237 in FIGS. 44 and 45 .

Inhibition of IL-33 Binding to mAb by Purified IgG

The ability of anti-IL-33 antibodies to inhibit the binding ofbiotinylated His Avi human IL-33 or cynomolgus His Avi IL-33 to theDyLight labelled 33_640117 IgG was assessed in a biochemical HTRF®(Homogeneous Time-Resolved Fluorescence, Cisbio International)competition assays as described above.

FIG. 44A shows inhibition of the FRET signal after 1 hour incubation,produced by biotinylated human IL-33 (IL33-01) binding toDyLight-labeled 33_640117 IgG with increasing concentrations ofantibodies 33v20064, 33_640050, 33_640082-6, 33_640087-7, 33_640201 and33_640237, wherein the x-axis is the concentration of antibody in molarconcentration and the y-axis is percent specific binding.

FIG. 44B shows inhibition of the FRET signal after overnight incubation,produced by biotinylated human IL-33 (IL33-01) binding toDyLight-labeled 33_640117 IgG with increasing concentrations ofantibodies 33v20064, 33_640050, 33_640082-6, 33_640087-7, 33_640201 and33_640237, wherein the x-axis is the concentration of antibody in molarconcentration and the y-axis is percent specific binding.

FIG. 44C shows inhibition of the FRET signal after 1 hour incubation,produced by biotinylated cynomolgus His Avi IL-33 binding toDyLight-labeled 33_640117 IgG with increasing concentrations ofantibodies 33v20064, 33_640050, 33_640082-6, 33_640087-7, 33_640201 and33_640237, wherein the x-axis is the concentration of antibody in molarconcentration and the y-axis is percent specific binding.

TABLE 32 IC50 values of IgG1 antibodies in 117 epitope competitionassays IC50 (nM) 117-WT 117-WT 117-cyno Antibody 1 hour Overnight 1 hour33v20064 IgG 150 689 788 33_640050 IgG 0.3 1.5 4.1 33_640076-4 IgG 0.10.1 0.6 33-640081 IgG 0.3 0.6 10 33_640082-6 IgG 0.1 0.1 0.2 33_640082-7IgG 0.1 0.1 0.2 33_640084-2 IgG 0.3 0.3 0.8 33_640086-6 IgG 0.1 0.1 0.233_640087-7 IgG 0.1 0.1 0.2 33_640201 IgG 0.2 0.2 0.3 33_640237 IgG 0.10.1 1.8

Inhibition of IL-8 Production in Huvec by IgG

IgGs were tested in a Huvec IL-8 production assay. Cells were exposed toN-terminal His Avi IL-33 (IL33-01, SEQ ID NO 632) or mammalian fulllength IL-33 cell lysate (FL-IL33 lysate) in the presence or absence oftest antibody as previously described. IC₅₀ values were calculated andare summarized in Table 33 below.

FIG. 45A shows HUVECs stimulated with IL33-01 in the presence of testantibodies 33_640050, 33_640082-6, 33_640087-7, 33_640201 and 33_640237,wherein the x-axis is the concentration of antibody in molarconcentration and the y-axis is a percentage of the maximum response(IL-8 production).

FIG. 45B shows HUVECs stimulated with full length IL-33 cell lysate inthe presence of test antibodies 33_640050, 33_640082-6, 33_640087-7,33_640201 and 33_640237, wherein the x-axis is the concentration ofantibody in molar concentration and the y-axis is a percentage of themaximum response (IL-8 production).

TABLE 33 IC50 values in the Huvec IL-8 assay IC50 (nM) vs. full lengthIL-33 Antibody vs. His Avi IL-33 cell lysate 33_640076 -4 0.032 0.09533_640082-6 0.030 0.097 33_640082-7 0.031 0.095 33_640084-2 0.036 0.13233_640086-6 0.026 0.081 33_640087-7 0.025 0.073 33_640201 0.046 0.10133_640237 0.056 0.091

Germlining IGLJ Sequence

The amino acid sequences of the V_(L) framework regions of antibodies33_640076-4, 33_640081-A, 33_640082-6, 33_640082-7, 33_640084-2,33_640086-6, 33_640087-7, 33_640201-2 and 33_640237-2 were aligned toknown human IGLJ germline sequences in the IMGT database (Lefranc, M. P.et al. Nucl. Acids Res. 2009. 37(Database issue): D1006-D1012), and theclosest germline was identified by sequence similarity. For all of theseantibodies this was IGLJ2, which has a single amino acid difference tothe antibodies at position 104 of the V_(L) region (Kabat numbering).This residue was reverted to germline as described in Example 3 usingstandard molecular biology methods. The resulting antibodies were named33_640076-4B, 33_640081-AB, 33_640082-6B, 33_640082-7B, 33_640084-2B,33_640086-6B, 33_640087-7B, 33_640201-2B and 33_640237-2B correspondingto their parental lineage of 33_640076-4, 33_640081-A, 33_640082-6,33_640082-7, 33_640084-2, 33_640086-6, 33_640087-7, 33_640201-2 and33_640237-2 respectively. The SEQ IDs of the V_(H) and V_(L) regions ofthese antibodies are shown in Table 34.

TABLE 34 Sequences of germlined IL33 antibodies IgG1 VH Sequence VLSequence 33_640076-4B SEQ ID NO: 592 SEQ ID NO: 594 33_640081-AB SEQ IDNO: 596 SEQ ID NO: 598 33_640082-6B SEQ ID NO: 600 SEQ ID NO: 60233_640082-7B SEQ ID NO: 604 SEQ ID NO: 606 33_640084-2B SEQ ID NO: 608SEQ ID NO: 610 33_640086-6B SEQ ID NO: 612 SEQ ID NO: 614 33_640087-7BSEQ ID NO: 616 SEQ ID NO: 618 33_640201-2B SEQ ID NO: 620 SEQ ID NO: 62233_640237-2B SEQ ID NO: 624 SEQ ID NO: 626

Example 9 In Vivo Airway Inflammation Model Cloning, Expression andPurification of IL-33 Cytokine Trap

Protein sequences for mouse IL-1RAcP and mouse ST2 were obtained fromSwiss Prot (accession numbers Q61730 and P14719 respectively). MouseIL-33 cytokine trap was designed based on Economides et al 2003 andconsisted of amino acids 1-359 Q61730 and amino acids 27-332 P14719fused to the Fc portion of human IgG1. Protein sequences were codonoptimised (Geneart) and cloned into pDEST12.2 OriP proteins weresecreted from cells into the media utilizing the native signal peptidesfrom IL-1RAcP. For expression in CHO cells, the gateway linker wasremoved by overlapping primer PCR. Trap expression vector wastransfected into CHO-transient mammalian cells. Mouse IL-33 trap wasexpressed and secreted into the medium. Harvests were pooled andfiltered prior to purification using Protein A chromatography. Culturesupernatants were loaded onto a 5 ml Hitrap Protein A column (GEHealthcare) and washed with 1×DPBS, bound Trap was eluted from thecolumn using 0.1 M Sodium Citrate (pH 3.0) and neutralized by theaddition of Tris-HCl (pH 9.0). The eluted material was further purifiedby SEC in 1×DPBS using a S200 16:600 Superdex column (GE healthcare) andthe concentration determined spectrophotometrically using an extinctioncoefficient based on the amino acid sequence (Mach et al., Anal.Biochem. 200(1):74-80 (1992)).

Humanized IL-33 Mice

Methods for generation of humanized IL-33 mice have been previouslydescribed in Example 4. The humanized mice are used in models of airwaysand/or allergic inflammation to assess the effect of anti-human IL-33antibodies.

In Vivo Airway Inflammation Model

Models of Alternaria alternata (ALT) induced airway inflammation in micehave been previously described (Kouzaki et al. J. Immunol. 2011, 186:4375-4387; Bartemes et al J Immunol, 2012, 188: 1503-1513). EndogenousIL-33 is released rapidly following ALT exposure and drivesIL-33-dependent IL-5 production and eosinphilia in the lung. Male orfemale wildtype or humanized IL-33 mice (6-10 weeks) were anaesthetizedbriefly with isofluorane and administered either 25 μg of ALT extract(Greer, Lenoir, NC) or vehicle intranasally in a total volume of 50 μl.Mice were treated intraperitoneally or intranasally with testsubstances: IL330004 IgG (SEQ ID Nos. 12 and 17), H338L293 IgG (SEQ IDNos. 182 and 187), mouse IL-33 Trap, 33_640050 (SEQ ID nos. 302 and307), isotype control IgG (NIP228) or vehicle (PBS, 10 ml/kg) at 24hours prior (for intraperitoneal treatment) or 2 hours prior (forintranasal treatment) to intranasal challenge with ALT. At 24 hoursafter challenge, mice were terminally anaesthetised with pentobarbitalsodium prior to exsanguination and bronchoalveolar lavage (BAL).Bronchoalveolar lavage fluid (BALF) was collected by lavage (0.3 ml, 0.3ml & 0.4 ml) via tracheal cannula. BALF was centrifuged, cells counted(total cells by FACS (FacsCALIBER, BD)) and supernatant was analysed forcytokines by ELISA (Meso Scale Discovery, Rockville, MD). Differentialcell counts (200 cells/slide) were performed on cytospin preparationsstained with Diff-Quik (Fisher Scientific, UK). All work was carried outto UK Home Office ethical and husbandry standards under the authority ofan appropriate project licence.

FIG. 46 shows that H338L293 dose-dependently inhibits ALT-induced BALIL-5 and eosinophilia in wild type BALB/c mice. Test substances weredosed intranasally (10, 30 or 100 mg/kg as indicated in brackets) at −2hours prior to challenge with 25 ug of ALT. BALF was harvested at 24hours post ALT challenge and analysed for presence of IL-5 (FIG. 46A)and eosinophils (FIG. 46B). Significant effect of test substances wasdetermined using one-way ANOVA with Bonferroni's multiple comparisonstest. ***p<0.001, ˜˜p<0.01 compared to control mAb (n=4-8). Mouse IL-33Trap was used as a positive control.

FIG. 47 shows that H338L293 (30 mg/kg) and mouse IL-33 Trap (10 mg/kg),but not IL330004 (30 mg/kg), inhibit ALT-induced BAL IL-5 in humanizedIL-33 mice. Test substances were dosed intranasally at −2 hours prior tochallenge with 25 ug of ALT. BALF was harvested at 24 hours post ALTchallenge and analysed for presence of IL-5. Significant effect of testsubstances was determined using one-way ANOVA with Bonferroni's multiplecomparisons test. ***p<0.001, **p<(n=4).

FIG. 48 shows that 33_640050 dose dependently inhibitsAlternaria-induced BAL IL-5 in humanized IL-33 mice. Test substanceswere dosed intraperitoneally (0.3, 3 or 30 mg/kg as indicated inbrackets) at −24 hours prior to challenge with 25 ug of Alternaria. BALFwas harvested at 24 hours post ALT challenge and analysed for presenceof IL-5. Significant effect of test substances was determined usingone-way ANOVA with Bonferroni's multiple comparisons test. ***p<0.001,**p<(n=4-5).

Example 10 Characterization of Anti-IL-33 Antibodies Inhibition of IL-33Binding to ST2 by Purified IgG

The ability of anti-IL-33 antibodies to inhibit the binding ofbiotinylated IL33-01 to the FLAG®-His tagged ST2 receptor was assessedin a biochemical HTRF® (Homogeneous Time-Resolved Fluorescence, CisbioInternational) competition assay, the principles of which are describedabove. Activity of purified IgG preparations were determined bycompeting a dilution series of the purified IgG against human FLAG®-Histagged ST2 for binding to human biotinylated human IL33-01 (SEQ ID No.632).

FIG. 49A: shows the inhibition of the FRET signal after overnightincubation, produced by human IL-33 binding to human ST2 with increasingconcentrations of antibodies 33v20064, 33_640087-7, 33_640087-7B,33_640050 and 33_640237-2B, wherein the x-axis is the concentration ofantibody in molar concentration and the y-axis is percent specificbinding.

Inhibition of IL-8 Production in Huvec by IgG

IgGs were tested in a Huvec IL-8 production assay. Cells were exposed toN-terminal His Avi IL-33 (IL33-01, SEQ ID NO 632) in the presence orabsence of test antibody as previously described. IC₅₀ values werecalculated and are summarized in Table 35 below. Data shows thatgermlining of the IGLJ Sequence did not have any effect on antibodypotency.

FIG. 49B shows HUVECs stimulated with IL33-01 in the presence of testantibodies 33_640087-7, 33_640087-7B, 33_640237-2 and 33_640237-2B,wherein the x-axis is the concentration of antibody in molarconcentration and the y-axis is a percentage of the maximum response(IL-8 production).

TABLE 35 IC50 values in the Huvec IL-8 assay Antibody IC50 (nM) vs. HisAvi IL-33 33_640087-7 0.041 33_640087-7B 0.046 33_640237-2 0.10533_640237-2B 0.067

Selectivity and Cross-Reactivity of Anti-IL-33 Antibodies

Selectivity and cross-reactivity of germlined anti-IL-33 antibodies wasdetermined using a homogeneous FRET (fluorescence resonance energytransfer) HTRF® (Homogeneous Time-Resolved Fluorescence, CisbioInternational) based IL-33:mAb-binding assay. In this assay, samplescompeted with biotinylated human IL-33-01 (SEQ ID No. 632) for bindingto DyLight labelled 33_640087-7B IgG (SEQ ID Nos. 618 and 618) or33_640237-2B IgG (SEQ ID Nos. 624 and 626).

Human, cyno and mouse IL-33 FLAG® His (described in Example 1 and Table21), Human IL-1 alpha and IL-1 beta (R&D Systems) (Table 21) or ratIL-33 (GenScript) were tested for inhibition of human IL-33 binding toDyLight650 labelled 33_640087-7B or DyLight650 labelled 33_640237-2B byadding 5 microlitres of each dilution of sample to a 384 well low volumeassay plate (Costar, 3673). Next, a solution containing 1.2 nMDyLight650 labelled 33_640087-7B or 33_640237-2B was prepared and 2.5microlitres added to the assay plate (labelled using kit (InnovaBiosciences, 326-0010) as per manufacturer's instructions). This wasfollowed by the addition of 2.5 microlitres of a solution containing0.12 nM biotinylated human IL-33-01 combined with 0.75 nM streptavidincryptate detection (Cisbio International, 610SAKLB). All dilutions wereperformed in assay buffer containing 0.8 M potassium fluoride (VWR,26820.236) and 0.1% bovine serum albumin (BSA, PAA, K05-013) inDulbeccos PBS (Invitrogen, 14190185). Assay plates were incubated for 4hours at room temperature followed by 18 hours at 4 degrees Celsius andtime resolved fluorescence was read at 620 nm and 665 nm emissionwavelengths using an EnVision plate reader (Perkin Elmer). Data wereanalysed by calculating the 665/620 nm ratio followed by the % Delta Fvalues for each sample. The 665/620 nm ratio was used to correct forsample interference using Equation 1. The % Delta F for each sample wasthen calculated using Equation 2. The negative control (non-specificbinding) was defined by replacing biotinylated human IL-33 combined withstreptavidin cryptate detection with streptavidin cryptate detectiononly. The % Delta F values were subsequently used to calculate %specific binding as described in Equation 3. IC₅₀ values were determinedusing GraphPad Prism software by curve fitting using a four-parameterlogistic equation (Equation 4). These results demonstrated that33_640087-7B and 33_640237-2B cross react with cynomolgus IL-33 but notmouse IL-33, rat IL-33, human IL-1 alpha or human IL-1 beta.

FIG. 50A: shows the inhibition of the FRET signal, produced bybiotinylated human IL-33-01 binding to DyLight labelled 33_640087-7B(SEQ ID Nos. 618 and 618), with increasing concentrations of testproteins, wherein the x-axis is the concentration of test sample inmolar concentration and the y-axis is percent specific binding.Inhibition of the FRET signal was observed with human and cynomolgus,but not mouse or rat IL-33, human IL-1 alpha or human IL-1 beta.

FIG. 50B: shows the inhibition of the FRET signal, produced bybiotinylated human IL-33-01 binding to DyLight labelled 33_640237-2B(SEQ ID Nos. 624 and 626), with increasing concentrations of testproteins, wherein the x-axis is the concentration of test sample inmolar concentration and the y-axis is percent specific binding.Inhibition of the FRET signal was observed with human and cynomolgus,but not mouse or rat IL-33, human IL-1 alpha or human IL-1 beta.

Neutralisation of Endogenous IL-33 in the HUVEC IL-8 Assay

In order to determine whether antibodies were able to neutralizeendogenous IL-33, human lung tissue was used to provide a source ofendogenous IL-33 protein. The study was approved by the NRES East ofEngland (Cambridge East) Research Ethics Committee (reference number08/H0304/56

5) and tissue was donated with the informed consent of patients.Non-cancerous adjacent tissue from lung cancer patients and from lungtransplant surgeries were supplied in Aqix RS-I medium (Aqix Ltd) on iceby Papworth Hospital NHS Trust Research Tissue Bank. Tissue was dilutedwith 400 mg/mL in PBS and homogenized for 30 seconds using a tissuehomogenizer. Cell debris was removed by centrifugation. HUVECs werestimulated with lung lysates at varying concentrations. An EC₅₀concentration of lysate that stimulated IL-8 release was selected forantibody neutralization studies. Cells were exposed to lung lysate inthe presence or absence of test antibody as previously described. sST2inhibited the IL-8 response by a maximum of approximately 70%,suggesting that most, but not all, of the IL-8 production was driven byendogenous IL-33 within the lung lysate. 33_640050 and 33_640087-7B IgGinhibited the IL-8 response to a similar extent as sST2, demonstratingtheir ability to bind and neutralize endogenous IL-33. 33_640050 IgGneutralized the lung lysate with an IC₅₀ of 0.032 nM. 33_640087-7Bneutralized the lung lysate with an IC₅₀ of sST2 neutralized the lunglysate with an IC₅₀ of 0.019 nM

FIG. 51 shows HUVECs stimulated with human lung lysate in the presenceof test antibodies 33_640050 and 33_640087-7B in comparison with sST2,wherein the x-axis is the concentration of antibody in molarconcentration and the y-axis is a percentage of the maximum response(IL-8 production). sST2 inhibited the IL-8 response by a maximum ofapproximately 70%, suggesting that most, but not all, of the IL-8production was driven by endogenous IL-33 within the lung lysate. Bothantibodies inhibited the IL-8 response to a similar extent as sST2,demonstrating their ability to bind and neutralize endogenous IL-33.

In Vivo Airway Inflammation Model

Methods for generation of humanized IL-33 mice have been previouslydescribed in Example 4. Humanized mice were used in a model ofAlternaria alternata (ALT) induced airway inflammation as described inExample 9 to assess the effect of 33_640087-7B. Male or female wild typeor humanized IL-33 mice (6-10 weeks) were anaesthetized briefly withisofluorane and administered either 25 μg of ALT extract (Greer, Lenoir,NC) or vehicle intranasally in a total volume of 50 μl. Mice weretreated intraperitoneally with test substances: 33_640087-7B IgG (SEQ IDNos. 618 and 618), isotype control IgG (NIP228) or vehicle (PBS, 10ml/kg) at 24 hours prior to intranasal challenge with ALT. At 24 hoursafter challenge, mice were terminally anaesthetised with pentobarbitalsodium prior to exsanguination and bronchoalveolar lavage (BAL).Bronchoalveolar lavage fluid (BALF) was collected by lavage (0.3 ml, 0.3ml & 0.4 ml) via tracheal cannula. BALF was centrifuged and supernatantwas analysed for cytokines by ELISA (Meso Scale Discovery, Rockville,MD). All work was carried out to UK Home Office ethical and husbandrystandards under the authority of an appropriate project licence.

FIG. 52 shows that 33_640087-7B dose dependently inhibitsAlternaria-induced BAL IL-5 in humanized IL-33 mice. Test substanceswere dosed intraperitoneally (0.1, 1, 3 or 10 mg/kg as indicated inbrackets) at −24 hours prior to challenge with 25 ug of Alternaria. BALFwas harvested at 24 hours post ALT challenge and analysed for presenceof IL-5. Significant effect of test substances was determined usingone-way ANOVA with Bonferroni's multiple comparisons test. ***p<0.001,**p<0.01 (n=5-6).

Example 11 Affinity of Anti-IL-33 Antibodies

The affinity of the anti-IL-33 antibody fragment (Fab) for recombinanthuman IL33 was determined using real time interaction montoring byBIACORE™ and at equilibrium using KinExA™ for 33_640087-7B. For bothmethodologies the human IL33 protein was purified by SEC-HPLC to ensurequality of the antigen and also of the Fab for the biacore analysis.

Biacore Affinity Analysis

Fab fragments were generated by papain cleavage from full length IgG1and purified by SEC. The affinity of the antibody fragment (Fab) wasmeasured using the Biacore T100 at 25° C. Streptavidin was covalentlyimmobilised to a C1 chip surface using standard amine couplingtechniques at a concentration of 4 μg/ml in 10 mM Sodium acetate pH 4.5.Typical final streptavidin surface densities in the range 115-170 RUswere achieved. Recombinant, enzymatically biotinylated human IL-33(produced in-house) was titrated onto the streptavidin chip surface at 4μg/ml in HBS-EP+ buffer to enable ˜30 RUs of Fab binding at saturation(Rmax). This low level of analyte binding ensured minimal mass transporteffects.

The IL-33 Fab was serially diluted from 5 nM to 78 pM in HBS-EP+bufferand flowed over the chip at 50 μl/min, with 3 minutes association and upto 30 minutes dissociation. Multiple buffer only injections were madeunder the same conditions to allow for double reference subtraction ofthe final sensorgram sets, which were analysed using the BiaEvalsoftware (version 2.0.1). The chip surface was fully regenerated withpulses of 3M MgCl₂.

The affinity of ST2-Flag-His10 (SEQ. ID no. 650) expressed in HEK-EBNAcells for human IL-33 was determined by BIACORE™ using the same methodsdescribed above.

TABLE 36 Biacore Affinity Results for anti-IL-33 Fab k_(a) k_(d) K_(D)Analyte Fit setting (M⁻¹ s⁻¹) (s⁻¹) (pM) R_(max) Chi² 33_640001 Fab Rmaxglobal 9.76E+6 3.26E−2 3340 27.0 0.022 33_640050 Fab Rmax local 3.08E+71.05E−4 3.4 48.9 0.022 33_640087-7B Fab Rmax local 2.20E+7 9.42E−6 0.4330.7-32.8 0.010 ST2-FH monomer Rmax local 1.52E+7 4.35E−5 2.9 23.4 0.022

KinExA Affinity Analysis

In order to confirm the high affinity found with the SPR assay we turnedto Kinetic Exclusion Assays (KinExA). KinExA is increasingly findingfavour for resolving higher-affinity protein:protein interactions,especially those in the pM to sub-pM ranges where surface basedbiosensor techniques reach their practical limits (Rathanaswami P,Roalstad S, Roskos L, Qiaojuan J S, Lackie S, Babcook J. Demonstrationof an in vivo generated sub picomolar affinity fully human monoclonalantibody to interleukin-8. Biochemical and Biophysical ResearchCommunications. 2005; 334: 1004-1013).

The affinity of the antibody 33_640087-7B was measured by kineticexclusion assays performed on the KinExA 3200. The sampling beads wereprepared by mixing 200 mg of dry UltraLink Biosupport Azlactone beadswith 110 μg of IL-33 (as mentioned previously) in 2.5 ml of 50 mM sodiumhydrogen bicarbonate pH 8.4 at room temperature for 2 hours withconstant agitation. The beads were rinsed and blocked with 10 mg/ml BSAin 1M Tris pH 8.7. Prior to use, the beads were resuspended into D-PBS,0.02% sodium azide. 33_640087-7B/IL-33 equilibrium mixtures wereprepared in sample buffer composed of 1 mg/ml BSA, 0.02% sodium azide inDPBS (Dulbecco's PBS). Two different IgG concentrations were used withvarying IL-33 concentrations, 5 pM of 33_640087-7B with IL-33 seriallydiluted from 125 pM to 61fM and 500fM 33_640087-7B with IL-33 seriallydiluted from 62.5 pM to 15fM, both were carried out with zero IL-33controls. The fluorescent secondary detection reagent was Alexa Fluor647 goat anti-human-Fc diluted in lmg/ml BSA, 0.02% sodium azide, 0.1%Tween 20 in DPBS. The samples were run on the KinExA whilst housed in atemperature controlled cabinet set at 25° C. The data was analysed usingthe KinExA Pro software version 4.1.11.

KinExA assays indicate that 33_640087-7B has a K_(D) of <142 fM(femtomolar) for human IL-33 (Table 37).

TABLE 37 KinExA Affinity Results for 33_640087-7B IgG Upper 95% Lower95% Estimated confidence interval confidence interval Analyte K_(D) (pM)K_(D) (pM) K_(D) (pM) 33_640087-7B 0.03 0.142 undefined

Example 12 Activity of Oxidized IL-33 In Vivo Pilot Study to ExploreActivity of Oxidized IL-33

In Example 4 (see also Cohen, E. S. et al. Oxidation of the alarminIL-33 regulates ST2-dependent inflammation. Nat. Commun. 6:8327 doi:10.1038/ncomms9327 (2015)) we describe the discovery of an oxidized,disulphide bonded form of IL-33 (DSB IL-33) and showed that this formdoes not bind ST2. To investigate if oxidized IL-33 had an alternativeactivity independent of ST2, ST2-deficient mice were treatedintraperitoneally or intranasally with repeated doses of human IL-33 for2, 4 or 6 weeks. Histological analysis was performed on multipletissues.

ST2-deficient mice were generated as previously described (Townsend, M.J., Fallon, P. G., Matthews, D. J., John, H. E., and McKenzie, A. N. J.(2000). T1/ST2-deficient mice demonstrate the importance of T1/ST2 indeveloping primary T helper cell type 2 responses. J. Exp. Med. 191,1069-1076). Female ST2-deficient mice (12 weeks) were anaesthetizedbriefly with isofluorane and administered either 10 μg of N-terminal HisAvi IL-33 (IL33-01, SEQ ID NO 632; lot number CCH168, endotoxin levels0.03 EU/mg), or vehicle (PBS) intranasally in a total volume of 50 μl.Alternatively, the IL-33 or vehicle was administered by i.p. injection.This process was repeated 3× weekly for a total 18 treatments. Mice thatreceived only 2 or 4 weeks treatment with IL-33 were administered PBSfor the first 4 or 2 weeks of dosing, prior to receiving IL-33.

At 24 hours after the last treatment, mice were terminally anaesthetisedwith pentobarbital sodium prior to exsanguination and bronchoalveolarlavage (BAL). Blood was collected by cardiac bleed using an EDTA flushedsyringe. Blood haematology was done using Sysmex XTVet haematologyanalyser. The remaining blood was centrifuged and plasma extracted.Bronchoalveolar lavage fluid (BALF) was collected by lavage (0.3 ml, 0.3ml & 0.4 ml) via tracheal cannula. BAL cells were counted (BAL totalcells by flowcytometer (MACSquant, Miltenye Biotec) and BALF wascentrifuged to separate supernatant, that was analysed for cytokines byELISA (Meso Scale Discovery, Rockville, MD). Differential cell counts(200 cells/slide) were performed on cytospin preparations stained withDiff-Quik (Fisher Scientific, UK). Following PBS lavage lungs wereinflated with 10% neutral buffered formalin (NBF) via a trachealinfusion to maintain lung architecture and immerse-fixed in NBF for24-48 hours. Fixed lung samples were then cut transversely into 4 equalcross-sections before being processed through a series of alcohols,xylene and into paraffin wax. Finally the lung cross-sections were thenembedded into paraffin wax blocks. 4 μm histological sections were cutand stained with haematoxylin and eosin (H&E) for analysis andinflammation scoring assessment. All work was carried out to UK HomeOffice ethical and husbandry standards under the authority of anappropriate project licence.

To investigate IL-33 exposure via intraperitoneal or intranasal routes,human IL-33 was measured in BALF and plasma using Millipore human IL-33assay (Cat #HTH17MAG-14K lot 2159117) as described in Example 4. Abilityof sST2-Fc to reduce the assay signal was used to determine the presenceof ST2-binding (reduced) vs non-ST2-binding (oxidized) IL-33. Followingintranasal administrations, IL-33 was consistently detected in BALF andplasma at 2, 4 and 6 week endpoints. The majority of the IL-33 detectedwas oxidised. Following a single intraperitoneal administration, IL-33was detected transiently in the plasma 5 hours after dosing but wasundetectable by 24 hours. Following repeated IL-33 administrations,human IL-33 was not consistently detected in BALF or plasma at the 2, 4or 6 week endpoints. These data indicated that the best systemicexposure of oxidized IL-33 is achieved through intranasal dosing.

FIG. 53A. Experimental design of in vivo pilot study. ST2-deficient micewere treated intraperitoneally or intranasally with repeatedadministration of human IL-33 or vehicle (PBS) for 6 weeks (n=3-4 pergroup). Tissues, BALF and serum were collected 24 hours following thefinal IL-33 administration.

FIG. 53B. Analysis of human IL-33 exposure in BAL fluid followingrepeated administration of human IL-33 to BALB/c mice. Human IL-33 wasmeasured in BALF from mice treated as described in FIG. 53A, wherein thex-axis shows the treatment group and the y-axis shows the human IL-33assay signal in arbitrary units. IL-33 was only detected in BALF afterintra-nasal dosing. The IL-33 detected was found to be predominantlyoxidized (non-ST2 binding).

FIG. 53C Analysis of IL-33 exposure in plasma following a singleintraperitoneal administration of human IL-33 (10 ug). Human IL-33 wasmeasured in plasma at 2, 5, 24 and 48 hours after administration,wherein the x-axis shows the time point of analysis and the y-axis showsthe human IL-33 assay signal in arbitrary units. IL-33 was detectedtransiently in the plasma 5 hours after dosing but was undetectable by24-48 hours.

FIG. 53D Analysis of IL-33 exposure in plasma following repeatedadministration of human IL-33 to BALB/c mice. Human IL-33 was measuredin plasma from mice treated as described in FIG. 53A, wherein the x-axisshows the treatment group and the y-axis shows the human IL-33 assaysignal in arbitrary units. IL-33 was only detected in plasma afterintra-nasal dosing. The IL-33 detected was found to be predominantlyoxidized (non-ST2 binding).

Histological analysis was performed on multiple tissues. No relevantabnormalities in human IL-33 treated mice compared to controls in liver,brain, spleen, skin, stomach, lymph node or heart. In the lung,increased lymphocytic perivascular inflammation was present in IL-33treated mice compared to controls only in the intranasal group and onlyafter 6 weeks of treatment. This is consistent with the highest exposureto oxidized IL-33 (FIG. 53 ). In conclusion, the treatment of ST2 KOmice with IL-33 increases the presence of perivascular lymphocyticinfiltrate in lungs of IL-33 treated mice compared to controls. Thispathology may be mediated through oxidized IL-33.

FIG. 54A shows representative H&E stained paraffin sections of lungtissue from mice administered PBS intranasally for 6 weeks (n=3)

FIG. 54B shows representative H&E stained paraffin sections of lungtissue from mice administered IL-33 intranasally for 6 weeks (n=4).

Pathway Analysis of IL-33 Treated Mouse Lung

To gain insight into the pathways modulated by oxidized IL-33 in themouse lung leading to the inflammatory response observed, microarrayanalysis was performed on lung tissue from 6 week PBS treated versus 6week IL-33-treated animals.

Lung tissues from 7 ST2KO mice (3 dosed with PBS and 4 dosed withIL33-01 as described above) were collected and directly placed into 350uL of RLT buffer (Qiagen #79216). Tissue was then disrupted using aQiagen TissueLyser (Qiagen #85300) according to manufacturer's protocoland RNA was purified using the RNeasy Fibrous Tissue kit (Qiagen#74704). Purified RNA from this kit was then concentrated using RNeasyMicro Columns (Qiagen #74004) according to manufacturer's protocol. RNAwas then amplified to single stranded DNA using Affymetrix's GeneChip WTPlus Reagent kit (Affymetrix #902513) and hybridised onto MouseTranscriptome 1.0 (MTA1.0) genechips (Affymetrix #900720), washed inAffymetrix Fluidics Station and scanned on the Affymetrix GenechipScanner 3000 7G. Data was then processed in Affymetrix Expressionconsole. Data were analysed in Microsoft Excel and sorted for geneswhere at least 2 out of 4 IL33-treated mice had greated than ±1.2-foldchange in signal from the control group average. The sorted gene listwere converted to KEGG IDs using Biological Database Network (BioDBnetv2.1) and analysed in KEGG pathway analysis (www.kegg.jp; KEGG Mapperv2.5). The same genes that were analysed in KEGG pathway were alsoanalysed using Ingenuity Pathway Analysis (IPA) (Qiagen). IPA analysissuggested pathways relating to cell cycle appeared modulated. Examplegenes are listed in Table 38.

TABLE 38 Genes modulated in ST2-deficient mice by intranasal IL-33treatment Gene Symbols Upregulated genes relating to cell cycle HSPA1A,CEBP, CDKN1A, (>1.2 average fold change) JUNB, AHCY, SOX2, MYC, ID2,HRAS, EGR1, WT1, JUND, COX4I1 Downregulated genes relating to cell cycleIL1A, HGF, ERG, ZEB1, (>−1.2 average fold change) P10, DMTF1, ARHGAP18,PLA2R1, NSMCE2, CAV1

Signalling of DSB IL-33 in Huvecs

To acertain whether a response to oxidized (DSB) human IL-33 could beobserved on human cells, stimulation of human cells in vitro wasexplored. The mouse microarray analysis indicated activation of pathwaysrelating to cell cycle and therefore p38 MAP Kinase and JAK-STATsignaling were investigated. Human umbilical vein endothelial cells(Huvecs) were cultured according to manufacturer's instructions andstimulated with reduced or DSB IL-33. Nuclear translocation of p-p38MAPK or p-STAT5 was detected by immunofluorecence staining. Imaging andquantification of the nuclear staining intensity was performed onArrayScan VTi HCS Reader (Cellomics). The assay was essentially the sameas that described for NFkB p65/RelA nuclear translocation but with thefollowing modifications.

For p-p38 MAPK assay, Huvecs were seeded at 1×10⁴/75 μl/well in culturemedia [EBM-2 (Lonza, #CC-3156) with EGM-2 SingleQuot Kit Suppl. & GrowthFactors (Lonza, #CC-4176)] into 96-well black walled, clearflat-bottomed Collagen I coated plates (Greiner #655956) and incubatedat 37° C., 5% CO₂ for 18-24 hours. Test samples of reduced or DSB IL-33(in duplicate) were diluted to the desired concentration in completeculture media in 96 well U-bottom polypropylene plates (Greiner, 650201)and 75 uL added to the Huvec plates to initiate the stimulation.Following 15 or 30 minute assay incubation at 37° C., cells were fixedfor 15 minutes in 3.7% formaldehyde solution (by addition of 50 uL of16% solution that had been pre-warmed to 37° C.). Fixative was aspiratedand cells were washed twice with 100 μL/well of PBS. Cells were stainedfor p-p38 with Phospho-p38 antibody (Cell signalling #9211S) at 1:250dilution. Briefly, cells were permeabilised for 15 minutes at roomtemperature, blocked for 15 minutes and stained for 1 hour with primaryantibody solution in a volume of 50 μL. Plates were washed ×2 inblocking buffer and stained for 1 hour at room temperature withsecondary antibody solution (DyLight 488-labelled goat anti-rabbit IgG;ThermoFisher Scientific #35552 at 1:400 dilution) and Hoechst nuclearstain (ThermoFisher Scientific #62249 at 1:10000 dilution). Plates werewashed ×2 in PBS. Cells were stored in a final volume of 150 μL/well PBSand covered with a black, light-blocking seal (Perkin Elmer, #6005189)before reading on ArrayScan VTi HCS Reader. The intensity of nuclearstaining was calculated using a suitable algorithm. Data were analysedusing Graphpad Prism software.

For pSTAT5 assay, Huvecs were seeded at 1×10⁴/75 μl/well in culturemedia [EBM-2 (Lonza, #CC-3156) with EGM-2 SingleQuot Kit Suppl. & GrowthFactors (Lonza, #CC-4176)] into 96-well black walled, clearflat-bottomed Collagen I coated plates (Greiner, #655956) and incubatedat 37° C., 5% CO₂ for 18-24 hours. Following this complete media wasaspirated, the cells were washed 2× in 100 uL PBS/well, the PBS wasaspirated and 75 uL of Starve media [EBM-2 (Lonza, #CC-3156) withpen/strep] was added to each well. Cells were then were incubated at at37° C., 5% CO₂ for 18 hours. Test samples of reduced or DSB IL-33 (induplicate) were diluted to the desired concentration in starve media in96 well U-bottom polypropylene plates (Greiner, 650201) and 75 uL addedto the Huvec plates to initiate the stimulation. Following 15 or 30minute assay incubation at 37° C., cells were fixed for 15 minutes in3.7% formaldehyde solution (by addition of 50 uL of 16% solution thathad been pre-warmed to 37° C.). Fixative was aspirated and cells werewashed twice with 100 μL/well of PBS. Cells were stained for p-STAT5with Phospho-STAT5 rabbit antibody C71E5 (Cell Signalling #9314S) at1:250 dilution, which was detected as described above.

Reduced IL-33 triggered p-p38 MAPK signaling, which was lost uponoxidation to the DSB form (FIG. 55A), similar to that previouslydescribed for NFkB signaling (Examples 4-6). However DSB IL-33, but notreduced IL-33, triggered p-STAT5 signalling (FIG. 55B). Thus a clearswitch in signaling pathway activation was observed upon conversion ofhuman IL-33 from the reduced to the DSB form, suggesting that DSB IL-33may have activity distinct of known IL-33 pathways.

To confirm the result from the nuclear translocation assays, IL-33signalling was determined by Western blot analysis. Huvecs werestimulated as above with reduced or DSB IL-33 (3 ng/mL) for 15 minutes.Cells were then washed twice in ice cold PBS and lysed with 250 uL RIPABuffer (Pierce #89901) containing HALT protease inhibitors (Pierce#78430). Samples were subjected to SDS-PAGE under reducing conditions.Samples were mixed 3:1 with 4× NuPAGE gel loading buffer (Invitrogen)and denatured at 90° C. for 3 minutes. Reduced samples contained 2%beta-mercaptoethanol. Samples were run on NuPAGE Novex 4-12% Bis-Trismini gels (Invitrogen) with MOPS running buffer (Invitrogen) accordingto manufacturer's instructions. Proteins were transfered toNitrocellulose membranes (Invitrogen cat. no. IB3010-02) and detected bywestern blotting with rabbit phospho-p38 MAPK antibody (Cell signalling#9211S), rabbit phospho-STAT5 antibody C71E5 (Cell Signalling #9314S) orrabbit p-JAK2 antibody (Cell Signalling #3771S). Primary antibodies weredetected with anti-rabbit-HRP (Cell Signalling #7074) and visualizedusing ECL reagent (Thermo Scientific #34096).

FIG. 55A shows p-p38 MAPK nuclear translocation activity in Huvecs inresponse to reduced IL-33 or DSB IL-33 (IL33-01 pre-treated with IMDMmedia), wherein the x-axis shows the IL-33 concentration and the y-axisshows the nuclear translocation signal in arbitrary units. Aconcentration dependent signal was observed for reduced but not oxidizedIL-33.

FIG. 55B shows p-STAT5 nuclear translocation in Huvecs in response toreduced IL-33 or DSB IL-33 (IL33-01 pre-treated with IMDM media),wherein the x-axis shows the IL-33 concentration and the y-axis showsthe nuclear translocation signal in arbitrary units. A concentrationdependent signal was observed for DSB but not reduced IL-33.

FIG. 55C. Western blot analysis of for p-p38 MAPK, p-JAK2 and p-STAT5 inHuvecs stimulated for 15 minutes with reduced IL-33 or DSB IL-33(IL33-01 pre-treated with IMDM media). Activation of p-p38 MAPK wasdetected following stimulation with reduced but not DSB IL-33.Activation of p-JAK2 and p-STAT5 was detected following stimulation withDSB IL-33 but not reduced IL-33.

Signalling of DSB IL-33 is Mediated Via the Receptor for AdvancedGlycation End Products (RAGE)

To gain insight into the pathways modulated by DSB IL-33 in Huvecs,Huvecs were cultured as described previously, plated at 1×10⁶ cells/wellin a 6 well tissue culture treated plate (Nunc 140675). Followingovernight incubation, cells were stimulated with DSB IL-33 for 2 or 6hours. Cells were collected in 350 uL of RLT buffer (Qiagen #79216). RNAwas purified using the RNeasy Micro Kit (Qiagen #74004) according tomanufacturer's protocol. RNA was then amplified to single stranded DNAusing Affymetrix's GeneChip WT Plus Reagent kit (Affymetrix #902513) andhybridised onto Human Genome U133A 2.0 (U133A 2.0) genechips (Affymetrix#900469), washed in Affymetrix Fluidics Station and scanned on theAffymetrix Genechip Scanner 3000 7G. Data was then processed inAffymetrix Expression console and sorted for genes with greater than±1.8-fold change in signal from the untreated control. Very few geneexpression changes were observed (Table 39). Nevertheless, the limitedgene panel were analyzed using Ingenuity Pathway Analysis (IPA)(Qiagen), which suggested EIF2 signaling pathway at 2 hours and AGERsignaling at 6 hours. Potentially these suggested scavenging/receptorfor advanced glycation endproducts (RAGE) pathway activation.

TABLE 39 Genes modulated in DSB-IL-33 stimulated Huvecs. Gene SymbolsTimepoint Regulated genes >±1.8 fold change 2 hours EIF3F, RPL14, RPL38,RPL27A, RPL37A, RPS10, RPS27L 6 hours IFIT1, S100A8

The receptor for advanced glycation end-products (RAGE) is amulti-ligand receptor that belongs to the immunoglobulin superfamily,and recognizes a variety of ligands, including high-mobility group box 1(HMGB-1), 5100 family of proteins, advanced glycation end-products (AGE)and β-sheet fibrillar materials. It is thought to be involved inoxidative stress and has been linked to the pathogenesis of numerousdiseases.

To assess whether DSB directly interacted with RAGE, an ELISA format wasused to explore RAGE binding to reduced IL-33 versus DSB IL-33 (FIG.56A). Reduced or DSB N-terminal His Avi IL-33 (IL33-01, SEQ ID NO 632)were biotinylated as described in Example 7. Streptavidin plates (ThermoScientific, AB-1226) were coated with biotinylated antigen at 50 μg/mlin PBS and incubated at room temperature for 1 hour. Plates were washed3× with PBS-T (PBS+1% (v/v) Tween-20) and blocked with 300 μl/wellblocking buffer (PBS with 1% BSA (Sigma, A9576)) for 1 hour. Plates werewashed 3× with PBS-T. RAGE-Fc (R&D Systems #1145-RG) was diluted inblocking buffer, added to the IL-33-coated or control (no IL-33) wellsand incubated at room temperature for 1 hour. RAGE-Fc was detected withanti-human IgG HRP (Sigma, A0170) diluted 1:5000 in blocking buffer, 50μl/well for 1 hour at room temperature. Plates were washed 3× with PBS-Tand developed with TMB, 50 μl/well (Sigma, T0440). The reaction wasquenched with 50 μl/well 0.1M H₂SO₄ before reading on an EnVision™ platereader, or similar equipment, at 450 nm.

To further confirm the interaction of DSB IL-33 with RAGE, the abilityof RAGE-Fc or anti-RAGE antibodies to inhibit the ST2-independent pSTAT5signalling in Huvecs was evaluated. To this purpose, varyingconcentrations of DSB IL-33 (IMDM-treated IL33-01) were used tostimulate Huvecs according to the protocol described above in thepresence or absence of RAGE-Fc (R&D Systems #1145-RG), ST2-Fc (R&DSystems #523-ST), anti-RAGE mAb (from WO 2008137552) or controlreagents. Neutralisation of DSB IL-33 with RAGE-Fc (FIG. 56B), orneutralization of the receptor with anti-RAGE mAb (FIG. 56C) were ableto completely inhibit the pSTAT5 signal.

FIG. 56A. Binding of RAGE-Fc to reduced IL-33 or DSB plate surface byELISA, wherein the x-axis shows the RAGE-Fc concentration and the y-axisshows the absorbance @450 nM. Data showed increased binding of RAGE toDSB IL-33 compared with reduced IL-33.

FIG. 56B shows the pSTAT5 response to DSB IL-33 in Huvec in the presenceof RAGE-Fc (50 ug/mL), ST2-Fc (50 ug/mL) or anti-NIP IgG1 negativecontrol antibody, NIP228 (50 ug/mL). pSTAT5 signalling was completelyinhibited by RAGE-Fc but not ST2-Fc or NIP228.

FIG. 56C shows the pSTAT5 response to DSB IL-33 in Huvec in the presenceof anti-RAGE mAb, m4F4 (10 ug/mL), or mouse IgG1 negative controlantibody (10 ug/mL). pSTAT5 signalling was completely inhibited by m4F4but not control mAb.

Prevention of DSB IL-33 Activity with Anti-IL-33 Antibodies

As described in Example 8, antibodies that bind IL-33 may preventoxidation of IL-33 to the DSB form (FIG. 43A). The ability of IL-33antibodies to prevent pSTAT5 signaling in Huvecs was evaluated.

Fixed concentrations of 33_640087-7B (SEQ ID Nos 616 and 618), Anti-ST2(from WO 2013/173761 Ab2; SEQ ID 85 and SEQ ID 19) and isotype controlmAbs were prepared in IMDM and then combined (100 uL with 100 uL) with atitration of WT IL-33 (also prepared in IMDM) in 96 well U-bottomplates. Plates were incubated at 37° C. and 5% CO2 overnight. 75 uL fromeach well of these ‘preincubation treatment’ plates was added to‘starved’ cells prepared as described above for pSTAT5 assay andincubated at 37° C. for 15 mins. Cells were then washed twice in icecold PBS and 100 uL Lysis Buffer from the eBioscience Phospho-STATSA/BInstant One ELISA (eBioscience #85-86112-11) was added to each well.pSTAT5 activity in cell lysates was then measured according tomanufacturers instructions.

FIG. 57 shows the pSTAT5 response in Huvecs to IL-33 treated with IMDMin the presence of 33_640087-7B (10 ug/mL) or Anti-ST2 mAb, Ab2, (10ug/mL), wherein the x-axis is the concentration of IL-33 and the y axisis the pSTAT5 signal. pSTAT5 signalling was completely inhibited by33_640087-7B but not anti-ST2, confirming that this response isST2-independent.

Anti-IL-33 Antibodies Inhibit RAGE-Dependent Response in EpithelialCells

RAGE is expressed highly in lung epithelial cells. Lung epithelial celllines were evaluated for DSB IL-33 dependent responses. To this purpose,A549 cells were cultured in F12K Media (Gibco #21127022) supplementedwith 1% Penicillin/Streptomycin and 10% FBS. Cells were harvested withTrypsin-EDTA (Gibco, #15400-054), washed and seeded in 96 well plates at1×10⁵/cells/well in culture media. Cells were then were incubated at at37° C., 5% CO₂ for 24 hours. The following day complete media wasremoved, cells were washed twice in PBS and media replaced with ‘starve’media (F12K media with 1% Pen/Strep) and plates incubated for 24 hoursat 37° C. and 5% CO₂.

Fixed concentrations of 33_640087-7B (SEQ ID Nos 616 and 618), Anti-ST2(WO 2013/173761 Ab2 (SEQ ID 85 and SEQ ID 19)), anti-RAGE m4F4 (from WO2008137552) and isotype control mAbs were prepared in IMDM and thencombined (100 uL with 100 uL) with WT IL-33 (also prepared in IMDM) in96 well U-bottom plates. Both cell and treatment plates were incubatedat 37° C. and 5% CO₂ overnight. 75 uL from each well of these‘preincubation treatment’ plates was added to ‘starved’ cells preparedas described above and plates incubated for 24 hours at 37° C. and 5%CO₂. The 96 well transwell system (Corning #CLS3422-48EA) is then set upby adding a 96 well transwell plate to a low binding 96 well receiverplate. 235 uL of complete media (F12K media supplemented with 10% FBSand 1% Pen/Strep) was added to the bottom chamber of the transwellsystem. Each well of the 96 well treated A549 cells were then washed inPBS, trypsinised to detach, centrifuged at 1000 rpm for 5 min,resuspended in 75 uL ‘starve’ media and added to the top chamber of thetranswell system. The transwell plate was then incubated at 37° C., 5%CO₂ for 16 hours. Media was then removed from both top and bottomchambers and cells removed from the bottom chamber using 235 uL trypsin.100 uL of the trypsin/cell suspension was then added to 100 uL of CellTiter Glo (Promega #G7571). A titration of fresh A549 cells is preparedin trypsin and added 50:50 to Cell Titer Glo to create a standard curveof cell number. Plates were then incubated and read according tomanufacturer's instructions.

FIG. 58A shows the migration of A549 cells after treatment with IL33-01incubated in the presence of 33_640087-7B (10 ug/mL), Anti-ST2 mAb, Ab2,(10 ug/mL), or anti-RAGE mAb 4F4, wherein the x-axis shows the cellpre-treatment condition and the y axis is the number of cells migrated.Data demonstrate that pre-treatment of A549 cells with DSB IL-33 reducessubsequent cell migration. This inhibition of migration was reversed byanti-RAGE mAb and 33_640087-7B but not by anti-ST2.

FIG. 58B shows the migration of A549 cells after treatment with DSBIL33-01 incubated in the presence of 33_640087-7B (10 ug/mL) or Anti-ST2mAb, Ab2, (10 ug/mL, wherein the x-axis shows the cell pre-treatmentcondition and the y axis is the number of cells migrated. Datademonstrate that pre-treatment of A549 cells with DSB IL-33 reducessubsequent cell migration. This inhibition of migration was not reversedby 33_640087-7B or anti-ST2

Together, these data confirm that 33_640087-7B inhibits DSB-IL_33activity by preventing the conversion of reduced IL-33 to DSB IL-33rather than neutralizing DSB IL-33 directly, consistent with its abilityto bind only the reduced, ST2-active form of IL-33.

What is claimed is:
 1. A method for treating a subject with an inflammatory condition comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof which specifically binds to IL-33.
 2. The method of claim 1, wherein the antibody or antigen-binding fragment thereof inhibits IL-33 driven cytokine production.
 3. The method of claim 1, wherein the antibody or antigen-binding fragment thereof inhibits RAGE mediated effects.
 4. The method of claim 1, wherein the inflammatory condition is an allergic disorder.
 5. The method of claim 1, wherein the inflammatory condition is asthma or COPD.
 6. The method of claim 1, wherein the inflammatory condition is in the airway of the subject.
 7. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a VHCDR1 having the sequence of SEQ ID NO: 183, a VHCDR2 having the sequence of SEQ ID NO: 184, a VHCDR3 having the sequence of SEQ ID NO: 185, a VLCDR1 having the sequence of SEQ ID NO: 188, a VLCDR2 having the sequence of SEQ ID NO: 189, and a VLCDR3 having the sequence of SEQ ID NO:
 190. 8. The method of claim 7, wherein the VH and VL of the antibody or antigen-binding fragment thereof comprise amino acid sequences at least 95%, 90%, or 85% identical to SEQ ID NO: 182 and SEQ ID NO: 187, respectively.
 9. The method of claim 8, wherein the VH has the sequence of SEQ ID NO: 182 and the VL has the sequence of SEQ ID NO:
 187. 10. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a VHCDR1 having the sequence of SEQ ID NO: 543, a VHCDR2 having the sequence of SEQ ID NO: 544, a VHCDR3 having the sequence of SEQ ID NO: 545, a VLCDR1 having the sequence of SEQ ID NO: 548, a VLCDR2 having the sequence of SEQ ID NO: 549, and a VLCDR3 having the sequence of SEQ ID NO:
 550. 11. The method of claim 10, wherein the VH and VL of the antibody or antigen-binding fragment thereof comprise amino acid sequences at least 95%, 90%, or 85% identical to SEQ ID NO: 542 and SEQ ID NO: 547, respectively.
 12. The method of claim 11, wherein the VH has the sequence of SEQ ID NO: 542 and the VL has the sequence of SEQ ID NO:
 547. 13. The method of claim 10, wherein the VH and VL of the antibody or antigen-binding fragment thereof comprise amino acid sequences at least 95%, 90%, or 85% identical to SEQ ID NO: 616 and SEQ ID NO: 618, respectively.
 14. The method of claim 13, wherein the VH has the sequence of SEQ ID NO: 616 and the VL has the sequence of SEQ ID NO:
 618. 15. The method of claim 1, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a human antibody, a chimeric antibody, and a humanized antibody.
 16. The method of claim 1, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a naturally-occurring antibody, an scFv fragment, an Fab fragment, an F(ab′)2 fragment, a minibody, a diabody, a triabody, a tetrabody, and a single chain antibody.
 17. The method of claim 1, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody. 